Frontiers in Neuroscience:

Recent Advances in Research and Therapeutics

Editors

Abhishek, Ashish Patel,
Ajab Singh Choudhary,
Hemlata Bhatt, Bhawana Sati



Mantra Publication

Publiished by
Mantra Publication
(An International Publication)

Frontiers in Neuroscience: Recent Advances in Research and Therapeutics

Book Editors

Abhishek
10 Church Street, Coventry, West Midlands, CV1 4GA, United Kingdom

Ashish Patel
Associate Professor, Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy Parul University, Limda, Waghodia, Vadodara, Gujarat 391760, India

Ajab Singh Choudhary
Assistant Professor, Department of Medical Laboratory Technology, School of Allied Health Sciences (SOAHS), Noida International University, Sector 17A, Yamuna Expressway, Greater Noida, Uttar Pradesh 203201, India

Hemlata Bhatt
Assistant Professor, Department of Pharmaceutical Sciences, Hemvati Nandan Bahuguna Garhwal University, Srinagar Garhwal, Uttarakhand 246174, India

Bhawana Sati
Assistant Professor, Department of Pharmacy, Banasthali Vidyapith, Tonk, Rajasthan 304022, India

Published, marketed, and distributed by:
Mantra Publication
An International Publication
https://mantrapublicationservices.com/books-publication/
editorbooks@mantrapublicationservices.com
Whatsapp: +91 9236371090

P-ISBN: 978-81-68473-02-7
E-ISBN: 978-81-68473-03-4

DOI: https://doi.org/10.5281/zenodo.22727731

Citation: Abhishek, Patel, A., Choudhary, A. S., Bhatt, H., & Sati, B. (Eds.). (2026). *Frontiers in Neuroscience: Recent Advances in Research and Therapeutics*. Mantra Publication. https://doi.org/10.5281/zenodo.22727731

Preface

Neuroscience represents one of the most rapidly advancing fields of biomedical research, continuously expanding our understanding of the structure, function, and disorders of the nervous system. Advances in molecular biology, pharmacology, biotechnology, artificial intelligence, and translational medicine have significantly transformed the landscape of neurological research and therapeutic development. However, increasing prevalence of neurodegenerative, neuropsychiatric, and neurological disorders continues to present major challenges, emphasizing the need for innovative diagnostic strategies, novel therapeutic approaches, and multidisciplinary research.

The edited book entitled **"Frontiers in Neuroscience: Recent Advances in Research and Therapeutics"** aims to provide a comprehensive overview of recent developments in neuroscience, focusing on emerging concepts, molecular mechanisms, technological advancements, and therapeutic innovations. This book brings together contributions from researchers, academicians, and experts working in diverse areas of neuroscience and related disciplines.

The chapters included in this book explore contemporary topics such as neurodegenerative disorders, neuroprotective strategies, neuropharmacology, natural products and phytotherapeutics, advanced drug delivery systems, molecular targets, computational approaches, and future directions in neurological research. Special emphasis has been given to understanding disease mechanisms, improving therapeutic outcomes, and translating scientific discoveries into clinically relevant applications.

This book is designed to serve as a valuable resource for undergraduate and postgraduate students, researchers, academicians, healthcare professionals, and scientists interested in neuroscience and therapeutic innovation. We hope that the information presented in this volume will encourage further research, collaboration, and exploration of new frontiers in the field of neuroscience.

We sincerely acknowledge the efforts of all contributing authors whose expertise and dedication have enriched this book. Their valuable insights and scientific contributions have played a crucial role in developing this comprehensive volume.

Editors
Abhishek
Ashish Patel
Ajab Singh Choudhary
Hemlata Bhatt
Bhawana Sati

Acknowledgement

The successful completion of the edited book **"Frontiers in Neuroscience: Recent Advances in Research and Therapeutics"** would not have been possible without the valuable support and contributions of many individuals and institutions.

First and foremost, we express our sincere gratitude to all the chapter authors for sharing their scientific knowledge, research expertise, and valuable perspectives. Their commitment and scholarly contributions have significantly enhanced the quality and scope of this book.

We extend our heartfelt appreciation to our respective institutions and academic organizations for providing continuous encouragement, resources, and an environment that promotes research and academic excellence. We are grateful to our colleagues, collaborators, and mentors for their guidance, motivation, and constructive suggestions throughout the preparation of this volume.

We would also like to thank **Mantra Publication** for providing the platform and support required for bringing this scholarly work to the scientific community. The dedication and cooperation of the editorial and publishing team have been instrumental in completing this project successfully.

Finally, we acknowledge our families, friends, and well-wishers for their constant encouragement, patience, and support during the preparation of this book. Their motivation and understanding have been a source of strength throughout this journey.

We hope that this book will contribute meaningfully to the field of neuroscience and inspire future advancements in neurological research and therapeutic development.

Editors
Abhishek
Ashish Patel
Ajab Singh Choudhary
Hemlata Bhatt
Bhawana Sati

List of Chapters & Contributors

Chapter 1: Blood–Brain Barrier: Physiology, Challenges and Emerging Strategies for CNS Drug Delivery

Bhavana Singh[*1], Ajab Singh[2], Sunil Kumar Tiwari[3], Anup Pramanik[4], Prabhat Kumar[5]

[1]Assistant Professor, School of Pharmacy, Sharda University, Plot No. 32,34, Knowledge Park-III, Greater Noida, Uttar Pradesh, India.

[2]Assistant Professor, Medical Laboratory Technology (SOAHS), Noida International University, Sector 17 A, Yamuna Expressway, Greater Noida, Uttar Pradesh, India.

[3]Assistant Professor, School of Pharmaceutical Sciences, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, India 244102.

[4]Assistant Professor, Department of Pharmacy, Usha Martin University, Narayansoso, Ranchi–Purulia Road Highway, Angara, Ranchi, Jharkhand, India.

[5]Assistant Professor, Department of Pharmaceutics, Usha Martin University, Angara, Ranchi, Jharkhand 835103, India.

*Corresponding Author: Bhavana Singh, Assistant Professor, School of Pharmacy, Sharda University, Plot No. 32,34, Knowledge Park-III, Greater Noida, Uttar Pradesh, India.

Abstract

The blood–brain barrier (BBB) is a highly specialized physiological interface that maintains central nervous system (CNS) homeostasis while restricting the entry of many therapeutic agents into the brain. Although this protective function is essential for neuronal health, it represents one of the major obstacles in the development of effective treatments for neurological disorders. BBB permeability is governed by multiple interacting factors, including physicochemical properties of therapeutic molecules, tight-junction integrity, carrier-mediated transport, receptor-mediated transcytosis, and active efflux systems. Conventional approaches based primarily on molecular optimization and passive diffusion have demonstrated limited applicability, particularly for biologics, peptides, proteins, and nucleic-acid therapeutics. Consequently, increasing attention has been directed toward advanced approaches capable of crossing, bypassing, or temporarily modulating the BBB. These include intranasal delivery, direct CNS administration, pharmacological transporter modulation, focused ultrasound-assisted BBB opening, receptor-targeted delivery, nanocarriers, extracellular vesicles, biomimetic systems, and gene- and RNA-based therapeutics. Emerging developments in artificial intelligence, computational permeability prediction, BBB-on-chip models, organoids, stimuli-responsive nanocarriers, and personalized drug-delivery platforms are further expanding the possibilities for precision CNS therapy. However, challenges related to reproducibility, long-term safety, manufacturing scalability, disease-specific BBB alterations, and translation from experimental models to humans remain unresolved. This chapter discusses the physiological basis of BBB function, major determinants of drug permeability, mechanisms responsible for restricted CNS drug access, conventional and advanced BBB-crossing strategies, and emerging technologies with potential for clinical translation. A multidisciplinary integration of nanotechnology, biotechnology, computational science, and precision medicine may ultimately enable safer, more effective, and patient-specific CNS drug delivery.

Keywords: Blood–brain barrier; CNS drug delivery; BBB permeability; drug transport; receptor-mediated transcytosis; nanocarriers; intranasal delivery; focused ultrasound; extracellular vesicles; gene therapy; artificial intelligence; precision medicine.

1. Introduction

The blood–brain barrier (BBB) is a highly specialized physiological interface that separates the circulating blood from the brain microenvironment. Rather than functioning as a simple physical wall, the BBB operates as a dynamic and selective neurovascular system that controls the movement of nutrients, metabolites, signaling molecules, and potentially harmful substances between the systemic circulation and the central nervous system (CNS). The concept of a selective barrier between blood and brain developed from early experimental observations and has subsequently evolved into the modern understanding of the BBB as an integrated component of the neurovascular unit (Abbott et al., 2010; Sweeney et al., 2018). Anatomically, the principal barrier is formed by specialized brain microvascular endothelial cells, although the blood–brain interface also involves pericytes, astrocytes, basement membrane, extracellular matrix, neurons, and microglia. This cellular organization enables the BBB to respond dynamically to physiological and pathological signals. It is also important to distinguish the BBB from the blood–cerebrospinal fluid (CSF) barrier, which is primarily associated with the choroid plexus, and from other brain–CSF interfaces that contribute to CNS homeostasis through different cellular and molecular mechanisms (Daneman & Prat, 2015).

The structural integrity of the BBB depends mainly on the specialized properties of brain endothelial cells. These cells exhibit low rates of nonspecific transcytosis and are interconnected by highly developed tight junctions and adherens junctions. Tight-junction proteins such as claudins, occludin, and zonula occludens-1 (ZO-1) regulate paracellular permeability, whereas vascular endothelial cadherin contributes to endothelial cell adhesion and vascular stability (Zhao et al., 2015). Pericytes are embedded within the vascular basement membrane and contribute to endothelial stability, vessel maturation, and regulation of BBB permeability. Astrocytic end-feet surround the abluminal surface of cerebral vessels and provide important biochemical and signaling support. Together with the basement membrane and extracellular matrix, these components form a functional neurovascular unit rather than an isolated endothelial barrier (Sweeney et al., 2018).

The principal physiological function of the BBB is to maintain a stable environment for neuronal activity. It selectively regulates the entry of glucose, amino acids, ions, and other essential nutrients while restricting potentially toxic molecules and many circulating xenobiotics. Transport proteins and receptor-mediated mechanisms permit essential substances to reach the brain despite their limited ability to cross the endothelial membrane by passive diffusion. At the same time, efflux transporters, including P-glycoprotein and breast cancer resistance protein, actively remove numerous foreign compounds from the CNS and therefore provide an additional protective mechanism (Abbott et al., 2010; Daneman & Prat, 2015). The BBB also contributes to the regulation of ionic balance, neurotransmitter concentrations, metabolic signaling, and immune surveillance, thereby supporting normal neuronal and synaptic function.

The molecular organization of the BBB is particularly important for controlling permeability. Claudins, occludin, and ZO-1 form interconnected junctional complexes that restrict paracellular movement, while adherens-junction proteins strengthen endothelial contacts. Transporters and efflux systems provide selective molecular traffic across the endothelial layer. This highly coordinated arrangement means that BBB permeability is not fixed but can change in response to inflammation,

oxidative stress, hypoxia, infection, aging, and neurological disease (Zhao et al., 2015; Sweeney et al., 2018).

The BBB should therefore be viewed as an integrated component of the neurovascular unit. Endothelial cells interact continuously with pericytes, astrocytes, neurons, and microglia to regulate vascular function and barrier integrity. Disruption of these interactions can contribute to altered BBB permeability and has been associated with several neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, and brain tumors (Sweeney et al., 2018). Importantly, the same protective properties that preserve CNS homeostasis create a major obstacle for drug development. Many potentially effective therapeutic molecules, particularly large biologics, peptides, nucleic-acid therapeutics, and hydrophilic compounds, exhibit limited penetration into the brain. Consequently, understanding BBB physiology, transport mechanisms, and disease-associated alterations is essential for developing effective CNS therapies and designing BBB-aware drug-delivery strategies (Pardridge, 2012; Daneman & Prat, 2015).

2. Transport Mechanisms Across the Blood–Brain Barrier and Determinants of Drug Permeability

The blood–brain barrier (BBB) is a highly selective interface in which endothelial membranes, junctional complexes, influx transporters, receptor-mediated pathways, and efflux systems collectively determine whether a molecule can enter the brain. Consequently, BBB penetration cannot be predicted solely from molecular size or lipophilicity; rather, passive diffusion and multiple active transport processes operate simultaneously. Recent work emphasizes that understanding the combined contribution of physicochemical properties and transport mechanisms is essential for rational CNS drug design (Cornelissen et al., 2023; Wu et al., 2023).

2.1 Physicochemical Determinants of BBB Permeability

The physicochemical characteristics of a drug strongly influence its ability to cross the BBB. Small molecules generally have an advantage because they can diffuse more readily through endothelial membranes, whereas increasing molecular size usually decreases passive permeability. Lipophilicity is another important determinant because sufficiently lipophilic molecules partition into the endothelial cell membrane and may subsequently diffuse across it. However, excessive lipophilicity is not necessarily advantageous because it can increase nonspecific binding, membrane retention, and metabolic liabilities (Zhao et al., 2022; Cornelissen et al., 2023).

Hydrogen-bonding capacity and topological polar surface area are also important because highly polar compounds generally have difficulty entering the hydrophobic core of endothelial membranes. Ionization is similarly critical: neutral species usually exhibit greater passive membrane permeability than permanently charged molecules, although ionized compounds may still reach the brain through specific transport mechanisms. Molecular flexibility and the number of rotatable bonds can further influence permeability by affecting molecular conformation and polar surface exposure. Plasma protein binding adds another layer of complexity because only the unbound fraction is generally available for membrane diffusion or transporter-mediated uptake. Thus, BBB penetration reflects the combined effect of molecular size, lipophilicity, polarity, charge, hydrogen bonding, flexibility, protein binding, and transporter affinity rather than a single molecular property (Zhao et al., 2022; Bickel, 2022).

Table 2.1. Major physicochemical factors influencing BBB permeability

Property	General influence on BBB penetration	Drug-development implication
Molecular size	Increasing size generally reduces passive diffusion	Optimize molecular weight while retaining pharmacological activity
Lipophilicity	Moderate lipophilicity favors membrane partitioning	Excessive lipophilicity may increase nonspecific binding
Hydrogen bonding	Extensive hydrogen bonding generally reduces membrane permeability	Minimize unnecessary hydrogen-bond donors/acceptors
Polar surface area	High polar surface area generally limits passive penetration	Reduce exposed polarity where pharmacologically feasible
Ionization/pKa	Neutral molecules usually cross membranes more readily	Consider pKa and ionization state at physiological pH
Molecular flexibility	High flexibility can adversely affect permeability and drug-like properties	Rationally control rotatable bonds and molecular conformation
Plasma protein binding	High binding may reduce the freely diffusible fraction	Evaluate unbound plasma and brain concentrations
Transporter affinity	Can enhance influx or reduce CNS exposure through efflux	Incorporate transporter liability into lead optimization

2.2 Passive Transcellular Diffusion

Passive transcellular diffusion represents an important route for BBB penetration, particularly for small, sufficiently lipophilic and relatively non-ionized molecules. In this process, a compound partitions from the blood into the endothelial lipid membrane, traverses the endothelial cytoplasm, and subsequently enters the brain interstitial compartment. The process does not directly require metabolic energy and is generally governed by concentration gradients and membrane permeability. Many clinically successful CNS small molecules exploit this route, although passive diffusion alone does not explain the brain distribution of every compound (Cornelissen et al., 2023).

The major advantage of passive diffusion is its relative simplicity and lack of dependence on a specific transporter. Nevertheless, this pathway favors a restricted chemical space. Large, highly polar, strongly ionized, or extensively hydrogen-bonded molecules generally show poor passive penetration. Furthermore, a molecule that readily enters endothelial cells may still be prevented from accumulating in the brain by active efflux transporters. Therefore, passive permeability must be considered together with active influx and efflux processes when predicting CNS exposure (Bickel, 2022; Cornelissen et al., 2023).

2.3 Paracellular Transport

Paracellular movement occurs through the spaces between adjacent endothelial cells. Under normal physiological conditions, this pathway is extremely restricted because BBB endothelial cells possess highly developed tight-junction complexes. Claudins, occludin, ZO proteins, and associated junctional

components effectively limit the uncontrolled passage of hydrophilic molecules and ions through the intercellular space (Singh & Vellapandian, 2023).

Although restricted paracellular permeability is essential for CNS homeostasis, it can change during disease. Inflammatory mediators, oxidative stress, ischemia, infection, trauma, and other pathological stimuli may alter endothelial junctional organization and increase barrier permeability. From a drug-delivery perspective, temporary BBB disruption can increase access of otherwise poorly permeable therapeutics, but uncontrolled barrier opening may expose the brain to toxins, inflammatory mediators, and systemic immune components. Consequently, therapeutic BBB disruption requires spatial and temporal control (Zhao et al., 2022; Wu et al., 2023).

2.4 Carrier-Mediated Transport

The BBB is not simply impermeable to hydrophilic substances; it contains highly specialized carrier systems that selectively transport essential nutrients and metabolites. Solute carrier (SLC) transporters facilitate the movement of endogenous substrates and, in some cases, structurally related drugs. GLUT1 is particularly important for glucose transport because glucose represents a major energy substrate for the brain. Other transporter systems facilitate the movement of amino acids, monocarboxylates, nucleosides, ions, and organic cations or anions (Singh & Vellapandian, 2023; Chaves et al., 2024).

Large neutral amino acids are transported through systems including LAT1, while monocarboxylate transporters participate in the movement of lactate, pyruvate, and related substrates. Organic anion and organic cation transport systems also contribute to the exchange of endogenous metabolites and xenobiotics. These transport mechanisms are particularly attractive for CNS drug development because medicinal chemists can modify therapeutic molecules to resemble endogenous transporter substrates. However, transporter-mediated delivery is often saturable and may produce competition with physiological substrates or other drugs (Chaves et al., 2024).

2.5 Receptor-Mediated and Adsorptive-Mediated Transcytosis

Receptor-mediated transcytosis (RMT) provides an important mechanism for transporting large molecules across the BBB. In this process, a therapeutic molecule or drug carrier interacts with a receptor located on the luminal surface of brain endothelial cells, undergoes receptor-associated endocytosis, is transported within vesicular compartments, and is subsequently released toward the brain side. Receptors associated with physiological macromolecular transport, including the transferrin receptor and insulin receptor, have therefore attracted substantial interest as potential molecular “shuttles” for CNS therapeutics (Wu et al., 2023; Bell, 2022).

Low-density lipoprotein receptor-related proteins, particularly LRP-family pathways, have also been investigated for brain-targeted delivery. These systems can potentially transport antibodies, peptides, proteins, and nanocarriers that would otherwise exhibit negligible BBB penetration. The principal challenge is achieving sufficient transcytosis without triggering excessive receptor degradation, endothelial sequestration, or peripheral toxicity. The design of receptor-binding affinity is therefore critical because extremely strong receptor binding does not necessarily translate into efficient delivery across the endothelial cell (Bell, 2022).

Adsorptive-mediated transcytosis differs from RMT because it is driven predominantly by electrostatic interactions between positively charged molecules and negatively charged components of the endothelial surface. This approach can facilitate transport of selected macromolecules but generally has lower molecular specificity. Consequently, both RMT and adsorptive-mediated transcytosis are being investigated as strategies for overcoming the size and polarity limitations of conventional passive diffusion (Pawar et al., 2022; Wu et al., 2023).

2.6 Efflux Transport Systems

Efflux transporters represent one of the most important obstacles to CNS drug delivery. Rather than transporting molecules from blood into the brain, these proteins actively move selected compounds from endothelial cells back toward the blood, thereby reducing their net accumulation within the CNS. The ATP-binding cassette transporter P-glycoprotein (P-gp/ABCB1) is a major BBB efflux system, while breast cancer resistance protein (BCRP/ABCG2) and several multidrug resistance-associated proteins (MRPs) also contribute to xenobiotic efflux (Chaves et al., 2024).

Efflux activity can substantially reduce brain exposure even when a compound possesses favorable passive membrane permeability. This explains why some highly lipophilic drugs demonstrate unexpectedly low CNS concentrations. Efflux transporters may also contribute to drug–drug interactions and interindividual differences in CNS pharmacokinetics. Consequently, modern CNS drug discovery increasingly evaluates both passive permeability and transporter-mediated efflux during lead optimization rather than treating BBB penetration as a simple diffusion problem (Cornelissen et al., 2023; Chaves et al., 2024).

Table 2.2. Major BBB transport mechanisms relevant to CNS drug delivery

Transport mechanism	Representative system	Typical substrates/targets	Major significance
Passive transcellular diffusion	Lipid membrane	Small lipophilic molecules	Major route for many small CNS drugs
Paracellular transport	Tight-junction pathway	Small hydrophilic molecules under disrupted conditions	Normally highly restricted
Carrier-mediated influx	GLUT1, LAT1, MCTs	Glucose, amino acids, monocarboxylates	Selective nutrient and drug transport
Organic ion transport	OAT/OCT-related systems	Organic anions/cations and xenobiotics	Regulates endogenous and exogenous compounds
Receptor-mediated transcytosis	TfR, insulin receptor, LRP-related pathways	Proteins, peptides, engineered carriers	Enables macromolecular BBB transport
Adsorptive transcytosis	Electrostatic surface interactions	Selected charged macromolecules	Potential nonspecific macromolecular delivery
Active efflux	P-gp, BCRP, MRPs	Diverse xenobiotics and drugs	Limits brain accumulation and therapeutic exposure

2.7 Drug Properties and BBB Penetration

Small-molecule drugs remain the most established class of therapeutics capable of achieving meaningful BBB penetration because their size and chemical properties can often be optimized for passive diffusion or transporter-mediated uptake. Nevertheless, successful CNS drug design requires balancing BBB permeability with target affinity, metabolic stability, selectivity, solubility, and safety. Contemporary medicinal chemistry therefore increasingly considers brain penetration and intracerebral distribution simultaneously rather than optimizing permeability in isolation (Cornelissen et al., 2023).

Peptides and proteins face greater limitations because of their molecular size, hydrophilicity, enzymatic instability, and limited passive membrane permeability. Monoclonal antibodies are even less capable of freely crossing the intact BBB, creating a major challenge for treating CNS targets located within brain parenchyma. Receptor-mediated transcytosis and other targeted delivery systems have consequently become important approaches for improving macromolecular brain exposure (Wu et al., 2023; Bell, 2022).

Nucleic-acid therapeutics, including siRNA, antisense oligonucleotides, mRNA, and gene-editing components, present additional delivery challenges because of their large size, negative charge, susceptibility to degradation, and limited membrane permeability. Nanomedicines can address some of these limitations by protecting therapeutic cargo and incorporating BBB-targeting ligands or transport mechanisms. Liposomes, polymeric nanoparticles, lipid-based nanoparticles, extracellular-vesicle-derived systems, and peptide-functionalized carriers are therefore being investigated for brain-targeted delivery (Pawar et al., 2022; Wu et al., 2023).

Importantly, the development of BBB-penetrating therapeutics is shifting from the traditional concept of simply making molecules more lipophilic toward a more integrated strategy involving physicochemical optimization, transporter profiling, receptor targeting, computational prediction, and advanced delivery technologies. Recent research indicates that combining experimental permeability measurements with computational approaches may improve prediction of CNS exposure and accelerate identification of drug candidates with appropriate brain distribution (Cornelissen et al., 2023).



Figure 2.1. Conceptual framework of drug transport across the BBB

3. Challenges in CNS Drug Delivery and BBB Dysfunction in Disease

3.1 The BBB as a Major Barrier to Drug Development

The blood–brain barrier (BBB) represents one of the most important obstacles in the development of effective central nervous system (CNS) therapeutics. Its highly selective endothelial interface restricts the entry of many therapeutic molecules, particularly large, hydrophilic, highly charged, and transporter-sensitive compounds. Consequently, systemic administration does not necessarily result in adequate drug exposure within the brain, and plasma pharmacokinetics may poorly predict actual concentrations achieved in CNS tissues. This problem becomes particularly important when the therapeutic effect requires sustained exposure within specific brain regions. Although increasing systemic doses may improve brain exposure for some compounds, this approach can simultaneously increase peripheral toxicity and narrow the therapeutic window (Liu et al., 2025; Pedder et al., 2025).

The challenge is not simply to make a molecule cross the BBB but to achieve **sufficient, selective, and therapeutically relevant delivery** while preserving BBB integrity. Efflux transporters, metabolic processes, protein binding, and disease-related changes in cerebral vascular permeability further complicate CNS pharmacokinetics. These limitations contribute substantially to the gap between promising preclinical findings and successful clinical translation.

3.2 Disease-Associated BBB Alterations

BBB dysfunction is increasingly recognized as an active component of CNS pathology rather than merely a consequence of neurological disease. Neuroinflammation, oxidative stress, mitochondrial dysfunction, endothelial injury, and altered signaling between endothelial cells, pericytes, astrocytes,

and immune cells can compromise barrier integrity. Changes in tight-junction organization, endothelial glycocalyx, transporter activity, and cellular signaling may increase vascular permeability and permit abnormal entry of plasma proteins, inflammatory mediators, and immune cells into the brain (Yu et al., 2025).

Neuroinflammation can promote endothelial activation and disrupt junctional complexes, whereas oxidative stress can damage endothelial membranes and associated proteins. At the same time, alterations in influx and efflux transporters may change the distribution and clearance of endogenous metabolites and therapeutic agents. Thus, BBB dysfunction may create a complex situation in which permeability increases for some substances while active transport and efflux mechanisms remain highly restrictive for others. Importantly, BBB alterations are dynamic and can vary according to disease type, stage, brain region, and treatment status.

3.3 BBB Dysfunction in Major Neurological Disorders

BBB disruption has been documented across a broad spectrum of neurological disorders, although its magnitude, timing, and underlying mechanisms differ among diseases. In Alzheimer's disease (AD), BBB dysfunction has been associated with endothelial abnormalities, pericyte alterations, impaired transport processes, neuroinflammation, and accumulation of pathological proteins. Increasing evidence suggests that interactions involving β-amyloid and tau may themselves contribute to vascular dysfunction, creating a potentially self-reinforcing relationship between neurodegeneration and BBB impairment (Wu et al., 2024).

Parkinson's disease (PD) is also associated with alterations in BBB integrity, transporter function, endothelial signaling, inflammation, and oxidative stress. Such changes may influence both disease progression and the ability of therapeutic agents to reach vulnerable dopaminergic brain regions (Lau et al., 2024). Multiple sclerosis (MS) provides another clear example in which inflammatory disruption of the BBB facilitates the entry of pathogenic immune cells into the CNS, contributing to demyelination and neurological injury (Zierfuss et al., 2024).

BBB dysfunction is additionally implicated in amyotrophic lateral sclerosis (ALS), epilepsy, ischemic stroke, traumatic brain injury (TBI), brain tumors, and CNS infections. In stroke, ischemic injury and subsequent inflammatory and oxidative processes can produce substantial changes in endothelial permeability and vascular integrity. Following TBI, spreading depolarization, neurovascular dysfunction, inflammation, and mechanical injury can interact to produce prolonged BBB abnormalities (van Hameren et al., 2024). In brain tumors, abnormal tumor-associated vasculature may produce heterogeneous barrier properties, creating substantial variability in drug penetration. Similarly, CNS infections can alter BBB function through pathogen-associated inflammatory responses, although the extent of disruption differs among infectious agents and disease stages.

Table 3.1. Major neurological disorders associated with BBB dysfunction

Neurological condition	Major BBB-associated alterations	Potential consequences
Alzheimer's disease	Pericyte dysfunction, endothelial injury, altered transport, inflammatory signaling	Impaired clearance, neuroinflammation and neuronal dysfunction
Parkinson's disease	Tight-junction alterations, oxidative	Altered CNS homeostasis and

	stress, endothelial dysfunction	therapeutic penetration
Multiple sclerosis	Inflammatory endothelial activation and immune-cell transmigration	CNS immune infiltration and demyelination
ALS	Vascular dysfunction and altered barrier integrity	Neuroinflammation and impaired neuronal environment
Epilepsy	Increased permeability and transporter alterations	Neuroinflammation and altered drug responsiveness
Ischemic stroke	Endothelial injury, junctional disruption and vascular leakage	Edema, inflammation and secondary neuronal damage
Brain tumors	Heterogeneous and abnormal tumor-associated barrier	Variable and often inadequate drug penetration
Traumatic brain injury	Mechanical and inflammatory vascular injury	Edema, inflammation and secondary brain injury
CNS infections	Pathogen- and inflammation-associated barrier disruption	Immune infiltration and altered CNS homeostasis

3.4 Challenges Associated with Conventional CNS Drug Delivery

Conventional systemic drug delivery faces several simultaneous barriers. Poor aqueous solubility can limit formulation and systemic exposure, whereas rapid metabolism or elimination can reduce the amount of drug available for brain delivery. Even when adequate plasma concentrations are achieved, poor BBB permeability may prevent therapeutically meaningful CNS exposure. Furthermore, compounds that do enter the brain may be actively removed through efflux systems such as P-glycoprotein and breast cancer resistance protein, substantially reducing intracellular or parenchymal drug concentrations (Liu et al., 2025).

These problems become more pronounced for drugs with short biological half-lives or narrow therapeutic windows. Increasing the dose is not always a suitable solution because systemic exposure may increase disproportionately relative to CNS exposure, resulting in toxicity without achieving adequate therapeutic concentrations. Therefore, contemporary CNS drug-development programs increasingly consider BBB permeability, transporter interactions, brain pharmacokinetics, and regional CNS exposure during early drug discovery rather than treating BBB penetration as a late-stage consideration.

3.5 Delivery of Biologics Across the BBB

The development of biologics has intensified the BBB challenge. Peptides, recombinant proteins, monoclonal antibodies, enzymes, nucleic acids, and gene-editing systems generally exhibit limited spontaneous penetration through the intact BBB because of their molecular size, polarity, charge, and susceptibility to biological degradation. Consequently, therapeutic success may require specialized delivery strategies capable of transporting these molecules across or around the BBB (Pedder et al., 2025).

Several approaches are being investigated, including receptor-mediated transcytosis, peptide-mediated targeting, engineered antibodies, nanoparticles, extracellular vesicles, intranasal delivery, and temporary BBB modulation. Particularly promising strategies exploit endogenous transport pathways to ferry therapeutic cargo across brain endothelial cells while minimizing nonspecific barrier disruption. Nanocarriers can additionally protect sensitive biological cargo from degradation and

provide opportunities for controlled or targeted release. Recent advances in nanocarrier engineering have therefore expanded the possibilities for delivering proteins, nucleic acids, and other complex therapeutics to the CNS (Liu et al., 2025).

3.6 Safety and Translational Challenges

Overcoming the BBB must be balanced against the fundamental protective function of this barrier. Excessive or prolonged BBB disruption can expose neural tissue to plasma proteins, inflammatory mediators, toxins, and immune components and may consequently produce edema, inflammation, neuronal injury, or neurotoxicity. Therefore, approaches designed to temporarily increase BBB permeability require precise control over location, magnitude, and duration of barrier opening.

Immunogenicity and off-target effects represent additional concerns, particularly for biologics, nanoparticles, viral vectors, and gene-based therapies. Long-term accumulation of nanomaterials or repeated exposure to BBB-modulating technologies also requires careful evaluation. Another major challenge is reproducibility and translational validity. Conventional animal models and simplified in vitro BBB systems cannot fully reproduce the cellular complexity and molecular heterogeneity of the human BBB. Differences in transporter expression, receptor distribution, endothelial phenotype, and disease biology can lead to discrepancies between experimental and clinical outcomes (Deli et al., 2024; Yin & Wang, 2024).

Human stem-cell-derived BBB models, three-dimensional systems, organoids, and BBB-on-chip platforms are consequently being developed to improve prediction of human drug transport. However, these advanced systems also require standardization of barrier characteristics, transporter activity, cellular composition, and experimental conditions before they can fully replace or complement conventional models.

Table 3.2. Major translational challenges in CNS drug delivery

Challenge	Underlying problem	Implication for drug development
Limited BBB permeability	Restricted entry of many therapeutic molecules	Insufficient CNS exposure
Efflux transport	Active removal of drugs from brain endothelial cells	Reduced therapeutic concentration
Biologic size and polarity	Poor passive diffusion	Requires specialized transport systems
BBB heterogeneity	Regional and disease-dependent differences	Variable drug distribution
Barrier disruption	Risk of edema and neuroinflammation	Safety concerns
Immunogenicity	Immune response to biologics or delivery systems	Reduced efficacy and adverse effects
Off-target delivery	Uptake by peripheral tissues	Reduced selectivity and toxicity
Long-term accumulation	Persistence of some nanomaterials or vectors	Uncertain chronic safety
Model limitations	Differences between animal/in vitro	Poor clinical predictability

	and human BBB	
Manufacturing and reproducibility	Complexity of advanced delivery systems	Difficult scale-up and regulatory translation

Overall, the BBB represents a **dual challenge** in CNS therapeutics: its physiological integrity protects the brain but simultaneously restricts therapeutic access. Disease-associated BBB dysfunction further complicates this relationship by producing dynamic and heterogeneous changes in permeability and transport. Current research is therefore shifting from nonspecific barrier disruption toward more precise approaches that exploit endogenous transport pathways, engineered nanocarriers, human-relevant BBB models, and disease-specific targeting. Such strategies may ultimately enable safer and more predictable delivery of both conventional drugs and complex biologics to the CNS (Pedder et al., 2025; Liu et al., 2025).

4. Conventional and Advanced Strategies for Overcoming the BBB

The restrictive nature of the blood–brain barrier (BBB) has encouraged the development of diverse strategies designed either to improve the intrinsic ability of therapeutic molecules to enter the brain or to provide alternative pathways that bypass or temporarily modulate the barrier. These approaches range from relatively simple chemical modification and prodrug design to intranasal delivery, direct CNS administration, focused ultrasound-mediated BBB opening, and sophisticated nanocarrier systems. Current research increasingly emphasizes **selective and controlled transport rather than nonspecific disruption**, because successful CNS delivery requires an appropriate balance between therapeutic exposure and preservation of BBB function (Butola & Nainwal, 2024; Shaw et al., 2025).

4.1 Chemical Modification of Therapeutic Molecules

Chemical optimization remains one of the earliest approaches for improving BBB penetration. Increasing lipophilicity can facilitate passive transcellular diffusion through endothelial cell membranes; however, excessive lipophilicity may increase nonspecific protein binding, reduce aqueous solubility, alter metabolism, and increase peripheral toxicity. Therefore, BBB-oriented drug design generally seeks an appropriate balance among molecular size, lipophilicity, hydrogen-bonding capacity, ionization, polar surface area, and metabolic stability rather than simply maximizing hydrophobicity.

Prodrug design provides another important strategy. A poorly permeable parent drug can be chemically converted into a more BBB-compatible derivative that undergoes enzymatic or chemical conversion after reaching the CNS. Prodrugs may exploit endogenous transport mechanisms or temporarily mask polar functional groups, thereby improving membrane permeability. Molecular conjugation can similarly attach therapeutic compounds to peptides, lipids, or other targeting moieties capable of interacting with BBB transport systems. Recent work has emphasized combining prodrug chemistry with transporter recognition and nanomedicine rather than relying on physicochemical optimization alone (Sahoo et al., 2024).

Peptide engineering is particularly relevant for biologics and macromolecules. BBB-penetrating peptides can facilitate receptor-mediated or adsorptive-mediated transport and may be incorporated into therapeutic conjugates or nanocarriers. However, peptide stability, proteolytic degradation, immunogenicity, and nonspecific uptake remain important considerations. Thus, chemical

modification is most effective when molecular properties are optimized together with the intended transport mechanism.

4.2 Pharmacological Modulation of BBB Transport

The BBB expresses numerous influx and efflux transport systems that influence the cerebral exposure of drugs. Pharmacological manipulation of these systems has therefore been investigated as a means of increasing CNS concentrations. Inhibition of efflux transporters such as P-glycoprotein and breast cancer resistance protein can theoretically reduce active drug extrusion from endothelial cells and enhance brain exposure. However, these transporters also protect the CNS against xenobiotics, making systemic inhibition potentially hazardous.

An alternative approach is to design therapeutic molecules that utilize endogenous carrier or receptor systems. Transporter-targeted prodrugs and molecular conjugates can exploit nutrient transport pathways, while receptor-mediated transcytosis can utilize receptors such as transferrin or insulin receptors to facilitate endothelial transport. The major advantage of these approaches is that they can potentially increase CNS delivery without physically disrupting the BBB. Their limitations include transporter saturation, competition with endogenous substrates, heterogeneous receptor expression, peripheral receptor-mediated uptake, and uncertain translation from experimental models to humans

Table 4.1. Major conventional approaches for improving BBB penetration

Strategy	Principal mechanism	Major advantage	Important limitation
Increasing lipophilicity	Enhanced passive membrane diffusion	Simple chemical optimization	May increase toxicity and protein binding
Prodrug design	Temporary masking of polar groups or transporter exploitation	Can improve permeability and pharmacokinetics	Requires reliable CNS conversion
Molecular conjugation	Attachment of targeting or membrane-permeable moieties	Enables selective transport	Complex synthesis and possible off-target effects
BBB-penetrating peptides	Receptor/adsorptive-mediated transport	Useful for macromolecules	Stability and specificity concerns
Efflux inhibition	Reduced active extrusion from BBB	May increase brain exposure	Possible systemic toxicity and loss of BBB protection
Carrier-mediated targeting	Utilization of endogenous influx pathways	Potentially selective transport	Transporter saturation and competition
Receptor-mediated transcytosis	Vesicular transport across endothelial cells	Applicable to biologics	Peripheral receptor expression and variable efficiency

4.3 Intranasal Drug Delivery

Intranasal or **nose-to-brain delivery** has emerged as an attractive non-invasive alternative to conventional systemic administration. The anatomical connections between the nasal cavity and CNS provide potential pathways through which drugs can reach the brain while partially bypassing the

BBB. Two major pathways are generally emphasized: the **olfactory pathway**, which connects the upper nasal cavity with the olfactory bulb, and the **trigeminal pathway**, which provides connections between nasal tissues and deeper CNS regions (Huang et al., 2024; Butola & Nainwal, 2024).

Intranasal administration can reduce hepatic first-pass metabolism, provide relatively rapid absorption, and potentially increase CNS exposure while avoiding invasive intracranial procedures. It is particularly attractive for drugs that require rapid onset or are poorly suited to oral administration. Recent studies have investigated liquid formulations, powders, microemulsions, in situ gels, mucoadhesive systems, nanoparticles, lipid nanocarriers, and other advanced formulations for improving nasal residence time and brain targeting.

Despite these advantages, the nasal route has several limitations. Mucociliary clearance can rapidly remove administered formulations, while enzymatic degradation, limited nasal surface area, poor permeability, variable deposition, and mucosal irritation may reduce effective delivery. Patient-dependent differences in nasal anatomy and administration technique can further influence dose reproducibility. Consequently, current research increasingly focuses on mucoadhesive formulations, permeation-enhancing approaches, precision nasal devices, and nanocarriers capable of protecting the drug and prolonging residence at the nasal mucosa (Huang et al., 2024; Butola & Nainwal, 2024).



Figure 4.1. Conceptual pathways for overcoming the BBB

4.4 Direct CNS Delivery Approaches

Direct CNS administration bypasses much of the BBB and can produce high drug concentrations near the intended site of action. Intracerebroventricular (ICV) administration introduces therapeutic agents directly into the ventricular system, whereas intrathecal administration delivers drugs into the CSF, usually through lumbar or other specialized access. These approaches are useful when systemic administration cannot produce sufficient CNS exposure and have particular relevance for selected biologics, antisense therapeutics, enzymes, and other macromolecules.

Intracerebral administration places the therapeutic agent directly into brain tissue and can provide highly localized delivery. Convection-enhanced delivery (CED) extends this concept by using a pressure-driven infusion system to distribute therapeutics through the extracellular space over a relatively larger volume. CED has attracted particular interest for brain tumors because systemic drug administration may produce inadequate concentrations within tumor tissue.

However, direct CNS delivery is invasive and may involve risks including infection, hemorrhage, tissue injury, catheter-related complications, inflammation, and heterogeneous drug distribution. It is therefore generally more suitable for carefully selected indications than for routine systemic therapy. The challenge is to obtain the exposure advantages of direct delivery while reducing procedural burden and neurological risk.

4.5 Temporary BBB Disruption

Rather than permanently altering BBB integrity, temporary and spatially controlled BBB opening has emerged as a promising strategy. Historically, osmotic disruption involved administration of hyperosmolar agents to alter endothelial tight-junction integrity. Although this approach demonstrated that controlled BBB opening could increase CNS drug delivery, concerns regarding nonspecific barrier disruption and associated neurological risks stimulated development of more precise technologies.

Among emerging approaches, **focused ultrasound (FUS) combined with microbubbles** has received substantial attention. Ultrasound is focused on a defined brain region while intravenously administered microbubbles interact with the acoustic field. Controlled cavitation produces mechanical effects on the cerebral microvasculature, resulting in transient increases in BBB permeability. This approach can potentially provide spatially targeted delivery while allowing the BBB to subsequently recover.

FUS-mediated BBB opening is being investigated for delivery of chemotherapeutics, antibodies, nanoparticles, and other therapeutic agents, particularly in brain tumors and neurodegenerative diseases. Nevertheless, acoustic pressure, microbubble characteristics, treatment duration, vascular condition, and target location must be carefully controlled. Excessive cavitation can cause vascular injury, hemorrhage, edema, or inflammatory responses. Consequently, the future of FUS-based delivery depends heavily on precise dosimetry, real-time monitoring, and standardized safety criteria.

Pharmacological modulation represents another potential route for transiently altering BBB permeability. However, because the BBB is fundamental to CNS protection, nonspecific pharmacological opening remains associated with considerable safety concerns. The preferred direction is therefore **reversible, localized, and minimally disruptive modulation** rather than sustained barrier breakdown.

4.6 Nanotechnology-Based BBB Transport

Nanotechnology has substantially expanded the possibilities for CNS drug delivery because nanocarriers can simultaneously modify drug solubility, stability, circulation time, cellular uptake, targeting, and release characteristics. Nanocarriers may facilitate BBB transport through passive interactions, receptor-mediated transcytosis, adsorptive mechanisms, or alternative routes such as intranasal delivery. Their surfaces can be functionalized with antibodies, peptides, proteins, carbohydrates, or other ligands to improve interaction with specific endothelial receptors (Shaw et al., 2025).

Liposomes are versatile vesicular systems capable of encapsulating hydrophilic and lipophilic compounds. Their composition can be modified to improve stability and incorporate targeting ligands. **Polymeric nanoparticles** offer controlled degradation and sustained drug release, while **solid lipid**

nanoparticles (SLNs) and **nanostructured lipid carriers (NLCs)** provide lipid-compatible platforms with potential advantages for poorly soluble drugs. Recent research has specifically explored SLNs and NLCs for intranasal nose-to-brain delivery because of their ability to improve drug stability and residence at the nasal mucosa (Zheng et al., 2024).

Dendrimers provide highly branched structures with controllable surface functionality and can be engineered for drug conjugation or targeting. Polymeric micelles are particularly useful for improving the solubility and delivery of hydrophobic molecules. Their small size and core–shell architecture also permit incorporation of targeting ligands and stimuli-responsive components.

More recently, exosomes and extracellular vesicles have attracted considerable interest as biologically derived delivery vehicles. Their natural membrane composition, endogenous cellular communication functions, and potential ability to transport proteins and nucleic acids make them attractive for CNS applications. However, challenges related to isolation, characterization, cargo loading, batch-to-batch consistency, scalability, and regulatory standardization remain significant.

Table 4.2. Nanotechnology platforms for BBB and CNS drug delivery

Nanocarrier	Key characteristics	Potential CNS application	Major limitation
Liposomes	Biocompatible vesicles; carry hydrophilic and lipophilic drugs	Targeted delivery of small molecules and biologics	Stability and rapid clearance
Polymeric nanoparticles	Controlled degradation and sustained release	Small molecules, proteins and nucleic acids	Manufacturing complexity
Solid lipid nanoparticles	Lipid matrix with good drug compatibility	CNS and intranasal delivery	Limited loading for some drugs
Nanostructured lipid carriers	Mixed lipid matrix with improved loading capacity	Nose-to-brain and systemic CNS delivery	Physical stability concerns
Dendrimers	Highly branched, multifunctional architecture	Drug and gene delivery	Potential surface-associated toxicity
Polymeric micelles	Solubilization of poorly water-soluble drugs	Hydrophobic CNS therapeutics	Dilution and structural instability
Exosomes/EVs	Naturally derived vesicles capable of molecular cargo transport	RNA, proteins and targeted therapeutics	Isolation, characterization and scale-up
Hybrid nanocarriers	Combination of multiple material properties	Multifunctional targeted delivery	Increased formulation complexity

Overall, no single BBB-penetrating strategy is universally optimal. Chemical modification may be appropriate for small molecules, transporter-based strategies can exploit endogenous biological pathways, intranasal delivery provides a non-invasive alternative route, direct CNS administration can achieve high local concentrations, and FUS offers spatially controlled temporary BBB modulation. Nanotechnology can further integrate targeting, protection, controlled release, and alternative administration routes into a single platform. Current research is therefore moving toward multimodal delivery systems in which drug chemistry, targeting ligand, carrier composition, route of administration, and BBB-modulation technology are designed as an integrated system**.**

5. Emerging and Next-Generation Strategies for CNS Drug Delivery

The limitations of conventional CNS drug delivery have encouraged the development of highly engineered systems capable of improving BBB transport, enhancing cellular specificity, protecting fragile therapeutic cargo, and providing controlled drug release. Recent advances increasingly combine nanotechnology, biomimetic materials, nucleic-acid therapeutics, focused ultrasound, artificial intelligence (AI), and stimuli-responsive materials into integrated delivery platforms. Rather than simply attempting to increase BBB permeability, next-generation approaches aim to achieve **selective transport, disease-site accumulation, intracellular delivery, and spatiotemporally controlled therapeutic action** (Shaw et al., 2025; Liu et al., 2025).

5.1 Targeted Nanocarrier Systems

Targeted nanocarriers represent an important transition from passive drug delivery toward biologically programmed CNS delivery. Nanoparticles can be functionalized with antibodies, peptides, proteins, aptamers, or other ligands that recognize receptors expressed on brain endothelial cells or diseased neural tissues. Receptor-mediated transcytosis is particularly attractive because the therapeutic carrier can bind to endogenous transport systems and undergo vesicular transport across brain endothelial cells. Commonly investigated targets include transferrin receptors, insulin receptors, low-density lipoprotein receptor-related proteins, and other endothelial transport-associated receptors (Kochman et al., 2025; Nájera-Maldonado et al., 2025).

Ligand-functionalized nanoparticles may improve brain accumulation by increasing receptor recognition while simultaneously protecting the therapeutic cargo from enzymatic degradation. Antibody-conjugated systems provide high molecular specificity, whereas short peptides can offer advantages in terms of size, synthesis, stability, and reduced immunogenicity. Peptide-mediated targeting is also useful for directing nanoparticles toward specific neural or tumor cell populations after BBB passage.

Biomimetic nanoparticles provide another level of targeting by incorporating biological membranes or membrane-derived components onto synthetic cores. Such systems can inherit biological recognition properties, improve immune evasion, and facilitate interactions with BBB endothelial cells. Recent research has emphasized the potential of erythrocyte-, platelet-, immune-cell-, stem-cell-, and tumor-cell-derived membranes for CNS delivery (Kaur et al., 2025).

An important challenge is that increased receptor affinity does not necessarily guarantee productive transcytosis. Excessive ligand density may promote endothelial retention or lysosomal degradation rather than transport into the brain parenchyma. Therefore, future targeted nanocarriers require

optimization of ligand density, particle size, surface charge, shape, stiffness, protein corona formation, and intracellular trafficking simultaneously (Nájera-Maldonado et al., 2025).

5.2 Extracellular Vesicles and Exosome-Based Delivery

Extracellular vesicles (EVs), particularly exosomes, have emerged as naturally derived nanoscale carriers for CNS therapeutics. Exosomes are membrane-enclosed vesicles containing proteins, lipids, messenger RNA, microRNA, and other biomolecules. Their endogenous biological origin provides several potentially useful properties, including biocompatibility, relatively low immunogenicity, membrane stability, and intrinsic cell-to-cell communication capacity (Mehdizadeh et al., 2025).

Exosomes may interact with BBB endothelial cells through surface proteins and receptor–ligand interactions, followed by endocytosis, intracellular trafficking, and release of their cargo. Their nanoscale dimensions and biological membrane composition can facilitate transport mechanisms that are difficult to reproduce using conventional synthetic particles. Importantly, exosomes can be engineered or loaded with small molecules, proteins, siRNA, miRNA, mRNA, and other nucleic-acid therapeutics.

Loading approaches include endogenous loading through manipulation of donor cells and exogenous techniques such as incubation, electroporation, sonication, extrusion, and membrane permeabilization. Surface engineering can additionally introduce brain-targeting peptides or other ligands, thereby converting naturally occurring vesicles into precision delivery systems.

The major limitation is manufacturing reproducibility. Exosome composition can vary according to donor-cell source, cell culture conditions, passage number, isolation method, and purification procedure. Differences in size distribution, cargo content, surface markers, and biological activity can consequently affect therapeutic performance. Large-scale production, standardized characterization, removal of contaminants, storage stability, potency testing, and regulatory definition remain important barriers to clinical translation (Mehdizadeh et al., 2025).

Table 5.1. Emerging biological and targeted platforms for CNS drug delivery

Strategy	Major principle	Potential CNS application	Key advantages	Major limitations
Receptor-targeted nanoparticles	Receptor-mediated transcytosis	Neurodegenerative diseases, brain tumors	Active BBB targeting	Receptor heterogeneity; endothelial sequestration
Ligand-functionalized nanocarriers	Ligand–receptor recognition	Targeted delivery to BBB/neural cells	Improved specificity	Ligand density and protein-corona effects
Antibody-conjugated systems	Antibody-mediated recognition	Large-molecule and biologic delivery	High molecular specificity	Size, immunogenicity, manufacturing complexity
Peptide-targeted nanoparticles	Peptide-mediated BBB transport	CNS therapeutics and imaging	Small size and flexible engineering	Variable affinity and stability

Exosomes/EVs	Natural intercellular transport	RNA, protein and drug delivery	Biocompatibility and biological functionality	Isolation, heterogeneity and scalability
Cell-membrane-coated nanoparticles	Biomimetic biological interface	Brain tumors and neurodegeneration	Immune evasion and targeting	Complex fabrication and characterization
Stem-cell-derived vesicles	Cell-derived paracrine transport	Neurorepair and neuroinflammation	Biological signaling capacity	Standardization and safety
Hybrid biomimetic carriers	Synthetic core + biological interface	Precision CNS therapy	Combines engineering and biological properties	Regulatory and manufacturing complexity

5.3 Cell-Based and Cell-Membrane-Mimicking Strategies

Cell-based delivery systems attempt to exploit the natural trafficking properties of living cells. Stem cells and immune cells can migrate toward inflammatory or injured tissues and therefore have been investigated as biological carriers for therapeutic molecules. Mesenchymal stem-cell-based systems are particularly interesting because of their tissue-homing characteristics and secretion of extracellular vesicles and neuroprotective factors.

Immune-cell-mediated delivery uses cells such as macrophages, monocytes, and neutrophils as carriers capable of interacting with inflamed or tumor-associated microenvironments. However, cell-based approaches require careful control of cell phenotype, viability, biodistribution, immunological behavior, and potential off-target effects.

A less complex alternative is the development of **cell-membrane-coated nanoparticles**, in which naturally derived membranes are integrated with synthetic nanoparticle cores. The resulting particles can retain selected membrane proteins, adhesion molecules, and recognition signals while maintaining the drug-loading and controlled-release characteristics of synthetic nanomaterials. Recent studies indicate that erythrocyte, platelet, macrophage, neutrophil, stem-cell, and tumor-cell membranes can be used for CNS-oriented biomimetic systems (Kaur et al., 2025).

These platforms are particularly promising for brain tumors, where tumor-cell or platelet-membrane characteristics may improve tumor localization, and for neuroinflammatory diseases where immune-cell-derived membranes may enhance interaction with inflamed tissue. Nevertheless, membrane extraction, preservation of membrane proteins, batch-to-batch consistency, and large-scale manufacturing remain important challenges.

5.4 Gene and RNA-Based CNS Therapeutics

Gene- and RNA-based therapeutics have expanded the therapeutic possibilities for neurological disorders because they can regulate disease-associated genes rather than simply inhibit individual proteins. However, nucleic acids are generally large, hydrophilic, negatively charged, and susceptible to enzymatic degradation, resulting in poor spontaneous BBB penetration and limited intracellular delivery (Liang et al., 2025).

siRNA can selectively silence pathogenic genes through RNA interference, whereas **miRNAs** can regulate multiple genes involved in inflammation, apoptosis, synaptic dysfunction, and neurodegeneration. **Antisense oligonucleotides (ASOs)** bind specific RNA sequences and modify RNA stability, splicing, or translation. **mRNA therapeutics** provide transient expression of therapeutic proteins and may be particularly useful when protein replacement or regenerative signaling is required.

CRISPR/Cas-based systems provide an even more powerful strategy by enabling targeted genome editing or transcriptional regulation. However, their clinical translation requires precise delivery of Cas proteins or nucleic acids to the correct CNS cell population while minimizing unwanted genomic effects.

Nanocarriers are increasingly being investigated to protect nucleic acids and facilitate BBB penetration, cellular uptake, endosomal escape, and intracellular release. Lipid nanoparticles, polymeric nanoparticles, peptide-based systems, exosomes, and programmable nucleic-acid nanomaterials are among the platforms being explored. Recent work on framework nucleic-acid nanomaterials highlights the possibility of integrating BBB penetration, cell-specific targeting, cellular uptake, and endosomal escape into a single programmable architecture (Chen et al., 2025).

A major future direction is therefore the development of **cell-specific RNA delivery**, rather than simply increasing total brain accumulation. Neurons, astrocytes, microglia, oligodendrocytes, endothelial cells, and brain tumor cells have different biological functions and molecular targets, requiring delivery systems with corresponding targeting profiles.

5.5 Focused Ultrasound and Image-Guided BBB Modulation

Focused ultrasound (FUS), particularly when combined with circulating microbubbles, provides a noninvasive method for producing temporary and spatially localized BBB opening. Ultrasound-induced microbubble oscillation generates mechanical forces at the neurovascular interface, temporarily increasing BBB permeability. After treatment, barrier integrity can return toward baseline, providing an important safety advantage over permanent BBB disruption (McMahon et al., 2021; Young et al., 2024).

The major strength of FUS is **spatial control**. Image guidance, particularly magnetic resonance guidance, can be used to identify the desired brain region and control ultrasound exposure. This creates opportunities for delivering drugs, antibodies, nanoparticles, and other therapeutic agents specifically to disease-associated regions.

FUS can also be combined with nanoparticles. In such systems, the nanoparticle provides controlled drug transport while ultrasound temporarily modifies the BBB to increase access to the target tissue. This combination may be particularly valuable for brain tumors and neurodegenerative disorders in which systemic administration is limited by poor brain exposure.

Recent clinical and translational investigations have demonstrated increasing interest in FUS-mediated BBB modulation for Alzheimer's disease, Parkinson's disease, and brain tumors. Nevertheless, optimization of acoustic parameters, microbubble characteristics, treatment frequency, opening magnitude, drug timing, and long-term safety remains necessary (Rao et al., 2024).

5.6 Artificial Intelligence and Computational BBB Drug Design

AI is emerging as a powerful tool for reducing the experimental burden associated with CNS drug development. Machine-learning models can use molecular descriptors, fingerprints, SMILES representations, physicochemical properties, and structural information to predict whether a molecule is likely to penetrate the BBB.

Traditional machine-learning approaches, including random forests, support vector machines, gradient-boosting algorithms, and quantitative structure–activity relationship models, can classify compounds according to BBB permeability. More advanced deep-learning approaches, including graph neural networks, can learn molecular representations directly from chemical structures. A 2025 meta-review concluded that traditional descriptor-based models remain competitive, whereas graph-based approaches provide considerable potential but require sufficiently large and well-curated datasets (Grant et al., 2025).

AI can also support **virtual screening**, allowing thousands or millions of compounds to be prioritized before laboratory testing. Molecular-property prediction can identify candidates with favorable molecular weight, lipophilicity, polarity, hydrogen-bonding characteristics, and transporter interactions.

Beyond small molecules, AI may increasingly contribute to nanocarrier design by predicting how particle size, shape, surface chemistry, ligand density, charge, and composition influence BBB interactions. Integration of AI with physiologically based pharmacokinetic models may further improve predictions of brain exposure and tissue distribution (Azeez & Ahn, 2025).

However, AI models remain highly dependent on the quality and representativeness of training datasets. Differences between experimental BBB models, animal studies, and human physiology can introduce significant prediction errors. Model interpretability, external validation, dataset bias, and experimental confirmation therefore remain essential.

5.7 Stimuli-Responsive Delivery Systems

Stimuli-responsive nanocarriers are designed to remain relatively stable during circulation but release their cargo when exposed to specific biological or externally applied stimuli. This approach provides an additional level of control after the carrier has reached the CNS.

pH-responsive systems exploit differences between physiological compartments and acidic intracellular or pathological environments. **Enzyme-responsive carriers** use disease-associated enzymes to trigger degradation of a carrier or cleavage of a drug–carrier linkage. **Redox-responsive systems** can respond to intracellular glutathione or other redox conditions, facilitating controlled release within target cells.

Externally activated systems provide greater temporal control. Ultrasound-responsive carriers can be activated using focused ultrasound, whereas magnetic nanoparticles can be manipulated using external magnetic fields. Light-responsive materials can provide highly localized release, although their application to deep brain tissue is limited by light penetration and may require specialized approaches.

The combination of endogenous and exogenous stimuli may produce **dual- or multi-responsive systems**, which could improve specificity by requiring more than one trigger for drug release. Recent work has emphasized pH-, redox-, enzyme-, photo-, magnetic-, and ultrasound-responsive systems for neurological disorders (Dai et al., 2025).

5.8 Emerging Biomaterials and Smart Delivery Platforms

The next generation of CNS delivery systems is increasingly moving toward multifunctional materials capable of integrating targeting, transport, imaging, protection, and controlled release into a single platform. BBB-targeting peptides can be incorporated into nanoparticles, liposomes, dendrimers, micelles, and other nanosystems to promote receptor-mediated interactions.

Self-assembling nanomaterials are particularly attractive because their architecture can form spontaneously through molecular recognition and non-covalent interactions. Framework nucleic acids represent an emerging example in which programmable molecular structures can be designed to carry therapeutic cargo while providing targeting and intracellular delivery functions (Chen et al., 2025).

Hybrid nanocarriers combine different materials—for example, lipid–polymer, polymer–inorganic, or biomaterial–nanoparticle systems—to overcome the limitations of individual components. Such systems can provide improved stability, drug loading, controlled release, targeting, and imaging.

Multifunctional **theranostic platforms** integrate therapy with diagnostic or imaging capabilities. A single carrier may therefore deliver a therapeutic molecule while simultaneously enabling fluorescence, magnetic resonance, photoacoustic, or other forms of imaging. This could permit real-time assessment of biodistribution and treatment response.

Precision-targeted CNS delivery ultimately requires integration of **material science, molecular targeting, disease biology, pharmacokinetics, imaging, and computational modeling**. Rather than developing a universal BBB-crossing nanoparticle, future systems are likely to be designed for specific diseases, brain regions, cellular targets, and therapeutic cargos. Recent reviews similarly emphasize rational nanomaterial design, biomimetic interfaces, and programmable targeting as important directions for next-generation CNS therapeutics (Nájera-Maldonado et al., 2025; Shaw et al., 2025).

Table 5.2. Smart and next-generation CNS delivery technologies

Technology	Trigger/target	Principal function	Major opportunity	Key translational challenge
AI-designed therapeutics	Molecular/biological datasets	BBB prediction and virtual screening	Faster CNS drug discovery	Dataset bias and validation
Stimuli-responsive nanoparticles	pH, enzymes, redox	Site-specific drug release	Reduced off-target exposure	Complex formulation
Ultrasound-responsive systems	Focused ultrasound	Temporally controlled delivery	Noninvasive spatial control	Acoustic optimization and safety

Magnetic nanocarriers	External magnetic field	Targeting and controlled release	Remote manipulation	Deep-tissue targeting
Light-responsive systems	Specific wavelength	On-demand release	High temporal precision	Limited tissue penetration
Self-assembling nanomaterials	Molecular interactions	Programmable carrier formation	Structural precision	Stability and manufacturing
Framework nucleic acids	Molecular recognition	Cargo transport and targeting	Programmable CNS delivery	Large-scale production
Hybrid nanocarriers	Multiple material components	Multimodal delivery	Combined functions	Complex characterization
Theranostic systems	Imaging + therapy	Simultaneous diagnosis and treatment	Treatment monitoring	Regulatory complexity
Biomimetic carriers	Biological membranes	BBB recognition and immune evasion	Improved biological compatibility	Reproducibility

Overall Perspective

The emerging CNS drug-delivery landscape is shifting from simple BBB penetration toward **precision delivery across multiple biological barriers**. Targeted nanoparticles, exosomes, biomimetic membranes, RNA-loaded nanoplatforms, FUS-mediated BBB modulation, AI-guided molecular design, and stimuli-responsive systems each address different stages of the delivery process. Their greatest potential may arise from rational combinations—for example, an AI-designed BBB-targeting ligand incorporated into a biomimetic nanoparticle carrying an RNA therapeutic and activated by focused ultrasound. Such integrated systems could provide improved brain localization, cellular specificity, controlled release, and reduced systemic toxicity.

Despite impressive preclinical progress, clinical translation remains constrained by reproducibility, manufacturing scale-up, long-term toxicity, immune responses, heterogeneous BBB physiology, insufficient human models, and uncertainty regarding quantitative brain exposure. Consequently, the future of CNS drug delivery will depend not merely on developing increasingly sophisticated carriers, but on establishing **predictable structure–transport–distribution–response relationships** that can be validated across experimental models and ultimately translated to patients.

6. Translational Perspectives, Future Directions and Conclusions

6.1 From Experimental Models to Clinical Translation

The successful development of CNS drug-delivery systems depends strongly on the ability of preclinical models to reproduce the structural, functional, and transport characteristics of the human blood–brain barrier (BBB). Conventional in vitro systems, particularly monoculture and Transwell models, remain valuable for preliminary permeability screening because they are relatively simple, inexpensive, and suitable for controlled experimental comparisons. However, they often fail to reproduce the three-dimensional architecture, physiological shear stress, cellular interactions, transporter expression, and dynamic behavior of the human neurovascular unit. Consequently,

permeability values obtained from simple models may not accurately predict human brain exposure (Vetter et al., 2025; da Silva et al., 2025).

Transwell models containing brain microvascular endothelial cells, astrocytes, and pericytes provide a more biologically relevant platform for evaluating barrier integrity, permeability, transporter activity, and nanoparticle transport. Measurements such as transepithelial electrical resistance (TEER), apparent permeability coefficient, and marker permeability can be combined to assess whether an experimental system possesses appropriate BBB characteristics. Nevertheless, the static nature of conventional Transwell systems remains a major limitation because cerebral microvessels continuously experience fluid flow and mechanical forces.

Three-dimensional spheroids and organoid-based models have therefore gained increasing attention. Human cell-derived BBB spheroids can reproduce multicellular interactions more effectively than two-dimensional cultures and may provide a useful intermediate platform for evaluating biologics and receptor-mediated transcytosis. Recent studies using human BBB spheroid models have demonstrated their applicability for screening brain-penetrant therapeutic antibodies and assessing receptor-mediated BBB transport (Ohki et al., 2026).

Microfluidic BBB-on-chip platforms represent a further advancement by incorporating controlled fluid flow, three-dimensional organization, extracellular matrices, and multiple human cell types. These systems can reproduce several physiological characteristics of the neurovascular unit and permit real-time assessment of barrier integrity and drug transport. Recent developments have positioned BBB-on-chip technologies as potentially important tools for disease modelling, drug screening, and translational research (Vetter et al., 2025; da Silva et al., 2025).

Animal models remain essential for evaluating systemic pharmacokinetics, biodistribution, toxicity, therapeutic efficacy, and interactions between the BBB and peripheral organs. However, species-specific differences in receptor expression, transporter activity, immune responses, and BBB physiology can produce major translational discrepancies. Humanized BBB models may help address some of these limitations. For example, humanized transferrin receptor 1 models have recently been developed to evaluate human-specific receptor-mediated transport and brain delivery of biologics, demonstrating the value of species-relevant models for translational CNS research (2025).

The future preclinical pipeline is therefore likely to involve a **multimodal model hierarchy**, beginning with high-throughput computational and in vitro screening, progressing through 3D and microfluidic human BBB models, and subsequently incorporating humanized animal models and carefully designed clinical studies. Integration of these complementary approaches may reduce the translational gap between experimental BBB permeability and actual human brain exposure.

6.2 Evaluation of BBB Drug Delivery

Reliable evaluation of CNS delivery requires more than demonstrating that a drug or nanocarrier can cross an artificial BBB. The central objective is to establish a quantitative relationship between **barrier transport, brain exposure, target engagement, pharmacological response, and toxicity**. In vitro permeability assays remain useful for initial screening and comparative assessment. Apparent permeability coefficients, permeability ratios, efflux ratios, and concentration-dependent transport measurements can provide information regarding passive diffusion and transporter-mediated processes.

TEER measurements are commonly used to evaluate BBB integrity in cellular models. An increase in TEER generally indicates the development of tighter intercellular junctions, whereas a reduction may indicate barrier disruption. However, TEER values cannot be interpreted independently because electrical resistance is influenced by cell type, culture conditions, membrane characteristics, temperature, and experimental configuration. Therefore, TEER should ideally be combined with paracellular marker permeability and molecular characterization of tight-junction proteins.

Transporter studies are particularly important because BBB penetration depends not only on passive permeability but also on influx and efflux systems. Transporters such as P-glycoprotein, breast cancer resistance protein, organic anion transporters, organic cation transporters, and solute carrier systems can strongly influence the concentration of therapeutics reaching the brain. A delivery system that appears permeable in a simplified model may therefore exhibit substantially different behavior in vivo.

Advanced imaging techniques can provide additional information by allowing visualization of nanoparticle localization, BBB opening, cellular uptake, and tissue distribution. Fluorescence microscopy, confocal imaging, positron emission tomography, magnetic resonance imaging, photoacoustic imaging, and intravital microscopy can be integrated with pharmacokinetic measurements to determine whether apparent brain accumulation represents genuine parenchymal delivery or simply retention within cerebral blood vessels.

Brain-to-plasma concentration ratios are frequently used as an initial indicator of CNS exposure. However, this parameter must be interpreted cautiously because whole-brain measurements may include residual blood and therefore overestimate actual parenchymal exposure. More sophisticated studies should distinguish vascular, extracellular, and intracellular compartments whenever technically feasible. Recent pharmacokinetic modelling approaches increasingly advocate integration of in vitro, in vivo, and computational data to improve prediction of CNS exposure (Tregub et al., 2025).

Ultimately, CNS delivery should be evaluated through integrated pharmacokinetic/pharmacodynamic analysis. Plasma exposure, brain exposure, target engagement, biomarker changes, therapeutic response, and adverse effects should be assessed together. Such integration is particularly important for biologics, gene therapies, nanoparticles, and BBB-modulating technologies because conventional plasma pharmacokinetics may not adequately represent therapeutic concentrations at the CNS target.

6.3 Regulatory and Manufacturing Considerations

Translation of advanced CNS delivery systems into clinical use requires reproducible manufacturing and well-defined quality attributes. Nanomedicines present particular challenges because their biological behavior can be influenced by particle size, morphology, surface charge, composition, drug loading, encapsulation efficiency, surface ligands, aggregation state, degradation products, and protein-corona formation. Small changes in manufacturing conditions may consequently alter biodistribution and therapeutic performance.

Reproducibility must therefore be considered from the earliest stages of formulation development rather than being addressed only during scale-up. Quality-by-Design (QbD) approaches can identify critical material attributes, critical process parameters, and critical quality attributes and can establish scientifically justified design spaces for manufacturing. Recent pharmaceutical nanotechnology

literature emphasizes the integration of QbD with experimental design, process optimization, characterization, and regulatory planning as an important strategy for improving commercial translation (Bhattacharya et al., 2025).

Scale-up is another major challenge. Laboratory-scale nanoparticle production may use methods that are difficult to reproduce at industrial scale. Changes in mixing, shear stress, temperature, solvent removal, filtration, sterilization, or drying conditions can influence particle characteristics and biological performance. Therefore, scalable manufacturing technologies and process analytical technologies should be incorporated early in development.

Comprehensive characterization should include particle size and size distribution, surface charge, morphology, drug content, encapsulation efficiency, release profile, chemical stability, physical stability, sterility, endotoxin levels, and degradation behavior. For targeted systems, ligand density and biological activity must also be controlled. For biologically derived systems such as extracellular vesicles, additional characterization of vesicle identity, cargo composition, purity, potency, and biological activity becomes necessary.

Toxicological assessment should extend beyond acute toxicity. Long-term accumulation, neuroinflammation, immunogenicity, complement activation, hepatic and renal clearance, reproductive effects, and potential alterations of BBB physiology require consideration. This is especially important for systems intended for repeated administration.

The translational framework for nanomedicines increasingly emphasizes simultaneous consideration of formulation design, manufacturing, preclinical evaluation, clinical development, and regulatory requirements. The DELIVER framework, for example, highlights the importance of integrating design, experimental, manufacturing, preclinical, clinical, regulatory, and business considerations rather than treating them as independent stages (2024).

6.4 Personalized and Precision CNS Drug Delivery

CNS drug delivery is moving gradually toward personalized and precision-based approaches because BBB properties are not identical among all patients. Age, genetics, disease type, disease severity, neuroinflammation, vascular pathology, prior treatment, and disease stage can influence BBB permeability and transporter activity. Consequently, a delivery system that performs well in a healthy experimental model may behave differently in patients with Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumors, stroke, or traumatic brain injury.

Patient-specific BBB characteristics could potentially be assessed through imaging, circulating biomarkers, cerebrospinal-fluid analysis, molecular profiling, and pharmacokinetic measurements. Disease-associated biomarkers may then be used to select appropriate therapeutic targets or delivery technologies. For example, changes in endothelial receptors, inflammatory mediators, transporters, or disease-associated proteins could guide the selection of receptor-targeted carriers.

Personalized nanomedicine may ultimately involve adjusting particle composition, ligand density, therapeutic dose, administration route, and treatment frequency according to individual biological characteristics. Integration of genomics, transcriptomics, proteomics, imaging, and pharmacokinetic data could help identify patients most likely to benefit from a particular BBB-targeting strategy.

The emergence of humanized BBB models provides an additional opportunity for patient-specific prediction. Human cellular systems may allow therapeutic candidates to be evaluated against receptor and transporter profiles that more closely resemble those of the intended patient population. This concept is particularly relevant for biologics targeting human receptors because receptor sequence and expression differences can limit the predictive value of conventional animal models (Ohki et al., 2026).

In the longer term, **precision CNS drug delivery may combine patient-derived cellular models, molecular biomarkers, imaging, pharmacokinetics, and computational prediction** to determine which delivery system, therapeutic cargo, dose, and administration route are most appropriate for an individual patient.

6.5 Major Research Gaps

Despite substantial progress in BBB research, important gaps remain in understanding the human barrier at molecular, cellular, and functional levels. The BBB is a dynamic component of the neurovascular unit rather than a simple endothelial wall. Differences among endothelial cells, pericytes, astrocytes, neurons, immune cells, extracellular matrix components, and transport systems must therefore be incorporated into future models.

One of the most significant challenges is the incomplete predictive value of conventional animal models. Differences between humans and experimental species can affect receptor-mediated transcytosis, transporter expression, immune responses, and nanoparticle biodistribution. The development of humanized and human-cell-based models is consequently becoming increasingly important (Ohki et al., 2026).

Standardization of BBB permeability testing also remains a major research requirement. Differences in cell source, culture conditions, membrane properties, TEER measurement procedures, permeability markers, incubation times, and data interpretation can produce substantially different outcomes between laboratories. Recent reviews of BBB-on-chip technology emphasize the need for standardized design, characterization, and validation before these platforms can become routine components of pharmaceutical development (Vetter et al., 2025; da Silva et al., 2025).

Long-term safety is another unresolved issue. Technologies that temporarily alter BBB integrity, including focused ultrasound and other barrier-modulating approaches, require extensive assessment of repeated exposure, neuroinflammation, vascular injury, hemorrhagic complications, and possible alterations of normal BBB function.

Advanced nanocarriers also face difficulties related to manufacturing complexity, batch-to-batch variation, stability, characterization, and cost. A formulation may demonstrate excellent performance in a laboratory environment but become commercially impractical because of complicated synthesis, expensive raw materials, low production yield, or difficult sterilization requirements. Recent analyses of clinical translation have emphasized that manufacturing feasibility, reproducibility, regulatory compatibility, and clinically meaningful endpoints are as important as biological performance (Wang et al., 2026).

Another major gap is the distinction between **BBB crossing and effective CNS delivery**. Detection of a therapeutic molecule in whole-brain tissue does not necessarily demonstrate delivery to the

relevant cellular compartment. Future studies should therefore prioritize quantitative assessment of vascular escape, parenchymal distribution, intracellular localization, target engagement, and pharmacological activity.

6.6 Future Perspectives

The future of CNS drug delivery is likely to depend on convergence rather than the dominance of a single delivery technology. Smart nanocarriers may integrate targeting ligands, therapeutic cargo, imaging components, and stimuli-responsive elements within a single platform. Such multifunctional systems could potentially recognize the BBB, undergo receptor-mediated transport, selectively accumulate in diseased tissue, release their cargo intracellularly, and simultaneously provide an imaging signal.

AI-driven BBB drug design is expected to become increasingly important in this development process. Machine-learning and deep-learning algorithms can evaluate molecular descriptors, chemical structures, transporter interactions, and experimental permeability data to identify compounds with favorable CNS delivery characteristics. Recent meta-analyses indicate that descriptor-based machine-learning models currently remain highly competitive, while graph neural networks and other deep-learning approaches offer opportunities for learning more complex relationships when sufficiently large datasets are available (Grant et al., 2025; Nabi et al., 2025).

Future computational systems may move beyond binary classification of compounds as BBB-permeable or BBB-impermeable. More useful models would predict quantitative brain exposure, transporter dependence, disease-specific permeability, toxicity, intracellular localization, and therapeutic response. Integration of AI with physiologically based pharmacokinetic modelling and experimental BBB platforms may further improve prediction of human CNS exposure (Tregub et al., 2025).

BBB-on-chip systems and organoid technologies may also become increasingly important as intermediate platforms between conventional cell culture and animal studies. Their ability to incorporate human cells, physiological flow, three-dimensional extracellular matrices, and disease-specific phenotypes creates opportunities for more human-relevant drug screening (Vetter et al., 2025; da Silva et al., 2025).

Another important direction is the development of disease-specific targeting rather than generic BBB penetration. The pathological brain differs substantially from the healthy brain, and disease-associated receptors, inflammatory signals, vascular changes, and extracellular matrix alterations may provide new opportunities for selective delivery. Humanized models have already demonstrated how species-specific receptor systems can be incorporated into translational drug-delivery research (2025).

Combination strategies are likely to be particularly powerful. Focused ultrasound could transiently increase BBB permeability while targeted nanoparticles provide selective delivery; AI could optimize the therapeutic molecule and nanocarrier simultaneously; and imaging could verify regional delivery in real time. Such integration could transform BBB modulation from a relatively nonspecific barrier-opening approach into a precisely controlled therapeutic intervention.

Ultimately, the field is moving toward **a** closed-loop CNS drug-delivery paradigm, in which computational design, human-relevant modelling, targeted delivery, real-time imaging,

pharmacokinetic monitoring, and therapeutic response are continuously integrated. The objective should not simply be to cross the BBB, but to deliver the right therapeutic molecule to the right cellular population, at the right concentration, for the right duration, while minimizing systemic and neurological toxicity.

6.7 Conclusion

The blood–brain barrier represents one of the most important protective interfaces of the human body while simultaneously functioning as one of the greatest obstacles to effective CNS pharmacotherapy. Its highly selective transport properties preserve cerebral homeostasis but substantially restrict the entry of many potentially valuable therapeutic molecules. Successful CNS drug development therefore requires a detailed understanding of BBB structure, transport mechanisms, disease-associated alterations, and the relationship between barrier penetration and therapeutic response.

Over the past decade, CNS drug delivery has progressed from conventional approaches based primarily on passive diffusion and direct administration toward targeted, biomimetic, multifunctional, and intelligent delivery systems. Nanoparticles, liposomes, extracellular vesicles, biologics, gene and RNA therapeutics, focused ultrasound, receptor-mediated transport, and computational technologies have expanded the possibilities for overcoming or selectively exploiting the BBB. However, biological complexity remains a major barrier to translation, and impressive preclinical permeability does not automatically translate into clinically meaningful therapeutic benefit.

Future progress will depend on integrating human-relevant experimental models, quantitative pharmacokinetics, advanced imaging, precision targeting, scalable manufacturing, computational modelling, and rigorous safety evaluation. BBB-on-chip platforms, humanized models, AI-assisted drug design, and precision nanomedicine are particularly promising because they address different components of the translational problem. Recent advances suggest that combining these technologies rather than developing them independently may provide the most effective path toward clinically useful CNS therapeutics (Wang et al., 2026; Vetter et al., 2025).

The next generation of CNS drug-delivery systems should therefore be designed around four fundamental principles: **human relevance, precision, controllability, and scalability**. A successful platform must demonstrate meaningful brain exposure, reproducible therapeutic activity, predictable pharmacokinetics, acceptable long-term safety, and practical manufacturing feasibility. With continued integration of nanotechnology, biotechnology, microphysiological systems, focused ultrasound, artificial intelligence, and precision medicine, the BBB may increasingly be viewed not merely as an obstacle to CNS drug delivery, but as a biological interface that can be selectively understood, targeted, and therapeutically exploited.

References

- Abbott, N. J., Rönnbäck, L., & Hansson, E. (2010). Astrocyte–endothelial interactions at the blood–brain barrier. *Nature Reviews Neuroscience, 11*(9), 569–581. https://doi.org/10.1038/nrn2934
- Bell, R. D. (2022). Considerations when developing blood-brain barrier crossing drug delivery technology. *Handbook of Experimental Pharmacology, 273*, 83–95. https://doi.org/10.1007/164_2021_453

- Bickel, U. (2022). Modeling blood–brain barrier permeability to solutes and drugs in vivo. *Pharmaceutics, 14*(8), 1696. https://doi.org/10.3390/pharmaceutics14081696
- Butola, M., & Nainwal, N. (2024). Non-invasive techniques of nose to brain delivery using nanoparticulate carriers: Hopes and hurdles. *AAPS PharmSciTech, 25*(8), 256. https://doi.org/10.1208/s12249-024-02946-z
- Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024). Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1870*(2), 166967. https://doi.org/10.1016/j.bbadis.2023.166967
- Chen, X., Luo, X., Yin, W., Cui, W., He, Y., Tian, T., & Lin, Y. (2025). Framework nucleic acid nanomaterials for central nervous system therapies: Design for barrier penetration, targeted delivery, cellular uptake, and endosomal escape. *ACS Nano, 19*(27), 24335–24376. https://doi.org/10.1021/acsnano.5c03945
- Cornelissen, F. M. G., Markert, G., Deutsch, G., Antonara, M., Faaij, N., Bartelink, I., Noske, D., Vandertop, W. P., Bender, A., & Westerman, B. A. (2023). Explaining blood–brain barrier permeability of small molecules by integrated analysis of different transport mechanisms. *Journal of Medicinal Chemistry, 66*(11), 7253–7267. https://doi.org/10.1021/acs.jmedchem.2c01824
- Dai, X.-J., Li, W.-J., Xie, D.-D., Liu, B.-X., Gong, L., & Han, H.-H. (2025). Stimuli-responsive nano drug delivery systems for the treatment of neurological diseases. *Small, 21*(9), e2410030. https://doi.org/10.1002/smll.202410030
- Daneman, R., & Prat, A. (2015). The blood–brain barrier. *Cold Spring Harbor Perspectives in Biology, 7*(1), a020412. https://doi.org/10.1101/cshperspect.a020412
- Deli, M. A., Porkoláb, G., Kincses, A., Mészáros, M., Szecskó, A., Kocsis, A. E., Vigh, J. P., Valkai, S., Veszelka, S., Walter, F. R., & Dér, A. (2024). Lab-on-a-chip models of the blood–brain barrier: Evolution, problems, perspectives. *Lab on a Chip, 24*, 1030–1063. https://doi.org/10.1039/D3LC00996C
- Gokce, C., Altun, B., Kirit, E., Yavuz, H., Uyar, R., Celik, D., & Yilmazer, A. (2025). Unlocking the human blood-brain barrier (BBB) characteristics for the development of nano-delivery strategies for central nervous system therapies. *Journal of Drug Delivery Science and Technology, 108*, 106961. https://doi.org/10.1016/j.jddst.2025.106961
- Grant, N., Machado Reyes, D., Yang, Z., Wan, L., Wang, C., & Yan, P. (2025). Blood brain barrier permeability prediction with artificial intelligence and machine learning: A meta-review and future directions. *Discover Artificial Intelligence, 5*, 254. https://doi.org/10.1007/s44163-025-00494-4
- Huang, Q., Chen, Y., Zhang, W., Xia, X., Li, H., Qin, M., et al. (2024). Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases. *Journal of Controlled Release*. https://doi.org/10.1016/j.jconrel.2023.12.054
- Iqbal, M. K., Khan, B., Hifsa, & YuXuan, G. (2024). The impact of the blood–brain barrier and its dysfunction in Parkinson's disease: Contributions to pathogenesis and progression. *ACS Omega, 9*(46), 45663–45678.
- Kaur, J., Thakran, A., & Naqvi, S. (2025). Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges. *Asian Journal of Pharmaceutical Sciences, 20*(4), 101060. https://doi.org/10.1016/j.ajps.2025.101060
- Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2025). Targeted nanoparticles for drug delivery across the blood–brain barrier in early and

late stages of Alzheimer's disease: A review. *Molecular Neurobiology, 63*(1), 75. https://doi.org/10.1007/s12035-025-05417-z

- Korszun-Karbowniczak, J., Krysiak, Z. J., & Saluk, J. (2024). The progress in molecular transport and therapeutic development in human blood–brain barrier models in neurological disorders. *Cellular and Molecular Neurobiology, 44*, 34.
- Lau, K., Kotzur, R., & Richter, F. (2024). Blood–brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy. *Translational Neurodegeneration, 13*, 37. https://doi.org/10.1186/s40035-024-00430-z
- Liang, F., Cui, S., Yang, J., He, Z., & Zhu, L. (2025). Nanoplatform-enabled genetic interventions for central nervous system disorders: Advances in delivery strategies and therapeutic potential. *Advanced Genetics, 6*(2), e00010. https://doi.org/10.1002/ggn2.202500010
- Liu, J., Wang, T., Dong, J., & Lu, Y. (2025). The blood–brain barriers: Novel nanocarriers for central nervous system diseases. *Journal of Nanobiotechnology, 23*, 146.
- McMahon, D., O'Reilly, M. A., & Hynynen, K. (2021). Therapeutic agent delivery across the blood–brain barrier using focused ultrasound. *Annual Review of Biomedical Engineering, 23*, 89–113. https://doi.org/10.1146/annurev-bioeng-062117-121238
- Mehdizadeh, S., Mamaghani, M., Hassanikia, S., Pilehvar, Y., & Ertas, Y. N. (2025). Exosome-powered neuropharmaceutics: Unlocking the blood-brain barrier for next-gen therapies. *Journal of Nanobiotechnology, 23*, 329. https://doi.org/10.1186/s12951-025-03352-8
- Moyer, T. C., et al. (2025). Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier. *Molecular Therapy, 33*(8), 3902–3916. https://doi.org/10.1016/j.ymthe.2025.04.046
- Nabi, A. E., Pouladvand, P., Liu, L., Hua, N., & Ayubcha, C. (2025). Machine learning in drug development for neurological diseases: A review of blood brain barrier permeability prediction models. *Molecular Informatics, 44*(3), e202400325. https://doi.org/10.1002/minf.202400325
- Nájera-Maldonado, L., et al. (2025). Cracking the blood-brain barrier code: Rational nanomaterial design for next-generation neurological therapies. *Pharmaceutics, 17*(9), 1169. https://doi.org/10.3390/pharmaceutics17091169
- Ohki, S., Fukatsu, T., Morimoto, H., Kinoshita, M., Imakiire, A., Yamamoto, R., Morio, H., Sonoda, H., & Furihata, T. (2026). Translational applicability of human blood-brain barrier spheroid models for the development of brain-penetrant therapeutic antibodies. *Fluids and Barriers of the CNS, 23*, 30. https://doi.org/10.1186/s12987-025-00752-8
- Pardridge, W. M. (2012). Drug transport across the blood–brain barrier. *Journal of Cerebral Blood Flow & Metabolism, 32*(11), 1959–1972. https://doi.org/10.1038/jcbfm.2012.126
- Pawar, B., Vasdev, N., Gupta, T., Mhatre, M., More, A., Anup, N., & Tekade, R. K. (2022). Current update on transcellular brain drug delivery. *Pharmaceutics, 14*(12), 2719. https://doi.org/10.3390/pharmaceutics14122719
- Pedder, J. H., Sonabend, A. M., Cearns, M. D., Michael, B. D., Zakaria, R., Heimberger, A. B., Jenkinson, M. D., & Dickens, D. (2025). Crossing the blood–brain barrier: Emerging therapeutic strategies for neurological disease. *The Lancet Neurology, 24*(3), 246–260. https://doi.org/10.1016/S1474-4422(24)00476-9
- Pineda-Pardo, J. A., et al. (2024). The road ahead to successful BBB opening and drug-delivery with focused ultrasound. *Journal of Controlled Release*. https://doi.org/10.1016/j.jconrel.2024.07.006

- Sahoo, S. K., et al. (2024). *Recent approaches to chemical and molecular strategies for improving blood–brain barrier transport*.
- Shaw, T. K., et al. (2025). Cutting-edge strategies for delivering drugs to the brain based on nanocarriers. *Drug Development and Industrial Pharmacy, 51*(12), 1625–1638. https://doi.org/10.1080/03639045.2025.2555858
- Singh, S. A., & Vellapandian, C. (2023). Structure of the blood brain barrier and its role in the transporters for the movement of substrates across the barriers. *Current Drug Metabolism, 24*(4), 250–269. https://doi.org/10.2174/1389200224666230608110349
- Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2018). Blood–brain barrier: From physiology to disease and back. *Physiological Reviews, 99*(1), 21–78. https://doi.org/10.1152/physrev.00050.2017
- Tregub, P. P., Bystrov, D. A., Kushnir, I. A., Korsakova, S. A., Yurchenko, S. O., & Salmina, A. B. (2025). Blood-brain barriers and drug pharmacokinetics: Mechanisms and models. *European Journal of Pharmacology, 1003*, 177872. https://doi.org/10.1016/j.ejphar.2025.177872
- van Hameren, G., Aboghazleh, R., Parker, E., Dreier, J. P., Kaufer, D., Friedman, A., et al. (2024). From spreading depolarization to blood–brain barrier dysfunction: Navigating traumatic brain injury for novel diagnosis and therapy. *Nature Reviews Neurology, 20*, 408–425.
- Vetter, J., Palagi, I., Waisman, A., & Blaeser, A. (2025). Recent advances in blood-brain barrier-on-a-chip models. *Acta Biomaterialia, 197*, 1–28. https://doi.org/10.1016/j.actbio.2025.03.041
- Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026). Clinical translation of nanomedicines for brain diseases: Current challenges and future directions. *Journal of Controlled Release, 389*, 114426. https://doi.org/10.1016/j.jconrel.2025.114426
- Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023). The blood–brain barrier: Structure, regulation and drug delivery. *Signal Transduction and Targeted Therapy, 8*, 217. https://doi.org/10.1038/s41392-023-01481-w
- Wu, Y.-C., Bogale, T. A., Koistinaho, J., Pizzi, M., Rolova, T., & Bellucci, A. (2024). The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders. *Acta Neuropathologica, 147*, 39.
- Yin, P., & Wang, X. (2024). Progresses in the establishment, evaluation, and application of *in vitro* blood–brain barrier models. *Journal of Neuroscience Research, 102*(6), e25359. https://doi.org/10.1002/jnr.25359
- Yu, X. P., Chen, Z. Y., et al. (2025). Blood–brain barrier (BBB) dysfunction in CNS diseases: Paying attention to pericytes. *CNS Neuroscience & Therapeutics*. https://doi.org/10.1111/cns.70422
- Young, C. M., Viña-González, A., Salmeron de Toledo Aguiar, R., Kalman, C., Pilitsis, J. G., Martin-Lopez, L. I., Mahani, T., & Pineda-Pardo, J. A. (2024). A scoping review of focused ultrasound enhanced drug delivery across the blood-brain barrier for brain tumors. *Operative Neurosurgery, 27*(5), 523–532. https://doi.org/10.1227/ONS.0000000000001175
- Zhao, Y., Gan, L., Ren, L., Lin, Y., Ma, C., & Lin, X. (2022). Factors influencing the blood-brain barrier permeability. *Brain Research, 1788*, 147937. https://doi.org/10.1016/j.brainres.2022.147937
- Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015). Establishment and dysfunction of the blood–brain barrier. *Cell, 163*(5), 1064–1078. https://doi.org/10.1016/j.cell.2015.10.067

- Zheng, Y., Cui, L., Lu, H., Liu, Z., Zhai, Z., Wang, H., Shao, L., Lu, Z., Song, X., & Zhang, Y. (2024). Nose to brain: Exploring the progress of intranasal delivery of solid lipid nanoparticles and nanostructured lipid carriers. *International Journal of Nanomedicine, 19*, 12343–12368. https://doi.org/10.2147/IJN.S497480
- Zierfuss, B., Prat, A., et al. (2024). Blood–brain barrier dysfunction in multiple sclerosis: Causes, consequences, and potential effects of therapies. *The Lancet Neurology*. https://doi.org/10.1016/S1474-4422(23)00377-0

Chapter 2: Nanotechnology-Based Drug Delivery Systems for Neurological Disorders: Recent Advances

Bhavana Singh[*1], Amisha Varshney[2], Chayanika Bordoloi[3], Minal Chetan Solanki[4], Soumya Tripathi[5]

[1]Assistant Professor, School of Pharmacy, Sharda University, Plot No. 32,34, Knowledge Park-III, Greater Noida, Uttar Pradesh, India.

[2]Assistant Professor, School of Pharmaceutical Sciences, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, India.

[3]Assistant Professor (Senior), Department of Pharmaceutical Sciences, Institute of Pharmacy, Assam Don Bosco University, Tapesia Campus, Kamarkuchi, Sonapur 782402, Guwahati, Assam, India.

[4]Assistant Professor, Department of Pharmaceutics, JSPMs Rajarshi Shahu College of Pharmacy and Research, Pune, Maharashtra, India.

[5]Assistant Professor, Department of Pharmacy, Noida Institute of Engineering and Technology (Pharmacy), Knowledge Park-2, Greater Noida, Uttar Pradesh, India.

*Corresponding Author: Bhavana Singh, Assistant Professor, School of Pharmacy, Sharda University, Plot No. 32,34, Knowledge Park-III, Greater Noida, Uttar Pradesh, India.

Abstract

Neurological disorders remain a major global health challenge because effective treatment is frequently limited by poor drug solubility, rapid metabolism, systemic toxicity, inefficient brain accumulation, and the restrictive blood–brain barrier (BBB). Nanotechnology-based drug delivery systems have emerged as promising platforms for overcoming these limitations by enabling controlled drug release, improved stability, enhanced BBB penetration, targeted cellular delivery, and combination therapy. This chapter provides an overview of recent advances in nanotechnology-based approaches for neurological disorders, including lipid-based nanoparticles, polymeric nanoparticles, micelles, dendrimers, inorganic and hybrid nanocarriers, nanogels, nanoemulsions, exosomes, and biomimetic systems. Advanced BBB-targeting strategies, including receptor-mediated transport, cell-penetrating peptides, intranasal delivery, stimuli-responsive systems, and focused ultrasound-assisted delivery, are also discussed. Applications in Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, stroke, brain tumors, CNS infections, and other neurological disorders are highlighted. Particular emphasis is placed on next-generation approaches involving gene and RNA delivery, lipid nanoparticles, exosome engineering, nanotheranostics, multifunctional nanoplatforms, AI-assisted design, and neuroregenerative nanomaterials. Finally, nanotoxicology, pharmacokinetics, preclinical models, manufacturing, regulatory requirements, and clinical translation are considered. Continued integration of precision targeting, advanced biological models, artificial intelligence, and personalized medicine may accelerate the development of safer and more effective nanotherapeutics for neurological diseases.

Keywords: Nanotechnology; CNS drug delivery; neurological disorders; blood–brain barrier; nanoparticles; lipid nanoparticles; polymeric nanocarriers; exosomes; RNA delivery; nanotheranostics; precision nanomedicine; neuroregeneration.

1. Introduction to Neurological Disorders and Nanotechnology-Based Drug Delivery

Neurological disorders represent a diverse group of diseases affecting the central and peripheral nervous systems and include neurodegenerative, cerebrovascular, inflammatory, neoplastic, infectious, and seizure-related conditions. Alzheimer's disease (AD) and Parkinson's disease (PD) are among the most prominent neurodegenerative disorders and are characterized by progressive neuronal dysfunction and loss. Epilepsy is associated with recurrent seizures, whereas multiple sclerosis involves immune-mediated damage to the central nervous system. Stroke produces acute neurological injury through disruption of cerebral blood flow, while primary and metastatic brain tumors cause neurological dysfunction through uncontrolled cellular proliferation and tissue invasion. In addition, neuromuscular diseases and CNS infections contribute substantially to neurological morbidity and mortality worldwide (Feigin et al., 2020; World Health Organization [WHO], 2024). The clinical diversity and complex pathological mechanisms of these disorders create significant challenges for developing effective therapies.

The global burden of neurological disorders has increased considerably because of population ageing, longer life expectancy, environmental influences, and improved disease recognition. Neurological conditions contribute substantially to mortality, disability, cognitive impairment, loss of independence, and healthcare expenditure. Neurodegenerative diseases are particularly challenging because neuronal damage is often progressive and irreversible, while available treatments frequently provide symptomatic benefits without completely modifying the underlying disease process (Feigin et al., 2020). Conventional pharmacotherapy is further limited by poor drug solubility, inadequate bioavailability, rapid systemic elimination, enzymatic degradation, and difficulty maintaining therapeutic concentrations within the brain. These limitations highlight the need for delivery approaches capable of improving drug stability, localization, and therapeutic exposure.

One of the most important obstacles to CNS drug delivery is the blood–brain barrier (BBB), a highly specialized physiological interface that regulates the movement of substances between the systemic circulation and brain tissue. The BBB is primarily formed by brain microvascular endothelial cells connected by tight junctions and supported by pericytes, astrocytic end-feet, and the surrounding extracellular matrix. This neurovascular unit provides essential protection against potentially harmful substances while maintaining cerebral homeostasis (Daneman & Prat, 2015). However, its restrictive nature prevents many therapeutic molecules, particularly large, hydrophilic, and highly polar compounds, from reaching effective concentrations in the brain. Efflux transporters such as P-glycoprotein and breast cancer resistance protein further restrict the accumulation of many drugs within CNS tissues (Zhang et al., 2021). Although disease-associated alterations in BBB integrity may increase permeability in some neurological conditions, such changes are heterogeneous and cannot reliably be exploited for therapeutic delivery.

Nanotechnology has emerged as a promising strategy for overcoming several limitations associated with conventional CNS drug delivery. Nanocarriers can improve the apparent solubility, stability, bioavailability, and pharmacokinetic characteristics of poorly soluble or rapidly degraded therapeutic agents. Their physicochemical properties, including particle size, surface charge, composition, morphology, and surface functionality, can be engineered to influence biological distribution and cellular uptake. Nanoparticles can also provide controlled and sustained drug release, potentially reducing dosing frequency and fluctuations in systemic drug concentrations (Patel et al., 2018). Importantly, surface modification with specific ligands, peptides, antibodies, or biomimetic

components may facilitate receptor-mediated transport across the BBB and enhance accumulation in particular brain regions or cell populations.

The rationale for applying nanotechnology to neurological disorders therefore extends beyond simple drug encapsulation. Appropriately designed nanocarriers may combine drug protection, controlled release, BBB interaction, cellular targeting, and reduced peripheral exposure within a single delivery platform. Liposomes, lipid nanoparticles, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, micelles, nanogels, inorganic nanoparticles, exosomes, and hybrid nanocarriers are being investigated for the delivery of small molecules, proteins, peptides, nucleic acids, and combination therapeutics (Saraiva et al., 2016; Patra et al., 2018). Intranasal nanodelivery has also attracted considerable attention because it provides a potential nose-to-brain pathway that may partially bypass the BBB and facilitate direct access to CNS tissues (Lochhead & Thorne, 2012).

Recent developments have shifted the field toward multifunctional and disease-specific nanomedicine platforms. These include receptor-targeted nanoparticles, stimuli-responsive systems, exosome-based carriers, lipid nanoparticles for RNA delivery, magnetic nanoparticles, and nanotheranostic platforms capable of integrating diagnosis with therapy. Nanotechnology is also increasingly being combined with focused ultrasound, gene therapy, RNA therapeutics, imaging technologies, and regenerative medicine. Such approaches offer opportunities for precision drug delivery in complex neurological disorders; however, challenges related to nanotoxicity, long-term accumulation, reproducibility, manufacturing, regulatory approval, and clinical translation remain important. Overall, nanotechnology provides a versatile platform for improving CNS drug delivery and represents an important direction for the development of more effective, targeted, and personalized neurological therapeutics.

2. Major Nanotechnology-Based Drug Delivery Systems for Neurological Disorders

Nanotechnology-based drug delivery systems encompass a broad range of engineered and biologically derived carriers designed to improve drug stability, solubility, brain exposure, cellular uptake, and therapeutic specificity. Their performance depends strongly on particle size, morphology, surface charge, composition, drug-loading capacity, and surface functionalization. Different nanocarriers offer distinct advantages; therefore, selection of an appropriate platform depends on the physicochemical properties of the therapeutic molecule, intended route of administration, neurological pathology, and desired release profile (Patel et al., 2023).

2.1 Lipid-Based Nanocarriers

Lipid-based nanocarriers are among the most extensively investigated platforms for CNS drug delivery because of their biocompatibility and ability to incorporate both hydrophilic and lipophilic therapeutic agents. Liposomes consist of phospholipid bilayers surrounding an aqueous core and can encapsulate a wide range of molecules. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) provide improved physical stability and controlled release, while NLCs generally offer greater drug-loading capacity because of their combination of solid and liquid lipids. Lipid nanoparticles (LNPs) have gained particular importance for nucleic-acid delivery because their composition can protect fragile cargos and facilitate intracellular delivery. Surface modification with polyethylene glycol (PEG) or targeting ligands can alter circulation time, reduce nonspecific interactions, and improve interactions with BBB-associated transport mechanisms (Khan et al., 2022;

Mura et al., 2022). Nevertheless, lipid systems may experience problems such as physical instability, oxidation, drug leakage, and challenges associated with large-scale manufacturing. Recent work continues to explore lipid nanostructures for both systemic and nose-to-brain delivery of neurological therapeutics.

2.2 Polymeric Nanoparticles

Polymeric nanoparticles provide considerable flexibility in controlling drug encapsulation, degradation, surface characteristics, and release kinetics. Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), and chitosan have been investigated for CNS applications. PLGA-based systems are particularly attractive because their degradation can be adjusted through polymer composition and molecular characteristics. Chitosan additionally provides mucoadhesive properties and is therefore relevant to intranasal delivery. PEGylation can improve colloidal stability and alter biological interactions, while combinations of natural and synthetic polymers can provide complementary properties. Polymeric nanoparticles are also increasingly investigated through the nose-to-brain pathway, where nanoscale formulations may improve residence time at the nasal mucosa and enhance brain bioavailability (Agrahari et al., 2023).

2.3 Polymeric Micelles and Dendritic Nanocarriers

Polymeric micelles are self-assembled nanostructures consisting of hydrophobic and hydrophilic domains and are particularly useful for solubilizing poorly water-soluble drugs. Their small size and modifiable surfaces make them attractive for CNS delivery, especially when combined with intranasal administration or active targeting. Dendrimers, including polyamidoamine (PAMAM) systems, possess highly branched and structurally defined architectures with numerous surface functional groups. These characteristics allow drug conjugation, encapsulation, and attachment of targeting ligands. Dendrimers have consequently been investigated for transporting small molecules, nucleic acids, and anti-inflammatory or neuroprotective agents to the brain. Their major limitations include possible generation-dependent toxicity, surface-charge-associated cellular interactions, and the requirement for careful control of formulation characteristics (Kaur et al., 2023).

2.4 Inorganic and Hybrid Nanocarriers

Inorganic nanomaterials provide properties that are difficult to obtain with conventional organic carriers. Gold nanoparticles offer optical and photothermal properties, whereas iron oxide nanoparticles provide magnetic responsiveness and can support both imaging and drug delivery. Mesoporous silica nanoparticles (MSNs) possess tunable pore structures, high surface areas, and modifiable surfaces, enabling efficient drug loading and controlled release. They have been explored for Alzheimer's disease, Parkinson's disease, epilepsy, brain tumors, and other neurological conditions (Attia et al., 2023). Magnetic iron oxide nanoparticles are particularly relevant to theranostics because their magnetic properties can be exploited for MRI, magnetic targeting, and controlled therapeutic delivery (Chen et al., 2023). Quantum dots and other inorganic nanostructures may provide additional imaging capabilities, although concerns regarding long-term accumulation and material-associated toxicity remain important. Hybrid organic–inorganic systems attempt to combine the drug-loading and biocompatibility advantages of organic carriers with the optical, magnetic, or structural properties of inorganic materials (Tan et al., 2023).

2.5 Nanogels and Nanoemulsion-Based Systems

Nanogels are three-dimensional nanoscale polymeric networks capable of incorporating substantial quantities of therapeutic molecules while providing controlled and sometimes stimuli-responsive release. Their hydrated structure can be advantageous for transporting proteins, peptides, nucleic acids, and small molecules. Nanoemulsions provide another useful platform for improving the solubility and bioavailability of poorly water-soluble compounds. Intranasal nanoemulsions are particularly attractive because the olfactory and trigeminal pathways can provide a potential route for transporting therapeutics toward the brain while avoiding some limitations of systemic BBB delivery. Formulation variables such as droplet size, surfactant composition, mucoadhesion, and viscosity influence nasal residence and drug transport (Sharma et al., 2023).

2.6 Exosome-Based and Biomimetic Nanocarriers

Exosomes and other small extracellular vesicles represent naturally derived nanoscale delivery systems with intrinsic biological properties. Their membrane composition, cellular origin, and natural intercellular communication functions can facilitate cellular uptake and interaction with biological barriers. Evidence suggests that exosomes can interact with and cross the BBB, although the precise mechanisms and determinants of transport remain incompletely understood (Zhang et al., 2023). Therapeutic cargos including small molecules, proteins, and nucleic acids can be loaded into exosomes, while surface engineering may improve tissue-specific targeting. Cell-membrane-coated nanoparticles and other biomimetic systems similarly attempt to reproduce natural biological interactions while retaining the controlled formulation characteristics of synthetic nanoparticles. These systems may provide improved immune compatibility and BBB interaction, but heterogeneity, isolation procedures, scalability, cargo loading, and regulatory standardization remain significant barriers to translation (Yadav et al., 2024).

Table 2.1. Major Nanocarrier Platforms for CNS Drug Delivery

Nanocarrier	Major characteristics	Principal advantages	Important limitations
Liposomes	Phospholipid bilayer with aqueous core	Versatile drug loading, biocompatibility, surface modification	Leakage, oxidation, stability
SLNs/NLCs	Solid or mixed lipid matrix	Controlled release, improved stability	Limited loading for some drugs, polymorphic changes
LNPs	Ionizable/structural lipid-based systems	Excellent nucleic-acid delivery potential	Formulation complexity, stability concerns
Polymeric nanoparticles	Biodegradable polymer matrix	Controlled degradation and release	Polymer-associated toxicity and scale-up issues
Micelles	Amphiphilic self-assembled structures	Solubilization of poorly soluble drugs	Possible dilution-related instability
Dendrimers	Highly branched polymers	High functional-group density and targeting potential	Surface-charge-related toxicity
Inorganic nanoparticles	Gold, silica, iron oxide, etc.	Imaging, magnetic/optical	Persistence and toxicity concerns

		functions	
Nanogels/nanoemulsions	Hydrated networks or dispersed droplets	Controlled release and intranasal potential	Physical stability and formulation sensitivity
Exosomes/biomimetic carriers	Biological or bio-inspired vesicles	Biocompatibility and natural cellular interactions	Heterogeneity, isolation and standardization

2.7 Comparative Evaluation of Nanocarrier Platforms

No single nanocarrier is universally optimal for neurological drug delivery. Particle size and surface charge influence circulation, cellular uptake, and interaction with the BBB, whereas encapsulation efficiency and drug-loading capacity determine the amount of therapeutic payload that can be delivered. Biocompatibility and biodegradability are especially important for chronic neurological diseases requiring prolonged treatment. Targeting efficiency should be evaluated not only by total brain accumulation but also by the ability of the nanocarrier to reach the desired cell type or pathological region. Translational potential additionally depends on reproducible manufacturing, storage stability, sterilization, scalability, toxicity, and regulatory feasibility.

Table 2.2. Key Parameters for Comparative Evaluation of CNS Nanocarriers

Parameter	**Importance in CNS delivery**
Particle size	Influences biodistribution, cellular uptake, and barrier interaction
Surface charge	Affects stability, protein adsorption, cellular interaction, and toxicity
Encapsulation efficiency	Determines the proportion of drug successfully incorporated
Drug-loading capacity	Determines therapeutic payload per unit carrier
Release profile	Controls duration and consistency of drug exposure
BBB penetration	Determines potential brain accessibility
Targeting efficiency	Indicates selective delivery to brain cells or pathological sites
Biocompatibility	Essential for minimizing immune and neurological toxicity
Translational potential	Depends on scalability, reproducibility, stability, and regulatory feasibility

3. Advanced Strategies for BBB Penetration and Targeted Brain Delivery

The restrictive nature of the blood–brain barrier (BBB) remains one of the major obstacles to achieving therapeutically relevant concentrations of drugs in the CNS. Recent nanomedicine strategies therefore focus not only on producing nanoscale carriers but also on engineering their surface, transport mechanism, administration route, and responsiveness to disease-associated stimuli. These approaches include receptor-mediated transport, cell-penetrating peptides, nose-to-brain delivery, stimuli-responsive systems, and externally controlled BBB modulation. Such strategies can potentially improve brain accumulation while reducing peripheral exposure and nonspecific toxicity (Moreira et al., 2024).

3.1 Mechanisms of Nanoparticle Transport Across the BBB

Nanoparticles can interact with the BBB through several mechanisms depending on their size, surface characteristics, composition, and targeting ligands. Very small and appropriately lipophilic molecules

may undergo passive diffusion, whereas nanoparticles generally require vesicular or carrier-associated mechanisms. Adsorptive-mediated transcytosis (AMT) can occur when positively charged nanoparticles interact electrostatically with the negatively charged endothelial surface. Cell-penetrating peptides such as TAT can enhance this process and increase endothelial and neuronal uptake (Kumar et al., 2024). Receptor-mediated transcytosis (RMT) uses endogenous BBB transport receptors, including transferrin receptor, insulin receptor, and low-density lipoprotein receptor-related protein 1 (LRP1), to shuttle functionalized nanoparticles across endothelial cells. Carrier-mediated transport can exploit nutrient transport systems, while cell-mediated transport may involve macrophages or other carrier cells. Under pathological conditions, BBB integrity may become compromised, increasing paracellular permeability; however, uncontrolled barrier disruption may also increase neuroinflammation and toxicity.

Table 3.1. Major Mechanisms for Nanoparticle Transport Across the BBB

Transport mechanism	Principal feature	Nanomedicine application
Passive diffusion	Movement across lipid membranes	Small lipophilic molecules
Adsorptive-mediated transcytosis	Electrostatic interaction with endothelial surface	Cationic nanoparticles and CPP-functionalized systems
Receptor-mediated transcytosis	Receptor–ligand interaction	Transferrin, insulin, Angiopep-2
Carrier-mediated transport	Utilization of endogenous nutrient transporters	Glucose and amino-acid transporter targeting
Cell-mediated transport	Cellular carriers transport therapeutic cargo	Immune-cell and biomimetic delivery
Paracellular transport	Passage through compromised tight junctions	Mainly relevant to pathological BBB conditions

3.2 Surface Functionalization and Ligand-Mediated Targeting

Surface functionalization provides a major strategy for converting nonspecific nanoparticles into actively targeted systems. **Transferrin/transferrin-receptor targeting** exploits the high expression of transferrin receptors on brain endothelial cells and can facilitate RMT. Lactoferrin is another promising ligand because it can interact with receptors involved in BBB transport and may provide additional biological effects. **Angiopep-2**, a peptide targeting LRP1, has received substantial attention because LRP1 participates in transcytosis at the BBB and is also relevant to brain tumor targeting. Other approaches exploit glucose transport pathways such as GLUT1 or insulin receptors. Antibodies, aptamers, peptides, and small molecules can further provide cell-specific targeting toward neurons, astrocytes, microglia, or tumor cells (Moreira et al., 2024; Piper et al., 2024). However, receptor targeting must be carefully optimized because excessive ligand density may increase endothelial retention rather than productive transcytosis.

3.3 Cell-Penetrating Peptides and Brain-Penetrating Ligands

Cell-penetrating peptides (CPPs) provide another route for enhancing cellular internalization and BBB transport. **TAT**, derived from HIV-1 transactivator protein, is one of the most extensively studied CPPs and can facilitate the intracellular delivery of proteins, nucleic acids, and nanoparticles. **RGD peptides** interact primarily with integrin receptors and have been investigated for BBB and glioma targeting. **RVG-derived peptides** possess neuronal targeting properties through interactions with

nicotinic acetylcholine receptor-associated pathways and have been explored for delivery of nucleic acids and nanoparticles. Other BBB-penetrating peptides are being identified through phage display, computational screening, and molecular engineering. Recent research emphasizes that successful BBB penetration depends on peptide size, charge, hydrophobicity, receptor interaction, and cellular trafficking rather than simply membrane penetration ability (Castanho et al., 2024). Thus, rational peptide selection and controlled surface density are important for achieving efficient brain delivery.

3.4 Intranasal Nanotechnology-Based Drug Delivery

Intranasal administration represents an attractive non-invasive strategy for CNS delivery because it can exploit the anatomical connections between the nasal cavity and brain. Nanotherapeutics may access the CNS through the olfactory and trigeminal pathways, potentially reducing dependence on systemic BBB transport. Nanoparticles, liposomes, micelles, nanostructured lipid carriers, and nanoemulsions can improve drug retention, protect unstable molecules, and enhance transport across the nasal mucosa. Mucoadhesive polymers may prolong residence time and increase contact with the absorption surface. Recent evidence indicates that nanoparticle properties strongly influence interaction with the nose-to-brain pathway and consequently affect brain distribution (Xu et al., 2024). Despite these advantages, intranasal delivery can be affected by mucociliary clearance, limited administration volume, enzymatic degradation, nasal irritation, and variability in deposition. Therefore, formulation design and device optimization remain essential.

3.5 Stimuli-Responsive Nanocarriers

Stimuli-responsive nanocarriers are designed to release their payload in response to specific endogenous or externally applied triggers**.** pH-responsive systems can exploit differences between physiological, endosomal, and pathological environments, whereas enzyme-responsive carriers can respond to disease-associated proteases. Redox-responsive systems commonly use cleavable chemical linkages that respond to intracellular reducing conditions, while ROS-responsive systems may exploit elevated oxidative stress associated with neuroinflammation and neurodegeneration. Temperature-responsive materials can release drugs following local heating, whereas light-, magnetic-, and ultrasound-responsive systems allow externally controlled drug release. These approaches provide the possibility of spatially and temporally regulated therapy while minimizing premature drug release. Stimuli-responsive nanomaterials have increasingly been investigated for neurological disorders and brain tumors (Chen et al., 2024).

3.6 Externally Assisted Brain Delivery

External physical technologies can complement nanocarriers by transiently modifying the BBB or controlling nanoparticle localization. **Focused ultrasound (FUS)** combined with circulating microbubbles can produce localized and reversible BBB opening through controlled acoustic effects. This approach can temporarily increase vascular permeability and facilitate delivery of therapeutic molecules, antibodies, genes, and nanomedicines into predefined brain regions. Recent clinical investigations have examined FUS-mediated BBB opening in neurodegenerative diseases and brain tumors, although treatment parameters, safety, monitoring, and reproducibility require further optimization (Piper et al., 2024; Young et al., 2024). Magnetic nanoparticles provide another externally controlled strategy in which an applied magnetic field can influence nanoparticle localization and, in some systems, support imaging or magnetically induced therapeutic effects. Photothermal and photodynamic approaches can similarly combine nanomaterials with light-

responsive mechanisms, particularly for tumor therapy, although limited tissue penetration of light remains an important consideration.

3.7 Disease-Specific Targeting of Pathological Brain Regions

Precision nanomedicine increasingly aims to target pathological structures rather than simply increasing total brain accumulation. In **Alzheimer's disease**, nanocarriers can be engineered toward amyloid-β aggregates, tau-associated pathology, activated microglia, or other disease-associated targets. In Parkinson's disease, targeting strategies may focus on dopaminergic neurons and pathological α-synuclein-associated processes. For glioblastoma, nanoparticles can be functionalized with ligands recognizing receptors expressed by tumor cells or the tumor microenvironment, while stimuli-responsive systems can exploit tumor-associated pH, enzymes, hypoxia, or redox conditions (Gao et al., 2024). In ischemic stroke, targeting inflammatory endothelium, ischemic tissue, or activated immune cells may improve localized therapy. Similarly, neuroinflammatory lesions associated with multiple sclerosis and other inflammatory CNS disorders provide opportunities for cell-specific nanocarrier targeting. Such disease-specific approaches could improve therapeutic precision by combining BBB crossing + pathological-site recognition + controlled intracellular drug release**.**

Overall, advanced BBB-penetrating strategies are moving CNS nanomedicine from nonspecific brain accumulation toward receptor-selective, cell-specific, disease-responsive, and externally controlled delivery**.** The combination of nanocarriers with biological targeting ligands, intranasal administration, stimuli responsiveness, and FUS may provide complementary solutions to the BBB problem, although clinical translation requires careful evaluation of safety, reproducibility, targeting efficiency, and long-term effects.

4. Nanotechnology Applications in Major Neurological Disorders

Nanotechnology has expanded the therapeutic possibilities for neurological disorders by enabling improved drug solubility, protection of unstable molecules, controlled release, BBB interaction, and targeting of pathological cells or tissues. Importantly, the optimal nanocarrier differs according to disease pathology; for example, amyloid and tau pathology in Alzheimer's disease requires a different targeting strategy from dopaminergic neuronal loss in Parkinson's disease or the infiltrative tumor microenvironment of glioblastoma. Recent research therefore emphasizes disease-specific nanocarriers capable of combining therapeutic delivery with targeting, imaging, and, in some cases, regenerative functions (Mitchell et al., 2021).

4.1 Alzheimer's Disease

Alzheimer's disease (AD) is characterized by progressive cognitive decline and pathological accumulation of amyloid-β and hyperphosphorylated tau, accompanied by oxidative stress, neuroinflammation, synaptic dysfunction, and neuronal loss. Nanotechnology offers opportunities to improve delivery of anti-amyloid and anti-tau therapeutics that otherwise exhibit poor brain penetration. Functionalized nanoparticles have been investigated for transporting antibodies, peptides, small molecules, and nucleic acids toward pathological brain regions. Nanocarriers containing antioxidants and anti-inflammatory agents may additionally reduce oxidative damage and microglial activation. Delivery of cholinesterase inhibitors through lipidic or polymeric nanoparticles can

improve drug stability and potentially prolong CNS exposure. RNA-based nanotherapeutics, including siRNA and miRNA delivery systems, are also being investigated for regulating genes associated with amyloid processing, tau phosphorylation, inflammation, and neuronal survival (Saber et al., 2023). Thus, multifunctional nanocarriers may simultaneously address several interconnected pathological mechanisms.

4.2 Parkinson's Disease

Parkinson's disease (PD) involves degeneration of dopaminergic neurons in the substantia nigra and subsequent disruption of dopamine-dependent motor pathways. Nanocarriers may improve the delivery of dopamine, levodopa-related therapeutics, dopamine agonists, and neuroprotective compounds while reducing premature degradation and peripheral adverse effects. Nanoparticle-mediated delivery of antioxidants may counteract oxidative stress, while targeted systems are being explored for modulating α-synuclein aggregation and clearance. Polymeric and lipid nanocarriers have also been investigated for delivering genes, proteins, and neurotrophic factors to dopaminergic neurons. Such approaches are particularly relevant because conventional dopamine replacement does not directly prevent progressive neuronal degeneration. Recent advances in nanomedicine are therefore moving toward combined symptomatic, neuroprotective, and disease-modifying strategies (Rashid et al., 2023).

4.3 Epilepsy

Epilepsy presents a major challenge for drug delivery because recurrent seizures may involve altered BBB permeability, neuroinflammation, neuronal hyperexcitability, and changes in drug transporter expression. Nanocarriers can improve the brain delivery of antiepileptic drugs while providing sustained release and reducing fluctuations in drug concentrations. Importantly, overexpression of efflux transporters such as P-glycoprotein may contribute to pharmacoresistance, making transporter-aware nanocarrier design particularly relevant. Liposomes, polymeric nanoparticles, solid lipid nanoparticles, and nanogels have been investigated for enhancing brain accumulation and prolonging therapeutic exposure. Region-specific delivery toward epileptogenic areas may further improve efficacy while minimizing systemic exposure. Nanotechnology may therefore be particularly valuable for drug-resistant epilepsy, although clinical translation requires stronger evidence regarding long-term safety and precise seizure-focus targeting (Alam et al., 2022).

4.4 Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating CNS disorder involving immune-mediated damage to myelin and axons. Nanotechnology can facilitate delivery of immunomodulatory agents to inflammatory lesions and immune-cell populations while potentially reducing systemic immunosuppression. Nanocarriers have been investigated for delivering corticosteroids, immunomodulatory drugs, peptides, and nucleic acids. Targeting activated macrophages, microglia, dendritic cells, or lymphocytes may improve treatment selectivity. In addition, nanoparticles carrying antioxidant or myelin-protective molecules may address oxidative injury and support remyelination. The development of immune-cell-targeted nanoparticles represents an important direction because disease progression involves complex interactions between peripheral immune cells and CNS-resident inflammatory pathways (Mitragotri et al., 2023).

4.5 Stroke

Stroke requires rapid therapeutic intervention because ischemic injury can trigger excitotoxicity, oxidative stress, inflammation, mitochondrial dysfunction, BBB disruption, and neuronal death. Nanocarriers can be designed to improve the delivery of neuroprotective, antioxidant, anti-inflammatory, and thrombolytic agents. Targeting ischemic endothelial cells or inflammatory cells may enhance accumulation at the injured region. Nanoparticle-assisted delivery of thrombolytic agents has attracted interest because controlled localization could potentially improve clot dissolution while reducing systemic bleeding risk. Nanotechnology is also being explored for delivery of growth factors, stem cells, and regenerative molecules to support tissue repair following cerebral ischemia. However, the dynamic nature of the post-stroke BBB means that nanocarrier behavior may vary substantially according to the timing and severity of injury (Teleanu et al., 2022).

4.6 Brain Tumors

Brain tumors, particularly glioblastoma, remain difficult to treat because of tumor heterogeneity, infiltrative growth, limited drug penetration, and the presence of BBB or blood–tumor barrier regions. Nanoparticles can improve the delivery of chemotherapeutic agents and enable simultaneous delivery of multiple therapeutic cargos. Surface ligands targeting receptors overexpressed on glioma cells or tumor-associated vasculature may increase tumor selectivity. Nanoparticles have also been investigated for photothermal therapy (PTT) and photodynamic therapy (PDT)**,** where externally activated nanomaterials generate cytotoxic heat or reactive oxygen species. Magnetic nanoparticles provide additional opportunities for targeted delivery, magnetic hyperthermia, and imaging. Combining chemotherapy, gene therapy, immunotherapy, and imaging within a single nanoplatform may facilitate development of multifunctional nanotheranostic systems for glioblastoma (Shi et al., 2023).

4.7 CNS Infections

CNS infections caused by bacteria, viruses, fungi, and parasites are complicated by limited antimicrobial penetration across the BBB and the potential for serious neurological damage. Nanocarriers can improve the stability and CNS distribution of antimicrobial agents and may facilitate their accumulation at infected tissues or within intracellular pathogens. Liposomal, polymeric, metallic, and lipid-based systems have been investigated for antibacterial and antiviral delivery. Nanotechnology may also be useful against fungal and parasitic CNS infections by enhancing drug solubility and reducing systemic toxicity. Targeting infected cells or microorganisms could potentially increase antimicrobial activity while minimizing exposure of healthy tissues. In the context of antimicrobial resistance, nanocarriers may additionally support combination therapy or co-delivery of antimicrobial agents and resistance-modulating molecules, although clinical evidence remains comparatively limited (Hajipour et al., 2023).

4.8 Other Neurological and Neurodegenerative Disorders

The potential application of nanotechnology extends to several less extensively studied neurological conditions. In Huntington’s disease, nanoparticles can facilitate delivery of siRNA, antisense oligonucleotides, or gene-editing components designed to regulate mutant huntingtin expression. For amyotrophic lateral sclerosis (ALS)**,** nanocarriers may improve delivery of neuroprotective compounds and nucleic-acid therapeutics to motor neurons. Nanostructured materials and nanofibrous

scaffolds are also being investigated for spinal cord injury, where controlled delivery of growth factors, anti-inflammatory molecules, and regenerative cells may support axonal repair. In neurodevelopmental disorders and peripheral neuropathies, nanocarriers may improve delivery of neuroactive drugs and genetic therapeutics. These applications illustrate the broader potential of nanomedicine for disorders in which conventional systemic treatment is limited by biological barriers and inadequate tissue targeting.

Table 4.1. Disease-Specific Applications of Nanotechnology in Neurological Disorders

Neurological disorder	Major pathological target	Nanotechnology-based therapeutic strategy
Alzheimer's disease	Amyloid-β, tau, oxidative stress, neuroinflammation	Anti-amyloid/tau delivery, antioxidants, RNA therapeutics
Parkinson's disease	Dopaminergic neuronal loss, α-synuclein	Dopaminergic drug, antioxidant, protein and gene delivery
Epilepsy	Hyperexcitability, inflammation, drug resistance	Sustained antiepileptic delivery and epileptogenic-region targeting
Multiple sclerosis	Immune-mediated demyelination	Immunomodulator delivery and immune-cell targeting
Stroke	Ischemia, oxidative stress, inflammation	Neuroprotective, antioxidant, thrombolytic and regenerative delivery
Brain tumors	Glioma cells and tumor microenvironment	Chemotherapy, gene therapy, PTT/PDT, magnetic therapy
CNS infections	Pathogens and infected cells	Targeted antimicrobial and antiviral delivery
Huntington's disease/ALS	Mutant proteins and neuronal degeneration	RNA, gene and neuroprotective therapeutics
Spinal cord injury	Inflammation and impaired regeneration	Growth factors, regenerative agents and cell-associated delivery

Table 4.2. Therapeutic Roles of Nanotechnology in Neurological Disorders

Therapeutic role	Expected benefit
BBB-targeted delivery	Increased therapeutic exposure within CNS
Controlled release	Prolonged and stable drug concentrations
Cell-specific targeting	Improved selectivity and reduced off-target effects
RNA/gene delivery	Modulation of disease-associated molecular pathways
Combination delivery	Simultaneous targeting of multiple pathological mechanisms
Imaging + therapy	Disease localization and treatment monitoring
Regenerative delivery	Support for neuronal repair and tissue regeneration
Resistance modulation	Potential improvement of treatment in drug-resistant conditions

Overall, disease-specific nanotechnology provides a framework for overcoming the limitations of conventional neurological pharmacotherapy. The most promising systems combine BBB penetration with selective pathological targeting, controlled release, and multifunctional therapeutic activity. Nevertheless, differences among disease stages, BBB integrity, cellular targets, and nanoparticle

biodistribution remain important challenges that must be resolved before widespread clinical translation.

5. Next-Generation Nanomedicine: Gene, RNA, Exosome and Theranostic Approaches

The next generation of CNS nanomedicine is moving beyond conventional small-molecule delivery toward systems capable of transporting nucleic acids, proteins, therapeutic cells, and multiple cargos simultaneously. These platforms can be engineered to cross biological barriers, recognize specific brain cells, respond to disease-associated signals, and combine diagnosis with treatment. Such approaches are particularly relevant to neurological disorders in which pathological mechanisms involve altered gene expression, protein aggregation, neuroinflammation, oxidative stress, and neuronal degeneration.

5.1 Nanotechnology for Nucleic Acid Delivery

Nucleic-acid therapeutics provide opportunities to modify disease-associated molecular pathways at the genetic or post-transcriptional level. Nanocarriers can protect fragile DNA, mRNA, siRNA, miRNA, and antisense oligonucleotides from enzymatic degradation and improve their cellular uptake. siRNA and antisense oligonucleotides (ASOs) can selectively suppress pathogenic gene expression, whereas mRNA can transiently produce therapeutic proteins without requiring permanent genomic modification. miRNA-based systems may regulate multiple genes involved in inflammation, apoptosis, and neuronal survival. Nanoparticle-mediated delivery of gene-editing components, including CRISPR/Cas systems, represents a further emerging strategy, although efficient CNS targeting, immunogenicity, editing specificity, and long-term safety remain important concerns (Kulkarni et al., 2022). Thus, nanotechnology can serve as a protective and targeting platform for otherwise difficult-to-deliver genetic therapeutics.

5.2 Lipid Nanoparticles for RNA-Based CNS Therapeutics

Lipid nanoparticles (LNPs) have become an important platform for nucleic-acid delivery because their lipid composition can be systematically modified to improve RNA encapsulation, protection, cellular uptake, and endosomal escape. A typical LNP contains an ionizable lipid, helper phospholipid, cholesterol, and a PEG-lipid**,** although composition varies according to cargo and intended application. Ionizable lipids remain relatively neutral under physiological conditions but become positively charged in acidic environments, facilitating RNA association and intracellular release. Recent research is exploring LNP surface modification and administration strategies to improve CNS exposure and BBB interaction. LNPs have particular potential for delivering mRNA, siRNA, and gene-editing components for neurodegenerative diseases, although efficient delivery to specific brain cell populations remains a major challenge (Kulkarni et al., 2022; Samaridou et al., 2020).

5.3 Exosome-Mediated Therapeutic Delivery

Exosomes are nanoscale extracellular vesicles naturally involved in intercellular communication and can transport proteins, lipids, and nucleic acids between cells. Their biological origin provides potential advantages for biocompatibility and cellular uptake compared with some synthetic systems. Exosomes can be engineered or loaded with therapeutic drugs, siRNA, miRNA, mRNA, or other

molecular cargos. Surface modification may enhance targeting toward specific CNS cell populations. Their ability to interact with biological barriers and their intrinsic cell-communication properties make them attractive for neurological applications. However, variability in exosome composition, source-dependent biological activity, purification, loading efficiency, scalability, and characterization remain major translational challenges (Kalluri & LeBleu, 2020). Standardized production and rigorous characterization are therefore essential for clinical development.

5.4 Nanotheranostics

Nanotheranostics integrate diagnostic imaging and therapeutic delivery within a single nanoscale platform. Such systems can incorporate MRI-active materials, fluorescent probes, photoresponsive components, or magnetic nanoparticles together with therapeutic cargos. MRI-visible nanoparticles can assist in tracking localization and biodistribution, while optical and fluorescent nanoprobes may support cellular or molecular imaging. Magnetic nanoparticles can additionally provide magnetic targeting or hyperthermia, whereas photothermal and photodynamic nanomaterials can generate therapeutic effects following external activation. The combination of diagnosis, localization, treatment, and treatment monitoring may be particularly valuable for brain tumors and other disorders requiring precise spatial targeting (Janib et al., 2010).

5.5 Multifunctional and Smart Nanoplatforms

Multifunctional nanoplatforms are designed to perform several therapeutic functions simultaneously. A single nanoparticle may incorporate a conventional drug together with siRNA, mRNA, or another biological cargo, allowing complementary disease pathways to be targeted. Self-assembling nanostructures can form spontaneously through noncovalent interactions and may facilitate efficient cargo incorporation. Smart nanocarriers can respond to pH, enzymes, ROS, temperature, ultrasound, or other stimuli to provide controlled release. Increasingly, artificial intelligence (AI) and machine learning are being explored to predict nanoparticle properties, optimize formulations, identify targeting ligands, and analyze structure–activity relationships. AI-assisted design may eventually support precision nanomedicine, in which nanocarrier characteristics are adapted to disease phenotype and patient-specific biological parameters (Mitchell et al., 2021).

5.6 Nanotechnology for Neuroregeneration

Nanotechnology also provides opportunities for repairing damaged neural tissue rather than simply delivering symptomatic drugs. Nanoparticles can transport neurotrophic factors, proteins, genes, or signaling molecules involved in neuronal survival and regeneration. Nanostructured scaffolds can provide three-dimensional environments that support neural stem cells, axonal extension, and tissue organization. Conductive nanomaterials and nanofibrous structures have additionally been investigated for guiding neuronal growth and improving cell–material interactions. Controlled delivery of growth factors from biodegradable nanomaterials may overcome the short half-life and rapid diffusion associated with conventional administration. These approaches are particularly relevant to spinal cord injury and neurodegenerative conditions where restoration of neuronal connectivity is a major therapeutic objective (Vijayavenkataraman, 2016).

5.7 Emerging Trends

The field is increasingly moving toward biomimetic and patient-adapted nanomedicine**.** Cell-membrane-coated nanoparticles can reproduce selected biological surface properties, while cell-derived nanovesicles provide alternative platforms for cargo transport. Personalized nanomedicine aims to consider individual differences in BBB permeability, disease-associated receptors, genetic characteristics, and therapeutic response when selecting nanocarrier properties. AI and machine-learning tools may accelerate this process by integrating molecular, imaging, pharmacokinetic, and clinical datasets. Future systems are likely to combine nanocarriers with RNA therapeutics, gene editing, immunotherapy, regenerative medicine, focused ultrasound, and advanced imaging. Such integration could transform CNS nanomedicine from passive drug delivery toward programmable, targeted, multifunctional therapeutic systems**.**

Table 5.1. Next-Generation Nanomedicine Strategies for Neurological Disorders

Strategy	Major cargo/function	Potential CNS application
RNA nanodelivery	siRNA, miRNA, mRNA, ASOs	Gene regulation and disease modification
LNPs	RNA and gene-editing components	Neurodegenerative and genetic disorders
Engineered exosomes	Drugs, proteins, RNA	BBB-compatible targeted delivery
Nanotheranostics	Drug + imaging probe	Brain tumors and treatment monitoring
Smart nanoplatforms	Multiple cargos/stimuli-responsive systems	Multifactorial neurological diseases
AI-designed nanoparticles	Optimized formulation and targeting	Precision nanomedicine
Regenerative nanomaterials	Cells, growth factors, genes	Neural repair and spinal cord injury
Biomimetic systems	Cell-derived membranes/vesicles	Improved biological recognition and targeting

Overall, next-generation nanomedicine is expanding the therapeutic scope of CNS drug delivery by integrating gene regulation, RNA therapeutics, biological vesicles, imaging, smart release, and neuroregeneration. The future development of these systems will depend on achieving efficient cell-specific brain delivery while maintaining reproducibility, safety, scalability, and regulatory compatibility.

6. Safety, Translational Challenges, Clinical Perspectives and Future Directions

6.1 Nanotoxicology and CNS Safety

The therapeutic advantages of nanocarriers must be balanced against their potential for nanoparticle-associated toxicity. In CNS applications, safety is particularly important because nanoparticles may interact directly with neurons, astrocytes, microglia, endothelial cells, and other components of the neurovascular unit. Surface charge, particle size, morphology, composition, degradation rate, and

protein corona formation can influence cellular uptake and biological responses. Excessive reactive oxygen species generation may produce oxidative stress, mitochondrial dysfunction, membrane damage, apoptosis, and neuroinflammatory signaling. Persistent or poorly biodegradable nanoparticles may also accumulate in organs or neural tissues, creating concerns regarding chronic exposure. Therefore, CNS nanomedicines require systematic assessment of acute and chronic neurotoxicity, immunotoxicity, mitochondrial effects, biodegradation, and clearance before clinical translation. FDA emphasizes that nanomaterial-containing products should be evaluated according to their specific physicochemical characteristics, safety, effectiveness, and intended biological context rather than being considered inherently safe or harmful (U.S. Food and Drug Administration [FDA], 2024).

6.2 Pharmacokinetics and Pharmacodynamics of CNS Nanomedicines

Nanocarriers can substantially modify the pharmacokinetic and pharmacodynamic behavior of conventional therapeutics. Important parameters include systemic absorption, plasma protein interaction, circulation time, BBB transport, brain accumulation, cellular internalization, intracellular trafficking, controlled drug release, metabolism, and elimination. Although increased brain accumulation is frequently reported in preclinical studies, therapeutic benefit depends on whether the drug reaches the appropriate cellular or subcellular target at an effective concentration. Engineered nanoparticles therefore need to be evaluated using integrated pharmacokinetic–pharmacodynamic approaches rather than relying only on total brain drug concentration. Recent advances in precision nanoparticle engineering emphasize disease-specific targeting, controlled release, and improved tissue exposure as important factors for achieving meaningful CNS therapeutic effects (Gao et al., 2024).

6.3 Preclinical Evaluation

Preclinical evaluation should progress from physicochemical characterization to increasingly physiologically relevant biological models. Conventional Transwell BBB models remain useful for assessing permeability, transport mechanisms and TEER, but they incompletely reproduce the multicellular and dynamic nature of the human BBB. Three-dimensional models, brain organoids and microphysiological systems can provide additional information concerning cell–cell interactions, disease-associated changes and nanoparticle behavior. BBB-on-chip systems are particularly promising because they incorporate fluid flow and multicellular architecture and can be used for transport, toxicity and disease-modelling studies (Deli et al., 2024). Brain-on-a-chip platforms may further support screening of nanomedicines under more human-relevant conditions and potentially contribute to personalized drug-delivery development (Korszun-Karbowniczak et al., 2024).

Animal studies remain important for evaluating systemic pharmacokinetics, biodistribution, brain accumulation, toxicity and therapeutic efficacy. However, differences between animal and human BBB physiology can contribute to poor clinical predictability. Consequently, future preclinical pipelines should integrate **in vitro, organoid, organ-on-chip and animal data** rather than relying on a single model.

6.4 Manufacturing and Pharmaceutical Development

Translation of laboratory-scale nanocarriers into pharmaceutical products requires reproducible and scalable manufacturing. Critical variables include particle size distribution, morphology, surface characteristics, encapsulation efficiency, drug loading, residual solvents, sterility, endotoxin levels,

physical stability and release behavior. Small changes in raw materials or processing conditions can alter nanoparticle characteristics and subsequently affect biological performance.

Quality-by-Design (QbD) approaches can establish relationships between critical material attributes, critical process parameters and critical quality attributes. Recent work has emphasized the integration of QbD, risk management, process optimization and scalable manufacturing to improve nanomedicine reproducibility (Maheshwari et al., 2025). Importantly, translational manufacturing problems can become clinically significant; a recent analysis highlighted manufacturing and scale-up as major factors contributing to the limited progression of nanomedicines from laboratory research to durable clinical products (Zhang et al., 2025).

6.5 Regulatory and Clinical Translation

Regulatory assessment of CNS nanomedicines requires simultaneous consideration of quality, safety, efficacy and nanomaterial-specific characteristics**.** Particle size, size distribution, composition, surface properties, aggregation, stability, drug release and degradation products should be adequately characterized. FDA guidance emphasizes that products containing nanomaterials are evaluated under existing regulatory frameworks, while their unique nanoscale properties may require additional characterization and risk assessment.

Clinical translation is further complicated by differences between animal models and humans, heterogeneous disease biology, limited understanding of brain distribution, interpatient variability and difficulty predicting long-term safety. The recently proposed DELIVER framework emphasizes coordinated consideration of design, experimental testing, manufacturing, preclinical studies, clinical development, regulation and commercialization from the early stages of nanomedicine development (Joyce et al., 2024).

For CNS applications, the translational gap remains particularly substantial. A recent 2026 review concluded that although nanomedicine has progressed considerably, brain-targeted applications remain limited because of the BBB, complex CNS biology and difficulties in achieving reproducible clinical outcomes (Wang et al., 2026).

6.6 Major Knowledge Gaps and Translational Barriers

Several important knowledge gaps continue to restrict the clinical development of CNS nanomedicines. First, BBB transport mechanisms are highly heterogeneous and may change with disease progression, age and patient-specific pathology. Second, nanoparticle heterogeneity can produce differences in biodistribution and therapeutic performance even when formulations appear similar based on conventional characterization.

Another major concern is the limited availability of long-term safety data. Most experimental studies evaluate short-term efficacy and toxicity, whereas clinical use may involve repeated or chronic administration. Furthermore, differences in nanoparticle composition, animal models, dosing schedules and analytical methods make cross-study comparison difficult. Standardized characterization, harmonized biodistribution protocols and clinically relevant endpoints are therefore essential for improving reproducibility. These issues are consistent with broader translational barriers identified for nanomedicines, including physicochemical characterization, reproducibility, biocompatibility, scale-up and regulatory complexity (Joyce et al., 2024).

6.7 Future Perspectives

The future of CNS nanomedicine is expected to move from nonspecific nanoparticle delivery toward precision and personalized nanomedicine. Advanced targeting ligands, biomimetic surfaces, cell-derived vesicles and stimuli-responsive systems may improve delivery to specific brain regions or cell populations. AI and machine-learning approaches could assist in predicting nanoparticle size, composition, surface properties, drug loading, BBB interaction and therapeutic performance, thereby reducing empirical formulation development.

Integration of nanotechnology with imaging, molecular diagnostics and therapeutic delivery may also enable multifunctional theranostic systems capable of simultaneously identifying disease-associated targets and delivering therapy. Precision nanoparticle engineering is increasingly focused on controlling tissue and cellular exposure rather than simply increasing total brain accumulation (Gao et al., 2024).

Future development should therefore combine patient-specific disease biology, advanced BBB models, computational formulation design, QbD manufacturing and clinically meaningful pharmacokinetic–pharmacodynamic endpoints**.** Such integration could accelerate the transition from proof-of-concept nanocarriers to reproducible and clinically useful CNS therapeutics.

Table 6.1. Major Translational Challenges and Potential Solutions in CNS Nanomedicine

Challenge	**Major concern**	**Potential solution**
Nanotoxicity	Oxidative stress, mitochondrial injury, neuroinflammation	Long-term toxicity and biodegradation studies
BBB penetration	Limited and heterogeneous brain delivery	Receptor-mediated, intranasal and biomimetic targeting
Pharmacokinetics	Poor correlation between brain concentration and therapeutic response	Integrated PK/PD and cellular biodistribution studies
Preclinical models	Limited human predictability	Organoids, BBB-on-chip and brain-on-chip models
Manufacturing	Scale-up and batch variability	QbD, PAT and controlled manufacturing processes
Characterization	Nanoparticle heterogeneity	Standardized CQAs and orthogonal analytical methods
Clinical translation	Limited CNS clinical evidence	Better patient stratification and translational endpoints
Long-term safety	Accumulation and delayed toxicity	Chronic exposure, clearance and post-treatment monitoring
Personalization	Interpatient BBB and disease variability	AI-assisted and patient-specific nanocarrier design

6.8 Conclusion

Nanotechnology has substantially expanded the possibilities for CNS drug delivery by improving drug solubility, stability, controlled release, BBB transport and targeting. Nevertheless, successful neurological nanomedicine requires more than demonstrating enhanced brain accumulation in experimental models**.** Safety, pharmacokinetics, reproducible manufacturing, standardized

characterization, clinically predictive models and regulatory compatibility must be incorporated throughout development.

The next phase of CNS nanomedicine will likely emphasize precision targeting, intelligent nanocarriers, AI-assisted formulation design, advanced human BBB models and integrated diagnostic–therapeutic platforms. Recent translational frameworks similarly emphasize early integration of manufacturing, preclinical, clinical and regulatory considerations rather than treating translation as a final step (Joyce et al., 2024). With these developments, nanotechnology has the potential to progress from promising experimental delivery systems toward safer, more predictable and clinically meaningful therapies for neurological disorders.

References

- Agrahari, V., Alzahrani, A. M., Alqahtani, M. S., & Kaur, K. (2023). Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. *Acta Pharmaceutica Sinica B, 13*(5), 1866–1886. https://doi.org/10.1016/j.apsb.2022.07.003
- Castanho, M. A. R. B., Neves, V., et al. (2024). Molecular determinants for brain targeting by peptides: A meta-analysis approach with experimental validation. *Fluids and Barriers of the CNS, 21*, 37. https://doi.org/10.1186/s12987-024-00545-5
- Chen, Y., et al. (2023). Magnetic iron oxide nanoparticles for brain imaging and drug delivery. *Advanced Drug Delivery Reviews, 197*, 114822. https://doi.org/10.1016/j.addr.2023.114822
- Chen, Y., et al. (2024). Biomedical applications of stimuli-responsive nanomaterials. *MedComm, 5*(7), e643. https://doi.org/10.1002/mco2.643
- Daneman, R., & Prat, A. (2015). The blood–brain barrier. *Cold Spring Harbor Perspectives in Biology, 7*(1), a020412. https://doi.org/10.1101/cshperspect.a020412
- Deli, M. A., Porkoláb, G., Kincses, A., Mészáros, M., Szecskó, A., Kocsis, A. E., Vigh, J. P., Valkai, S., Veszelka, S., & Dér, A. (2024). Lab-on-a-chip models of the blood–brain barrier: Evolution, problems, perspectives. *Lab on a Chip, 24*, 1030–1063. https://doi.org/10.1039/D3LC00996C
- Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Parmar, P., Brainin, M., Murray, C. J. L., & GBD 2019 Neurology Collaborators. (2020). The global burden of neurological disorders: Translating evidence into policy. *The Lancet Neurology, 19*(3), 255–265. https://doi.org/10.1016/S1474-4422(19)30411-5
- Gao, J., Xia, Z. J., Gunasekar, S., Jiang, C., Karp, J. M., Joshi, N., et al. (2024). Precision drug delivery to the central nervous system using engineered nanoparticles. *Nature Reviews Materials, 9*, 567–588. https://doi.org/10.1038/s41578-024-00695-w
- Gao, X., et al. (2024). Stimuli-responsive polymeric nanocarriers accelerate on-demand drug release to combat glioblastoma. *Biomacromolecules, 25*(10), 6250–6282. https://doi.org/10.1021/acs.biomac.4c00722
- Hajipour, M. J., Fromm, K. M., Ashkarran, A. A., Jimenez de Aberasturi, D., de Larramendi, I. R., Rojo, T., Serpooshan, V., Parak, W. J., & Mahmoudi, M. (2023). Antimicrobial nanomaterials: From synthesis to clinical applications. *Trends in Biotechnology, 41*(5), 671–688.

- Janib, S. M., Moses, A. S., & MacKay, J. A. (2010). Imaging and drug delivery using theranostic nanoparticles. *Advanced Drug Delivery Reviews, 62*(11), 1052–1063. https://doi.org/10.1016/j.addr.2010.07.004
- Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., Popat, A., Prestidge, C. A., Rijcken, C. J. F., Sarmento, B., Schmid, R. B., Schroeder, A., Subramaniam, S., Thorn, C. R., Whitehead, K. A., Zhao, C.-X., & Santos, H. A. (2024). A translational framework to DELIVER nanomedicines to the clinic. *Nature Nanotechnology, 19*, 1597–1611. https://doi.org/10.1038/s41565-024-01754-7
- Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications of exosomes. *Science, 367*(6478), eaau6977. https://doi.org/10.1126/science.aau6977
- Kaur, A., Singh, N., Kaur, H., et al. (2023). Neurodegenerative diseases and brain delivery of therapeutics: Bridging the gap using dendrimers. *Journal of Drug Delivery Science and Technology, 87*, 104868. https://doi.org/10.1016/j.jddst.2023.104868
- Khan, A., et al. (2022). Lipid-based nanocarriers for neurological disorders: A review of the state-of-the-art and therapeutic success to date. *Pharmaceutics, 14*(4), 836. https://doi.org/10.3390/pharmaceutics14040836
- Korszun-Karbowniczak, J., Krysiak, Z. J., Saluk, J., et al. (2024). The progress in molecular transport and therapeutic development in human blood–brain barrier models in neurological disorders. *Cellular and Molecular Neurobiology, 44*, 34.
- Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2022). Lipid nanoparticles enabling gene therapies: From concepts to clinical utility. *Nucleic Acid Therapeutics, 32*(6), 1–17.
- Lochhead, J. J., & Thorne, R. G. (2012). Intranasal delivery of biologics to the central nervous system. *Advanced Drug Delivery Reviews, 64*(7), 614–628. https://doi.org/10.1016/j.addr.2011.11.002
- Maheshwari, R., Kapoor, D., Polaka, S., Bhattacharya, S., & Prajapati, B. (2025). Roadmap for commercial nanomedicine development: Integrating Quality by Design principles with pharmaceutical nanotechnology. *Molecular Pharmaceutics, 22*(8), 4337–4372. https://doi.org/10.1021/acs.molpharmaceut.5c00056
- Mitragotri, S., Anderson, D. G., Chen, X., Chow, E. K., Ho, D., Kabanov, A. V., Karp, J. M., Kataoka, K., & Kleinstiver, B. P. (2023). Accelerating the development of nanomedicines for neurological and immune-mediated diseases. *Nature Reviews Materials, 8*, 493–511.
- Moreira, R., et al. (2024). Brain-targeted drug delivery—Nanovesicles directed to specific brain cells by brain-targeting ligands. *Journal of Nanobiotechnology, 22*, 260. https://doi.org/10.1186/s12951-024-02511-7
- Mura, S., et al. (2022). Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier to manage neurological disorders. *Advanced Drug Delivery Reviews, 185*, 114274.
- Patel, T., Zhou, J., Piepmeier, J. M., & Leblanc, R. M. (2018). Polymeric nanoparticles for drug delivery to the central nervous system. *Advanced Drug Delivery Reviews, 119*, 37–49. https://doi.org/10.1016/j.addr.2017.08.006
- Patel, V., et al. (2023). Advances and opportunities in nanoparticle drug delivery for central nervous system disorders: A review of current advances. *Nanomedicine, 18*(16), 1379–1397.
- Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., & Shin, H. S. (2018). Nano based drug delivery systems: Recent developments and future prospects. *Journal of Nanobiotechnology, 16*, 71. https://doi.org/10.1186/s12951-018-0392-8

- Piper, K., et al. (2024). Consensus review on strategies to improve delivery across the blood-brain barrier including focused ultrasound. *Neuro-Oncology, 26*(9), 1545–1556. https://doi.org/10.1093/neuonc/noae087
- Rashid, M. H., Marton, J., Kovács, A., et al. (2023). Nanomedicine approaches for Parkinson's disease: Current status and future perspectives. *International Journal of Nanomedicine, 18*, 5431–5455.
- Saber, M. M., et al. (2023). Nanotechnology-based therapeutic approaches for Alzheimer's disease: Recent advances and future perspectives. *Pharmaceutics, 15*, 2471.
- Samaridou, E., Heyes, J., & Lutwyche, M. (2020). Lipid nanoparticles for nucleic acid delivery: Current challenges, opportunities, and future perspectives. *Advanced Drug Delivery Reviews, 174*, 197–217. https://doi.org/10.1016/j.addr.2020.08.007
- Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release, 235*, 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044
- Sharma, P., et al. (2023). Nose-to-brain targeting via nanoemulsion: Significance and evidence. *Pharmaceutics, 15*(1), 23. https://doi.org/10.3390/pharmaceutics15010023
- Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2023). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer, 23*, 79–97.
- Tan, Q., Zhao, S., Xu, T., Wang, Q., Zhang, M., Yan, L., Chen, X., & Lan, M. (2023). Inorganic nano-drug delivery systems for crossing the blood–brain barrier: Advances and challenges. *Coordination Chemistry Reviews, 494*, 215344. https://doi.org/10.1016/j.ccr.2023.215344
- Teleanu, D. M., Negut, I., Grumezescu, V., Grumezescu, A. M., & Teleanu, R. I. (2022). Nanomaterials for drug delivery to the central nervous system. *Nanomaterials, 12*, 3211.
- U.S. Food and Drug Administration. (2024). *Considerations for drug products that contain nanomaterials*. U.S. Department of Health and Human Services.
- Vijayavenkataraman, S. (2016). Nerve guide conduits for peripheral nerve regeneration: A review on design, materials and fabrication methods. *Acta Biomaterialia, 24*, 1–15. https://doi.org/10.1016/j.actbio.2015.12.003
- World Health Organization. (2024). *Global status report on neurology*. World Health Organization.
- Xu, L., et al. (2024). Nose-to-brain delivery of nanotherapeutics: Transport mechanisms and applications. *WIREs Nanomedicine and Nanobiotechnology*. https://doi.org/10.1002/wnan.1956
- Yadav, K., Vijayalakshmi, R., Sahu, K. K., et al. (2024). Exosome-based macromolecular neurotherapeutic drug delivery approaches in overcoming the blood–brain barrier for treating brain disorders. *European Journal of Pharmaceutics and Biopharmaceutics, 199*, 114298. https://doi.org/10.1016/j.ejpb.2024.114298
- Young, C. M., Viña-González, A., Salmeron de Toledo Aguiar, R., Kalman, C., Pilitsis, J. G., Martin-Lopez, L. I., Mahani, T., & Pineda-Pardo, J. A. (2024). A scoping review of focused ultrasound enhanced drug delivery across the blood-brain barrier for brain tumors. *Neurosurgery, 94*(5), 523–532. https://doi.org/10.1227/ons.0000000000001175
- Zhang, X., Chan, H. W., Shao, Z., Wang, Q., Chow, S., & Chow, S. F. (2025). Navigating translational research in nanomedicine: A strategic guide to formulation and manufacturing. *International Journal of Pharmaceutics, 671*, 125202. https://doi.org/10.1016/j.ijpharm.2025.125202

- Zhang, Y., Sun, C., Wang, C., Jankovic, J., & Xie, X. (2021). Gold nanoparticles: Recent aspects for human biology and medicine. *Drug Delivery*, *28*(1), 2377–2391. https://doi.org/10.1080/10717544.2021.2005269
- Zhang, Y., et al. (2023). Insights into exosome transport through the blood–brain barrier and the potential therapeutical applications in brain diseases. *International Journal of Molecular Sciences*, *24*, 7647.
- Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026). Clinical translation of nanomedicines for brain diseases: Current challenges and future directions. *Journal of Controlled Release*, *389*, 114426. https://doi.org/10.1016/j.jconrel.2025.114426

Chapter 3: Nose-to-Brain and Targeted Drug Delivery Approaches for Central Nervous System Disorders

Lalatendu Mohanty[*1], Bhavana Singh[2], Ajab Singh Choudhary[3], Lata Choudhary[4], Gopal Vijaykumar Lohiya[5]

[1]Assistant Professor, Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Uttarakhand 249161, India.

[2]Assistant Professor, School of Pharmacy, Sharda University, Plot No. 32,34, Knowledge Park-III, Greater Noida, Uttar Pradesh, India.

[3]Assistant Professor, Medical Laboratory Technology, SOAHS, Noida International University, Sector 17 A, Yamuna Expressway, Greater Noida, Uttar Pradesh, India.

[4]Associate Professor, Department of Pharmacognosy/Natural Products, J.K. College of Pharmacy, Near Gatora Railway Station, Bilaspur, Chhattisgarh, Pin Code: 495550, India.

[5]Associate Professor, Department of Pharmaceutical Quality Assurance, Dayanand Education Society's, Dayanand College of Pharmacy, Barshi Road, Latur–413531, Maharashtra, India.

*Corresponding Author: Lalatendu Mohanty, Assistant Professor, Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Uttarakhand 249161, India.

Abstract

Nose-to-brain drug delivery is an emerging non-invasive approach for improving therapeutic access to the central nervous system by exploiting the olfactory and trigeminal pathways. This chapter discusses the anatomical and molecular mechanisms governing nasal-to-brain transport, advanced intranasal formulations, targeted nanocarriers, and applications in neurological and neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, stroke, traumatic brain injury, brain tumors, CNS infections, and psychiatric disorders. Particular emphasis is given to receptor-mediated targeting, lipid and polymeric nanoparticles, exosomes, peptides, antibodies, nucleic acids, and stimuli-responsive systems. The chapter also examines preclinical evaluation, pharmacokinetic and biodistribution assessment, safety, manufacturing, regulatory barriers, and clinical translation. Emerging technologies such as artificial intelligence, personalized nasal delivery, biomimetic carriers, and multifunctional nanocarriers may further enhance brain targeting and therapeutic efficacy. Overall, nose-to-brain delivery represents a promising platform for overcoming major limitations of conventional CNS drug administration and advancing precision neurological therapeutics.

Keywords: Nose-to-brain delivery; Intranasal drug delivery; Central nervous system; Blood–brain barrier; Nanocarriers; Brain targeting; Neurological disorders; Neurodegenerative diseases; Targeted drug delivery; CNS therapeutics.

1. Introduction to CNS Drug Delivery and the Nose-to-Brain Concept

CNS disorders represent a major global health burden because they frequently cause progressive neurological dysfunction, disability, cognitive decline, and mortality. Alzheimer's disease is characterized by progressive memory and cognitive impairment, whereas Parkinson's disease

primarily involves degeneration of dopaminergic neurons and motor dysfunction. Epilepsy, multiple sclerosis, stroke, traumatic brain injury, brain tumors, and CNS infections further contribute substantially to neurological morbidity. Despite advances in pharmacotherapy, effective treatment remains challenging because many therapeutic molecules cannot reach the brain at adequate concentrations (Feigin et al., 2021; World Health Organization, 2022).

A major limitation of conventional CNS pharmacotherapy is the presence of highly selective biological barriers, particularly the blood–brain barrier (BBB), which restricts the passage of most hydrophilic, large, and poorly lipophilic molecules from the systemic circulation into brain tissue. The blood–cerebrospinal fluid barrier also contributes to restricted CNS exposure, while systemic metabolism, renal clearance, inadequate solubility, poor permeability, and dose-limiting toxicity can further reduce therapeutic effectiveness. Consequently, increasing systemic drug doses does not necessarily produce proportional increases in brain concentrations and may instead increase peripheral adverse effects (Daneman & Prat, 2015; Pardridge, 2019).

The nose-to-brain approach has emerged as an attractive alternative strategy for circumventing or partially bypassing the BBB. Intranasally administered drugs can access the CNS through anatomical connections between the nasal cavity and brain, particularly through the olfactory and trigeminal pathways. This concept has evolved from simple intranasal administration of conventional drugs toward sophisticated formulations involving nanoparticles, liposomes, nanoemulsions, polymeric systems, mucoadhesive carriers, and biomimetic nanocarriers designed to enhance nasal residence, protect labile molecules, and improve brain accumulation (Illum, 2003; Mistry et al., 2009).

The anatomical organization of the nasal cavity is particularly important for nose-to-brain delivery. The nasal cavity contains respiratory and olfactory regions, with the olfactory epithelium providing a specialized interface between the external environment and the CNS. Drug molecules deposited in the upper nasal cavity may interact with the olfactory mucosa and subsequently reach the brain through pathways associated with olfactory neurons. In addition, the trigeminal nerve provides another potential route for transport toward deeper CNS regions, making the nasal cavity a promising non-invasive portal for brain-targeted therapy (Djupesland, 2013; Lochhead & Thorne, 2012).

The olfactory and trigeminal pathways can facilitate direct transport of certain molecules from the nasal cavity toward the CNS, potentially reducing dependence on systemic circulation and avoiding extensive BBB limitations. Transport may occur through extracellular spaces surrounding neuronal structures or through intracellular neuronal mechanisms, depending on the physicochemical and biological characteristics of the therapeutic agent and its formulation. The relative contribution of these pathways varies according to molecular size, lipophilicity, formulation characteristics, nasal deposition, and disease condition (Lochhead & Thorne, 2012; Dhuria et al., 2010).

Intranasal administration offers several potential advantages, including non-invasive delivery, rapid onset, avoidance of gastrointestinal degradation, partial avoidance of hepatic first-pass metabolism, and the possibility of achieving enhanced CNS exposure with lower systemic drug concentrations. It is particularly attractive for macromolecules and therapeutics with limited BBB permeability. However, nasal delivery also presents challenges, including limited administration volume, mucociliary clearance, enzymatic degradation, variability in nasal anatomy, restricted olfactory surface area, irritation, and inconsistent deposition at the desired nasal region (Illum, 2003; Djupesland, 2013).

The efficiency of nose-to-brain transport is influenced by numerous factors, including molecular weight, lipophilicity, aqueous solubility, ionization, enzymatic stability, formulation composition, particle size, surface characteristics, mucoadhesion, nasal residence time, and site of deposition. Physiological variables such as mucus secretion, mucociliary clearance, nasal blood flow, epithelial integrity, and individual anatomical differences can also substantially influence drug absorption and brain targeting. Therefore, rational formulation design is essential for improving nasal retention and maximizing transport toward the CNS (Mistry et al., 2009; Khan et al., 2017).

Overall, nose-to-brain delivery represents a promising platform for improving the treatment of neurological disorders by providing a relatively direct and non-invasive pathway to the CNS. Integration of nanotechnology, mucoadhesive systems, targeted ligands, biomimetic carriers, and advanced intranasal devices may further improve therapeutic localization and reduce systemic exposure. Nevertheless, differences between preclinical and clinical outcomes, uncertainties regarding transport mechanisms, formulation reproducibility, long-term safety, and regulatory requirements remain important barriers to translation. Continued optimization of formulation, nasal deposition, targeting mechanisms, and pharmacokinetic–pharmacodynamic evaluation is therefore essential for realizing the full therapeutic potential of this approach (Dhuria et al., 2010; Hanson & Frey, 2008).

2. Anatomical, Physiological and Molecular Mechanisms of Nose-to-Brain Transport

The nasal cavity represents a specialized anatomical interface between the external environment and the central nervous system (CNS), providing a potentially direct route for transporting therapeutics toward the brain. Its relevance to nose-to-brain delivery arises principally from the close association of the upper nasal cavity with the olfactory nerve and from extensive trigeminal innervation of the nasal mucosa. However, successful CNS delivery is not determined simply by placing a formulation inside the nose; deposition site, mucosal interactions, clearance, epithelial permeability, molecular properties, and transport pathways collectively determine the fraction of the administered dose that ultimately reaches the brain. Recent studies emphasize that the olfactory and respiratory regions should be considered functionally distinct targets rather than interchangeable nasal surfaces (Huang et al., 2024; D'Souza et al., 2026).

2.1 Nasal Cavity Architecture and Functional Regions

The nasal cavity is divided by the nasal septum and is anatomically organized into vestibular, respiratory, and olfactory regions. The vestibular region is positioned anteriorly and contains coarse hairs and a relatively keratinized epithelial surface, making it less suitable for efficient systemic or brain-directed absorption. The respiratory region occupies most of the nasal cavity and contains a highly vascularized mucosa responsible primarily for humidification, warming, filtration, and mucociliary clearance. The olfactory region is located in the superior portion of the nasal cavity and contains specialized olfactory epithelium with olfactory sensory neurons whose axons pass through the cribriform plate toward the olfactory bulb. Consequently, accurate deposition within or close to the olfactory region is an important consideration for maximizing direct nose-to-brain transport (Huang et al., 2024; D'Souza et al., 2026).

2.2 Nasal Mucosa and Its Role in Drug Absorption

The nasal mucosa provides both an absorption interface and a biological barrier. Beneath the mucus layer, the epithelial lining contains cells connected by tight junctions, while the underlying lamina

propria contains blood vessels, lymphatic structures, glands, immune components, and neural elements. Small, adequately soluble molecules may cross the nasal epithelium through transcellular or paracellular pathways and enter systemic circulation. For nose-to-brain delivery, however, the objective is not simply high systemic absorption but preferential access to neural pathways and CNS tissues. Therefore, formulation strategies must balance epithelial permeation with prolonged nasal residence and appropriate interaction with olfactory or trigeminal structures (Xu et al., 2024; Huang et al., 2024).

2.3 Olfactory Pathway-Mediated Transport

The olfactory pathway is considered one of the principal anatomical routes underlying direct nose-to-brain delivery. Olfactory sensory neurons extend from the olfactory epithelium through the cribriform plate and terminate within the olfactory bulb. Therapeutic molecules or nanocarriers deposited near the olfactory epithelium may therefore interact with neuronal structures and potentially move toward the olfactory bulb. Transport may involve intracellular neuronal uptake and axonal transport or extracellular movement through spaces surrounding olfactory nerve bundles. Recent evidence also suggests that selective targeting of the olfactory epithelium could improve direct brain delivery, although species-specific anatomical and molecular differences remain important considerations during translation (Xu et al., 2024; D'Souza et al., 2026).

2.4 Trigeminal Nerve-Mediated Transport

The trigeminal pathway provides a second major neural connection between the nasal cavity and CNS. Branches of the ophthalmic and maxillary divisions of the trigeminal nerve innervate portions of the nasal mucosa and connect with trigeminal ganglion and brainstem structures. Following intranasal administration, some molecules and nanocarriers may interact with trigeminal nerve endings and subsequently undergo neuronal or extracellular transport toward the brainstem and associated CNS regions. This pathway may be particularly important for formulations that do not achieve extensive deposition within the olfactory epithelium and may contribute to broader CNS distribution (Xu et al., 2024; Huang et al., 2024).

2.5 Extracellular and Intracellular Transport Mechanisms

Nose-to-brain transport can involve both extracellular and intracellular mechanisms. In extracellular transport, drug molecules or nanoparticles may move through perineural spaces associated with olfactory or trigeminal nerves, potentially reaching cerebrospinal fluid or adjacent CNS compartments. Intracellular transport involves uptake by olfactory or trigeminal neurons followed by vesicular trafficking and axonal movement. At the epithelial level, transcellular uptake, receptor-mediated endocytosis, carrier-mediated transport, and adsorption-mediated interactions may contribute to cellular entry. For nanocarriers, surface charge, ligand density, particle size, morphology, and surface chemistry can influence their interaction with mucus, epithelial cells, and neural structures (Xu et al., 2024; Chen et al., 2024).

2.6 Direct and Indirect Brain Delivery Routes

Intranasally administered therapeutics may reach the CNS through several interconnected routes rather than through a single mechanism. The **direct route** involves olfactory and trigeminal neural or perineural pathways, allowing a fraction of the formulation to access CNS compartments while

reducing dependence on BBB passage. The **indirect route** involves absorption across the nasal mucosa into systemic circulation, followed by subsequent distribution to the brain. Thus, elevated brain concentrations after intranasal dosing should not automatically be interpreted as evidence of direct nose-to-brain transport. Appropriate experimental designs must distinguish direct CNS transport from systemic redistribution (Boyuklieva et al., 2023; Huang et al., 2024).

2.7 Role of Mucociliary Clearance

Mucociliary clearance is one of the most important physiological limitations of intranasal drug delivery. The nasal mucus layer traps foreign particles and is continuously transported toward the nasopharynx through coordinated ciliary movement. Although this mechanism protects the respiratory tract from inhaled pathogens and particulates, it can substantially reduce the residence time of intranasally administered formulations. Conventional solutions may therefore be cleared before sufficient drug absorption or neural interaction occurs. Mucoadhesive polymers, in situ gels, optimized particle characteristics, and appropriate deposition devices can increase nasal residence and potentially improve delivery efficiency (Huang et al., 2024; Huang et al., 2024).

2.8 Enzymatic and Physiological Barriers in the Nasal Cavity

The nasal cavity is not a passive absorption surface. Mucus, epithelial tight junctions, mucociliary clearance, enzymatic activity, local blood flow, immune responses, and physiological variations collectively restrict drug transport. Enzymatic degradation can be particularly problematic for peptides, proteins, nucleic acids, and other biologics. In addition, rapid systemic absorption from the respiratory mucosa may divert drug away from the desired neural pathways. Differences in receptor and enzyme expression between olfactory and respiratory epithelia may provide opportunities for selective targeting but can also create considerable interspecies differences between experimental animals and humans (Chen et al., 2024; D'Souza et al., 2026).

2.9 Influence of Molecular Size, Lipophilicity and Charge

Physicochemical characteristics strongly influence nasal absorption and subsequent CNS distribution. Low-molecular-weight and moderately lipophilic compounds generally have greater capacity for epithelial permeation, whereas hydrophilic macromolecules may require specialized carriers or permeation-enhancing strategies. Molecular charge can affect interaction with mucus, epithelial membranes, and cellular surfaces. For nanoparticles, size and surface properties are particularly important: very small particles may show improved tissue penetration in some settings, whereas larger or highly adhesive systems may exhibit prolonged mucosal residence but reduced penetration through mucus. Importantly, there is no universally optimal particle size or surface charge because the preferred characteristics depend on the intended transport mechanism and formulation composition (Xu et al., 2024; Chen et al., 2024).

Table 2.1. Major anatomical and physiological determinants of nose-to-brain transport

Determinant	Major characteristics	Influence on CNS delivery
Vestibular region	Anterior, relatively protective epithelial surface	Generally limited contribution to brain targeting
Respiratory epithelium	Highly vascularized, ciliated mucosa	Supports absorption and systemic exposure; may

		contribute indirectly to CNS delivery
Olfactory epithelium	Contains olfactory sensory neurons	Major anatomical target for direct neural transport
Mucus layer	Viscoelastic protective barrier	Can trap formulations and reduce epithelial access
Mucociliary system	Continuous mucus movement	Reduces nasal residence time
Epithelial tight junctions	Restrict paracellular transport	Limit movement of hydrophilic and larger molecules
Olfactory nerves	Connect nasal olfactory region with olfactory bulb	Potential direct CNS transport pathway
Trigeminal nerves	Extensive nasal sensory innervation	Potential pathway toward trigeminal ganglion and brainstem
Nasal blood circulation	Extensive vascular network	Promotes systemic absorption and indirect brain exposure
Enzymatic environment	Metabolic enzymes in mucosa and mucus	May degrade susceptible therapeutics

2.10 Drug–Mucus and Drug–Epithelium Interactions

The initial interaction between a formulation and nasal mucus can determine whether a therapeutic agent remains localized, becomes trapped, or penetrates toward the epithelial surface. Strong mucoadhesion can increase residence time, but excessive interaction with mucins may immobilize nanoparticles and decrease epithelial penetration. Conversely, highly mucus-penetrating formulations may move more efficiently through the mucus layer but may exhibit shorter residence. Surface charge, hydrophilicity, particle size, polymer composition, and surface coatings therefore need to be optimized according to the desired balance between retention and penetration. Nanocarriers can additionally interact with epithelial cells through nonspecific adsorption, receptor-mediated uptake, or endocytic pathways (Xu et al., 2024; Huang et al., 2024).

2.11 Factors Affecting Brain Targeting Efficiency and Bioavailability

Brain targeting efficiency is influenced by formulation, biological, anatomical, and administration-related variables. Important formulation factors include particle size, surface charge, drug loading, polymer characteristics, mucoadhesiveness, release kinetics, and targeting ligands. Biological variables include mucus composition, mucociliary clearance, epithelial integrity, enzymatic activity, nasal blood flow, and neuronal connectivity. Administration technique is equally important because inaccurate deposition may direct the formulation toward the respiratory rather than olfactory region. Consequently, improvements in brain concentration should be interpreted alongside plasma exposure, nasal retention, regional brain distribution, and quantitative targeting indices rather than by brain concentration alone (Huang et al., 2024; D'Souza et al., 2026).

Table 2. Key factors influencing nose-to-brain targeting and possible optimization strategies

Factor	Potential limitation	Optimization strategy
Particle size	Poor mucus penetration or rapid	Rational size optimization

	clearance	
Surface charge	Excessive mucus interaction or poor cellular uptake	Optimize surface charge and coating
Lipophilicity	Poor epithelial permeation for hydrophilic drugs	Lipid-based or nanocarrier systems
Molecular weight	Limited epithelial and neuronal transport	Nanocarriers, peptides, or permeation enhancers
Mucociliary clearance	Short nasal residence	Mucoadhesive/in situ gelling systems
Enzymatic degradation	Loss of unstable drugs and biologics	Protective encapsulation
Nasal deposition	Delivery to non-olfactory regions	Specialized intranasal devices
Formulation viscosity	Poor spreading or uncomfortable administration	Controlled rheological properties
Mucoadhesion	Excessive retention may restrict penetration	Balanced mucoadhesion–mucopenetration
Targeting ligands	Variable receptor expression	Ligand selection and density optimization
Disease-related changes	Altered mucosa and clearance	Disease-specific formulation design
Animal-to-human differences	Limited translational predictability	Human-relevant models and clinical validation

2.12 Experimental Approaches for Evaluating Nose-to-Brain Transport

Evaluation of nose-to-brain delivery requires complementary computational, in vitro, ex vivo, and in vivo approaches. Computational models can help predict deposition, diffusion, molecular interactions, and formulation behavior. In vitro nasal epithelial models are useful for assessing permeability, cytotoxicity, cellular uptake, and epithelial transport, whereas ex vivo nasal tissue models provide information regarding tissue penetration and local tolerability. In vivo animal studies remain important for determining pharmacokinetics, brain distribution, biodistribution, and therapeutic response. Analytical methods such as fluorescence imaging, radiolabeling, mass spectrometry, microscopy, and quantitative drug analysis can help establish the localization of administered therapeutics. Importantly, experimental designs should include intravenous or other systemic controls to distinguish direct nose-to-brain transport from systemic redistribution (Boyuklieva et al., 2023).

3. Formulation Strategies for Nose-to-Brain Drug Delivery

The effectiveness of nose-to-brain drug delivery depends strongly on formulation design because conventional nasal administration is limited by restricted nasal residence time, mucociliary clearance, enzymatic degradation, limited dosing volume, and variable mucosal permeability. Contemporary formulation strategies therefore focus on improving drug solubility, protecting unstable molecules, increasing nasal retention, facilitating epithelial and neuronal uptake, and enhancing brain bioavailability. Recent research has increasingly shifted from simple nasal liquids toward nanocarriers, mucoadhesive systems, in situ gels, lipid-based systems, biomimetic vesicles, and

multifunctional platforms capable of transporting small molecules as well as proteins, peptides and nucleic acids (Papakyriakopoulou & Valsami, 2025; Drath et al., 2025).

3.1 Conventional Intranasal Formulations

Conventional intranasal formulations remain important because of their relatively simple manufacturing, ease of administration, and established pharmaceutical technology. Nasal solutions and suspensions can provide rapid drug availability but may undergo rapid mucociliary elimination and may offer limited control over residence time. Nasal gels can increase viscosity and prolong contact with the mucosa, whereas emulsions and nanoemulsions can improve the solubilization of poorly water-soluble drugs. Mucoadhesive formulations containing polymers such as chitosan, carbomers, cellulose derivatives, or related materials can increase retention at the nasal mucosa and potentially improve absorption. Nevertheless, conventional liquid systems often have difficulty achieving precise deposition and sustained CNS exposure, encouraging the development of more sophisticated formulations (Papakyriakopoulou & Valsami, 2025).

3.2 Nanotechnology-Based Nose-to-Brain Delivery

Nanotechnology has substantially expanded the possibilities of nose-to-brain delivery by allowing drugs to be encapsulated or associated with nanoscale carriers. Nanocarriers can improve drug solubility, protect active molecules from degradation, regulate release, enhance mucosal interaction, and facilitate cellular uptake. They can also be surface-functionalized with targeting ligands to improve interactions with specific receptors or neural structures. Recent evidence indicates that lipid nanoparticles, liposomes, micelles, polymeric nanoparticles, SLNs, and NLCs can improve brain exposure compared with free drug formulations (Mititelu-Tartau et al., 2025; Drath et al., 2025).

Liposomes consist of phospholipid bilayers capable of incorporating hydrophilic and lipophilic drugs and are particularly useful for improving the stability and delivery of CNS therapeutics. Surface modification can further influence mucus interaction, cellular uptake, and targeting. SLNs provide a solid lipid matrix with good biocompatibility and controlled drug release, whereas NLCs incorporate both solid and liquid lipids to provide greater flexibility in drug loading and reduce some limitations associated with highly crystalline lipid matrices. Recent analyses of intranasal SLN and NLC studies have reported improved brain accumulation and pharmacodynamic effects in experimental CNS models (Elkordy et al., 2024).

Polymeric nanoparticles constructed from biodegradable polymers can provide sustained release and protect drugs from degradation. Polymeric micelles are particularly useful for solubilizing hydrophobic molecules, while dendrimers provide highly branched structures with modifiable surface groups that can be exploited for drug conjugation or targeting. Nanogels combine nanoscale dimensions with hydrogel-like properties and can provide high water content, controlled release, and responsiveness to environmental stimuli. Inorganic and hybrid nanoparticles, including magnetic and metallic systems, provide additional possibilities for imaging, external targeting, and multifunctional delivery, although long-term safety and biodegradability require careful consideration (Bolon et al., 2025; Paraiso et al., 2025).

3.3 Mucoadhesive and In Situ Gelling Systems

Mucoadhesive formulations are designed to increase the residence time of therapeutic agents on the nasal mucosa by establishing interactions with mucin. Increased residence time can provide a larger window for drug absorption and interaction with the olfactory or trigeminal regions. In situ gelling systems provide an additional advantage because they can be administered as low-viscosity liquids and subsequently undergo gelation following exposure to nasal physiological conditions. Thermosensitive polymers such as poloxamers, frequently combined with mucoadhesive polymers, can therefore provide a practical balance between administration convenience and prolonged nasal retention. A recent study of a thermosensitive mucoadhesive risperidone formulation demonstrated prolonged nasal gel residence and substantially greater brain exposure following intranasal administration compared with oral solution (Singh et al., 2025).

3.4 Thermosensitive and pH-Responsive Nasal Systems

Stimuli-responsive systems are designed to alter their physicochemical characteristics in response to environmental changes. Thermosensitive formulations remain sufficiently fluid during administration but undergo gelation at nasal temperature, thereby increasing residence time. pH-responsive systems can exploit differences between formulation and physiological environments to regulate gel formation or drug release. These systems are particularly attractive for drugs requiring prolonged exposure or protection from rapid clearance. Recent studies have demonstrated that thermosensitive nasal gels can improve retention and brain pharmacokinetics, supporting their potential as practical nose-to-brain platforms (Li et al., 2025; Singh et al., 2025).

3.5 Lipid-Based and Self-Emulsifying Drug Delivery Systems

Lipid-based formulations are valuable for poorly water-soluble CNS drugs because they can improve solubilization and facilitate membrane interaction. Nanoemulsions and self-emulsifying drug delivery systems can generate fine lipid droplets after contact with aqueous nasal fluids, increasing the interfacial area available for drug transfer. Lipid-based carriers may additionally improve drug stability and facilitate interaction with nasal epithelial membranes. Their composition can be modified using oils, surfactants, cosurfactants, phospholipids, and other excipients to optimize droplet size, viscosity, permeability, and tolerability. However, excessive surfactant concentrations may cause mucosal irritation, requiring careful optimization during formulation development (Drath et al., 2025; Papakyriakopoulou & Valsami, 2025).

3.6 Nanostructured and Biomimetic Carriers

Nanostructured carriers can be engineered to reproduce selected properties of biological transport systems. Biomimetic approaches include cell-membrane-coated nanoparticles, lipid vesicles, protein-associated nanoparticles, and other carriers designed to improve biological compatibility and cellular interactions. Such systems can potentially reduce nonspecific clearance while enhancing transport across biological interfaces. Surface modification with peptides, proteins, carbohydrates, or receptor-specific ligands may further promote selective cellular uptake. The emerging emphasis on biomimetic design reflects the need to move beyond passive drug encapsulation toward carriers capable of actively interacting with the nasal–brain interface (Paraiso et al., 2025).

3.7 Exosomes and Extracellular Vesicle-Based Delivery

Exosomes and other extracellular vesicles are naturally derived nanoscale carriers capable of transporting proteins, lipids, messenger RNA, microRNA, and other biological molecules. Their endogenous membrane composition can provide favorable biocompatibility and cellular interaction, making them attractive candidates for CNS delivery. Intranasal administration may exploit the nose-to-brain anatomical connection while avoiding some limitations associated with synthetic carriers. Engineered extracellular vesicles can additionally be modified to carry therapeutic nucleic acids or targeting molecules. Recent work has demonstrated the potential of modified extracellular vesicles for targeted intranasal siRNA delivery, including receptor-mediated uptake by olfactory neurons and subsequent brain distribution (Cai et al., 2025).

3.8 Peptide-, Protein- and Antibody-Loaded Nasal Systems

The nasal route is particularly attractive for delivering biologics because systemic administration of many proteins and peptides is limited by enzymatic degradation, poor membrane permeability, and BBB restriction. Encapsulation in nanoparticles, liposomes, nanogels, or mucoadhesive systems can protect these macromolecules and improve their retention. Cell-penetrating peptides, receptor-targeting peptides, and other surface ligands can be incorporated to facilitate epithelial or neuronal uptake. Antibody-based systems may enable selective modulation of disease-associated targets, although their large molecular size, structural stability, immunogenicity, and manufacturing complexity remain important considerations. Thus, formulation design must simultaneously address protection, nasal retention, cellular uptake, and biological activity.

3.9 RNA and Nucleic Acid Delivery Through the Nasal Route

RNA therapeutics, including siRNA, microRNA, mRNA, and antisense oligonucleotides, have significant potential for modifying disease-associated molecular pathways but are intrinsically vulnerable to enzymatic degradation and generally exhibit poor cellular uptake. Nanocarriers can protect RNA molecules and facilitate endocytosis, endosomal escape, and intracellular release. Intranasal administration provides an attractive route for delivering such systems directly toward the CNS. A recent study demonstrated that tyrosine-modified polymeric/dendrimer-based nanoparticles carrying siRNA against α-synuclein could distribute throughout the brain after intranasal administration and reduce SNCA expression in a Parkinson's disease mouse model (2025). Similarly, receptor-targeted extracellular-vesicle nanoparticles carrying siRNA have demonstrated olfactory-neuron uptake and therapeutic effects in experimental brain injury (Cai et al., 2025).

3.10 Strategies for Enhancing Nasal Residence Time and Brain Uptake

Improving nasal residence time is a central objective of formulation optimization. Mucoadhesive polymers, in situ gelling systems, optimized viscosity, controlled-release matrices, and appropriately engineered nanoparticles can reduce rapid mucociliary elimination. At the same time, excessive mucoadhesion may immobilize particles within mucus and reduce epithelial penetration; therefore, modern systems increasingly attempt to achieve an appropriate balance between retention and mucus penetration. Surface functionalization, receptor-targeting ligands, cell-penetrating peptides, permeation enhancers, enzyme inhibitors, and specialized nasal delivery devices can further increase brain exposure. Advanced devices are particularly important because precise deposition in the upper

nasal cavity may improve access to the olfactory region while reducing formulation loss to the nasopharynx (Drath et al., 2025; Papakyriakopoulou & Valsami, 2025).

Table 3.1. Major formulation platforms for nose-to-brain drug delivery

Formulation platform	Major advantages	Principal limitations	Typical applications
Nasal solutions/suspensions	Simple, inexpensive, rapid administration	Short residence time, rapid clearance	Small molecules, acute therapy
Nasal gels	Increased viscosity and retention	Potentially poor spreading	CNS-active drugs
Nanoemulsions	Improved solubilization and absorption	Surfactant-related irritation possible	Poorly soluble drugs
Liposomes	Encapsulation of hydrophilic/lipophilic drugs	Stability and manufacturing challenges	Small molecules, peptides, RNA
SLNs	Biocompatibility, stability, controlled release	Drug expulsion and limited loading for some drugs	Neurodegenerative disorders
NLCs	Improved loading and reduced crystallinity	Formulation complexity	Brain-targeted therapeutics
Polymeric nanoparticles	Controlled release and surface functionalization	Polymer-related toxicity/stability concerns	Small molecules and biologics
Polymeric micelles	Excellent solubilization of hydrophobic drugs	Dilution-related stability concerns	Poorly soluble CNS drugs
Dendrimers	Highly tunable surface chemistry	Potential cytotoxicity at high surface charge	Gene and targeted delivery
Nanogels	High water content and stimuli responsiveness	Complex manufacturing	Proteins, nucleic acids
Exosomes/EVs	Natural biological compatibility	Isolation, characterization and scale-up	RNA and biologics
Hybrid nanoparticles	Multifunctionality and combined properties	More complex characterization	Targeted and theranostic delivery

Recent reviews indicate that the field is moving toward multifunctional nanosystems rather than single-purpose carriers, with increasing emphasis on combining improved stability, nasal retention, cellular uptake, targeting and controlled release within the same formulation.

Table 3.2. Strategies for improving nasal retention and brain targeting

Strategy	Mechanism	Expected benefit
Mucoadhesive polymers	Interaction with mucin	Prolonged nasal residence
In situ gelation	Liquid-to-gel transition after administration	Reduced mucociliary loss
Thermoresponsive systems	Temperature-triggered gel	Improved retention and

	formation	sustained release
Mucus-penetrating surfaces	Reduced adhesive interaction with mucus	Improved epithelial access
Targeting ligands	Receptor-mediated cellular uptake	Increased cellular/brain targeting
Cell-penetrating peptides	Enhanced membrane interaction and internalization	Improved intracellular delivery
Nanoparticle encapsulation	Protection and controlled release	Improved stability and bioavailability
Lipid-based carriers	Enhanced solubilization and membrane interaction	Improved absorption of lipophilic drugs
Extracellular vesicles	Biomimetic transport	Potentially enhanced biological compatibility
Permeation enhancers	Increased epithelial permeability	Improved drug absorption
Enzyme inhibitors	Reduced nasal degradation	Greater drug stability
Specialized nasal devices	Improved deposition in upper nasal cavity	Better olfactory targeting
Stimuli-responsive carriers	Controlled response to local/external stimuli	Spatial and temporal control of release

Overall, formulation development for nose-to-brain delivery is progressing from conventional nasal dosage forms toward multifunctional, targeted and stimuli-responsive systems. The most promising platforms combine prolonged nasal residence with efficient mucus interaction, epithelial uptake, neural transport and controlled release. However, formulation complexity must be balanced against manufacturability, reproducibility, nasal tolerability, long-term safety and regulatory feasibility. Recent translational reviews emphasize that successful clinical development will require not only improved nanocarriers but also precise dosing technologies and robust pharmacokinetic and pharmacodynamic evaluation (Drath et al., 2025; Paraiso et al., 2025).

4. Targeted Drug Delivery Approaches for CNS Disorders

Targeted CNS drug delivery aims to increase the concentration of therapeutic agents at the desired brain region or cell population while reducing systemic exposure and off-target toxicity. Because the BBB restricts the passage of many therapeutic molecules, modern targeting approaches increasingly combine nanocarriers with receptor-specific ligands, peptides, antibodies, aptamers, biomimetic membranes, and stimulus-responsive components. Recent advances emphasize precision nanomedicine in which carrier physicochemical properties and biological targeting mechanisms are designed together rather than treating brain delivery as a simple barrier-crossing problem (Zhang et al., 2025; Wang et al., 2025).

4.1 Concept and Principles of Targeted CNS Drug Delivery

Targeted delivery involves directing a drug or carrier preferentially toward the CNS, a particular brain region, or a specific cellular population. An effective targeting system should provide adequate drug loading, stability, barrier interaction, cellular uptake, controlled intracellular release, and minimal nonspecific accumulation. Targeting may be achieved through passive physicochemical properties,

receptor-mediated mechanisms, ligand–receptor interactions, neural pathways, or external physical stimuli. The ultimate objective is to improve the therapeutic index rather than simply maximize total brain drug concentration (Wang et al., 2025).

4.2 Receptor-Mediated Brain Targeting

Receptor-mediated transcytosis is an important strategy for transporting nanocarriers across the BBB. The **transferrin receptor (TfR)** is extensively investigated because of its role in iron transport and its availability on brain endothelial cells. Nanocarriers decorated with transferrin or TfR-binding ligands can undergo receptor-mediated endocytosis and transcytosis. Similarly, low-density lipoprotein receptor-related proteins, particularly LRP1, can be exploited using ligands such as apolipoprotein-derived peptides. The insulin receptor represents another potential transport pathway, although receptor activation and metabolic effects require careful control. Nicotinic acetylcholine receptor-directed systems have also been investigated for neuronal targeting and enhanced cellular uptake. Receptor targeting is highly dependent on ligand affinity, receptor density, carrier size, and the intracellular trafficking route following receptor binding (Wang et al., 2025).

4.3 Carrier-Mediated Transport Systems

Carrier-mediated transport exploits endogenous transport proteins expressed at the BBB or nasal epithelium. Nutrient transporters can facilitate delivery of appropriately designed substrates or prodrugs, while nanocarriers can be modified to interact with transporter-associated pathways. This strategy is particularly useful for molecules with poor intrinsic permeability. However, competition with endogenous substrates and transporter saturation can limit delivery efficiency. Therefore, rational molecular modification and controlled carrier design are necessary to achieve adequate transport without disrupting normal physiological transport functions.

4.4 Adsorptive-Mediated and Cell-Mediated Transport

Adsorptive-mediated transcytosis depends primarily on electrostatic interactions between positively charged carriers and negatively charged components of the endothelial surface. Cationic nanoparticles can therefore increase cellular association and internalization, although excessive positive charge may cause toxicity or nonspecific uptake. Cell-mediated transport represents another emerging approach in which immune cells, stem cells, macrophages, or other carrier cells transport therapeutic cargo toward CNS tissues. Such approaches may be particularly relevant for inflammatory neurological disorders in which immune cells naturally migrate toward pathological sites (Wang et al., 2025).

4.5 Ligand-Functionalized Nanocarriers

Ligand functionalization converts conventional nanoparticles into actively targeted systems. Antibodies, peptides, proteins, carbohydrates, aptamers, and small targeting molecules can be attached to the carrier surface. The ligand binds selectively to receptors expressed on endothelial cells or pathological brain cells, increasing cellular interaction and potentially improving transcytosis. Important design variables include ligand density, orientation, affinity, linker chemistry, and carrier stability. Excessive ligand density may increase particle aggregation or alter mucus and protein interactions, demonstrating the importance of systematic optimization.

4.6 Peptide-Based Brain-Targeting Strategies

Peptides offer several advantages as targeting molecules because they can be synthesized reproducibly and modified chemically. Brain-targeting peptides may interact with BBB receptors, promote cellular penetration, or facilitate transport through neural pathways. Cell-penetrating peptides such as TAT-derived sequences and other arginine-rich peptides can increase intracellular uptake, whereas receptor-specific peptides can provide greater targeting selectivity. Their limitations include enzymatic degradation, possible immunogenicity, rapid clearance, and variable receptor expression. Peptide-functionalized nanoparticles can therefore provide a useful compromise between molecular specificity and nanocarrier protection.

4.7 Antibody- and Aptamer-Mediated Targeting

Antibodies provide high molecular recognition and can be directed toward BBB transport receptors or disease-associated cellular markers. Bispecific antibodies are particularly attractive because one binding domain can recognize a BBB transport receptor while the other recognizes a therapeutic target. Aptamers are short nucleic-acid ligands capable of highly selective molecular recognition and can be incorporated into nanoparticles or extracellular vesicles. Compared with antibodies, aptamers can offer smaller size and easier chemical modification, although nuclease stability and in vivo pharmacokinetics remain important challenges.

4.8 Cell-Penetrating Peptides for CNS Delivery

Cell-penetrating peptides facilitate transport across cellular membranes and can improve intracellular delivery of proteins, nucleic acids, and nanoparticles. Their incorporation into CNS nanocarriers may increase endothelial uptake and facilitate intracellular trafficking. However, nonspecific uptake can occur because many cell-penetrating peptides interact broadly with cellular membranes. Consequently, combining cell-penetrating sequences with disease- or receptor-specific ligands may provide greater selectivity than using cell-penetrating peptides alone.

4.9 Exosome-Mediated Targeted Delivery

Exosomes and other extracellular vesicles possess naturally derived lipid membranes and can transport proteins, lipids, and nucleic acids. Their biological origin provides opportunities for relatively favorable biocompatibility and cellular interactions. Engineering exosomal surfaces with targeting ligands can potentially improve brain accumulation and cell-specific delivery. Current research increasingly focuses on engineering extracellular vesicles to control biodistribution, cellular specificity, cargo loading, and intracellular fate. However, heterogeneity, isolation, characterization, potency measurement, and scalable manufacturing remain major translational issues (Zhang et al., 2026; Rational design of extracellular vesicles, 2025).

4.10 Stimuli-Responsive Targeting Strategies

Stimuli-responsive systems are designed to remain relatively stable during transport but release their payload in response to specific environmental or externally applied triggers. **pH-responsive systems** exploit differences in acidity between compartments to control drug release or carrier destabilization. **Enzyme-responsive systems** incorporate linkers or matrices that are cleaved by disease-associated or intracellular enzymes. **Redox-responsive systems** respond to differences in reducing conditions, particularly intracellular glutathione concentrations, allowing intracellular drug release. Externally triggered systems may use magnetic fields, focused ultrasound, light, heat, or other physical stimuli to

achieve spatially controlled delivery. These approaches can provide temporal control and reduce premature drug release (Kamyab et al., 2026).

4.11 Dual-Targeted and Multi-Functional Nanocarriers

Single-target systems may be insufficient because CNS delivery involves multiple sequential barriers. Dual-targeted systems therefore combine two targeting mechanisms—for example, one ligand for BBB transport and another for neuronal or tumor-cell recognition. Multifunctional nanocarriers can simultaneously incorporate therapeutic cargo, targeting ligands, imaging agents, and stimulus-responsive components. Such systems could theoretically provide barrier transport, disease-cell recognition, controlled intracellular release, and therapeutic monitoring within one platform. However, increasing functional complexity also increases manufacturing, characterization, stability, and regulatory challenges.

4.12 Nose-to-Brain Delivery as a Platform for Site-Specific CNS Targeting

Nose-to-brain delivery provides an important alternative to systemic BBB-crossing strategies because therapeutic molecules can potentially access CNS tissues through olfactory and trigeminal pathways. Targeted nanoparticles can further improve this approach by increasing nasal retention, interacting with specific epithelial receptors, facilitating neuronal uptake, and providing controlled release. Current research is moving toward combining intranasal administration with nanocarrier engineering, ligand functionalization, biomimetic systems, and specialized delivery devices. Nevertheless, recent translational assessments emphasize that promising preclinical brain accumulation does not automatically establish clinically meaningful direct nose-to-brain transport, and rigorous biodistribution and pharmacokinetic controls remain essential (Zhang et al., 2025; Kamyab et al., 2026).

Table 4.1. Major targeted drug-delivery mechanisms for CNS therapy

Targeting approach	Principal mechanism	Major advantage	Key limitation
Transferrin receptor	Receptor-mediated transcytosis	Well-characterized BBB target	Receptor saturation/off-target effects
LRP1	Receptor-mediated transport	Useful for peptide/nanocarrier targeting	Variable receptor expression
Insulin receptor	Receptor-mediated transcytosis	Physiological BBB transport pathway	Metabolic effects and competition
Nicotinic receptors	Neuronal/receptor-mediated uptake	Potential neuronal targeting	Receptor heterogeneity
Carrier-mediated transport	Endogenous transporter utilization	Exploits physiological pathways	Competition and saturation
Adsorptive transcytosis	Electrostatic interaction	Simple surface modification	Nonspecific uptake/toxicity
Peptide targeting	Ligand–receptor interaction	Small and modifiable ligands	Enzymatic degradation
Antibody targeting	High-affinity	High specificity	Large size and

	molecular recognition		immunogenicity
Aptamer targeting	Nucleic-acid ligand recognition	Small and chemically programmable	Stability concerns
Exosome targeting	Biomimetic cellular interaction	Potentially favorable biocompatibility	Heterogeneity and scale-up
Cell-mediated delivery	Cellular trafficking	Can exploit natural migration	Complex biology and safety

Table 4.2. Stimuli-responsive and multifunctional CNS targeting strategies

Strategy	Trigger	Delivery function	Potential application
pH-responsive	Local pH variation	Triggered drug release	Intracellular/CNS delivery
Enzyme-responsive	Disease- or cell-associated enzymes	Selective carrier degradation	Tumors/neuroinflammation
Redox-responsive	Intracellular reducing environment	Intracellular cargo release	RNA and protein delivery
Magnetic targeting	External magnetic field	Spatial localization	Brain tumors/theranostics
Focused ultrasound	Acoustic energy	Transient BBB modulation	Localized CNS delivery
Light-responsive	Specific wavelength	On-demand release	Experimental precision delivery
Dual-ligand targeting	Two biological receptors	Sequential targeting	BBB + neuronal/tumor targeting
Multifunctional nanocarriers	Multiple mechanisms	Targeting + imaging + controlled release	Precision CNS therapy
Biomimetic carriers	Biological membrane/cell components	Improved biological interaction	Neurodegenerative and inflammatory disorders

Overall, targeted CNS delivery is evolving toward precision, multifunctional and biologically responsive systems**.** Receptor-mediated transport, ligand-functionalized nanoparticles, peptides, aptamers, engineered extracellular vesicles, and stimulus-responsive carriers provide complementary mechanisms for improving brain exposure. Importantly, the most effective future systems are likely to combine targeting with controlled release and appropriate administration routes rather than relying on a single barrier-crossing mechanism. Recent 2025–2026 literature particularly emphasizes multifunctional nanocarriers, engineered extracellular vesicles, and intranasal platforms as promising directions, while identifying safety, reproducibility, biodistribution and clinical translation as major remaining challenges.

5. Applications in Neurological and Neurodegenerative Disorders

Nose-to-brain (N2B) delivery has emerged as a promising strategy for neurological disorders because intranasally administered therapeutics can access the brain through olfactory and trigeminal pathways while reducing dependence on systemic circulation and the blood–brain barrier (BBB). Recent research has expanded this approach from conventional small molecules to peptides, proteins,

antibodies, nucleic acids, extracellular vesicles, and multifunctional nanocarriers. Importantly, most disease-specific evidence remains preclinical, although intranasal therapies such as esketamine and intranasal benzodiazepines demonstrate the clinical feasibility of CNS-directed nasal administration.

5.1 Nose-to-Brain Delivery in Alzheimer's Disease

Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) accumulation, tau hyperphosphorylation, oxidative stress, neuroinflammation, synaptic dysfunction, and progressive neuronal loss. N2B delivery is particularly attractive for AD because it can facilitate regional brain exposure to therapeutics that otherwise exhibit poor BBB penetration. Recent approaches include intranasal insulin, antioxidant compounds, peptides, and nanocarriers designed for Aβ clearance or modulation of disease-associated pathways (Komal et al., 2025).

An emerging strategy combines multiple mechanisms within a single nanocarrier. For example, targeted lipid nanoparticles containing α-mangostin and siRNA against BACE1 have been investigated for simultaneous Aβ scavenging and suppression of Aβ production. Intranasal administration produced enhanced brain targeting and improved pathological and behavioral outcomes in an AD mouse model, illustrating the potential of multifunctional N2B systems (2025). Tau-directed peptides, proteins, RNA therapeutics, and neuroprotective antioxidants may similarly benefit from direct nasal-to-CNS administration.

5.2 Parkinson's Disease

Parkinson's disease (PD) involves degeneration of dopaminergic neurons in the substantia nigra, resulting in dopamine deficiency, motor dysfunction, mitochondrial abnormalities, oxidative stress, and neuroinflammation. Intranasal administration has been explored for levodopa-related therapy, dopamine-modulating agents, glutathione, insulin, fibroblast growth factors, and other neuroprotective approaches. Clinical investigations have included intranasal glutathione and levodopa, while experimental studies increasingly examine nanocarriers for improving brain exposure and reducing peripheral limitations (Qiu et al., 2025).

N2B systems may also facilitate delivery of genes, siRNA, proteins, and growth factors to dopaminergic pathways. Such approaches could shift therapy from symptomatic dopamine replacement toward neuroprotection and disease modification.

5.3 Epilepsy and Seizure Disorders

Epilepsy represents one of the most clinically relevant applications of intranasal CNS delivery because rapid drug action is desirable during acute seizures. Intranasal administration can provide rapid absorption and is already clinically relevant for rescue treatment of seizures. Beyond conventional rescue drugs, nanotechnology is being investigated to improve brain retention and sustained anticonvulsant action.

A recent study developed phospholipid magnesomes containing kaempferol for intranasal brain targeting. The formulation demonstrated substantially enhanced brain uptake compared with conventional intravenous and intranasal drug solutions, supporting the potential of nanovesicular N2B systems for neuroprotective seizure management (Hatem et al., 2025).

5.4 Multiple Sclerosis and Neuroinflammatory Disorders

Multiple sclerosis (MS) involves autoimmune-mediated demyelination, neuroinflammation, axonal injury, and progressive neurological dysfunction. N2B delivery may allow immunomodulatory, anti-inflammatory, antioxidant, and remyelinating agents to achieve higher CNS exposure while potentially reducing systemic adverse effects.

Recent experimental work has evaluated intranasal fingolimod, demonstrating enhanced brain availability together with evidence of remyelination and restoration of neuronal morphology in an experimental MS model (Sharma et al., 2025). Other approaches include intranasal dimethyl fumarate nanoemulsions, monoclonal antibodies, insulin, and cell-derived extracellular vesicles.

5.5 Ischemic Stroke and Cerebrovascular Disorders

Stroke presents an acute therapeutic challenge because the BBB may restrict delivery of neuroprotective agents to ischemic tissue. N2B delivery provides a non-invasive alternative for transporting small molecules, proteins, growth factors, and nucleic acids into injured brain regions.

A particularly notable 2025 study developed intranasal lipid nanoparticles containing circular RNA SCMH1. The system increased circRNA accumulation in peri-infarct tissue while reducing nonspecific organ distribution compared with intravenous administration. Treatment promoted synaptic plasticity, vascular repair, reduction of neuroinflammation, and functional recovery in experimental stroke models (Jia et al., 2025). These findings highlight the potential of N2B delivery for regenerative as well as neuroprotective stroke therapy.

5.6 Traumatic Brain Injury

Traumatic brain injury (TBI) produces oxidative stress, neuroinflammation, neuronal damage, edema, and secondary injury processes. Intranasal delivery may provide a non-invasive means of administering neuroprotective drugs directly to the brain during the secondary injury phase. Emerging systems include nanoparticles, nanoemulsions, proteins, growth factors, and cell-based therapeutics.

Recent investigations have particularly focused on formulations capable of improving nasal retention and brain exposure while minimizing systemic toxicity. Thus, N2B delivery could potentially support treatment of post-traumatic neuroinflammation, oxidative injury, cognitive impairment, and neuronal degeneration. Current evidence remains predominantly experimental, and optimization of dose, timing, and disease-stage targeting is still required.

5.7 Brain Tumors and Glioblastoma

Glioblastoma (GBM) presents major drug-delivery challenges because of the BBB, tumor heterogeneity, infiltrative growth, and immunosuppressive tumor microenvironment. N2B delivery can potentially increase drug exposure within brain tumors while limiting systemic toxicity. Approaches include chemotherapeutics, targeted nanoparticles, immune modulators, and combination therapies.

A recent study investigated intranasal PEGylated cationic liposomes containing the STING agonist diABZI in an orthotopic GBM model. Intranasal treatment activated interferon signaling, increased

immune-cell infiltration, and prolonged survival, demonstrating the potential of combining N2B delivery with tumor immunotherapy (Kotmakci et al., 2025). Future systems may integrate chemotherapy, immunotherapy, radiosensitizers, and molecularly targeted agents within multifunctional nasal nanocarriers.

5.8 CNS Infections

N2B delivery is particularly relevant to CNS infections because conventional systemic anti-infective therapy may show limited penetration into the brain and cerebrospinal fluid. Emerging research has explored intranasal delivery against bacterial, viral, fungal, and mycobacterial infections.

For example, methyl-β-cyclodextrin microparticles containing isoniazid and rifampicin have been investigated for intranasal treatment of CNS tuberculosis, demonstrating enhanced delivery of anti-tubercular drugs to the CNS and improved mycobacterial clearance in experimental studies. Cationic nano-embedded microparticles have also been developed for targeted nasal delivery of anti-TB drugs (2025). Similar strategies could be adapted for CNS viral and fungal infections using antiviral RNA, antimicrobial peptides, antifungal agents, or targeted nanocarriers.

5.9 Psychiatric and Neurobehavioral Disorders

Psychiatric disorders provide an important clinical application for intranasal CNS delivery. The rapid onset and direct CNS access of nasal administration can be advantageous when systemic administration is associated with delayed action or extensive peripheral exposure.

Intranasal esketamine represents an established example of a CNS-active therapy delivered through the nasal route for treatment-resistant depression. N2B research is also investigating intranasal insulin, neurotrophic factors, peptides, and other neuromodulatory agents for depression, cognitive dysfunction, and related neurobehavioral conditions (Qiu et al., 2025).

5.10 Delivery of Biologics, Peptides, Proteins and Nucleic Acids

One of the major advantages of N2B technology is its potential applicability to macromolecules that exhibit poor systemic CNS penetration. Intranasal delivery has been investigated for insulin, growth factors, antibodies, peptides, siRNA, microRNA, circular RNA, and extracellular-vesicle-associated cargo. Nanoparticles and lipid nanoparticles can protect nucleic acids from enzymatic degradation while improving cellular uptake.

For AD specifically, recent research emphasizes intranasal delivery of biologics, including proteins and peptide-based therapeutics directed toward amyloid and tau pathology. Similarly, the successful experimental delivery of circSCMH1 by intranasal LNPs demonstrates the expanding role of N2B technology for RNA-based neurological therapy (Jia et al., 2025).

5.11 Comparative Evaluation of Nose-to-Brain and Conventional CNS Delivery

Compared with oral, intravenous, or other systemic routes, N2B delivery can provide faster CNS access, reduce dependence on BBB transport, and potentially lower systemic exposure. However, the nasal cavity has limited dosing capacity, mucociliary clearance, enzymatic degradation,

interindividual anatomical variability, and formulation-related limitations. Consequently, N2B should be considered complementary rather than universally superior to conventional CNS delivery.

Table 5.1. Comparative characteristics of nose-to-brain and conventional CNS drug delivery approaches

Parameter	Nose-to-brain delivery	Oral/systemic delivery	Intravenous delivery	Direct intracranial delivery
BBB dependence	Relatively low	High	High	Bypassed
Route of administration	Non-invasive	Non-invasive	Minimally invasive	Invasive
CNS targeting	Potentially high	Generally low	Moderate/low	Very high/local
Onset of CNS action	Rapid for suitable drugs	Usually slower	Rapid systemically	Rapid/local
Systemic exposure	Can be reduced	Usually substantial	Usually substantial	Variable
Macromolecule delivery	Promising with advanced systems	Limited	Often restricted by BBB	Possible
Patient convenience	High	Very high	Moderate	Low
Dose capacity	Limited	High	High	Limited/local
Major limitation	Mucociliary clearance and variable nasal absorption	BBB and first-pass metabolism	BBB and systemic toxicity	Surgical risk
Current evidence	Strong preclinical; selected clinical applications	Established	Established	Specialized clinical use
Best opportunity	Brain-targeted small molecules, biologics, RNA and nanocarriers	Systemic therapy	Acute systemic therapy	Highly localized treatment

Overall, N2B delivery has progressed from a conceptual BBB-bypass strategy toward a versatile platform for disease-specific CNS therapeutics. Current evidence is particularly encouraging for AD, PD, epilepsy, MS, stroke, brain tumors, TBI, and CNS infections, with nanocarriers enabling increasingly sophisticated delivery of small molecules and biological therapeutics. Nevertheless, standardized pharmacokinetic methods, long-term nasal safety studies, reproducible brain targeting, scalable manufacturing, and well-designed clinical trials remain essential before many experimental N2B systems can achieve routine clinical translation.

6. Evaluation, Translational Challenges and Future Perspectives

Nose-to-brain delivery requires systematic preclinical evaluation involving formulation characterization, nasal deposition, permeability, brain distribution, pharmacokinetics, pharmacodynamics, and safety. In vitro nasal epithelial, Transwell, ex vivo mucosal, BBB, and

advanced 3D models can provide preliminary information, whereas animal studies are important for confirming biodistribution and therapeutic efficacy. However, differences between animal and human nasal anatomy remain an important translational limitation (Drath et al., 2025).

Pharmacokinetic assessment should include plasma and brain concentration–time profiles, AUC, C_max, T_max, half-life, brain-to-plasma ratios, and targeting indices. Brain targeting should not be established solely from increased brain concentrations because systemic absorption followed by BBB penetration may contribute to the observed exposure. Imaging, fluorescence, radiolabeling, molecular analysis, and tissue distribution studies can therefore provide complementary evidence for direct CNS transport. Physiologically based pharmacokinetic (PBPK) and computational models may further improve prediction of nasal deposition and human brain exposure (Forbes et al., 2025).

Safety evaluation must include nasal histopathology, mucosal irritation, ciliary function, inflammatory responses, systemic toxicity, and, particularly for nanocarriers, long-term accumulation and neurotoxicity. Manufacturing and scale-up also remain challenging because particle size, drug loading, viscosity, spray characteristics, stability, device compatibility, and dose uniformity must remain consistent. Selection of an appropriate nasal device is particularly important because conventional devices may not efficiently deposit sufficient drug in the upper olfactory region (Drath et al., 2025; Papakyriakopoulou & Valsami, 2025).

Clinical translation remains limited despite extensive preclinical research. Important barriers include interindividual differences in nasal anatomy, mucociliary clearance, limited administration volume, inconsistent experimental methodologies, inadequate human-relevant models, and limited clinical pharmacokinetic data. Standardized evaluation protocols and better in vitro–in vivo correlations are therefore required for reliable development of CNS-targeted intranasal products (Zhang et al., 2026).

Personalized nose-to-brain delivery may become possible through patient-specific nasal anatomy, three-dimensional nasal models, computational fluid dynamics, and optimized device parameters. Artificial intelligence and machine-learning approaches can integrate formulation, device, anatomical, deposition, and pharmacokinetic variables to predict optimal delivery conditions. Such computational approaches may reduce experimental screening and support individualized CNS therapy (Vishnumurthy et al., 2025).

Future systems are expected to incorporate smart and multifunctional nanocarriers capable of controlled release, receptor targeting, mucus interaction, cellular uptake, and environmentally responsive drug release. Biomimetic carriers, extracellular vesicles, lipid nanoparticles, and other advanced nanoplatforms may enable delivery of small molecules, proteins, peptides, antibodies, and nucleic acids. Integration of advanced formulations with precision devices, computational modeling, and personalized treatment strategies could substantially improve the clinical potential of nose-to-brain delivery (Paraiso et al., 2026).

Overall, nose-to-brain delivery represents a promising non-invasive approach for improving CNS drug exposure while reducing dependence on the BBB. Its future success will depend on reproducible targeting, long-term safety, scalable manufacturing, standardized evaluation, appropriate regulatory pathways, and convincing clinical evidence. The combination of nanotechnology, biomimetic systems, computational modeling, and personalized medicine is likely to define the next generation of CNS-targeted intranasal therapeutics (Zhang et al., 2026).

References

- Bolon, M., Fieux, M., Monge, C., & Richard, S. (2025). Polymeric nanoparticles for efficient nose-to-brain delivery. *Nanoscale, 17*, 17947–17979. https://doi.org/10.1039/D5NR00870K
- Boyuklieva, R., Zagorchev, P., & Pilicheva, B. (2023). Computational, in vitro, and in vivo models for nose-to-brain drug delivery studies. *Biomedicines, 11*(8), 2198. https://doi.org/10.3390/biomedicines11082198
- Cai, L., Li, S., Wan, C., Xu, B., Huang, H., & Xu, L. (2025). Nasal-to-brain siRNA delivery based on trace amine associated receptor for improving cognitive function. *Journal of Controlled Release, 388*(Pt. 2), 114373. https://doi.org/10.1016/j.jconrel.2025.114373
- Chen, Y., Zhang, C., Huang, Y., Ma, Y., Song, Q., Chen, H., Jiang, G., & Gao, X. (2024). Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. *Advanced Drug Delivery Reviews, 207*, 115196. https://doi.org/10.1016/j.addr.2024.115196
- Daneman, R., & Prat, A. (2015). The blood–brain barrier. *Cold Spring Harbor Perspectives in Biology, 7*(1), a020412. https://doi.org/10.1101/cshperspect.a020412
- Djupesland, P. G. (2013). Nasal drug delivery devices: Characteristics and performance in a clinical perspective—A review. *Drug Delivery and Translational Research, 3*, 42–62. https://doi.org/10.1007/s13346-012-0108-9
- Drath, I., Richter, F., & Feja, M. (2025). Nose-to-brain drug delivery: From bench to bedside. *Translational Neurodegeneration, 14*, 23. https://doi.org/10.1186/s40035-025-00481-w
- Dhuria, S. V., Hanson, L. R., & Frey, W. H., II. (2010). Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. *Journal of Pharmaceutical Sciences, 99*(4), 1654–1673. https://doi.org/10.1002/jps.21924
- D'Souza, A. A., DiFrancesco, V., Yang, A., Bleier, B. S., & Amiji, M. M. (2026). Differential targeting of olfactory epithelium and respiratory epithelium in nose-to-brain drug delivery. *Expert Opinion on Drug Delivery, 23*(1), 17–36. https://doi.org/10.1080/17425247.2025.2568093
- Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Parmar, P., Brainin, M., Murray, C. J. L., & Collaborators. (2021). The global burden of neurological disorders: Translating evidence into action. *The Lancet Neurology, 20*(7), 555–567. https://doi.org/10.1016/S1474-4422(21)00001-9
- Forbes, B., et al. (2025). Challenges and opportunities for incorporating physiological information into pharmacokinetic models of intranasal drug delivery to the brain: A review of the current status and future trajectories. *Molecular Pharmaceutics, 22*(7), 3563–3577. https://doi.org/10.1021/acs.molpharmaceut.5c00297
- Hanson, L. R., & Frey, W. H., II. (2008). Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system and treats neurodegenerative disease. *BMC Neuroscience, 9*(Suppl. 3), S5. https://doi.org/10.1186/1471-2202-9-S3-S5
- Hatem, S., Sayyed, M. E., & El-Kayal, M. (2025). Intranasal delivery of kaempferol via magnesomes for brain seizure treatment: Design, characterization, and biodistribution studies. *Journal of Pharmaceutical Sciences, 114*(6), 103780. https://doi.org/10.1016/j.xphs.2025.103780
- Huang, Q., Chen, X., Yu, S., Gong, G., & Shu, H. (2024). Research progress in brain-targeted nasal drug delivery. *Frontiers in Aging Neuroscience, 15*, 1341295. https://doi.org/10.3389/fnagi.2023.1341295

- Huang, Q., Chen, Y., Zhang, W., Xia, X., Li, H., Qin, M., & Gao, H. (2024). Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases. *Journal of Controlled Release, 366*, 519–534. https://doi.org/10.1016/j.jconrel.2023.12.054
- Illum, L. (2003). Nasal drug delivery—Possibilities, problems and solutions. *Journal of Controlled Release, 87*(1–3), 187–198. https://doi.org/10.1016/S0168-3659(02)00363-2
- Jadhav, K., et al. (2025). Targeted nasal route delivery of cationic anti-TB drug-loaded nano-embedded microparticles for mycobacterial elimination in the CNS. *Molecular Pharmaceutics, 22*(6), 3164–3178. https://doi.org/10.1021/acs.molpharmaceut.5c00106
- Jia, Y., Xu, L., Leng, S., Sun, Y., Huang, X., Wang, Y., Ren, H., Li, G., Bai, Y., Zhang, Z., Han, B., Shen, L., Ju, M., Chen, L., & Yao, H. (2025). Nose-to-brain delivery of circular RNA SCMH1-loaded lipid nanoparticles for ischemic stroke therapy. *Advanced Materials, 37*, 2500598. https://doi.org/10.1002/adma.202500598
- Kamyab, H., Jamalpour, S., Khalili, E., & Rajendran, S. (2026). Advances in nanocarrier-based nose-to-brain drug delivery systems for neurological disorders: A comprehensive review. *Powder Technology, 474*, 122244. https://doi.org/10.1016/j.powtec.2026.122244
- Khan, A. R., Liu, M., & Wang, X. (2017). Nasal drug delivery: A promising approach for the treatment of neurological disorders. *Pharmaceutical Research, 34*, 182–200.
- Komal, K., Ghosh, R., Sil, D., Sharma, R., Kumar, S., Pandey, P., & Kumar, M. (2025). Advancements in nose-to-brain drug targeting for Alzheimer's disease: A review of nanocarriers and clinical insights. *Inflammopharmacology, 33*(2), 605–626. https://doi.org/10.1007/s10787-024-01636-3
- Kotmakci, M., Bara, B., Yildirim, Z., Oner, E., Yaman, B., Akalin, T., Ozgiray, E., Kosova, B., & Bozok, V. (2025). Comparison of nose-to-brain and systemic delivery of STING agonist-loaded liposomes for glioblastoma treatment. *Journal of Drug Delivery Science and Technology, 109*, 107000. https://doi.org/10.1016/j.jddst.2025.107000
- Li, D., Chen, L., Chen, Y., Jiang, L., Wang, R., & Li, W. (2025). Temperature-sensitive hydrogel: An effective treatment for nasal drug delivery targeting the brain. *Current Drug Metabolism*. https://doi.org/10.2174/0113892002365157250422114917
- Lochhead, J. J., & Thorne, R. G. (2012). Intranasal delivery of biologics to the central nervous system. *Advanced Drug Delivery Reviews, 64*(7), 614–628. https://doi.org/10.1016/j.addr.2011.11.002
- Mistry, A., Stolnik, S., & Illum, L. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. *International Journal of Pharmaceutics, 379*(1), 146–157. https://doi.org/10.1016/j.ijpharm.2009.06.019
- Mititelu-Tartau, L., et al. (2025). Advancements in nanocarrier systems for nose-to-brain drug delivery. *Pharmaceutics, 17*.
- Papakyriakopoulou, P., & Valsami, G. (2025). The nasal route for nose-to-brain drug delivery: Advanced nasal formulations for CNS disorders. *Expert Opinion on Drug Delivery, 22*(6), 823–839. https://doi.org/10.1080/17425247.2025.2489553
- Paraiso, W. K., Palacín Ramos, C., Hossain, P. M., Alvarez Gordi, C., Guillen-Poza, P. A., Zagmutt, S., Quader, S., & Rodríguez-Rodríguez, R. (2026). Overcoming barriers: Nanomedicine-based strategies for nose-to-brain delivery. *Nanoscale, 18*, 66–89. https://doi.org/10.1039/D5NR02259B
- Pardridge, W. M. (2019). Blood–brain barrier and delivery of protein and gene therapeutics to brain. *Frontiers in Aging Neuroscience, 11*, 373. https://doi.org/10.3389/fnagi.2019.00373

- Qiu, Y., Huang, S., Peng, L., Yang, L., Zhang, G., Liu, T., Yan, F., & Peng, X. (2025). The nasal–brain drug delivery route: Mechanisms and applications to central nervous system diseases. *MedComm, 6*(6), e70213. https://doi.org/10.1002/mco2.70213
- Sharma, A., Sharma, N., Khanna, K., Arora, A., Mehan, S., & Sharma, A. (2025). Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis. *Journal of Neuroscience Methods, 418*, 110415. https://doi.org/10.1016/j.jneumeth.2025.110415
- Singh, M., Kumar, S., Vinayagam, R., & Samivel, R. (2025). Thermosensitive mucoadhesive intranasal in situ gel of risperidone for nose-to-brain targeting: Physicochemical and pharmacokinetics study. *Pharmaceuticals, 18*(6), 871. https://doi.org/10.3390/ph18060871
- Vishnumurthy, P., Radulesco, T., Bouchet, G., Regard, A., & Michel, J. (2025). Computational fluid dynamics approach for direct nose-to-brain drug delivery: A systematic review and meta-analysis. *Journal of Personalized Medicine, 15*(10), 447. https://doi.org/10.3390/jpm15100447
- Wang, et al. (2025). Precision targeting of the CNS: Recent progress in brain-directed nanodrug delivery. *RSC Advances, 15*, 25910–25928. https://doi.org/10.1039/D5RA03578C
- World Health Organization. (2022). *Global status report on the public health response to dementia*. World Health Organization.
- Xu, K., Duan, S., Wang, W., Ouyang, Q., Qin, F., Guo, P., Hou, J., He, Z., Wei, W., & Qin, M. (2024). Nose-to-brain delivery of nanotherapeutics: Transport mechanisms and applications. *WIREs Nanomedicine and Nanobiotechnology, 16*(2), e1956. https://doi.org/10.1002/wnan.1956
- Yoo, S. H., Heo, S. C., Bae, J. S., Lee, J. H., Knowles, J. C., & Kim, H.-W. (2025). Intranasal delivery systems for traumatic brain injury: Advancements and perspectives. *Journal of Tissue Engineering, 16*, 20417314251372373. https://doi.org/10.1177/20417314251372373
- Zhang, X., Chow, S., Chan, H. W., & Chow, S. F. (2026). Overcoming translational barriers in nose-to-brain drug delivery for clinical applications. *Journal of Pharmaceutical Sciences, 115*(2), 104156. https://doi.org/10.1016/j.xphs.2026.104156
- Zhang, Y., Liu, M., Wang, Y., Hu, D., Wu, S., Zhao, B., Zhou, B., & Yang, L. (2025). Nasal nanotherapeutics for central nervous system disorders: Bridging the translational gap in central nervous system drug delivery. *European Journal of Pharmacology, 1003*, 177958. https://doi.org/10.1016/j.ejphar.2025.177958
- Zhang, et al. (2025). Advances in CNS drug delivery strategies to cross the blood–brain barrier. *Chinese Chemical Letters*. https://doi.org/10.1016/j.cclet.2025.111524
- Zhang, et al. (2026). Engineered exosomes as precision tools for brain-targeted drug delivery and treatment of central nervous system diseases. *Cell Biomaterials, 2*(7), 100344. https://doi.org/10.1016/j.celbio.2025.100344

Chapter 4: Alzheimer's Disease: Molecular Pathogenesis, Biomarkers and Recent Pharmacological Advances

Hemlata Bhatt[*1], Parmar Devshree Naginbhai[2], Km Sonam[3], Mukesh Kumar Meena[4], Apurwa Amit Rewatkar[5]

[1]Assistant Professor, Departmennt of Pharmaceutical Sciences, H.N.B. Garhwal University, Srinagar Garhwal, Uttarakhand, India.

[2]Assistant Professor, Department of Pharmacology, Parul Institute of Pharmaceutical Education and Research, Faculty of Pharmacy, Parul University, Waghodia, Limda, Vadodara, Gujarat, India.

[3]Assistant Professor, School of Pharmaceutical Sciences, Faculty of Pharmacy, IFTM University, Lodhipur Rajput, Moradabad, Uttar Pradesh, India.

[4]Assistant Professor, Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, Udaipur, Rajasthan–313001, India.

[5]Assistant Professor, School of Pharmacy, G H Raisoni Skill Tech University, Shraddha Park, Hingna Wadi Link Road, Nagpur, Maharashtra, India.

*****Corresponding Author: Hemlata Bhatt, Assistant Professor, Departmennt of Pharmaceutical Sciences, H.N.B. Garhwal University, Srinagar Garhwal, Uttarakhand, India.

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and a leading cause of dementia worldwide, characterized by progressive cognitive decline, memory impairment, behavioral changes, and loss of functional independence. The pathogenesis of AD involves complex interactions among amyloid-β accumulation, tau hyperphosphorylation, neuroinflammation, oxidative stress, mitochondrial dysfunction, and synaptic degeneration, resulting in widespread neuronal loss and brain atrophy. Advances in molecular neuroscience have improved the understanding of disease mechanisms and enabled the identification of reliable biomarkers for early diagnosis and disease monitoring. Cerebrospinal fluid biomarkers, blood-based markers such as amyloid-β and phosphorylated tau, neuroimaging techniques, and emerging multi-omics approaches have significantly enhanced diagnostic accuracy and therapeutic development. Pharmacological management has progressed from symptomatic therapies, including cholinesterase inhibitors and NMDA receptor antagonists, toward disease-modifying strategies involving anti-amyloid monoclonal antibodies, anti-tau therapies, neuroinflammation modulators, and mitochondrial-targeted approaches. Furthermore, innovative drug delivery platforms, including nanotechnology-based systems, liposomes, polymeric nanoparticles, and blood–brain barrier-targeted approaches, offer promising solutions for improving therapeutic efficacy. Recent research trends involving precision medicine, gene and cell therapy, RNA-based therapeutics, and artificial intelligence-assisted diagnosis and drug discovery are opening new avenues for personalized Alzheimer's treatment. Despite significant progress, challenges related to early diagnosis, therapeutic delivery, clinical trial limitations, and disease complexity remain. Future approaches integrating biomarkers, artificial intelligence, multi-target therapeutics, and preventive strategies may provide more effective interventions and improve outcomes for individuals affected by Alzheimer's disease.

Keywords: Alzheimer's disease; amyloid-β; tau pathology; neuroinflammation; biomarkers; precision medicine; anti-amyloid therapy; nanotechnology; artificial intelligence; neurodegeneration.

1. Introduction

Alzheimer's disease (AD) is the most common cause of dementia and is a progressive neurodegenerative disorder characterized by gradual deterioration of memory, cognition, and functional abilities. The disease is marked by the accumulation of extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, synaptic dysfunction, and neuronal loss, ultimately leading to irreversible cognitive impairment and disability (Scheltens et al., 2021). Alzheimer's disease has become one of the greatest public health challenges worldwide due to increasing life expectancy and the rapidly aging population. According to recent estimates, more than 55 million people are living with dementia globally, with Alzheimer's disease accounting for approximately 60–70% of all dementia cases. The prevalence is expected to rise substantially over the coming decades, creating significant social, economic, and healthcare burdens (World Health Organization [WHO], 2023). Beyond affecting patients, Alzheimer's disease places considerable emotional, physical, and financial stress on caregivers and healthcare systems, emphasizing the urgent need for improved diagnostic strategies and effective therapeutic interventions (Livingston et al., 2024).

Clinically, Alzheimer's disease typically begins with subtle memory impairment, particularly affecting recent memory, followed by progressive deterioration in learning, language, executive function, orientation, and problem-solving abilities. As the disease advances, patients frequently develop behavioral and psychological symptoms including depression, anxiety, agitation, hallucinations, sleep disturbances, and personality changes, which further reduce quality of life and increase caregiver burden (Scheltens et al., 2021). Disease progression generally occurs through preclinical, mild cognitive impairment (MCI), mild dementia, moderate dementia, and severe dementia stages, eventually resulting in complete dependence for daily activities and loss of independent functioning (Jack et al., 2018).

The development of Alzheimer's disease is influenced by multiple interacting risk factors. Advancing age remains the strongest non-modifiable risk factor, with disease incidence increasing markedly after 65 years of age. Genetic factors also play an important role, particularly mutations in the *APP*, *PSEN1*, and *PSEN2* genes associated with early-onset familial Alzheimer's disease, while the *APOE* ε4 allele significantly increases susceptibility to the more common late-onset form (Long & Holtzman, 2019). Environmental exposures, vascular disorders, traumatic brain injury, chronic inflammation, and metabolic abnormalities may further contribute to disease development. Additionally, modifiable lifestyle factors such as physical inactivity, smoking, obesity, diabetes mellitus, hypertension, unhealthy diet, excessive alcohol consumption, poor sleep quality, and limited cognitive engagement have been associated with an increased risk of Alzheimer's disease, highlighting the importance of preventive strategies aimed at reducing these risk factors (Livingston et al., 2024; WHO, 2023).

2. Molecular Pathogenesis of Alzheimer's Disease

Alzheimer's disease (AD) develops through a complex interaction of multiple molecular pathways that progressively impair neuronal function and ultimately result in cognitive decline. Although the

exact sequence of pathological events remains under investigation, the amyloid cascade hypothesis, tau pathology, neuroinflammation, oxidative stress, mitochondrial dysfunction, and synaptic degeneration are recognized as the principal mechanisms driving disease progression. These interconnected processes contribute to neuronal dysfunction, loss of synaptic connectivity, and irreversible neurodegeneration.

2.1 Amyloid Cascade Hypothesis

The amyloid cascade hypothesis remains the most widely accepted model explaining the initiation of Alzheimer's disease. Amyloid precursor protein (APP), a transmembrane glycoprotein normally involved in neuronal growth and synaptic maintenance, undergoes abnormal cleavage by β-secretase (BACE1) followed by γ-secretase instead of the non-amyloidogenic α-secretase pathway. This sequential cleavage generates amyloid-β (Aβ) peptides, particularly the highly aggregation-prone Aβ42 isoform. Soluble Aβ oligomers progressively aggregate into fibrils and extracellular amyloid plaques that disrupt synaptic signaling, activate inflammatory pathways, impair neuronal communication, and trigger downstream tau pathology and neuronal death.

Table 2.1. Amyloid cascade pathway in Alzheimer's disease

Component	Physiological Role	Pathological Change in AD
APP	Neuronal growth and synaptic maintenance	Abnormal enzymatic cleavage
β-Secretase (BACE1)	Initiates amyloidogenic processing	Increased Aβ production
γ-Secretase	Produces Aβ peptides	Generates toxic Aβ42
Amyloid-β oligomers	Normally absent/minimal	Synaptic toxicity
Amyloid plaques	Not present in healthy brain	Extracellular plaque deposition and neuronal injury

2.2 Tau Protein Pathology

Tau is a microtubule-associated protein responsible for stabilizing neuronal microtubules and maintaining axonal transport. In Alzheimer's disease, abnormal kinase activity causes excessive tau hyperphosphorylation, reducing its affinity for microtubules. The detached tau proteins aggregate into paired helical filaments and eventually form intracellular neurofibrillary tangles (NFTs). These tangles impair axonal transport, disrupt intracellular communication, and contribute directly to neuronal degeneration. The distribution of tau pathology closely correlates with disease severity and cognitive impairment.

2.3 Neuroinflammation

Persistent neuroinflammation is a major contributor to Alzheimer's disease progression. Amyloid-β accumulation activates microglia, the resident immune cells of the central nervous system. Initially, activated microglia help clear Aβ deposits; however, chronic activation leads to excessive production of inflammatory mediators. Astrocytes also become reactive, losing their supportive functions and further amplifying inflammation. Elevated levels of cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) promote neuronal injury, impair synaptic plasticity, and accelerate both amyloid and tau pathology.

2.4 Oxidative Stress and Mitochondrial Dysfunction

Oxidative stress occurs when excessive reactive oxygen species (ROS) overwhelm the brain's antioxidant defense system. In Alzheimer's disease, Aβ accumulation and mitochondrial dysfunction increase ROS generation, leading to lipid peroxidation, protein oxidation, DNA damage, and impaired cellular metabolism. Mitochondrial dysfunction further reduces ATP production and disturbs calcium homeostasis, ultimately activating apoptotic signaling pathways that contribute to progressive neuronal loss.

2.5 Synaptic Dysfunction and Neuronal Loss

Synaptic dysfunction represents one of the earliest pathological events in Alzheimer's disease and closely correlates with cognitive decline. Accumulation of amyloid-β and hyperphosphorylated tau disrupts neurotransmitter release, particularly affecting cholinergic and glutamatergic signaling. Progressive synaptic degeneration reduces neuronal connectivity and plasticity, while continuous neuronal loss leads to cerebral atrophy, especially in the hippocampus and cerebral cortex. These structural and functional alterations are responsible for progressive memory impairment and deterioration of higher cognitive functions.

Table 2.2. Major molecular mechanisms involved in Alzheimer's disease

Molecular mechanism	Major pathological event	Clinical consequence
Amyloid-β accumulation	Extracellular plaque formation	Synaptic dysfunction
Tau hyperphosphorylation	Neurofibrillary tangles	Neuronal degeneration
Neuroinflammation	Microglial and astrocyte activation	Chronic neuronal injury
Oxidative stress	ROS-mediated cellular damage	Apoptosis
Mitochondrial dysfunction	Reduced ATP production	Energy failure
Synaptic degeneration	Neurotransmitter imbalance	Cognitive decline
Brain atrophy	Progressive neuronal loss	Dementia progression

3. Biomarkers in Alzheimer's Disease

Biomarkers have transformed the diagnosis and management of Alzheimer's disease (AD) by enabling the detection of pathological changes years before the appearance of clinical symptoms. Current biomarkers evaluate the core pathological processes of amyloid deposition, tau pathology, neurodegeneration, and neuroinflammation. They are obtained from cerebrospinal fluid (CSF), blood, neuroimaging, and emerging multi-omics technologies, supporting early diagnosis, disease staging, prognosis, and therapeutic monitoring. Recent diagnostic criteria emphasize the integration of fluid and imaging biomarkers to establish a biological diagnosis of Alzheimer's disease.

3.1 Cerebrospinal Fluid (CSF) Biomarkers

CSF biomarkers remain the gold standard for detecting Alzheimer's disease pathology. A reduction in amyloid-β42 (Aβ42) reflects cerebral amyloid plaque deposition, whereas elevated total tau (t-tau) indicates neuronal injury and degeneration. Increased phosphorylated tau (p-tau181, p-tau217, or p-tau231) is highly specific for tau pathology and neurofibrillary tangle formation. The combined

assessment of Aβ42, t-tau, and p-tau provides excellent diagnostic accuracy and is widely used in both clinical practice and research for identifying early Alzheimer's disease.

3.2 Blood-Based Biomarkers

Blood-based biomarkers have emerged as minimally invasive and cost-effective alternatives to CSF analysis. Plasma Aβ42/40 ratio reflects cerebral amyloid pathology, while plasma phosphorylated tau, particularly p-tau217 and p-tau181, demonstrates high sensitivity and specificity for Alzheimer's disease. Neurofilament light chain (NfL) serves as a marker of axonal injury and neurodegeneration, whereas glial fibrillary acidic protein (GFAP) reflects astrocyte activation and neuroinflammation. These biomarkers have considerable potential for large-scale screening, disease monitoring, and identifying patients who may benefit from disease-modifying therapies.

Table 3.1. Major fluid biomarkers used in Alzheimer's disease

Biomarker	Sample	Clinical significance
Aβ42	CSF	Indicates amyloid plaque deposition
Total tau (t-tau)	CSF	Marker of neuronal injury
Phosphorylated tau (p-tau181/p-tau217)	CSF/Plasma	Specific indicator of tau pathology
Plasma Aβ42/40 ratio	Blood	Detects cerebral amyloid burden
Neurofilament light chain (NfL)	Blood/CSF	Marker of neurodegeneration
GFAP	Blood	Indicates astrocyte activation and neuroinflammation

3.3 Neuroimaging Biomarkers

Neuroimaging biomarkers provide valuable structural and functional information about Alzheimer's disease. Magnetic resonance imaging (MRI) detects hippocampal and cortical atrophy associated with disease progression. Fluorodeoxyglucose positron emission tomography (FDG-PET) evaluates regional cerebral glucose metabolism and identifies areas of neuronal dysfunction. Amyloid PET directly visualizes amyloid plaque deposition, while tau PET measures the distribution and progression of tau pathology. Together, these imaging techniques improve diagnostic accuracy, facilitate disease staging, and monitor therapeutic responses.

3.4 Emerging Biomarkers

Recent advances have expanded the range of biomarkers beyond conventional fluid and imaging methods. Exosomal biomarkers carry proteins and nucleic acids that reflect neuronal pathology, while circulating microRNAs regulate gene expression and may serve as early diagnostic indicators. Proteomics and metabolomics identify disease-associated protein and metabolic signatures, providing insights into disease mechanisms. Digital biomarkers derived from wearable devices, smartphones, and cognitive assessment platforms enable continuous monitoring of cognitive function. Furthermore, artificial intelligence (AI) and machine learning algorithms integrate multimodal biomarker datasets to improve early diagnosis, predict disease progression, and support personalized treatment strategies.

Table 3.2. Emerging biomarkers and their potential clinical applications

Emerging biomarker	Principle	Potential application
Exosomal biomarkers	Extracellular vesicle analysis	Early diagnosis and disease monitoring
MicroRNAs	Gene expression regulation	Diagnostic and prognostic biomarker
Proteomics	Protein profiling	Identification of novel therapeutic targets
Metabolomics	Metabolic fingerprinting	Disease mechanism and progression assessment
Digital biomarkers	Wearable devices and cognitive monitoring	Remote disease tracking
Artificial intelligence	Integration of multimodal biomarker data	Early diagnosis, prognosis, and personalized medicine

4. Pharmacological Advances in Alzheimer's Disease

Pharmacological management of Alzheimer's disease (AD) has evolved from symptomatic treatment approaches toward disease-modifying strategies targeting the underlying molecular mechanisms of neurodegeneration. Conventional drugs mainly improve neurotransmission and temporarily reduce cognitive symptoms, whereas newer therapeutic approaches aim to modify amyloid pathology, tau abnormalities, neuroinflammation, oxidative stress, and synaptic dysfunction. The development of biomarker-guided therapies and targeted drug delivery systems has opened new possibilities for precision treatment of Alzheimer's disease.

4.1 Currently Approved Drugs

Currently available pharmacological treatments primarily provide symptomatic benefits by improving neurotransmitter function. Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine increase acetylcholine availability by preventing its enzymatic degradation, thereby improving memory, attention, and cognitive performance in mild-to-moderate AD. However, their effects are temporary and do not prevent disease progression. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, regulates excessive glutamate-mediated excitotoxicity and is approved for moderate-to-severe AD. Combination therapy with cholinesterase inhibitors and memantine is frequently used to provide additional symptomatic improvement in advanced disease stages.

4.2 Disease-Modifying Therapies

Recent advances have shifted Alzheimer's treatment toward disease-modifying therapies that directly target pathological mechanisms. Anti-amyloid monoclonal antibodies represent the first successful class of disease-modifying agents. Drugs such as aducanumab, lecanemab, and donanemab selectively bind different forms of amyloid-β aggregates and promote their clearance through microglial-mediated mechanisms. Clinical studies demonstrate that these therapies can reduce amyloid plaque burden and moderately slow cognitive decline, particularly when administered during early symptomatic disease. However, their clinical use requires careful patient selection and monitoring because of adverse effects such as amyloid-related imaging abnormalities (ARIA).

Anti-tau therapies represent another important therapeutic direction because tau pathology correlates strongly with neuronal dysfunction and disease progression. Current approaches include tau

aggregation inhibitors, tau-directed antibodies, antisense oligonucleotides, and vaccines designed to reduce abnormal tau accumulation. Although several anti-tau candidates are under clinical investigation, achieving effective delivery across the blood–brain barrier remains a major challenge.

Table 4.1. Approved and emerging pharmacological therapies for Alzheimer's disease

Therapeutic category	Examples	Mechanism of action	Therapeutic outcome
Cholinesterase inhibitors	Donepezil, Rivastigmine, Galantamine	Increase acetylcholine levels	Improve cognitive symptoms
NMDA receptor antagonist	Memantine	Reduces glutamate excitotoxicity	Improves function in moderate-severe AD
Anti-amyloid antibodies	Lecanemab, Donanemab, Aducanumab	Removes amyloid-β plaques	Slows cognitive decline
Anti-tau therapies	Tau antibodies, tau aggregation inhibitors	Reduces tau pathology	Prevents neurodegeneration (under investigation)

4.3 Novel Therapeutic Targets

Because Alzheimer's disease involves multiple pathological pathways, several novel targets are being explored. Neuroinflammation modulators aim to regulate excessive activation of microglia and astrocytes while reducing inflammatory mediators such as IL-1β, IL-6, and TNF-α. Antioxidant-based therapies focus on reducing reactive oxygen species and protecting neurons from oxidative damage. Mitochondrial-targeted therapies attempt to restore energy metabolism, improve mitochondrial function, and prevent neuronal apoptosis.

Synaptic protection strategies are also gaining importance because synaptic loss strongly correlates with cognitive impairment. Therapeutic approaches targeting neurotrophic factors, synaptic signaling pathways, and neuronal plasticity may help preserve cognitive function. Recent research emphasizes multi-target approaches because amyloid removal alone provides limited clinical benefit due to the complex nature of Alzheimer's pathology.

4.4 Drug Delivery Approaches

Effective treatment of Alzheimer's disease is limited by poor penetration of many therapeutic molecules across the blood–brain barrier (BBB). Nanotechnology-based drug delivery systems have emerged as promising approaches to improve brain targeting and therapeutic efficiency. Liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles can enhance drug stability, controlled release, and BBB transport.

Polymeric nanoparticles can encapsulate small molecules, peptides, and genetic materials while providing sustained drug release and targeted delivery to neuronal tissues. Intranasal drug delivery is another promising strategy because it allows direct transport of therapeutics from the nasal cavity to the brain while reducing systemic exposure. Advanced BBB-targeting approaches using ligands, antibodies, and receptor-mediated transport systems are being investigated to improve therapeutic accumulation in affected brain regions.

4.5 Combination Therapy and Personalized Medicine

The multifactorial nature of Alzheimer's disease suggests that single-target therapies may not provide complete disease control. Combination therapy approaches aim to simultaneously target amyloid deposition, tau pathology, inflammation, oxidative stress, and neuronal dysfunction. Multi-target drugs and drug combinations may provide synergistic effects by addressing multiple pathological mechanisms.

Personalized medicine represents the future direction of Alzheimer's treatment, where therapeutic selection is guided by genetic information, biomarker profiles, disease stage, and individual patient characteristics. Integration of biomarkers, artificial intelligence, and pharmacogenomic approaches may allow clinicians to identify suitable therapies and optimize treatment outcomes.

Table 4.2. Emerging therapeutic strategies and future perspectives

Therapeutic strategy	Target/pathway	Potential advantage
Neuroinflammation inhibitors	Microglia and inflammatory cytokines	Reduces chronic neuronal damage
Antioxidant therapy	ROS and oxidative stress pathways	Protects neuronal cells
Mitochondrial therapies	Energy metabolism	Improves neuronal survival
Nanotechnology delivery	BBB penetration and controlled release	Enhances brain drug availability
Combination therapy	Multiple disease pathways	Provides synergistic effects
Personalized medicine	Genetic and biomarker-guided treatment	Improves therapeutic precision

5. Recent Research Trends and Future Perspectives

Recent advances in Alzheimer's disease (AD) research have shifted from conventional symptomatic management toward precision-based, multidisciplinary approaches that integrate genomics, advanced therapeutics, artificial intelligence (AI), and biomarker-guided strategies. Due to the complex and heterogeneous nature of AD, future interventions are expected to focus on individualized treatment approaches targeting specific molecular abnormalities, disease stages, and patient characteristics. (Kanda et al., 2025)

5.1 Precision Medicine

Precision medicine represents a major transformation in Alzheimer's disease management by tailoring prevention and treatment strategies according to individual biological characteristics. Genomic studies have identified several susceptibility genes, including *APOE*, *APP*, *PSEN1*, and *PSEN2*, that influence disease risk and progression. Pharmacogenomics further evaluates how genetic variations affect drug response, toxicity, and therapeutic outcomes, allowing improved selection of appropriate treatments. Integration of genetic information, molecular biomarkers, imaging findings, and clinical characteristics may enable personalized treatment plans and improve therapeutic success. (Kanda et al., 2025)

5.2 Gene and Cell Therapy

Gene and cell-based therapies represent emerging approaches aimed at correcting or modifying disease-associated molecular abnormalities. CRISPR-based gene-editing technologies provide opportunities to modify pathogenic genes, regulate amyloid and tau pathways, and restore neuronal function. Recent developments in CRISPR delivery systems, including viral vectors, lipid nanoparticles, and extracellular vesicles, may improve targeting of therapeutic molecules to the central nervous system. (Zhang et al., 2025)

Stem cell therapy is another promising strategy for replacing damaged neurons, enhancing neurogenesis, and restoring synaptic networks. Mesenchymal stem cells and induced pluripotent stem cell (iPSC)-derived neuronal models are being investigated for their regenerative and neuroprotective effects. Additionally, RNA-based therapeutics, including antisense oligonucleotides, microRNA modulators, and messenger RNA approaches, offer potential methods for regulating abnormal protein expression associated with Alzheimer's pathology.

5.3 Artificial Intelligence in Alzheimer's Research

Artificial intelligence has become an important tool in Alzheimer's research by enabling analysis of large-scale clinical, imaging, genetic, and molecular datasets. Machine learning and deep learning algorithms can improve early diagnosis by identifying subtle patterns in brain imaging, cognitive assessments, and biomarker profiles before significant clinical symptoms appear. AI-based approaches are also accelerating drug discovery through molecular screening, target identification, and prediction of therapeutic responses. (Qi et al., 2025)

AI-supported clinical decision systems may assist physicians in disease staging, treatment selection, and monitoring of disease progression. Digital biomarkers obtained from speech analysis, wearable devices, eye tracking, and behavioral monitoring are emerging as non-invasive tools for continuous assessment of cognitive changes. However, improving model reliability, interpretability, and clinical validation remains essential before widespread implementation. (Qi et al., 2025)

5.4 Current Challenges

Despite significant progress, several challenges continue to limit successful Alzheimer's disease treatment. Early diagnosis remains difficult because pathological changes begin years before clinical symptoms become evident. Although biomarkers have improved early detection, accessibility, cost, and standardization remain major limitations.

The blood–brain barrier (BBB) represents another significant obstacle by restricting the delivery of many therapeutic molecules into the brain. Advanced delivery platforms and targeting strategies are required to improve drug penetration and therapeutic effectiveness. Furthermore, many clinical trials have failed due to disease complexity, inappropriate treatment timing, insufficient patient selection, and the involvement of multiple pathological pathways beyond amyloid and tau. Safety concerns, including immune reactions and adverse effects associated with emerging therapies, also require careful evaluation. (Zafar et al., 2026)

5.5 Future Directions

Future Alzheimer's research is expected to move toward multi-target therapeutic strategies that simultaneously regulate amyloid accumulation, tau pathology, neuroinflammation, oxidative stress, and synaptic dysfunction. Biomarker-guided treatment selection will become increasingly important for identifying suitable patients and evaluating therapeutic responses.

The integration of precision neurology, artificial intelligence, multi-omics analysis, and advanced drug delivery systems may enable individualized disease prevention and management. Preventive strategies focusing on lifestyle modification, vascular health, cognitive stimulation, and early intervention during preclinical disease stages may significantly reduce the future burden of Alzheimer's disease. (Priyanka et al., 2025)

Table 5.1. Emerging research trends and future perspectives in Alzheimer's disease

Research area	Current advancement	Future potential
Precision medicine	Genomics, pharmacogenomics, biomarker-based treatment	Individualized therapeutic strategies
Gene therapy	CRISPR editing and RNA-based approaches	Correction of disease-associated molecular defects
Cell therapy	Stem cells and neuronal regeneration approaches	Restoration of damaged neural networks
Artificial intelligence	AI-based diagnosis, imaging analysis, and drug discovery	Predictive and personalized healthcare
Digital biomarkers	Wearable devices and behavioral monitoring	Continuous disease tracking
Multi-target therapy	Combined targeting of amyloid, tau, inflammation, and oxidative stress	Improved disease modification
Preventive strategies	Lifestyle and risk-factor management	Delayed disease onset and progression

6. Conclusion

Alzheimer's disease is a complex and multifactorial neurodegenerative disorder involving the interaction of several pathological pathways, including amyloid-β accumulation, tau hyperphosphorylation, neuroinflammation, oxidative stress, mitochondrial impairment, and progressive synaptic dysfunction. These molecular events do not occur independently but form interconnected networks that accelerate neuronal damage, brain atrophy, and cognitive decline. Understanding these mechanisms has provided important opportunities for developing targeted therapeutic strategies aimed at modifying disease progression rather than only managing symptoms.

The advancement of biomarker research has significantly improved the understanding, diagnosis, and monitoring of Alzheimer's disease. Cerebrospinal fluid biomarkers, blood-based biomarkers such as plasma phosphorylated tau and amyloid-β ratios, neuroimaging approaches, and emerging multi-omics technologies enable earlier detection of pathological changes and better evaluation of treatment responses. Biomarker-guided approaches are becoming increasingly important for patient selection,

monitoring disease progression, and improving the efficiency of clinical trials for disease-modifying therapies.

Pharmacological research in Alzheimer's disease has progressed from traditional symptomatic treatments, including cholinesterase inhibitors and NMDA receptor antagonists, toward disease-modifying therapies targeting amyloid and tau pathology. The emergence of anti-amyloid monoclonal antibodies represents an important milestone, while future therapies are expected to incorporate anti-tau strategies, neuroinflammation modulators, mitochondrial protectants, nanotechnology-based delivery systems, and combination approaches. Targeted drug delivery platforms, particularly those capable of improving blood–brain barrier penetration, may further enhance therapeutic effectiveness.

Despite remarkable progress, several challenges remain, including limited understanding of disease heterogeneity, difficulties in early diagnosis, restricted brain delivery of therapeutics, safety concerns, and inconsistent outcomes of clinical trials. Future research should focus on integrating precision medicine, artificial intelligence, biomarker-driven treatment selection, and preventive interventions to develop more effective and personalized approaches. A combination of molecular understanding, advanced diagnostics, and innovative therapeutics may ultimately improve disease prevention, delay progression, and enhance quality of life for individuals affected by Alzheimer's disease.

References

- Alan, E., Kerry, Z., & Sevin, G. (2023). Molecular mechanisms of Alzheimer's disease: From therapeutic targets to promising drugs. *Fundamental & Clinical Pharmacology, 37*(2), 229–255.
- Ankeny, S. E., Bacci, J. R., Decourt, B., Sabbagh, M. N., & Mielke, M. M. (2024). Navigating the landscape of plasma biomarkers in Alzheimer's disease: Focus on past, present, and future clinical applications. *Neurology and Therapy, 13*, 1541–1557.
- Bhatia, V., Chandel, A., Minhas, Y., & Kushawaha, S. K. (2025). Advances in biomarker discovery and diagnostics for Alzheimer's disease. *Neurological Sciences, 46*, 2419–2436. https://doi.org/10.1007/s10072-025-08023-y
- Chen, Y., & Yu, Y. (2023). Tau and neuroinflammation in Alzheimer's disease: Interplay mechanisms and clinical translation. *Journal of Neuroinflammation, 20*, 165.
- Choi, S. B., Kwon, S., Kim, J. H., Ahn, N. H., Lee, J. H., & Yang, S. H. (2023). The molecular mechanisms of neuroinflammation in Alzheimer's disease, the consequence of neural cell death. *International Journal of Molecular Sciences, 24*(14), 11757.
- Cummings, J., Aisen, P., Apostolova, L. G., et al. (2024). Acceptable performance of blood biomarker tests of amyloid pathology—Recommendations from the Global CEO Initiative on Alzheimer's Disease. *Nature Reviews Neurology*.
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., Salloway, S., & Jack, C. R. (2023). Lecanemab: Appropriate use recommendations. *The Journal of Prevention of Alzheimer's Disease, 10*, 362–377.
- Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., & Sperling, R. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia, 14*(4), 535–562.

- Jack, C. R., Jr., Bennett, D. A., Blennow, K., et al. (2024). Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & Dementia, 20*(8), 5143–5169.
- Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023). The neuroimmune axis of Alzheimer's disease. *Genome Medicine, 15*, 6.
- Kanda, A., Rani, A., & Mazumder, A. (2025). Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease. *Pharmacogenomics, 26*(10–12), 455–474. https://doi.org/10.1080/14622416.2025.2560296
- Livingston, G., Huntley, J., Liu, K. Y., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., … Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. *The Lancet*.
- Long, J. M., & Holtzman, D. M. (2019). Alzheimer disease: An update on pathobiology and treatment strategies. *Cell, 179*(2), 312–339.
- Mielke, M. M., & Fowler, N. R. (2024). Alzheimer disease blood biomarkers: Considerations for population-level use. *Nature Reviews Neurology, 20*, 495–504.
- Palmqvist, S., Whitson, H. E., Allen, L. A., Carrillo, M. C., Edelmayer, R. M., Galasko, D. R., Hansson, O., Karikari, T. K., Schindler, S. E., Teunissen, C. E., Zetterberg, H., & Tampi, M. (2025). Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. *Alzheimer's & Dementia, 21*, e70535. https://doi.org/10.1002/alz.70535
- Priyanka, S., Manjari, T., Hemalatha, S., Yılmaz, B., Aktürk, B., Arısan, E. D., Kumari, A., & Manojkumar, Y. (2025). Precision therapeutics for Alzheimer's disease. *Progress in Brain Research, 297*, 247–276. https://doi.org/10.1016/bs.pbr.2025.08.011
- Qi, W., Zhu, X., Wang, B., Shi, Y., Dong, C., Shen, S., Zhao, M., et al. (2025). Alzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review. *npj Digital Medicine, 8*, 366. https://doi.org/10.1038/s41746-025-01640-z
- Rafii, M. S., & Aisen, P. S. (2025). Amyloid-lowering immunotherapies for Alzheimer disease: Current status and future directions. *Nature Reviews Neurology, 21*, 490–498.
- Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021). Alzheimer's disease. *The Lancet, 397*(10284), 1577–1590.
- Schneider, L. S. (2025). Biomarkers and their place in dementia research and practice—the Lancet Commission recommendations. *Alzheimer's & Dementia, 20*(Suppl. 4), e085065. https://doi.org/10.1002/alz.085065
- Self, W. K., & Holtzman, D. M. (2023). Emerging diagnostics and therapeutics for Alzheimer disease. *Nature Medicine, 29*, 2187–2199.
- Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., & Mintun, M. A. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA, 330*(6), 512–527.
- Thal, D. R., Poesen, K., Vandenberghe, R., & De Meyer, S. (2025). Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers. *Molecular Neurodegeneration, 20*, 33.
- van Dyck, C. H. (2023). Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: A new era. *New England Journal of Medicine, 388*, 197–201.

- Walker, K. A., et al. (2024). Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology. *Archives of Clinical Neuropsychology, 39*(3), 313–324.
- Wang, H., Pan, J., Zhang, M., Tan, Z., et al. (2025). Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease. *Frontiers in Pharmacology, 16*, 1599048.
- Wiatrak, B., Jawień, P., Szeląg, A., & Jęśkowiak-Kossakowska, I. (2023). Does inflammation play a major role in the pathogenesis of Alzheimer's disease? *NeuroMolecular Medicine, 25*, 330–335.
- World Health Organization. (2023). *Dementia*. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dementia
- Yadollahikhales, G., et al. (2024). Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer's disease? An umbrella review. *IBRO Neuroscience Reports, 16*, 403–417.
- Zafar, I., Khan, M. S., Jamal, A., Shafiq, S., Bahwerth, F. S., & Khan, N. U. (2026). Precision therapeutic strategies for Alzheimer's disease: Amyloid β-targeted foundations and multimodal next-generation approaches. *Molecular and Cellular Neuroscience, 136*, 104070. https://doi.org/10.1016/j.mcn.2025.104070
- Zetterberg, H., & Bendlin, B. B. (2026). Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias. *Nature, 650*, 49–59.
- Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023). Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future. *Signal Transduction and Targeted Therapy, 8*, 248.
- Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2025). Critical nodes in precision diagnosis and treatment of Alzheimer's disease: Exploration of multidimensional biomarkers and prospects for targeted intervention. *Journal of the Neurological Sciences, 479*, 123734. https://doi.org/10.1016/j.jns.2025.123734
- Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2025). Next-generation CRISPR gene editing tools in the precision treatment of Alzheimer's and Parkinson's disease. *Ageing Research Reviews, 111*, 102851. https://doi.org/10.1016/j.arr.2025.102851
- Zhou, Y., Chen, Y., & Wang, X. (2025). Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: Current landscape and future perspectives. *Molecular Neurobiology*. https://pubmed.ncbi.nlm.nih.gov/39865265/

Chapter 5: Parkinson's Disease: Disease Mechanisms and Emerging Therapeutic Strategies

Amol Kalyanrao More[*1], Mr. Nilesh Pundlik Salunkhe[2], Dr. Manoj Kumar Katual[3], Sejal G. Patel[4], Chetana Sudhakar Selukar[5]

[1]*Assistant Professor, Department of Pharmacology, H.K. College of Pharmacy, HK Campus, Relief Road, Oshiwara, Jogeshwari West, Mumbai, Maharashtra, India.*

[2]*Research Scholar, Department of Pharmaceutics, Career Point University, Kota, NH 52, Opposite Alaniya Mata Ji Mandir, Alaniya, Kota, Rajasthan 325003, India.*

[3]*Principal & Professor, Department of Pharmaceutical Sciences, Florence College of Pharmacy, Irba, Ranchi, Jharkhand, India.*

[4]*Professor, Nootan Pharmacy College, Sankalchand Patel University, SK Campus, Visnagar–384315, Gujarat, India.*

[5]*Assistant Professor, Department of Pharmacy, G H Raisoni Skill Tech University, Shraddha Park, Wadi-Hingna Link Road, MIDC Road, Nagpur–440028, Maharashtra, India.*

*Corresponding Author: Amol Kalyanrao More, Assistant Professor, Pharmacology, H.K. College of Pharmacy, HK Campus, Relief Road, Oshiwara, Jogeshwari West, Mumbai, Maharashtra, India.

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and represents a major global health challenge due to progressive neuronal loss, increasing prevalence, and significant impact on patient quality of life. The disease is primarily characterized by degeneration of dopaminergic neurons in the substantia nigra, leading to impaired dopamine signaling and the development of cardinal motor symptoms, including tremor, bradykinesia, rigidity, and postural instability. In addition to motor dysfunction, Parkinson’s disease involves complex non-motor manifestations associated with cognitive impairment, mood disorders, sleep abnormalities, and autonomic dysfunction. The pathogenesis of PD is multifactorial and involves α-synuclein aggregation, Lewy body formation, mitochondrial dysfunction, oxidative stress, neuroinflammation, impaired protein clearance, genetic abnormalities, and altered gut–brain interactions. Current therapeutic approaches, including levodopa-based treatment, dopamine agonists, enzyme inhibitors, deep brain stimulation, and rehabilitation strategies, primarily provide symptomatic improvement but do not prevent disease progression. Recent advances in molecular neuroscience have identified several promising disease-modifying strategies, including α-synuclein-targeted therapies, gene and RNA-based approaches, stem cell-based regeneration, nanotechnology-mediated drug delivery, and neuroprotective compounds derived from natural products. Emerging diagnostic approaches involving biomarkers, advanced neuroimaging, artificial intelligence, and precision medicine are expected to improve early detection and individualized treatment strategies. This chapter summarizes the current understanding of Parkinson’s disease mechanisms, available therapeutic approaches, and future directions toward developing effective disease-modifying and regenerative therapies. Continued integration of molecular biology, genetics, nanotechnology, and computational approaches may provide new opportunities for delaying neurodegeneration and improving long-term outcomes in Parkinson’s disease patients.

Keywords: Parkinson's disease; neurodegeneration; dopaminergic neurons; α-synuclein; Lewy bodies; mitochondrial dysfunction; neuroinflammation; gene therapy; stem cell therapy; nanotechnology; precision medicine

1. Introduction and Overview of Parkinson's Disease

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized mainly by the degeneration of dopaminergic neurons in the substantia nigra region of the brain, resulting in impaired dopamine signaling and gradual loss of motor control. It is considered the second most common neurodegenerative disease after Alzheimer's disease and represents a major global health challenge due to increasing prevalence, disability, and healthcare burden (Dorsey et al., 2018). Parkinson's disease was first systematically described in 1817 by James Parkinson in his classical work *"An Essay on the Shaking Palsy,"* where he reported the characteristic tremor, abnormal posture, and movement difficulties associated with the disorder. Over time, research has revealed that PD is not limited to motor dysfunction but involves complex pathological changes affecting cognition, mood, sleep, and autonomic functions (Kalia & Lang, 2015). The global burden of Parkinson's disease has increased significantly due to population aging, improved life expectancy, and environmental influences, creating substantial challenges for patients, caregivers, and healthcare systems worldwide (World Health Organization [WHO], 2023).

The epidemiology of Parkinson's disease demonstrates considerable variation across populations, with age being the strongest risk factor. The incidence and prevalence of PD increase markedly in older adults, particularly after the age of 60 years. Males are generally affected more frequently than females, suggesting possible contributions from genetic, hormonal, and environmental differences (Dorsey et al., 2018). Recent epidemiological studies indicate that the number of individuals affected by PD continues to rise globally, partly due to increasing life expectancy and demographic changes (Ou et al., 2021). Genetic factors contribute significantly to disease susceptibility, particularly mutations associated with genes such as *SNCA*, *LRRK2*, *PINK1*, *PARKIN*, and *DJ-1*. However, most Parkinson's disease cases are sporadic and result from complex interactions between genetic predisposition and environmental exposures. Factors such as pesticide exposure, industrial toxins, head injury, and oxidative stress have been implicated in increasing disease risk, whereas physical activity and certain lifestyle factors may provide protective effects (Nalls et al., 2019; Dorsey et al., 2018).

Clinically, Parkinson's disease develops gradually and progresses through multiple stages. The classical motor symptoms include resting tremor, bradykinesia (slowness of movement), muscular rigidity, and postural instability. These symptoms occur mainly due to progressive loss of dopamine-producing neurons in the nigrostriatal pathway. In addition to motor abnormalities, PD patients frequently experience non-motor symptoms such as cognitive impairment, depression, anxiety, sleep disorders, fatigue, constipation, and autonomic dysfunction. Interestingly, many non-motor symptoms may appear years before the development of motor manifestations, indicating a long prodromal phase of disease progression (Poewe et al., 2017).

The progression of Parkinson's disease is commonly divided into early, middle, and advanced stages. In the early stage, patients usually experience mild motor symptoms that can be effectively controlled with medication. During the middle stage, symptoms become more pronounced, and complications related to long-term treatment may develop. In advanced disease stages, patients may experience severe movement difficulties, cognitive decline, and reduced independence, requiring continuous

medical and social support (Armstrong & Okun, 2020). Understanding the clinical progression and risk factors of Parkinson's disease is essential for developing early diagnostic strategies and effective disease-modifying therapies.

2. Molecular and Cellular Mechanisms of Parkinson's Disease

2.1 Neurodegeneration in Parkinson's Disease

Parkinson's disease is primarily characterized by progressive degeneration of dopaminergic neurons located in the substantia nigra pars compacta. These neurons are responsible for producing dopamine, a neurotransmitter essential for regulating voluntary movement. The loss of these neurons results in reduced dopamine availability in the striatum and disruption of the nigrostriatal pathway, which plays a critical role in motor coordination. Although the exact cause of neuronal vulnerability remains unclear, factors such as oxidative stress, mitochondrial impairment, protein aggregation, and neuroinflammation contribute to progressive neuronal damage (Braak et al., 2003).

The decline of dopaminergic signaling directly correlates with the severity of motor symptoms observed in Parkinson's disease. When approximately 50–60% of substantia nigra dopaminergic neurons are lost, patients begin to develop characteristic symptoms such as resting tremor, bradykinesia, rigidity, and postural instability. The selective vulnerability of these neurons is associated with their high metabolic activity, extensive axonal networks, and increased susceptibility to oxidative damage (Surmeier, 2018).

Table 2.1. Major Cellular Mechanisms Involved in Dopaminergic Neuronal Degeneration in Parkinson's Disease

Mechanism	Cellular Changes	Contribution to PD Progression
Dopaminergic neuronal loss	Death of substantia nigra neurons	Reduced dopamine levels and motor impairment
Mitochondrial dysfunction	Impaired ATP production and increased ROS generation	Energy failure and neuronal injury
Protein aggregation	Accumulation of misfolded α-synuclein	Formation of toxic intracellular inclusions
Neuroinflammation	Activation of microglia and inflammatory pathways	Chronic neuronal damage

2.2 Role of α-Synuclein Aggregation

α-Synuclein is a presynaptic neuronal protein involved in synaptic vesicle regulation, neurotransmitter release, and maintenance of neuronal function. In Parkinson's disease, abnormal folding and aggregation of α-synuclein lead to the formation of intracellular protein inclusions known as Lewy bodies and Lewy neurites, which are pathological hallmarks of the disease. Mutations or increased expression of the *SNCA* gene encoding α-synuclein can enhance aggregation and promote neuronal toxicity (Stefanis, 2012).

Misfolded α-synuclein oligomers are considered highly toxic because they interfere with mitochondrial function, disrupt membrane integrity, impair synaptic transmission, and activate

inflammatory responses. Furthermore, α-synuclein pathology can spread between interconnected brain regions through a prion-like mechanism, allowing disease progression from localized neuronal damage to widespread neurodegeneration (Braak et al., 2003). Impaired clearance of aggregated α-synuclein through autophagy and lysosomal pathways further accelerates disease progression.

2.3 Mitochondrial Dysfunction and Oxidative Stress

Mitochondrial dysfunction is a central mechanism contributing to Parkinson's disease pathogenesis. Dopaminergic neurons require high levels of energy due to their extensive axonal structures; therefore, mitochondrial impairment severely affects their survival. Defects in mitochondrial complex I activity reduce ATP production and increase the generation of reactive oxygen species (ROS), resulting in oxidative stress (Schapira et al., 2014).

Excessive ROS production causes oxidative damage to cellular components, including proteins, lipids, and DNA. Dopamine metabolism itself generates reactive molecules, making dopaminergic neurons particularly vulnerable to oxidative injury. Mitochondrial abnormalities also activate apoptotic pathways, leading to progressive neuronal death. Genetic studies have highlighted the importance of mitochondrial quality-control proteins such as PINK1 and Parkin, which regulate mitochondrial repair and removal of damaged mitochondria through mitophagy (Pickrell & Youle, 2015).

Table 2.2. Role of Mitochondrial Dysfunction and Oxidative Stress in Parkinson's Disease

Mitochondrial Abnormality	Effect on Neurons
Complex I dysfunction	Reduced ATP production and impaired energy metabolism
Increased ROS generation	Oxidative damage to proteins, lipids, and DNA
Defective mitophagy	Accumulation of damaged mitochondria
Activation of apoptosis	Progressive dopaminergic neuronal death

2.4 Neuroinflammation and Immune Dysregulation

Neuroinflammation is increasingly recognized as an important contributor to Parkinson's disease progression. In response to neuronal injury and abnormal protein accumulation, brain-resident immune cells such as microglia and astrocytes become activated. Activated microglia release inflammatory mediators, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), which promote chronic inflammation and neuronal damage (Tansey & Goldberg, 2010).

Astrocyte dysfunction also contributes to impaired neuronal support, altered antioxidant defense, and increased inflammatory signaling. In addition to central immune responses, peripheral immune alterations involving circulating immune cells and inflammatory molecules may influence disease progression. The interaction between α-synuclein accumulation, immune activation, and inflammatory signaling creates a self-amplifying cycle that accelerates neurodegeneration (Tansey et al., 2022). Targeting neuroinflammatory pathways is therefore considered a promising approach for developing disease-modifying therapies.

3. Genetic, Molecular, and Pathophysiological Pathways in Parkinson's Disease

3.1 Genetic Mechanisms of Parkinson's Disease

Parkinson's disease is a complex disorder influenced by both genetic and environmental factors. Although most cases are sporadic with no clear inheritance pattern, approximately 5–10% of patients develop familial Parkinson's disease due to pathogenic genetic mutations. Genetic studies have identified several Parkinson's-associated genes that regulate important cellular processes, including mitochondrial function, protein degradation, vesicle trafficking, and neuronal survival (Coukos & Krainc, 2024).

Mutations in the *SNCA* gene, which encodes α-synuclein, are among the earliest identified genetic causes of PD and contribute to abnormal protein aggregation and Lewy body formation. Mutations in *LRRK2* represent one of the most common genetic causes of late-onset familial PD and influence pathways related to vesicular transport, inflammation, and lysosomal function. Autosomal recessive genes such as *PARKIN (PRKN)*, *PINK1*, and *DJ-1 (PARK7)* are mainly associated with mitochondrial dysfunction, oxidative stress regulation, and impaired cellular protection. These genetic abnormalities ultimately converge on common pathological pathways leading to dopaminergic neuronal degeneration (Blauwendraat et al., 2020).

Table 3.1. Major Parkinson's Disease-Associated Genes and Their Functions

Gene	Encoded Protein	Major Cellular Function	Role in Parkinson's Disease
SNCA	α-Synuclein	Synaptic vesicle regulation	Protein aggregation and Lewy body formation
LRRK2	Leucine-rich repeat kinase 2	Vesicle trafficking and signaling	Neuroinflammation and abnormal protein processing
PARKIN (PRKN)	E3 ubiquitin ligase	Mitochondrial quality control	Defective mitophagy and neuronal survival
PINK1	Mitochondrial kinase	Regulation of damaged mitochondria	Impaired mitochondrial clearance
DJ-1 (PARK7)	Oxidative stress regulator	Antioxidant defense	Increased oxidative neuronal injury

3.2 Protein Quality Control and Cellular Dysfunction

Maintenance of protein homeostasis is essential for neuronal survival because neurons have limited regenerative capacity and high metabolic requirements. In Parkinson's disease, defects in protein quality-control systems result in accumulation of misfolded proteins, particularly α-synuclein aggregates. The autophagy–lysosomal pathway and ubiquitin–proteasome system are the major mechanisms responsible for removing damaged or unnecessary proteins from cells (Shimizu et al., 2026).

Impairment of autophagy and lysosomal degradation reduces the clearance of toxic protein aggregates, promoting neuronal dysfunction and degeneration. Several PD-associated genes,

including *LRRK2*, *PINK1*, *PARKIN*, and *DJ-1*, regulate these degradation pathways. Dysfunction of the ubiquitin–proteasome system further contributes to abnormal accumulation of damaged proteins and disruption of neuronal signaling. These alterations create a cycle of protein toxicity, mitochondrial impairment, and progressive neuronal loss.

3.3 Gut–Brain Axis and Parkinson's Disease

Recent evidence suggests that Parkinson's disease is not restricted to the brain but involves complex interactions between the gastrointestinal system and the central nervous system. Alterations in gut microbiota composition, intestinal barrier dysfunction, and chronic inflammation have been associated with PD development and progression. Changes in microbial populations may influence neuroinflammation, immune responses, and neurotransmitter metabolism (Cryan et al., 2019).

The gut–brain axis hypothesis proposes that pathological α-synuclein accumulation may begin in the gastrointestinal tract and spread toward the brain through neural pathways such as the vagus nerve. Intestinal inflammation and microbial imbalance may promote α-synuclein misfolding and accelerate neurodegenerative processes. Although the exact mechanisms remain under investigation, microbiome-based interventions, probiotics, dietary modification, and microbial metabolite regulation are emerging as potential therapeutic strategies for Parkinson's disease (Sampson et al., 2016).

3.4 Mechanisms of Neuronal Cell Death

Multiple programmed cell death pathways contribute to dopaminergic neuronal loss in Parkinson's disease. Apoptosis, a regulated form of cell death, is activated by mitochondrial dysfunction, oxidative stress, and abnormal protein accumulation. Activation of apoptotic proteins, including caspases, results in neuronal shrinkage and irreversible cell loss.

Ferroptosis, an iron-dependent form of regulated cell death, has recently gained attention in Parkinson's disease research. Increased iron accumulation in the substantia nigra, lipid peroxidation, and impaired antioxidant defense systems contribute to ferroptotic neuronal injury. Interactions between α-synuclein aggregation, iron metabolism, and oxidative stress may create a self-amplifying cycle of neurodegeneration (Wang et al., 2026).

Additionally, excitotoxicity caused by excessive glutamate signaling and calcium imbalance contributes to neuronal damage. Increased intracellular calcium levels enhance mitochondrial stress, ROS generation, and activation of cell death pathways. The combined effects of apoptosis, ferroptosis, excitotoxicity, and mitochondrial dysfunction accelerate progressive neuronal degeneration in Parkinson's disease.

Table 3.2. Major Pathophysiological Pathways Responsible for Neuronal Death in Parkinson's Disease

Cell Death Mechanism	Major Trigger	Consequences
Apoptosis	Mitochondrial damage and caspase activation	Programmed neuronal loss
Ferroptosis	Iron accumulation and lipid peroxidation	Oxidative neuronal membrane damage

Excitotoxicity	Excess glutamate and calcium overload	Mitochondrial injury and neuronal dysfunction
Impaired protein clearance	Autophagy and proteasome dysfunction	Toxic protein accumulation

4. Current Therapeutic Approaches for Parkinson's Disease

4.1 Pharmacological Treatment Strategies

Current pharmacological management of Parkinson's disease primarily focuses on improving motor symptoms by restoring dopaminergic activity or modifying dopamine metabolism. Although these therapies significantly improve quality of life, they mainly provide symptomatic relief and do not prevent progressive neuronal degeneration. Levodopa remains the most effective treatment for motor symptoms because it crosses the blood–brain barrier and is converted into dopamine within the brain. It is commonly administered with carbidopa, a peripheral dopamine decarboxylase inhibitor, to increase therapeutic efficacy and reduce peripheral side effects (Armstrong & Okun, 2020). Clinical guidelines recommend levodopa as a preferred initial therapy when motor symptoms significantly affect daily activities.

Dopamine receptor agonists such as pramipexole, ropinirole, and rotigotine directly stimulate dopamine receptors and may be used as monotherapy or as adjunct therapy. Monoamine oxidase-B (MAO-B) inhibitors, including rasagiline and selegiline, reduce dopamine degradation and prolong dopamine activity in the brain. Catechol-O-methyl transferase (COMT) inhibitors such as entacapone and opicapone are generally used with levodopa to reduce "wearing-off" effects. Amantadine, an N-methyl-D-aspartate (NMDA) receptor antagonist, provides benefits in reducing levodopa-induced dyskinesia and improving certain motor symptoms (Fox et al., 2018).

Table 4.1. Major Pharmacological Therapies Used in Parkinson's Disease

Drug Class	Examples	Mechanism of Action	Therapeutic Role
Dopamine precursor	Levodopa + carbidopa	Increases brain dopamine levels	Most effective symptomatic therapy
Dopamine agonists	Pramipexole, ropinirole, rotigotine	Direct stimulation of dopamine receptors	Improves motor symptoms and reduces levodopa requirement
MAO-B inhibitors	Rasagiline, selegiline	Prevent dopamine degradation	Prolongs dopamine activity
COMT inhibitors	Entacapone, opicapone	Blocks peripheral dopamine metabolism	Reduces motor fluctuations
NMDA antagonist	Amantadine	Modulates glutamate signaling	Controls dyskinesia and motor symptoms

4.2 Surgical and Device-Based Therapies

For patients with advanced Parkinson's disease who develop motor fluctuations, dyskinesia, or inadequate response to medications, surgical interventions provide additional therapeutic options. Deep brain stimulation (DBS) is the most established neurosurgical approach and involves

implantation of electrodes into specific brain regions to regulate abnormal neuronal activity. The subthalamic nucleus (STN) and globus pallidus internus (GPi) are the most commonly targeted regions for DBS therapy.

STN-DBS can significantly improve motor symptoms, reduce medication requirements, and enhance quality of life in appropriately selected patients. GPi stimulation is particularly beneficial for controlling dyskinesia and may be preferred in patients with specific clinical conditions. However, DBS does not stop disease progression and may have limitations, including surgical complications, cognitive effects, and reduced effectiveness for some non-motor symptoms (Okun, 2012).

Table 4.2. Surgical and Supportive Therapeutic Approaches in Parkinson's Disease

Therapy	Target/Approach	Benefits	Limitations
Deep brain stimulation (DBS)	STN or GPi stimulation	Improves motor fluctuations and dyskinesia	Surgical risks and does not modify disease progression
Physiotherapy	Exercise and movement training	Improves mobility, balance, and strength	Requires continuous patient participation
Speech therapy	Communication and swallowing training	Improves speech and swallowing problems	Mainly supportive
Occupational therapy	Daily activity training	Enhances independence	Does not alter disease pathology

4.3 Rehabilitation and Supportive Therapies

Non-pharmacological interventions play an essential role in improving functional ability and maintaining independence in Parkinson's disease patients. Physiotherapy and structured exercise programs improve balance, flexibility, gait function, and overall mobility. Regular physical activity may also support neuroplasticity and reduce complications associated with reduced movement.

Speech and language therapy helps manage communication difficulties, voice changes, and swallowing problems commonly observed in PD. Occupational therapy assists patients in adapting daily activities and maintaining independence. Psychological counseling and cognitive support are also important because depression, anxiety, sleep disorders, and cognitive decline significantly affect patient well-being. Multidisciplinary care involving neurologists, physiotherapists, psychologists, and rehabilitation specialists provides better management of disease-related complications (Radder et al., 2020).

4.4 Limitations of Current Therapies

Despite major advances in Parkinson's disease treatment, current therapies remain largely symptomatic and do not prevent or reverse neurodegeneration. Levodopa provides excellent motor improvement but long-term use is associated with complications such as motor fluctuations, "wearing-off" effects, and dyskinesia. Continuous stimulation of dopamine pathways and disease progression contribute to these treatment challenges (Armstrong & Okun, 2020).

Similarly, dopamine agonists and other medications may produce adverse effects including hallucinations, sleep disturbances, impulse-control disorders, and cardiovascular complications.

Surgical approaches such as DBS improve symptoms in selected patients but cannot restore damaged neurons or halt disease progression. Therefore, there is an urgent need for disease-modifying strategies, including neuroprotective drugs, gene therapies, stem-cell approaches, and targeted molecular therapies aimed at preventing neuronal loss and promoting regeneration (Poewe et al., 2017).

5. Emerging Therapeutic Strategies and Future Directions

5.1 Disease-Modifying Therapeutic Approaches

Current Parkinson's disease treatments mainly provide symptomatic improvement; therefore, disease-modifying therapies targeting the underlying pathological mechanisms are a major focus of research. One important strategy involves reducing α-synuclein accumulation, which is considered a central event in PD pathogenesis. Approaches such as inhibition of α-synuclein aggregation, enhancement of protein clearance pathways, and immunotherapy-based strategies are being investigated to prevent neuronal toxicity. Passive immunotherapies using monoclonal antibodies against aggregated α-synuclein aim to promote clearance of toxic protein species, whereas active vaccination approaches attempt to stimulate endogenous immune responses against pathological α-synuclein (Baba et al., 2019).

Protein degradation strategies targeting autophagy–lysosomal pathways and ubiquitin-mediated clearance mechanisms are also emerging as potential therapeutic approaches. Enhancing cellular ability to remove misfolded proteins may reduce neuronal stress and slow disease progression. However, achieving effective delivery and maintaining long-term safety remain important challenges.

5.2 Gene and Molecular Therapies

Advances in molecular medicine have created new opportunities for targeting genetic causes and molecular pathways involved in Parkinson's disease. Gene replacement therapy aims to restore the function of defective genes or increase the expression of protective proteins in dopaminergic neurons. Viral vector-based approaches have been investigated to deliver therapeutic genes involved in dopamine synthesis and neuronal survival (Barker et al., 2019).

RNA-based therapies, including antisense oligonucleotides and small interfering RNAs, provide opportunities to regulate abnormal gene expression, particularly genes associated with α-synuclein accumulation and genetic forms of PD. Additionally, CRISPR/Cas-based genome-editing technologies offer potential for correcting disease-associated mutations such as *LRRK2*, *SNCA*, and *PARKIN*. Despite promising results, challenges including delivery efficiency, off-target effects, and long-term safety must be addressed before clinical application.

5.3 Stem Cell and Regenerative Medicine Approaches

Stem cell-based therapies represent a promising regenerative strategy for Parkinson's disease by replacing damaged or lost dopaminergic neurons. Human pluripotent stem cells and induced pluripotent stem cells (iPSCs) can be differentiated into dopamine-producing neurons suitable for transplantation. Recent advances have improved the generation of functional dopaminergic neurons with characteristics similar to native substantia nigra neurons (Barker et al., 2019).

Regenerative approaches may restore dopamine production and improve motor function; however, several challenges remain, including immune rejection, uncontrolled cell growth, survival of transplanted cells, and potential tumor formation. Optimization of cell preparation, transplantation methods, and patient selection is essential for successful clinical translation.

5.4 Nanotechnology-Based Drug Delivery Systems

Nanotechnology provides innovative solutions for improving therapeutic delivery in Parkinson's disease. The blood–brain barrier (BBB) significantly limits the transport of many drugs into the central nervous system; therefore, nanoparticle-based systems are being developed to enhance brain targeting and drug availability. Liposomes, polymeric nanoparticles, solid lipid nanoparticles, and nanoemulsions can improve drug stability, controlled release, and BBB penetration (Saraiva et al., 2016).

Nanocarriers can deliver antioxidants, gene therapies, anti-inflammatory molecules, and neuroprotective compounds directly to affected brain regions. Surface modification of nanoparticles with targeting ligands may further enhance selective delivery to neuronal cells and reduce systemic side effects.

5.5 Natural Compounds and Nutraceutical Approaches

Natural bioactive compounds have attracted significant attention due to their antioxidant, anti-inflammatory, and neuroprotective properties. Compounds such as curcumin, quercetin, resveratrol, and coenzyme Q10 have demonstrated protective effects against oxidative stress, mitochondrial dysfunction, and neuroinflammation associated with Parkinson's disease.

Curcumin exhibits antioxidant and anti-inflammatory activity by regulating oxidative pathways and inflammatory cytokine production. Quercetin and resveratrol have shown potential in reducing oxidative neuronal injury and modulating cellular defense mechanisms. Coenzyme Q10 supports mitochondrial function by improving electron transport and reducing oxidative damage. Although preclinical studies show promising effects, issues related to bioavailability, dosage optimization, and clinical effectiveness require further investigation (Khan et al., 2021).

Table 5.1. Emerging Therapeutic Strategies for Parkinson's Disease

Therapeutic Strategy	Target/Mechanism	Potential Benefits	Current Challenges
α-Synuclein-targeted therapy	Reduction of protein aggregation and immune-mediated clearance	Prevents toxic protein accumulation	Limited clinical efficacy and safety concerns
Gene therapy	Correction or replacement of disease-related genes	Long-term molecular correction	Delivery and off-target effects
RNA-based therapy	Regulation of abnormal gene expression	Selective targeting of pathogenic pathways	Stability and delivery limitations
Stem cell therapy	Replacement of lost dopaminergic neurons	Potential neuronal restoration	Immune rejection and transplantation risks
Nanotechnology-based	BBB penetration and	Improved brain	Manufacturing and

delivery	controlled drug release	targeting and bioavailability	toxicity concerns
Natural compounds	Antioxidant and anti-inflammatory effects	Neuroprotection and reduced oxidative stress	Poor bioavailability and clinical validation

6. Future Perspectives, Challenges, and Conclusion

Parkinson's disease remains a major neurological challenge due to its complex and multifactorial nature involving genetic alterations, abnormal protein aggregation, mitochondrial dysfunction, neuroinflammation, and progressive neuronal loss. One of the major limitations in Parkinson's disease research is the lack of reliable methods for early diagnosis before significant neuronal damage occurs. Current diagnosis mainly depends on clinical symptoms, which appear after substantial degeneration of dopaminergic neurons. The identification of sensitive biomarkers, including α-synuclein species, inflammatory markers, genetic signatures, and metabolic changes, is therefore essential for early detection and timely intervention (Simuni et al., 2020). Additionally, the diversity of disease mechanisms among patients makes the development of universally effective therapies challenging. Despite advances in symptomatic management, effective disease-modifying treatments capable of preventing or reversing neurodegeneration remain unavailable.

Emerging diagnostic technologies and precision medicine approaches are expected to transform Parkinson's disease management. Biomarker discovery using cerebrospinal fluid analysis, blood-based biomarkers, and molecular imaging techniques may improve early diagnosis and disease monitoring. Advanced neuroimaging approaches, including positron emission tomography (PET) and magnetic resonance imaging (MRI), provide valuable information regarding neuronal function and disease progression. Furthermore, artificial intelligence (AI)-based approaches are increasingly being explored for analyzing clinical data, imaging patterns, and biological information to improve diagnostic accuracy and predict treatment responses (Prashanth et al., 2022). Integration of genomic information with patient-specific characteristics may support personalized therapeutic strategies tailored to individual disease mechanisms.

Future research is moving toward combination therapies that target multiple pathological pathways simultaneously, including α-synuclein aggregation, oxidative stress, mitochondrial dysfunction, inflammation, and neuronal death pathways. Neuroregenerative strategies involving stem cells, gene therapy, and advanced molecular approaches may provide opportunities to restore damaged neuronal networks. In addition, targeted drug delivery systems, particularly nanoparticle-based platforms, may overcome limitations associated with poor drug penetration across the blood–brain barrier and improve therapeutic effectiveness. The integration of genetics, molecular biology, artificial intelligence, and nanotechnology may accelerate the development of next-generation Parkinson's disease therapies.

In conclusion, Parkinson's disease is a complex neurodegenerative disorder involving interconnected molecular and cellular abnormalities. Understanding mechanisms such as α-synuclein pathology, mitochondrial dysfunction, neuroinflammation, genetic susceptibility, and impaired cellular clearance pathways has significantly improved knowledge of disease progression. Although current therapies mainly provide symptomatic relief, emerging strategies involving disease-modifying agents, regenerative medicine, precision medicine, and targeted delivery systems offer promising future directions. Continued multidisciplinary research is required to develop effective interventions that can

delay disease progression, restore neuronal function, and improve long-term outcomes for individuals affected by Parkinson's disease.

References

- Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. *JAMA, 323*(6), 548–560. https://doi.org/10.1001/jama.2019.22360
- Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M. Y., Trojanowski, J. Q., & Iwatsubo, T. (2019). Aggregation of α-synuclein and its role in Parkinson's disease: Therapeutic approaches targeting α-synuclein pathology. *Movement Disorders, 34*(7), 1012–1024. https://doi.org/10.1002/mds.27616
- Barker, R. A., Parmar, M., Studer, L., & Takahashi, J. (2019). Human trials of stem cell-derived dopamine neurons for Parkinson's disease: Dawn of a new era. *Cell Stem Cell, 21*(5), 569–573. https://doi.org/10.1016/j.stem.2019.09.014
- Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020). The genetic architecture of Parkinson's disease. *The Lancet Neurology, 19*(2), 170–178. https://doi.org/10.1016/S1474-4422(19)30287-X
- Braak, H., Del Tredici, K., Rüb, U., De Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiology of Aging, 24*(2), 197–211. https://doi.org/10.1016/S0197-4580(02)00065-9
- Coukos, R., & Krainc, D. (2024). Key genes and convergent pathogenic mechanisms in Parkinson disease. *Nature Reviews Neuroscience, 25*, 393–413. https://doi.org/10.1038/s41583-024-00812-2
- Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., … Dinan, T. G. (2019). The microbiota–gut–brain axis. *Physiological Reviews, 99*(4), 1877–2013. https://doi.org/10.1152/physrev.00018.2018
- Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. *Journal of Parkinson's Disease, 8*(s1), S3–S8. https://doi.org/10.3233/JPD-181474
- Fox, S. H., Katzenschlager, R., Lim, S. Y., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., & Sampaio, C. (2018). International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Movement Disorders, 33*(8), 1248–1266. https://doi.org/10.1002/mds.27372
- Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. *The Lancet, 386*(9996), 896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
- Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2021). Neuroprotective and antioxidant properties of natural compounds in Parkinson's disease: Current perspectives. *Frontiers in Pharmacology, 12*, 707527. https://doi.org/10.3389/fphar.2021.707527
- Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., Bras, J., Young, E., von Coelln, R., Simón-Sánchez, J., Schulte, C., Sharma, M., Krohn, L., Pihlstrøm, L., Siitonen, A., … Singleton, A. B. (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease. *Nature Genetics, 51*, 1453–1461. https://doi.org/10.1038/s41588-019-0518-5

- Okun, M. S. (2012). Deep-brain stimulation for Parkinson's disease. *New England Journal of Medicine, 367*, 1529–1538. https://doi.org/10.1056/NEJMct1208070
- Ou, Z., Pan, J., Tang, S., Duan, D., Yu, D., Nong, H., & Wang, Z. (2021). Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries and territories from 1990 to 2019. *Frontiers in Public Health, 9*, 776847. https://doi.org/10.3389/fpubh.2021.776847
- Pickrell, A. M., & Youle, R. J. (2015). The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron, 85*(2), 257–273. https://doi.org/10.1016/j.neuron.2014.12.007
- Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A. E., & Lang, A. E. (2017). Parkinson disease. *Nature Reviews Disease Primers, 3*, 17013. https://doi.org/10.1038/nrdp.2017.13
- Prashanth, R., Roy, S. D., Mandal, P. K., & Ghosh, S. (2022). High-accuracy detection of early Parkinson's disease through multimodal artificial intelligence approaches. *npj Parkinson's Disease, 8*, 30. https://doi.org/10.1038/s41531-022-00280-0
- Radder, D. L. M., de Lima, A. L. S., Domingos, J., Keus, S. H. J., van Nimwegen, M., Bloem, B. R., & de Vries, N. M. (2020). Physiotherapy in Parkinson's disease: A systematic review. *Journal of Parkinson's Disease, 10*(4), 1305–1323. https://doi.org/10.3233/JPD-202265
- Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release, 235*, 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044
- Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014). Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: Future therapeutic perspectives. *The Lancet, 384*(9942), 545–555. https://doi.org/10.1016/S0140-6736(14)61049-7
- Shimizu, T., Isik, S., Kamath, N., & Yue, Z. (2026). The emerging role and therapeutic targeting of autophagy–lysosome pathway in the pathogenesis of Parkinson's disease. *Translational Neurodegeneration, 15*, 21. https://doi.org/10.1186/s40035-026-00555-3
- Simuni, T., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., Coffey, C. S., & Parkinson's Progression Markers Initiative. (2020). Longitudinal change of clinical and biological markers in early Parkinson's disease: Parkinson's Progression Markers Initiative cohort. *Movement Disorders, 35*(8), 1355–1365. https://doi.org/10.1002/mds.28088
- Stefanis, L. (2012). α-Synuclein in Parkinson's disease. *Cold Spring Harbor Perspectives in Medicine, 2*(2), a009399. https://doi.org/10.1101/cshperspect.a009399
- Surmeier, D. J. (2018). Determinants of dopaminergic neuronal loss in Parkinson's disease. *FEBS Journal, 285*(19), 3657–3668. https://doi.org/10.1111/febs.14607
- Tansey, M. G., & Goldberg, M. S. (2010). Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. *Neurobiology of Disease, 37*(3), 510–518. https://doi.org/10.1016/j.nbd.2009.11.004
- Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022). Inflammation and immune dysfunction in Parkinson disease. *Nature Reviews Immunology, 22*, 657–673. https://doi.org/10.1038/s41577-022-00684-6
- Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021). Progress towards therapies for disease modification in Parkinson's disease. *The Lancet Neurology, 20*(7), 559–572. https://doi.org/10.1016/S1474-4422(21)00089-0

- Wang, L., Zhang, Y., & Guo, L. (2026). Ferroptosis in Parkinson's disease: A review of molecular mechanisms and emerging therapeutic strategies. *Frontiers in Neuroscience, 20,* 1780573. https://doi.org/10.3389/fnins.2026.1780573
- World Health Organization. (2023). *Parkinson disease*. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease

Chapter 6: Epilepsy, Stroke and Neuropsychiatric Disorders: Recent Advances in Pharmacological Management

Prashant Kumar[*1], Ankita Vijay Thul[2], Jainedra Kumar[3], Ujashkumar Shah[4], Bishwanath Mishra[5]

[1]Assistant Professor, Department of Pharmacology, Sahu Onkar Saran School of Pharmacy, Faculty of Pharmacy, IFTM University, Lodhipur Rajput, Moradabad, Uttar Pradesh, India.

[2]Assistant Professor, School of Pharmacy, G H Raisoni Skill Tech University, Shraddha Park, Hingna Wadi Link Road, MIDC, Nagpur, Maharashtra, India.

[3]Assistant Professor, Department of Pharmacology, IIMT College of Pharmacy, Greater Noida, Knowledge Park 3, Greater Noida, Uttar Pradesh, India.

[4]Professor & Head, Nootan Pharmacy College, Sankalchand Patel University, SK Campus, Visnagar–384315, Gujarat, India.

[5]Associate Professor, Department of Pharmacology, Institute of Pharmacy & Technology, Salipur, Cuttack, Odisha 754202, India.

*Corresponding Author: Prashant Kumar, Assistant Professor, Department of Pharmacology, Sahu Onkar Saran School of Pharmacy, Faculty of Pharmacy, IFTM University, Lodhipur Rajput, Moradabad, Uttar Pradesh, India.

Abstract

Neurological and neuropsychiatric disorders including epilepsy, stroke, and psychiatric conditions represent major global health challenges due to their high prevalence, complex pathophysiology, and significant impact on mortality, disability, and quality of life. Although conventional pharmacological therapies have improved disease management, limitations such as drug resistance, adverse effects, poor brain penetration, and lack of disease-modifying approaches continue to restrict therapeutic success. This chapter provides an overview of recent advances in the pharmacological management of epilepsy, stroke, and neuropsychiatric disorders, highlighting emerging therapeutic strategies and future directions. Advances in epilepsy treatment include the development of newer antiseizure medications, precision-based therapies, and novel approaches targeting neuroinflammation, oxidative stress, and genetic mechanisms. In stroke management, improvements in thrombolytic therapy, antithrombotic strategies, neuroprotective approaches, and regenerative medicine have expanded treatment possibilities. Pharmacological advances in neuropsychiatric disorders include novel antidepressants, antipsychotic therapies, rapid-acting treatments, and personalized therapeutic approaches based on molecular and genetic characteristics. Furthermore, innovative drug delivery systems such as nanoparticles, liposomes, and targeted brain delivery platforms are providing new solutions to overcome the limitations of the blood–brain barrier. Integration of pharmacogenomics, artificial intelligence, digital health technologies, gene therapy, and cell-based approaches is expected to transform future neuropharmacology by enabling safer and more effective personalized treatments. Overall, recent progress in neuroscience and pharmaceutical research provides promising opportunities for developing targeted, disease-modifying, and patient-specific therapeutic strategies for complex neurological and neuropsychiatric disorders.

Keywords: Epilepsy; Stroke; Neuropsychiatric disorders; Antiepileptic drugs; Neuroprotection; Nanotechnology-based drug delivery; Blood–brain barrier; Precision medicine; Pharmacogenomics; Gene therapy; Artificial intelligence; Personalized neuropharmacology.

1. Introduction to Neurological and Neuropsychiatric Disorders

Neurological and neuropsychiatric disorders represent a major global health challenge due to their increasing prevalence, complex pathophysiology, and significant contribution to disability and mortality. These disorders affect the central and peripheral nervous systems and include epilepsy, stroke, neurodegenerative diseases, movement disorders, and psychiatric conditions associated with brain dysfunction. According to global health estimates, neurological disorders are among the leading causes of disability worldwide, creating substantial healthcare and socioeconomic burdens (Feigin et al., 2021). Advances in neuroscience have improved understanding of disease mechanisms; however, effective prevention and long-term management remain challenging.

Epilepsy, stroke, and neuropsychiatric disorders are among the most clinically significant neurological conditions. Epilepsy is characterized by recurrent unprovoked seizures resulting from abnormal neuronal excitability and synchronization, whereas stroke occurs due to interruption of cerebral blood flow or bleeding within the brain, leading to neuronal injury and functional impairment. Neuropsychiatric disorders involve disturbances in cognition, mood, behavior, and emotional regulation caused by complex interactions between genetic, molecular, and environmental factors. These disorders share common mechanisms such as neuroinflammation, oxidative stress, neurotransmitter imbalance, excitotoxicity, and neuronal degeneration (Kumar et al., 2022). Risk factors including aging, genetic predisposition, hypertension, metabolic disorders, infections, and lifestyle-related factors contribute to disease development and progression.

Despite significant improvements in pharmacological therapy, the management of neurological disorders continues to face several limitations. Many patients experience incomplete therapeutic responses, disease recurrence, or treatment resistance. In epilepsy, drug-resistant seizures remain a major concern despite the availability of multiple antiepileptic drugs. Similarly, stroke therapies are limited by narrow therapeutic windows, secondary neuronal damage, and challenges associated with effective neuroprotection. Neuropsychiatric disorders often require long-term medication, where delayed therapeutic effects, adverse reactions, and poor patient adherence affect treatment outcomes (Stahl, 2021). The inability of many drugs to efficiently cross the blood–brain barrier further restricts the development of effective central nervous system therapies.

Recent advances in neuropharmacology have focused on developing targeted, safer, and more effective treatment approaches. Precision medicine has emerged as an important strategy by integrating genetic information, biomarkers, and individual patient characteristics to optimize drug selection and therapeutic response. Biomarker-based approaches help in early diagnosis, disease monitoring, and prediction of treatment outcomes. Furthermore, innovative strategies such as nanoparticle-based drug delivery, gene therapy, molecularly targeted drugs, and artificial intelligence-assisted drug discovery are providing new opportunities for improved management of neurological diseases (Kwon et al., 2023). These developments represent a shift from traditional symptomatic treatment toward personalized and disease-modifying therapeutic approaches.

2. Recent Advances in Pharmacological Management of Epilepsy

2.1 Introduction to Epilepsy

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity and excessive synchronization of neuronal networks in the brain. According to the International League Against Epilepsy (ILAE), seizures are classified into focal onset, generalized onset, and unknown onset seizures based on their origin and clinical manifestations (Scheffer et al., 2017). Epilepsy affects millions of individuals worldwide and represents a major cause of neurological disability due to recurrent seizures, cognitive impairment, psychological complications, and reduced quality of life (Beghi, 2020).

The development of epileptic seizures involves complex molecular mechanisms including imbalance between excitatory and inhibitory neurotransmission, altered ion channel activity, synaptic dysfunction, neuroinflammation, and neuronal network remodeling. Increased glutamate-mediated excitatory signaling and reduced gamma-aminobutyric acid (GABA)-mediated inhibition contribute to neuronal hyperexcitability and seizure generation. Abnormal regulation of sodium, potassium, and calcium channels also plays an important role in seizure initiation and propagation (Duncan et al., 2022).

2.2 Conventional Antiepileptic Drugs (AEDs)

Traditional antiepileptic drugs remain important components of epilepsy treatment and mainly act by reducing neuronal excitability or enhancing inhibitory neurotransmission. These drugs control seizures in approximately two-thirds of patients; however, long-term use may be associated with adverse effects and drug interactions (Perucca, 2021).

Sodium channel blockers such as phenytoin, carbamazepine, and valproic acid inhibit voltage-gated sodium channels and prevent repetitive neuronal firing. GABAergic drugs including phenobarbital, benzodiazepines, and valproate increase inhibitory neurotransmission by enhancing GABA receptor activity. Calcium channel modulators such as ethosuximide and gabapentin regulate calcium influx and reduce abnormal neuronal excitation.

Table 2.1. Major Conventional Antiepileptic Drugs and Their Mechanisms

Drug Class	Representative Drugs	Mechanism of Action
Sodium channel blockers	Phenytoin, Carbamazepine, Lamotrigine	Inhibition of voltage-gated sodium channels and reduction of neuronal firing
GABA-enhancing drugs	Phenobarbital, Diazepam, Valproate	Enhancement of inhibitory GABAergic neurotransmission
Calcium channel modulators	Ethosuximide, Gabapentin	Regulation of calcium-dependent neuronal excitability
Multiple mechanism AEDs	Valproate, Topiramate	Modulation of sodium channels, GABA activity, and glutamate signaling

2.3 Newer Antiepileptic Drugs and Emerging Therapies

The development of newer antiepileptic drugs has improved seizure control and safety profiles compared with earlier therapies. These drugs provide better tolerability, fewer drug interactions, and additional treatment options for patients with difficult-to-control epilepsy.

Levetiracetam is widely used due to its broad-spectrum activity and unique mechanism involving synaptic vesicle protein 2A (SV2A) modulation. Brivaracetam, a derivative of levetiracetam, provides higher SV2A affinity and improved seizure control in some patients. Lacosamide enhances slow inactivation of voltage-gated sodium channels and is effective in focal epilepsy. Perampanel acts as a selective antagonist of AMPA glutamate receptors, reducing excitatory neurotransmission. Cannabidiol-based therapies have recently gained attention, particularly for severe childhood epileptic syndromes such as Dravet syndrome and Lennox–Gastaut syndrome (Devinsky et al., 2018).

Table 2.2. Newer Antiepileptic Drugs and Therapeutic Targets

Drug/Therapy	Primary Target	Clinical Application
Levetiracetam	SV2A synaptic vesicle protein modulation	Focal and generalized seizures
Lacosamide	Slow sodium channel inactivation	Focal epilepsy
Brivaracetam	High-affinity SV2A binding	Drug-resistant focal seizures
Perampanel	AMPA receptor antagonism	Focal and generalized seizures
Cannabidiol	Endocannabinoid pathway modulation	Severe epilepsy syndromes

2.4 Novel Pharmacological Approaches

Recent epilepsy research has shifted toward disease-modifying and targeted therapeutic approaches rather than only controlling seizure symptoms. Neuroinflammation and oxidative stress are increasingly recognized as important contributors to epileptogenesis. Activation of inflammatory pathways, microglial dysfunction, and oxidative damage promote neuronal injury and seizure progression, making anti-inflammatory and antioxidant strategies potential therapeutic targets (Vezzani et al., 2019).

Precision medicine approaches are improving epilepsy management by integrating genetic testing, molecular biomarkers, and individual treatment responses. Identification of genetic mutations associated with epilepsy syndromes helps guide selection of appropriate therapies and avoids ineffective treatments. Gene-based therapies and molecular interventions are also being explored for correcting abnormal neuronal signaling pathways.

Nanotechnology-based drug delivery systems have emerged as promising approaches for improving brain-targeted delivery. Nanoparticles, liposomes, and polymeric carriers can enhance drug solubility, improve blood–brain barrier penetration, and provide controlled release of antiepileptic agents, potentially increasing therapeutic efficacy while reducing toxicity.

2.5 Management of Drug-Resistant Epilepsy

Drug-resistant epilepsy is defined as failure to achieve sustained seizure freedom despite adequate trials of two appropriate and tolerated antiepileptic medications. Approximately one-third of epilepsy

patients develop pharmacoresistance, which remains a major challenge in clinical practice (Kwan et al., 2010).

The development of resistance involves multiple mechanisms including alterations in drug transporters, changes in drug targets, genetic factors, abnormal neuronal networks, and disease progression. Combination therapy using AEDs with different mechanisms of action is commonly employed to improve seizure control while minimizing adverse effects.

Future therapeutic strategies for drug-resistant epilepsy include gene therapy, immune-targeted therapies, stem cell-based approaches, precision medicine, and advanced drug delivery systems. These approaches aim not only to suppress seizures but also to prevent epileptogenesis and modify disease progression.

3. Pharmacological Advances in Stroke Management

3.1 Introduction to Stroke

Stroke is a major neurological disorder characterized by sudden disruption of cerebral blood supply, resulting in neuronal injury and neurological deficits. It is one of the leading causes of death and long-term disability worldwide. Stroke is broadly classified into **ischemic stroke**, caused by blockage of cerebral arteries due to thrombosis or embolism, and **hemorrhagic stroke**, caused by rupture of blood vessels leading to intracranial bleeding. Ischemic stroke accounts for the majority of stroke cases and is primarily associated with atherosclerosis, hypertension, and cardiovascular disorders, whereas hemorrhagic stroke is strongly linked with uncontrolled blood pressure and vascular abnormalities (Campbell & Khatri, 2020).

The major risk factors for stroke include hypertension, diabetes mellitus, dyslipidemia, smoking, obesity, atrial fibrillation, and aging. The pathological progression of stroke involves a cascade of events including energy failure, excitotoxicity, calcium overload, oxidative stress, inflammation, blood–brain barrier disruption, and neuronal apoptosis. These mechanisms contribute to irreversible brain damage and functional impairment following cerebral ischemia or hemorrhage (Iadecola & Anrather, 2011).

3.2 Acute Pharmacological Management of Stroke

Rapid pharmacological intervention is essential for minimizing neuronal damage and improving functional outcomes after stroke. In acute ischemic stroke, thrombolytic therapy using recombinant tissue plasminogen activator (tPA; alteplase) remains the standard treatment for eligible patients within the therapeutic time window. tPA promotes conversion of plasminogen into plasmin, resulting in dissolution of thrombi and restoration of cerebral blood flow (Powers et al., 2019).

Antiplatelet agents such as aspirin and clopidogrel prevent platelet aggregation and reduce secondary thrombotic events. Anticoagulant therapy, particularly in patients with atrial fibrillation, helps prevent cardioembolic stroke recurrence. However, careful patient selection is necessary because anticoagulants may increase bleeding risk.

Table 3.1. Major Pharmacological Agents Used in Acute Stroke Management

Drug/Therapeutic Class	Mechanism of Action	Clinical Application
Alteplase (tPA)	Converts plasminogen into plasmin and dissolves thrombus	Acute ischemic stroke thrombolysis
Tenecteplase	Modified tPA with longer half-life and higher fibrin specificity	Emerging thrombolytic therapy
Aspirin	Inhibits platelet cyclooxygenase and thromboxane production	Prevention of recurrent ischemic events
Clopidogrel	Blocks P2Y12 platelet receptors	Antiplatelet therapy
Anticoagulants	Inhibit coagulation pathways	Prevention of cardioembolic stroke

3.3 Neuroprotective Strategies

Neuroprotection aims to preserve neuronal function by preventing secondary injury after stroke. During ischemic stroke, excessive glutamate release causes excitotoxic neuronal damage through overactivation of NMDA receptors and intracellular calcium accumulation. Therefore, inhibition of excitotoxic pathways has been investigated as a potential therapeutic strategy.

Oxidative stress and mitochondrial dysfunction contribute significantly to neuronal death following stroke. Antioxidant therapies targeting reactive oxygen species (ROS) generation and mitochondrial damage are being explored to reduce ischemic injury. Additionally, inflammatory pathways involving microglial activation and cytokine release contribute to post-stroke damage, making anti-inflammatory agents potential candidates for neuroprotection (Chamorro et al., 2016).

3.4 Secondary Prevention of Stroke

Secondary prevention focuses on reducing the risk of recurrent stroke through long-term pharmacological management and risk-factor control. Antihypertensive drugs including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics play a crucial role in maintaining optimal blood pressure.

Lipid-lowering therapy with statins reduces cholesterol levels and stabilizes atherosclerotic plaques, thereby decreasing the risk of recurrent ischemic events. Long-term antithrombotic therapy using antiplatelet agents or anticoagulants is selected according to the underlying stroke mechanism. Pharmacological interventions combined with lifestyle modifications significantly improve patient outcomes.

3.5 Emerging Stroke Therapies

Recent advances in stroke pharmacology focus on regenerative medicine, targeted drug delivery, and molecular therapies. Stem cell-based approaches are being investigated for their ability to promote neuronal repair, angiogenesis, and functional recovery after stroke. Although still under clinical investigation, stem cell therapies represent a promising future direction.

Nanomedicine-based approaches including polymeric nanoparticles, liposomes, and exosome-based systems have shown potential for improving drug delivery across the blood–brain barrier. These systems enhance therapeutic concentration at injury sites while reducing systemic toxicity.

Furthermore, novel molecular targets involving inflammation, apoptosis, angiogenesis, and neuroplasticity are being explored for developing disease-modifying stroke therapies (Xiong et al., 2022).

Table 3.2. Emerging Pharmacological Strategies in Stroke Therapy

Emerging Approach	Therapeutic Target/Mechanism	Potential Benefit
Stem cell therapy	Neuronal regeneration and angiogenesis	Functional recovery after stroke
Nanoparticle drug delivery	Improved BBB penetration and controlled release	Enhanced therapeutic efficacy
Anti-inflammatory therapy	Reduction of cytokine-mediated injury	Protection against secondary damage
Neurotrophic factors	Promotion of neuronal survival and repair	Neuroregeneration
Gene-based therapies	Regulation of disease-associated pathways	Targeted stroke treatment

4. Pharmacological Management of Neuropsychiatric Disorders

4.1 Overview of Neuropsychiatric Disorders

Neuropsychiatric disorders represent a group of complex conditions involving abnormalities in brain function that affect mood, cognition, behavior, and emotional regulation. These disorders include depression, anxiety disorders, schizophrenia, bipolar disorder, and psychiatric symptoms associated with neurodegenerative diseases. They arise from interactions between genetic susceptibility, neurotransmitter imbalance, environmental influences, and alterations in neuronal circuits (Owen et al., 2016).

The relationship between neurological and psychiatric disorders is bidirectional, as brain injury, neurodegeneration, and inflammatory processes can contribute to psychiatric symptoms, while chronic psychiatric disorders may increase the risk of neurological dysfunction. Important biological mechanisms involved in neuropsychiatric diseases include disturbances in dopamine, serotonin, glutamate, and GABA neurotransmission, hypothalamic–pituitary–adrenal (HPA) axis dysfunction, neuroinflammation, oxidative stress, and impaired synaptic plasticity (Miller & Raison, 2016).

4.2 Pharmacological Management of Depression and Anxiety Disorders

Depression and anxiety disorders are among the most prevalent neuropsychiatric conditions and significantly affect daily functioning and quality of life. Pharmacological treatment primarily targets neurotransmitter systems involved in mood regulation.

Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and escitalopram are commonly used as first-line antidepressants due to their efficacy and improved safety profile. Serotonin–norepinephrine reuptake inhibitors (SNRIs) including venlafaxine and duloxetine enhance both serotonin and norepinephrine signaling. Tricyclic antidepressants (TCAs) provide effective

treatment but are associated with more adverse effects due to their activity on multiple receptor systems.

Anxiolytic therapy commonly involves benzodiazepines, which enhance GABAergic inhibition, although long-term use may result in tolerance and dependence. Recently, novel antidepressant approaches including ketamine and esketamine-based therapies have gained attention due to their rapid antidepressant effects through modulation of glutamatergic neurotransmission (McIntyre et al., 2020).

4.3 Pharmacological Treatment of Schizophrenia and Psychotic Disorders

Schizophrenia is a chronic psychiatric disorder characterized by disturbances in perception, cognition, emotional regulation, and behavior. Pharmacological management primarily focuses on controlling positive symptoms such as hallucinations and delusions while improving negative and cognitive symptoms.

Typical antipsychotics such as haloperidol primarily act through dopamine D2 receptor blockade. Although effective, they are associated with extrapyramidal side effects. Atypical antipsychotics including risperidone, olanzapine, quetiapine, and clozapine act on dopamine and serotonin receptors, providing improved efficacy with reduced motor complications.

Dysregulation of glutamate signaling, particularly NMDA receptor dysfunction, has also contributed to the development of novel therapeutic strategies. Treatment-resistant schizophrenia remains a major clinical challenge, and clozapine continues to be the most effective pharmacological option for patients who do not respond adequately to other antipsychotic medications (Keepers et al., 2020).

Table 4.1. Major Pharmacological Treatments for Neuropsychiatric Disorders

Disorder	Drug Class	Examples	Primary Mechanism
Depression	SSRIs	Fluoxetine, Sertraline	Increase serotonin availability
Depression	SNRIs	Venlafaxine, Duloxetine	Increase serotonin and norepinephrine signaling
Anxiety	Benzodiazepines	Diazepam, Lorazepam	Enhance GABA-mediated inhibition
Schizophrenia	Typical antipsychotics	Haloperidol	Dopamine D2 receptor blockade
Schizophrenia	Atypical antipsychotics	Clozapine, Risperidone	Dopamine-serotonin receptor modulation

4.4 Pharmacotherapy of Neurodegenerative Psychiatric Conditions

Neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease are frequently associated with psychiatric manifestations, including depression, anxiety, psychosis, agitation, and cognitive impairment. Management requires a combination of disease-specific and symptom-targeted pharmacological approaches.

In Alzheimer's disease, cognitive-enhancing drugs such as acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) improve cholinergic neurotransmission and provide symptomatic

benefits. Memantine, an NMDA receptor antagonist, reduces glutamate-mediated excitotoxicity and is used in moderate-to-severe disease stages.

Parkinson's disease-associated psychiatric complications, including depression, hallucinations, and impulse control disorders, may occur due to disease progression and dopaminergic therapy. Treatment involves antidepressants, antipsychotics with minimal motor effects, and adjustment of dopaminergic medications. Development of therapies targeting neurodegeneration and synaptic dysfunction remains an important research area (Armstrong & Okun, 2020).

4.5 Emerging Neuropsychiatric Therapies

Recent advances in neuropsychiatric pharmacology focus on developing rapid-acting, personalized, and disease-modifying treatments. Psychedelic-assisted therapies, particularly compounds affecting serotonin 5-HT2A receptors, are being investigated for treatment-resistant depression and other psychiatric conditions. Controlled clinical studies have demonstrated potential benefits of agents such as psilocybin when combined with psychological support.

Neuroinflammation-targeted therapies are emerging due to increasing evidence linking immune activation with psychiatric disorders. Modulation of inflammatory pathways, oxidative stress, and microglial activation may provide new therapeutic opportunities. Neuroprotective agents targeting mitochondrial dysfunction and synaptic loss are also under investigation.

Digital health technologies, artificial intelligence-based prediction models, and pharmacogenomic approaches are supporting personalized treatment selection by identifying patients likely to respond to specific medications and reducing adverse effects.

Table 4.2. Emerging Therapeutic Approaches in Neuropsychiatric Disorders

Emerging Therapy	Target/Mechanism	Potential Application
Ketamine/Esketamine	NMDA receptor modulation and synaptic plasticity enhancement	Treatment-resistant depression
Psychedelic therapy	Serotonin 5-HT2A receptor activation	Severe depression and psychiatric disorders
Anti-inflammatory agents	Reduction of neuroinflammation	Depression and neurodegenerative disorders
Neuroprotective compounds	Mitochondrial and synaptic protection	Cognitive decline and neurodegeneration
Pharmacogenomics	Genetic-guided drug selection	Personalized psychiatric treatment

5. Novel Drug Delivery Systems and Future Therapeutic Strategies

5.1 Nanotechnology in Neurological Drug Delivery

The development of effective therapies for neurological disorders is often limited by the presence of the blood–brain barrier (BBB), which restricts the entry of most therapeutic molecules into the central

nervous system. The BBB maintains brain homeostasis but creates a major challenge for delivering drugs used in epilepsy, stroke, neurodegenerative diseases, and psychiatric disorders. Recent advances in nanotechnology have provided promising solutions by improving drug transport, stability, and targeted accumulation within brain tissues (Gao et al., 2024).

Nanoparticle-based delivery systems, including polymeric nanoparticles, liposomes, lipid nanoparticles, dendrimers, and nanoemulsions, have demonstrated potential for overcoming BBB limitations. These carriers can enhance drug solubility, protect therapeutic molecules from degradation, and provide controlled release. Polymeric platforms such as PLGA, chitosan, and PEG-based nanoparticles are increasingly explored due to their biocompatibility and ability to deliver small molecules, proteins, and nucleic acids to the brain (Zha & Liu, 2024).

5.2 Targeted Drug Delivery Approaches

Targeted drug delivery strategies aim to improve therapeutic concentration at specific brain regions while minimizing systemic toxicity. Brain-targeted delivery systems utilize receptor-mediated transport mechanisms involving receptors such as transferrin, insulin, and low-density lipoprotein receptors expressed on BBB endothelial cells. Ligand-functionalized nanoparticles can facilitate selective transport across the BBB through receptor-assisted endocytosis (Mhaske et al., 2024).

Controlled and sustained-release formulations provide prolonged drug exposure and reduce dosing frequency. Surface modification of nanocarriers with peptides, antibodies, carbohydrates, or other targeting ligands improves specificity and enhances therapeutic outcomes. These approaches are particularly valuable for chronic neurological diseases requiring long-term treatment.

5.3 Pharmacogenomics and Personalized Medicine

Pharmacogenomics has emerged as an important component of modern neuropharmacology by identifying genetic variations that influence drug metabolism, efficacy, and adverse reactions. Genetic differences in drug transporters, metabolic enzymes, and therapeutic targets can significantly affect individual responses to neurological medications.

Personalized medicine approaches integrate genetic information, clinical characteristics, and molecular biomarkers to select optimal therapies for individual patients. In epilepsy, genetic testing can help identify specific epilepsy syndromes and guide appropriate drug selection. Similarly, biomarker-guided strategies in psychiatric disorders may improve antidepressant and antipsychotic treatment outcomes by reducing trial-and-error prescribing.

5.4 Artificial Intelligence and Digital Health in Neuropharmacology

Artificial intelligence (AI) and digital health technologies are transforming neurological drug discovery, diagnosis, and treatment monitoring. AI-based platforms can analyze large biological datasets, predict drug–target interactions, identify therapeutic candidates, and accelerate drug development processes (Vora et al., 2024).

Machine learning models are increasingly used to predict treatment responses, identify disease progression patterns, and support personalized medication selection. Digital monitoring tools, wearable devices, and smartphone-based applications enable continuous assessment of symptoms,

medication adherence, seizure activity, and patient outcomes. Integration of AI with pharmacogenomics and nanotechnology may provide future opportunities for precision neuropharmacology.

Table 5.1. Emerging Technologies in Neurological Drug Delivery and Personalized Therapy

Technology	Mechanism/Approach	Potential Applications
Polymeric nanoparticles	Controlled drug release and BBB penetration	Epilepsy, stroke, neurodegenerative disorders
Liposomal systems	Encapsulation and improved drug transport	Brain-targeted therapy
Ligand-functionalized nanocarriers	Receptor-mediated BBB crossing	Specific brain-region targeting
Pharmacogenomics	Genetic-guided drug selection	Personalized neurological treatment
Artificial intelligence	Drug discovery and response prediction	Precision neuropharmacology
Digital health platforms	Continuous monitoring and data analysis	Disease management and adherence improvement

6. Current Challenges, Future Perspectives and Conclusion

The management of neurological and neuropsychiatric disorders has progressed significantly with the development of advanced pharmacological therapies; however, several challenges continue to limit optimal clinical outcomes. Drug resistance remains a major concern, particularly in epilepsy, psychiatric disorders, and neurodegenerative diseases, where patients may show inadequate response despite appropriate treatment. In addition, many neurological drugs are associated with adverse effects such as cognitive impairment, sedation, metabolic disturbances, and cardiovascular complications, which can negatively affect treatment adherence and quality of life. Long-term administration of medications also presents challenges related to toxicity, therapeutic tolerance, and disease progression.

A major limitation in neuropharmacology is the difficulty of delivering therapeutic molecules effectively into the central nervous system (CNS). The blood–brain barrier restricts the penetration of many promising drugs, reducing their therapeutic effectiveness. Although nanoparticle-based systems and targeted delivery platforms have improved CNS drug transport, achieving precise delivery to specific brain regions and cell types remains a significant challenge (Gao et al., 2024). These limitations highlight the need for safer, more selective, and disease-modifying therapeutic strategies.

Recent clinical developments have introduced several innovative therapies that have expanded treatment options for neurological disorders. Advances in epilepsy management include development of newer antiseizure medications with improved safety profiles and targeted mechanisms. In stroke therapy, improvements in thrombolytic approaches, neuroprotective strategies, and regenerative medicine have enhanced patient outcomes. Similarly, neuropsychiatric treatment has benefited from rapid-acting antidepressants, novel antipsychotic strategies, and biomarker-guided approaches. Translational research is increasingly focusing on converting molecular discoveries into clinically effective therapies through improved drug design, clinical trials, and precision medicine approaches.

Future neuropharmacological research is expected to focus on the development of disease-modifying therapies capable of preventing or reversing neuronal damage rather than only controlling symptoms. Gene-based therapies, genome editing technologies, and cell-based approaches are emerging as promising strategies for neurological diseases. Recent advances in gene therapy have demonstrated potential for correcting abnormal gene expression and targeting underlying disease mechanisms; however, challenges related to delivery, safety, immune response, and long-term effectiveness remain important considerations (Gao et al., 2024).

Cell-based therapies using stem cells and regenerative approaches offer new possibilities for repairing damaged neural circuits and restoring neurological function. Advances in induced pluripotent stem cells and engineered cell therapies have increased the potential application of regenerative medicine in disorders such as stroke, Parkinson's disease, and neurodegenerative conditions (Svendsen & Svendsen, 2024). However, extensive clinical validation and standardized protocols are required before widespread application.

Precision neuropharmacology represents another major future direction by integrating pharmacogenomics, biomarkers, artificial intelligence, and patient-specific characteristics to optimize therapeutic selection. Personalized treatment strategies may reduce adverse effects, improve efficacy, and minimize trial-and-error approaches. Integrated neurological care combining pharmacological therapy, rehabilitation, digital monitoring, and lifestyle interventions may provide a comprehensive approach for managing complex neurological disorders.

In conclusion, epilepsy, stroke, and neuropsychiatric disorders continue to represent major healthcare challenges due to their complex biological mechanisms and limitations of current therapies. Recent advances in targeted drug delivery, precision medicine, gene therapy, regenerative medicine, and artificial intelligence have created new opportunities for improved disease management. Future therapeutic success will depend on the development of safe, personalized, and disease-modifying strategies that address the underlying causes of neurological dysfunction rather than only providing symptomatic relief.

References

- Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. *JAMA*, *323*(6), 548–560. https://doi.org/10.1001/jama.2019.22360
- Beghi, E. (2020). The epidemiology of epilepsy. *Neuroepidemiology*, *54*(2), 185–191. https://doi.org/10.1159/000503831
- Campbell, B. C. V., & Khatri, P. (2020). Stroke. *The Lancet*, *396*(10244), 129–142. https://doi.org/10.1016/S0140-6736(20)31179-X
- Chamorro, Á., Dirnagl, U., Urra, X., & Planas, A. M. (2016). Neuroprotection in acute stroke: Targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. *The Lancet Neurology*, *15*(8), 869–881. https://doi.org/10.1016/S1474-4422(16)00114-9
- Chen, K. S., Koubek, E. J., & Sakowski, S. A. (2024). Stem cell therapeutics and gene therapy for neurologic disorders. *Neurotherapeutics*, *21*(4), e00427. https://doi.org/10.1016/j.neurot.2024.e00427
- Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2018). Trial of cannabidiol for drug-resistant seizures in the Dravet

syndrome. *New England Journal of Medicine, 378*(20), 1888–1897. https://doi.org/10.1056/NEJMoa1714631

- Duncan, J. S., Sander, J. W., Sisodiya, S. M., & Walker, M. C. (2022). Adult epilepsy. *The Lancet, 401*(10371), 689–701.
- Feigin, V. L., Stark, B. A., Johnson, C. O., Roth, G. A., Bisignano, C., Abady, G. G., et al. (2021). Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology, 20*(1), 1–22. https://doi.org/10.1016/S1474-4422(20)30399-5
- Gao, J., Gunasekar, S., Xia, Z., Shalin, K., Jiang, C., Lee, D., et al. (2024). Gene therapy for CNS disorders: Modalities, delivery and translational challenges. *Nature Reviews Neuroscience, 25*, 553–572. https://doi.org/10.1038/s41583-024-00829-7
- Gao, J., Xia, Z., Gunasekar, S., Jiang, C., Karp, J. M., & Joshi, N. (2024). Precision drug delivery to the central nervous system using engineered nanoparticles. *Nature Reviews Materials, 9*, 567–588. https://doi.org/10.1038/s41578-024-00695-w
- Iadecola, C., & Anrather, J. (2011). The immunology of stroke: From mechanisms to translation. *Nature Medicine, 17*(7), 796–808. https://doi.org/10.1038/nm.2399
- Kalia, L. V., Asis, A., Arbour, N., et al. (2024). Disease-modifying therapies for Parkinson disease: Lessons from multiple sclerosis. *Nature Reviews Neurology, 20*, 724–737. https://doi.org/10.1038/s41582-024-01023-0
- Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., et al. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. *American Journal of Psychiatry, 177*(9), 868–872.
- Kumar, A., Singh, S., & Kumar, V. (2022). Neuroinflammation and oxidative stress in neurological disorders: Molecular mechanisms and therapeutic perspectives. *Neuroscience & Biobehavioral Reviews, 132*, 1–15.
- Kwan, P., Schachter, S. C., & Brodie, M. J. (2010). Drug-resistant epilepsy. *New England Journal of Medicine, 365*(10), 919–926. https://doi.org/10.1056/NEJMra1004418
- Kwon, H. J., Kim, J. H., & Lee, J. Y. (2023). Emerging approaches in precision medicine and targeted drug delivery for neurological disorders. *International Journal of Molecular Sciences, 24*(5), 4521.
- McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., et al. (2020). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression. *American Journal of Psychiatry, 177*(8), 654–662.
- Mhaske, A., Shukla, S., Ahirwar, K., Singh, K. K., & Shukla, R. (2024). Receptor-assisted nanotherapeutics for overcoming the blood–brain barrier. *Molecular Neurobiology, 61*, 8702–8738. https://doi.org/10.1007/s12035-024-04015-9
- Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. *Nature Reviews Immunology, 16*, 22–34. https://doi.org/10.1038/nri.2015.5
- Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. *The Lancet, 388*(10039), 86–97. https://doi.org/10.1016/S0140-6736(15)01121-6
- Perucca, E. (2021). Pharmacological treatment of epilepsy: New drugs and future perspectives. *Acta Neurologica Scandinavica, 144*(3), 249–262.
- Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., et al. (2019). Guidelines for the early management of patients with acute ischemic stroke. *Stroke, 50*(12), e344–e418. https://doi.org/10.1161/STR.0000000000000211

- Sampson, S., Schoenfeld, A. J., & Vickers, K. (2021). Pharmacogenomics and personalized medicine in neuropsychiatric disorders. *Molecular Psychiatry, 26*, 1–15.
- Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., et al. (2017). ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. *Epilepsia, 58*(4), 512–521. https://doi.org/10.1111/epi.13709
- Stahl, S. M. (2021). *Stahl's essential psychopharmacology: Neuroscientific basis and practical applications* (5th ed.). Cambridge University Press.
- Svendsen, S. P., & Svendsen, C. N. (2024). Cell therapy for neurological disorders. *Nature Medicine, 30*, 2756–2770. https://doi.org/10.1038/s41591-024-03281-3
- Vezzani, A., Fujinami, R. S., White, H. S., & Aronica, E. (2019). Inflammation and immunity in epilepsy. *Cold Spring Harbor Perspectives in Medicine, 9*(8), a028759. https://doi.org/10.1101/cshperspect.a028759
- Vora, L. K., Gholap, A. D., Hatvate, N. T., et al. (2024). Advances in artificial intelligence for drug delivery and development: A comprehensive review. *Computers in Biology and Medicine, 178*, 108702. https://doi.org/10.1016/j.compbiomed.2024.108702
- Xiong, Y., Mahmood, A., & Chopp, M. (2022). Emerging treatments for stroke: Neurorestorative and regenerative approaches. *Nature Reviews Neurology, 18*, 435–450. https://doi.org/10.1038/s41582-022-00665-1
- Zha, S., & Liu, H. (2024). Functionalized nanomaterials capable of crossing the blood–brain barrier. *ACS Nano, 18*(5), 3890–3912.
- Zha, S., Liu, H., & colleagues. (2024). Blood–brain barrier-targeting nanoparticles: Biomaterial properties and biomedical applications in translational neuroscience. *Advanced Healthcare Materials, 13*, e2303085.

Chapter 7: Medicinal Chemistry of Central Nervous System Drugs: Recent Advances and Future Perspectives

Jitendra Jena[*1], Deepanshu Sharma[2], Ujashkumar Shah[3], Hema Arya[4], Sanmati Kumar Jain[5]

[1]*Associate Professor, Department of Pharmaceutical Chemistry, Pharmacy College, Itaura, Chandeshwar, Azamgarh, Uttar Pradesh 276128, India.*

[2]*Associate Professor, Department of Pharmaceutical Chemistry, Advanced Institute of Pharmacy, Delhi–Mathura Road, Aurangabad, Palwal, District Palwal, Haryana–121105, India.*

[3]*Professor & Head, Nootan Pharmacy College, Sankalchand Patel University, SK Campus, Visnagar–384315, Gujarat, India.*

[4]*Associate Professor, Department of Pharmaceutical Chemistry, Sharda University, Plot No. 32–34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India.*

[5]*Professor, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Koni, Bilaspur, India.*

*Corresponding Author**:** Jitendra Jena, Associate Professor, Department of Pharmaceutical Chemistry, Pharmacy College, Itaura, Chandeshwar, Azamgarh, Uttar Pradesh 276128, India.

Abstract

Central nervous system (CNS) drug discovery represents one of the most challenging areas of medicinal chemistry due to the complex biology of the brain, limited therapeutic targets, and restricted drug transport across the blood–brain barrier (BBB). Recent advances in molecular neuroscience and medicinal chemistry have significantly improved the identification of CNS drug targets and the development of innovative therapeutic approaches. This chapter provides an overview of the molecular mechanisms, medicinal chemistry strategies, recent advancements, and future perspectives in CNS drug development. The role of neurotransmitter systems, receptors, enzymes, and signaling pathways as therapeutic targets is discussed, highlighting their importance in disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, depression, schizophrenia, and other neurological conditions. Modern drug design approaches, including structure–activity relationship (SAR) studies, physicochemical optimization, computational drug discovery, artificial intelligence (AI)-based methods, and nanotechnology-assisted delivery systems, have enhanced the discovery of brain-penetrant and selective CNS therapeutics. Recent progress in disease-modifying therapies, biologics, gene-based approaches, RNA therapeutics, and advanced drug delivery platforms has opened new opportunities for managing complex CNS disorders. However, challenges including BBB permeability, toxicity, disease heterogeneity, and translational limitations remain significant barriers. Future CNS drug discovery will rely on interdisciplinary integration of medicinal chemistry, computational biology, precision medicine, artificial intelligence, and targeted delivery technologies to develop safer, more effective, and personalized neurological therapies.

Keywords

Central nervous system drugs; Medicinal chemistry; Neurodegenerative diseases; Blood–brain barrier; Structure–activity relationship; CNS drug design; Neurotransmitters; Artificial intelligence; Nanotechnology; Targeted drug delivery; Precision medicine; Neurotherapeutics.

1. Introduction to Central Nervous System (CNS) Drugs and Medicinal Chemistry

The central nervous system (CNS), consisting of the brain and spinal cord, is the major regulatory system responsible for controlling cognition, emotion, movement, sensory processing, memory, and vital physiological functions. The brain contains complex networks of neurons that communicate through electrical signals and chemical messengers known as neurotransmitters. Neurotransmitters such as dopamine, serotonin, acetylcholine, glutamate, and gamma-aminobutyric acid (GABA) play essential roles in maintaining neuronal communication and CNS balance. Proper regulation of these neurotransmitter systems is critical for normal brain function, while disturbances may contribute to the development of neurological and psychiatric disorders (Kandel et al., 2021).

CNS disorders represent a significant global health burden due to their increasing prevalence, chronic nature, and impact on quality of life. Major neurological and psychiatric disorders include Alzheimer's disease, Parkinson's disease, epilepsy, depression, anxiety disorders, schizophrenia, multiple sclerosis, stroke, and other neurodegenerative conditions. These diseases involve complex pathological mechanisms such as neuronal degeneration, oxidative stress, neuroinflammation, neurotransmitter imbalance, and abnormal protein aggregation. Despite major advances in drug discovery, effective treatment of CNS disorders remains challenging because of limitations such as the blood–brain barrier (BBB), inadequate drug selectivity, toxicity concerns, and the multifactorial nature of neurological diseases (Feigin et al., 2021).

The development of CNS drugs requires specialized medicinal chemistry approaches to design molecules with appropriate pharmacological and physicochemical properties. Medicinal chemistry plays a crucial role in identifying and optimizing drug candidates through structure–activity relationship (SAR) studies, molecular modification, and lead optimization strategies. The optimization of potency, receptor selectivity, metabolic stability, pharmacokinetic behavior, and ability to cross the BBB are essential factors in the development of successful CNS therapeutics. Modern CNS drug discovery integrates computational approaches, molecular modeling, and advanced drug delivery strategies to overcome traditional limitations and improve therapeutic outcomes (Patrick, 2023).

Recent progress in medicinal chemistry has enabled the development of innovative CNS-targeted therapies by modifying chemical structures to enhance efficacy and reduce adverse effects. Understanding the relationship between molecular structure and biological activity remains a fundamental aspect of designing safer and more effective CNS drugs. These advances provide new opportunities for the discovery of disease-modifying therapies for complex neurological disorders (Brunton et al., 2023).

2. Molecular Targets and Mechanisms of CNS Drugs

2.1 Neurotransmitter-Based Drug Targets

The activity of the central nervous system is primarily regulated by neurotransmitter signaling pathways, and many CNS drugs exert their therapeutic effects by modifying these pathways. Alterations in neurotransmitter levels or receptor activity contribute to neurological and psychiatric disorders; therefore, neurotransmitter systems represent important targets for drug discovery.

The **cholinergic system** plays a crucial role in learning, memory, and cognitive function. In Alzheimer's disease, reduced acetylcholine levels due to degeneration of cholinergic neurons contribute to cognitive impairment. Acetylcholinesterase inhibitors such as donepezil, rivastigmine, and galantamine improve cholinergic transmission by preventing acetylcholine degradation and are widely used for symptomatic management of Alzheimer's disease (Hampel et al., 2018).

The **dopaminergic system** regulates movement, motivation, and emotional responses. Dopamine deficiency in the substantia nigra is a major pathological feature of Parkinson's disease, while excessive dopaminergic signaling is associated with schizophrenia. Dopamine agonists such as pramipexole and ropinirole enhance dopamine activity in Parkinson's disease, whereas dopamine receptor antagonists are important therapeutic agents for schizophrenia management (Armstrong & Okun, 2020).

The **serotonergic system** plays an essential role in mood regulation, anxiety, and emotional processing. Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine and sertraline, increase serotonin availability by inhibiting its reuptake and are commonly used for depression and anxiety disorders. Serotonin receptor modulators are also being explored for improved efficacy and reduced adverse effects (Duman et al., 2019).

The **GABAergic and glutamatergic systems** regulate neuronal excitation and inhibition. GABA enhances inhibitory neurotransmission, while glutamate acts as the primary excitatory neurotransmitter. Drugs targeting GABA receptors, sodium channels, and glutamate receptors are widely used as antiepileptic agents. Modulation of glutamatergic signaling, particularly NMDA receptor activity, has also shown neuroprotective potential in neurodegenerative disorders (Löscher & Klein, 2021).

Table 2.1. Major Neurotransmitter-Based Targets in CNS Drug Development

Neurotransmitter System	Drug Target	Therapeutic Application	Examples of Drugs
Cholinergic	Acetylcholinesterase enzyme	Alzheimer's disease	Donepezil, Rivastigmine
Dopaminergic	Dopamine receptors	Parkinson's disease, Schizophrenia	Pramipexole, Risperidone
Serotonergic	Serotonin transporters/receptors	Depression, Anxiety	Fluoxetine, Sertraline
GABAergic	GABA receptors	Epilepsy, Anxiety	Diazepam, Gabapentin
Glutamatergic	NMDA receptors	Neuroprotection, Alzheimer's disease	Memantine

2.2 Receptors and Enzymes as CNS Drug Targets

Receptors and enzymes involved in neuronal signaling represent major targets for CNS drug development. Among these, **G-protein coupled receptors (GPCRs)** are highly important because they regulate multiple physiological processes, including neurotransmission, neuronal growth, and synaptic plasticity. Several CNS drugs act through GPCR modulation, including dopamine, serotonin, and opioid receptor-targeted therapies (Hauser et al., 2021).

Ion channels are another important class of CNS drug targets. Voltage-gated **sodium channels** regulate neuronal excitability and are targeted by antiepileptic drugs such as carbamazepine and lamotrigine. **Calcium channels** regulate neurotransmitter release and are targeted in epilepsy and pain disorders. Potassium channels influence neuronal membrane stability and represent emerging targets for neurological therapeutics.

Several enzymes are also associated with CNS disease progression. Monoamine oxidase-B (MAO-B) inhibitors such as selegiline and rasagiline increase dopamine availability and are used in Parkinson's disease. β-secretase (BACE-1) inhibitors have been investigated for reducing amyloid-β production in Alzheimer's disease. Kinases involved in neuronal signaling and inflammation are also considered potential targets for future CNS drug discovery (Cummings et al., 2021).

Table 2.2. Important Molecular Targets and Their Role in CNS Therapy

Molecular Target	Mechanism of Action	Associated Disorders	Drug Examples
GPCRs	Regulation of neurotransmitter signaling	Schizophrenia, depression	Antipsychotics, antidepressants
Sodium channels	Reduction of neuronal excitability	Epilepsy	Carbamazepine, Lamotrigine
Calcium channels	Regulation of neurotransmitter release	Epilepsy, neuropathic pain	Pregabalin
MAO-B enzyme	Inhibition of dopamine metabolism	Parkinson's disease	Rasagiline
β-secretase enzyme	Reduction of amyloid formation	Alzheimer's disease	Investigational inhibitors

2.3 Molecular Mechanisms of CNS Therapeutics

CNS therapeutics produce their effects through multiple molecular mechanisms, including modulation of neurotransmission, regulation of intracellular signaling pathways, reduction of neuroinflammation, and prevention of neuronal degeneration. Drugs may enhance or inhibit neurotransmitter activity by interacting with receptors, transporters, or metabolic enzymes.

Neuroprotective mechanisms have become an important focus in CNS drug development due to the increasing recognition of oxidative stress, mitochondrial dysfunction, and inflammation in neurological disorders. Anti-inflammatory approaches aim to reduce microglial activation and inflammatory mediator release, which contribute to neuronal damage.

Recent therapeutic strategies focus on disease modification rather than only symptom control. These approaches include targeting abnormal protein aggregation, improving neuronal survival pathways, and developing multifunctional molecules capable of acting on multiple disease pathways simultaneously (Cummings et al., 2021).

3. Medicinal Chemistry Approaches in CNS Drug Design

3.1 Structure–Activity Relationship (SAR) Studies

Structure–activity relationship (SAR) analysis is a fundamental approach in medicinal chemistry used to understand the relationship between the chemical structure of a molecule and its biological activity. In CNS drug discovery, SAR studies help identify essential structural features responsible for receptor binding, potency, selectivity, and therapeutic effects. Modification of functional groups, aromatic rings, linkers, and substituents allows researchers to optimize lead compounds and improve their pharmacological properties.

Lead identification and optimization involve systematic chemical modifications to enhance activity while reducing toxicity and unwanted interactions. For example, modification of dopamine agonists has resulted in improved selectivity and longer duration of action for Parkinson's disease treatment. Similarly, structural optimization of serotonin receptor ligands has contributed to the development of newer antidepressant and antipsychotic agents with improved safety profiles (Wermuth, 2021).

Table 3.1. Important SAR Parameters in CNS Drug Design

SAR Parameter	Role in CNS Drug Optimization	Example
Functional group modification	Improves receptor binding and potency	Modification of dopamine agonists
Aromatic ring substitution	Enhances selectivity and metabolic stability	Serotonin receptor ligands
Linker optimization	Controls molecular flexibility and activity	CNS receptor modulators
Molecular scaffold modification	Generates new lead molecules	Heterocyclic CNS drugs

3.2 Physicochemical Properties for CNS Drug Design

The physicochemical properties of drug molecules strongly influence their ability to reach and act on CNS targets. Since the brain is protected by the blood–brain barrier (BBB), CNS drugs require appropriate lipophilicity, molecular size, polarity, and hydrogen bonding capacity to achieve adequate brain exposure.

Lipophilicity, commonly expressed as logP, affects membrane permeability and BBB penetration. However, excessive lipophilicity may increase nonspecific binding, metabolic instability, and toxicity. Optimal CNS drug candidates generally possess balanced hydrophobic and hydrophilic properties. Molecular weight, hydrogen bond donors and acceptors, aqueous solubility, plasma protein binding, and metabolic stability are also important factors during drug optimization (Pajouhesh & Lenz, 2005).

Table 3.2. Physicochemical Requirements for CNS Drug Candidates

Property	Importance in CNS Drug Design
Lipophilicity (logP)	Influences BBB penetration and membrane permeability
Molecular weight	Lower molecular size generally improves CNS availability
Hydrogen bonding	Controls polarity and permeability
Solubility	Determines drug absorption and bioavailability
Metabolic stability	Improves drug half-life and therapeutic duration

3.3 Strategies to Improve Blood–Brain Barrier Penetration

The blood–brain barrier (BBB) is one of the major challenges in CNS drug development because it restricts the entry of many therapeutic molecules into brain tissue. The BBB consists of tightly connected endothelial cells, transport proteins, and metabolic enzymes that regulate molecular transport.

Medicinal chemistry strategies are used to enhance BBB penetration, including prodrug approaches, lipid modification, and optimization of molecular properties. Prodrugs are chemically modified inactive forms that undergo conversion into active drugs after crossing biological barriers. Lipid-based modifications increase membrane permeability, while nanocarrier-based systems such as liposomes, polymeric nanoparticles, and lipid nanoparticles provide targeted CNS delivery and improved drug stability (Saraiva et al., 2016).

3.4 Computational and Modern Drug Discovery Approaches

Modern CNS drug discovery increasingly integrates computational methods to accelerate identification and optimization of therapeutic molecules. Computer-aided drug design (CADD) enables prediction of molecular interactions, biological activity, and pharmacokinetic properties before experimental testing.

Molecular docking and molecular dynamics simulations are widely used to analyze drug–target interactions and evaluate binding stability. Artificial intelligence (AI) and machine learning approaches have further improved CNS drug discovery by enabling prediction of drug efficacy, toxicity, BBB permeability, and potential therapeutic candidates. These approaches reduce development time and improve the success rate of CNS drug discovery programs (Vamathevan et al., 2019).

Artificial intelligence-based platforms can analyze large chemical and biological datasets to identify novel drug candidates and optimize existing molecules. The integration of computational chemistry, biological data, and experimental validation represents a promising strategy for developing next-generation CNS therapeutics.

4. Recent Advances in CNS Drug Development

4.1 Advances in Neurodegenerative Disease Therapeutics

Recent advances in CNS drug development have shifted from symptomatic treatment toward disease-modifying strategies aimed at slowing or preventing neuronal damage. In **Alzheimer's disease (AD)**, therapeutic approaches have focused on targeting major pathological mechanisms including amyloid-β (Aβ) accumulation, tau protein abnormalities, and neuroinflammation. Anti-amyloid monoclonal

antibodies have shown potential in reducing amyloid plaque burden and slowing cognitive decline in early-stage disease. In addition, tau-targeting strategies such as tau aggregation inhibitors, anti-tau antibodies, and antisense oligonucleotide approaches are being investigated because tau pathology correlates strongly with disease progression (Congdon et al., 2023).

Neuroinflammation has also emerged as an important therapeutic target due to the involvement of activated microglia and inflammatory mediators in neuronal injury. Current research focuses on developing agents capable of regulating inflammatory pathways while preserving normal immune functions in the brain (Self & Holtzman, 2023).

In **Parkinson's disease (PD)**, traditional dopamine replacement therapies remain important for symptom control; however, recent approaches aim to develop disease-modifying treatments. These include α-synuclein-targeting antibodies, aggregation inhibitors, mitochondrial protective agents, and gene-based therapies designed to restore neuronal function and prevent dopaminergic neuron loss.

Table 4.1. Recent Therapeutic Strategies for Neurodegenerative Disorders

Disease	Molecular Target/Approach	Therapeutic Strategy	Examples
Alzheimer's disease	Amyloid-β	Reduction of amyloid plaque formation	Anti-Aβ antibodies
Alzheimer's disease	Tau protein	Inhibition of tau aggregation and spread	Anti-tau antibodies, ASOs
Alzheimer's disease	Neuroinflammation	Modulation of inflammatory pathways	Microglial-targeted therapies
Parkinson's disease	Dopamine pathway	Restoration of dopamine signaling	Levodopa, dopamine agonists
Parkinson's disease	α-Synuclein	Prevention of protein aggregation	Immunotherapy approaches

4.2 Novel Antidepressant and Antipsychotic Agents

The development of new CNS psychiatric medicines focuses on improving therapeutic response, reducing adverse effects, and achieving faster clinical benefits. Conventional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) require several weeks for therapeutic effects; therefore, rapid-acting antidepressant strategies have gained significant attention.

Ketamine and related glutamatergic modulators have demonstrated rapid antidepressant activity through regulation of NMDA receptor signaling and enhancement of synaptic plasticity. Additionally, novel serotonin receptor modulators are being explored to improve antidepressant efficacy while minimizing side effects associated with traditional therapies.

In schizophrenia treatment, newer antipsychotic drug candidates aim to achieve improved dopamine receptor selectivity along with activity at serotonin receptors to reduce extrapyramidal symptoms and metabolic complications. Multi-target receptor modulation represents an important strategy for next-generation psychiatric drug development.

Table 4.2. Emerging CNS Therapeutic Approaches

Therapeutic Area	New Approach	Mechanism	Potential Benefits
Depression	Rapid-acting antidepressants	NMDA receptor modulation and synaptic plasticity	Faster symptom improvement
Depression	Serotonin receptor modulators	Selective serotonergic regulation	Improved safety profile
Schizophrenia	Multi-receptor targeting drugs	Dopamine and serotonin modulation	Reduced adverse effects
Neurodegeneration	Disease-modifying agents	Targeting pathological proteins	Slowing disease progression

4.3 Advanced Drug Delivery Systems for CNS Disorders

Efficient delivery of therapeutic molecules to the brain remains a major challenge because of the blood–brain barrier (BBB). Advanced drug delivery systems have been developed to improve CNS drug transport, stability, and therapeutic effectiveness.

Nanotechnology-based approaches, including polymeric nanoparticles, liposomes, and solid lipid nanoparticles, provide controlled drug release and enhanced brain targeting. These systems can improve drug solubility, protect unstable molecules, and facilitate transport across biological barriers. Intranasal delivery has also emerged as a promising strategy because it provides a direct pathway to the brain through olfactory and trigeminal routes, reducing systemic exposure.

Nanocarrier-based delivery platforms are particularly valuable for biologics, RNA-based therapeutics, and poorly water-soluble CNS drugs where conventional administration methods show limited effectiveness (Saraiva et al., 2016).

4.4 Biologics and Emerging Therapeutic Approaches

Biological therapies have created new opportunities for treating complex CNS disorders. Monoclonal antibodies are being developed to target pathological proteins such as amyloid-β and tau, providing highly specific therapeutic effects. Recent advances in antibody engineering and delivery technologies have improved their potential application in neurological diseases.

Gene therapy represents another promising approach for CNS disorders by correcting genetic defects, enhancing protective pathways, or replacing defective proteins. Adeno-associated virus (AAV)-based delivery systems have shown potential for neurological disorders, although challenges related to immune response, delivery efficiency, and long-term safety remain.

RNA-based therapeutics, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and mRNA-based approaches, provide opportunities for regulating disease-associated genes and proteins. These strategies are being investigated for neurodegenerative disorders such as Alzheimer’s disease and other genetic neurological conditions (McCartan et al., 2023).

Stem cell-based therapies are also being explored for neuronal regeneration and replacement of damaged cells. Although clinical translation remains challenging, advances in regenerative medicine may provide future solutions for disorders involving irreversible neuronal loss.

5. Current Challenges and Future Perspectives in CNS Medicinal Chemistry

5.1 Challenges in CNS Drug Discovery

Central nervous system drug discovery remains one of the most challenging areas of pharmaceutical research because of the complex organization and functionality of the brain. Unlike many peripheral diseases, CNS disorders involve multiple interacting pathways, genetic factors, neuronal networks, and environmental influences, making the identification of single therapeutic targets difficult. The limited availability of reliable disease models and the poor translation of animal studies into human clinical outcomes represent major barriers during CNS drug development.

A major challenge is the **blood–brain barrier (BBB)**, which restricts the penetration of many therapeutic molecules into brain tissue. Poor BBB permeability, rapid metabolism, and inadequate drug distribution often reduce therapeutic effectiveness. Additionally, CNS drugs require careful safety evaluation because unwanted interactions with neuronal pathways may lead to toxicity, cognitive impairment, or psychiatric adverse effects. The long development period, high failure rate, and complex clinical evaluation requirements further increase the difficulty of CNS drug discovery (Hasselgren & Oprea, 2024).

Table 5.1. Major Challenges in CNS Drug Discovery

Challenge	Impact on Drug Development
Complex brain biology	Difficulty in identifying effective therapeutic targets
Limited predictive models	Poor translation from preclinical studies to humans
Blood–brain barrier limitation	Reduced drug delivery to brain tissue
Long development timelines	Increased research cost and failure risk
Safety and toxicity concerns	Risk of neurological adverse effects

5.2 Emerging Trends in CNS Drug Design

Recent advances in medicinal chemistry have introduced innovative strategies to overcome limitations associated with conventional CNS therapies. **Precision medicine** and personalized therapeutic approaches aim to develop treatments based on individual genetic, molecular, and clinical characteristics. These approaches improve patient selection and increase the probability of therapeutic success.

Multi-target-directed ligands (MTDLs) have gained importance because many CNS disorders involve multiple pathological mechanisms rather than a single target. MTDLs are designed to interact with multiple receptors, enzymes, or signaling pathways simultaneously, providing improved therapeutic effects. Hybrid molecule design, which combines structural features of different pharmacophores into one molecule, is also being explored for neurodegenerative and psychiatric disorders.

Neuroprotective drug development has become a major focus, with strategies aimed at reducing oxidative stress, mitochondrial dysfunction, neuroinflammation, and neuronal apoptosis. These approaches may provide disease-modifying effects rather than only symptomatic relief.

Table 5.2. Emerging Strategies in CNS Medicinal Chemistry

Strategy	Principle	Potential Application
Precision medicine	Treatment based on molecular and genetic profiles	Personalized CNS therapy
Multi-target-directed ligands	Simultaneous action on multiple pathways	Alzheimer's disease, Parkinson's disease
Hybrid molecules	Combination of different pharmacophores	Neurodegenerative disorders
Neuroprotective agents	Prevention of neuronal damage	Chronic CNS diseases

5.3 Role of Artificial Intelligence and Big Data

Artificial intelligence (AI) and big data analytics are transforming CNS drug discovery by improving target identification, molecular design, and prediction of drug properties. AI-based systems can analyze large biological datasets, including genomic, proteomic, imaging, and chemical information, to identify potential therapeutic targets and disease-associated pathways.

Machine learning algorithms are increasingly applied for virtual screening, quantitative structure–activity relationship (QSAR) modeling, toxicity prediction, and pharmacokinetic evaluation. These computational approaches reduce the time required for lead identification and allow researchers to prioritize promising molecules before experimental testing. Recent advances in AI-driven drug design have enabled improved molecular generation, property prediction, and optimization of drug candidates.

Drug repurposing is another important AI-supported strategy that identifies new therapeutic applications for existing drugs by analyzing large-scale clinical and molecular datasets. This approach can reduce development costs and accelerate CNS drug discovery.

5.4 Future Opportunities

Future CNS medicinal chemistry is expected to focus on developing disease-modifying therapies capable of slowing or reversing neurological damage. Advances in biomarker discovery will improve early diagnosis, patient stratification, and monitoring of therapeutic responses.

Combination therapies targeting multiple disease mechanisms may provide improved outcomes for complex disorders such as Alzheimer's disease and Parkinson's disease. In addition, advanced targeted delivery systems, including nanoparticles, liposomes, and ligand-based delivery platforms, are expected to enhance brain-specific drug delivery and overcome BBB limitations.

Integration of medicinal chemistry with artificial intelligence, computational biology, nanotechnology, and precision medicine will play a critical role in developing safer and more effective CNS therapeutics. AI-assisted approaches are expected to accelerate drug discovery by improving target prediction, molecular optimization, and personalized treatment strategies.

6. Conclusion

The field of central nervous system (CNS) drug discovery has undergone significant transformation with advances in molecular target identification, medicinal chemistry, and innovative therapeutic

strategies. Improved understanding of disease-associated pathways, neurotransmitter systems, protein aggregation mechanisms, and neuroinflammatory processes has enabled the development of more selective and effective CNS therapeutics. Modern medicinal chemistry approaches, including structure-based drug design, multi-target-directed ligands, and optimized drug delivery strategies, have expanded opportunities for treating complex neurological disorders.

Future CNS drug development will depend on the integration of multiple disciplines, including medicinal chemistry, computational biology, nanotechnology, and artificial intelligence (AI). Computational approaches and AI-based platforms are increasingly contributing to target identification, virtual screening, molecular optimization, toxicity prediction, and personalized therapeutic design. These technologies have the potential to accelerate CNS drug discovery by reducing development time and improving the selection of promising drug candidates (Kant et al., 2025).

Advanced delivery technologies, particularly nanocarrier-based systems, provide promising solutions for overcoming the blood–brain barrier and improving targeted drug transport to brain tissues. Nanoparticles, liposomes, and other engineered delivery platforms may enhance therapeutic efficacy while minimizing systemic toxicity. The combination of nanotechnology with computational approaches represents a future direction for precision CNS medicine (Senanayake et al., 2025).

The next generation of CNS therapeutics will likely focus on disease-modifying approaches, personalized medicine, and combination therapies capable of addressing the complex and multifactorial nature of neurological disorders. Interdisciplinary collaboration between medicinal chemists, neuroscientists, computational scientists, and clinicians will be essential for overcoming current limitations and developing safer, more effective, and patient-specific CNS medicines. Emerging technologies such as AI-driven drug discovery, genomic therapies, and advanced brain-targeted delivery systems provide significant opportunities to revolutionize the future of CNS therapeutics.

References

- Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. *JAMA, 323*(6), 548–560. https://doi.org/10.1001/jama.2019.22360
- Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). *Goodman & Gilman's the pharmacological basis of therapeutics* (14th ed.). McGraw Hill Education.
- Carini, C., & Seyhan, A. A. (2024). Tribulations and future opportunities for artificial intelligence in precision medicine. *Journal of Translational Medicine, 22*, 411. https://doi.org/10.1186/s12967-024-05067-0
- Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023). Tau-targeting therapies for Alzheimer disease: Current status and future directions. *Nature Reviews Neurology, 19*, 715–736. https://doi.org/10.1038/s41582-023-00883-2
- Cummings, J., Lee, G., Zhong, K., Fonseca, J., Taghavi, S., & Cheng, F. (2021). Alzheimer's disease drug development pipeline: 2021. *Alzheimer's & Dementia: Translational Research & Clinical Interventions, 7*(1), e12179. https://doi.org/10.1002/trc2.12179
- Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2019). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. *Nature Medicine, 25*, 1545–1554. https://doi.org/10.1038/s41591-019-0634-2

- Fang, S., Yin, Z., Cai, Q., Li, L., Zheng, P., & Chen, L. (2025). Harnessing artificial intelligence for brain disease: Advances in diagnosis, drug discovery, and closed-loop therapeutics. *Frontiers in Neurology, 16*, 1615523. https://doi.org/10.3389/fneur.2025.1615523
- Feigin, V. L., Stark, B. A., Johnson, C. O., Roth, G. A., Bisignano, C., Abady, G. G., et al. (2021). Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology, 20*(1), 1–22. https://doi.org/10.1016/S1474-4422(20)30399-5
- Hampel, H., Mesulam, M. M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., et al. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain, 141*(7), 1917–1933. https://doi.org/10.1093/brain/awy132
- Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2021). Trends in GPCR drug discovery: New agents, targets and indications. *Nature Reviews Drug Discovery, 20*, 829–842. https://doi.org/10.1038/s41573-021-00291-3
- Hasselgren, C., & Oprea, T. I. (2024). Artificial intelligence for drug discovery: Are we there yet? *Annual Review of Pharmacology and Toxicology, 64*, 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828
- Kandel, E. R., Koester, J. D., Mack, S. H., & Siegelbaum, S. A. (2021). *Principles of neural science* (6th ed.). McGraw Hill.
- Kant, S., Deepika, & Roy, S. (2025). Artificial intelligence in drug discovery and development: Transforming challenges into opportunities. *Discover Pharmaceutical Sciences, 1*, Article 7. https://doi.org/10.1007/s44395-025-00007-3
- Khan, M. K., Raza, M., Shahbaz, M. S., Hussain, I., Khan, M. F., Xie, Z., Shah, S. S. A., Tareen, A. K., Bashir, Z., & Khan, K. (2024). The recent advances in the approach of artificial intelligence (AI) towards drug discovery. *Frontiers in Chemistry, 12*, 1408740. https://doi.org/10.3389/fchem.2024.1408740
- Li, H., Yu, C., Markovic, T., Nestler, E. J., & Dong, Y. (2025). Chemical strategies for brain delivery of genomic therapy. *Nature Reviews Chemistry, 9*, 841–854. https://doi.org/10.1038/s41570-025-00770-y
- Ling, Q., Herstine, J. A., Bradbury, A., et al. (2023). AAV-based in vivo gene therapy for neurological disorders. *Nature Reviews Drug Discovery, 22*, 789–806. https://doi.org/10.1038/s41573-023-00766-7
- Löscher, W., & Klein, P. (2021). The pharmacology and clinical efficacy of antiseizure medications: From bromide salts to cenobamate and beyond. *CNS Drugs, 35*, 935–963. https://doi.org/10.1007/s40263-021-00840-5
- McCartan, R. M., Khorkova, O., Volmar, C. H., & Wahlestedt, C. (2023). Nucleic acid-based therapeutics for the treatment of central nervous system disorders. *Frontiers in Genetics, 14*, 1250276. https://doi.org/10.3389/fgene.2023.1250276
- Pajouhesh, H., & Lenz, G. R. (2005). Medicinal chemical properties of successful central nervous system drugs. *NeuroRx, 2*(4), 541–553. https://doi.org/10.1602/neurorx.2.4.541
- Patrick, G. L. (2023). *An introduction to medicinal chemistry* (7th ed.). Oxford University Press.
- Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release, 235*, 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044

- Self, W. K., & Holtzman, D. M. (2023). Emerging diagnostics and therapeutics for Alzheimer disease. *Nature Medicine*, *29*, 2187–2199. https://doi.org/10.1038/s41591-023-02505-2
- Senanayake, D., Yapa, P., Dabare, S., & Munaweera, I. (2025). Precision targeting of the CNS: Recent progress in brain-directed nanodrug delivery. *RSC Advances*, *15*, 25910–25928. https://doi.org/10.1039/D5RA03578C
- Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, *18*, 463–477. https://doi.org/10.1038/s41573-019-0024-5
- Wang, K., Huang, Y., Wang, Y., You, Q., & Wang, L. (2024). Recent advances from computer-aided drug design to artificial intelligence drug design. *RSC Medicinal Chemistry*, *15*, 3978–4000. https://doi.org/10.1039/D4MD00522H
- Wermuth, C. G. (2021). *The practice of medicinal chemistry* (5th ed.). Academic Press.

Chapter 8: Heterocyclic Scaffolds and Multi-Target-Directed Ligands for Neurodegenerative Disorders

Mohd Akram Khan[*1], Hema Arya[2], Sejal G. Patel[3], Mangilal Chouhan[4], Sanmati Kumar Jain[5]

[1]*Principal, Department of Pharmaceutical Chemistry, Anjuman-A-Ashraf Pharmacy College, Vill Vasi Sahsoli, Sihali Jageer, Tehsil Hasanpur, District Amroha, Uttar Pradesh, India.*

[2]*Associate Professor, Department of Pharmaceutical Chemistry, Sharda University, Plot No. 32–34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India.*

[3]*Professor, Nootan Pharmacy College, Sankalchand Patel University, SK Campus, Visnagar–384315, Gujarat, India*

[4]*Assistant Professor, Department of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, University Campus, Udaipur, Rajasthan–313001, India.*

[5]*Professor, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Koni, Bilaspur, India.*

*Corresponding Author: Mohd Akram Khan, Principal, Department of Pharmaceutical Chemistry, Anjuman-A-Ashraf Pharmacy College, Vill Vasi Sahsoli, Sihali Jageer, Tehsil Hasanpur, District Amroha, Uttar Pradesh, India.

Abstract

Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, represent major global health challenges due to their progressive nature, complex pathology, and limited availability of disease-modifying therapies. These disorders involve multiple interconnected pathological mechanisms such as abnormal protein aggregation, oxidative stress, neuroinflammation, mitochondrial dysfunction, neurotransmitter imbalance, excitotoxicity, and neuronal loss. Conventional single-target therapeutic approaches often provide only symptomatic improvement and fail to effectively halt disease progression. Therefore, the development of multifunctional therapeutic strategies has gained significant attention.

Heterocyclic scaffolds have emerged as valuable frameworks in neurodegenerative drug discovery due to their structural diversity, favorable pharmacological properties, and ability to interact with multiple biological targets. Nitrogen-, oxygen-, and sulfur-containing heterocycles, including quinoline, quinazoline, indole, benzimidazole, triazole, thiazole, coumarin, and chromone derivatives, have demonstrated promising neuroprotective activities through cholinesterase inhibition, monoamine oxidase modulation, anti-amyloid activity, antioxidant effects, metal chelation, and suppression of neuroinflammatory pathways. In parallel, multi-target-directed ligands (MTDLs) have introduced a novel therapeutic concept by integrating multiple pharmacophoric features into a single molecule capable of simultaneously regulating several disease-associated targets.

This chapter highlights recent advances in heterocyclic-based MTDLs for neurodegenerative disorders, focusing on their design strategies, molecular mechanisms, therapeutic targets, and pharmacological potential. The role of molecular hybridization, pharmacophore fusion, fragment-based approaches, computational drug design, artificial intelligence, and nanotechnology-based delivery systems in accelerating neuroprotective drug discovery is discussed. Furthermore, challenges

associated with blood–brain barrier penetration, pharmacokinetic optimization, toxicity, and clinical translation are addressed. Overall, heterocyclic MTDLs represent a promising direction toward the development of next-generation neuroprotective agents with improved efficacy and disease-modifying potential. Continued integration of medicinal chemistry, computational approaches, and advanced delivery technologies may accelerate the discovery of safer and more effective therapies for complex neurodegenerative diseases.

Keywords: Neurodegenerative disorders; Heterocyclic scaffolds; Multi-target-directed ligands; Alzheimer's disease; Parkinson's disease; Neuroprotection; Molecular hybridization; Medicinal chemistry; Computational drug design; Blood–brain barrier.

1. Introduction

Neurodegenerative disorders are a group of progressive diseases characterized by the gradual loss of structure and function of neurons in the central and peripheral nervous systems. These disorders are associated with irreversible neuronal degeneration, leading to cognitive impairment, memory loss, movement disorders, and behavioral abnormalities. Among the most common neurodegenerative disorders are Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), each of which involves distinct pathological mechanisms but shares common features such as protein misfolding, oxidative stress, mitochondrial dysfunction, neuroinflammation, and neuronal cell death (Armstrong & Okun, 2020; Feigin et al., 2021).

The prevalence of neurodegenerative disorders has increased substantially due to population aging and improved life expectancy. Alzheimer's disease is the leading cause of dementia worldwide, whereas Parkinson's disease is the second most common neurodegenerative disorder affecting millions of elderly individuals. Huntington's disease, although less common, is a hereditary disorder characterized by progressive motor dysfunction and cognitive decline, while ALS primarily affects motor neurons, leading to muscle weakness and respiratory failure. These disorders impose enormous social, emotional, and economic burdens on patients, caregivers, and healthcare systems across the world (Feigin et al., 2021).

Current therapeutic approaches mainly provide symptomatic relief without significantly altering disease progression. Clinically approved drugs, including cholinesterase inhibitors, NMDA receptor antagonists, dopamine replacement therapy, and monoamine oxidase inhibitors, improve symptoms for limited periods but fail to prevent neuronal degeneration. The complex and multifactorial nature of neurodegenerative diseases, involving amyloid-β aggregation, tau hyperphosphorylation, α-synuclein accumulation, oxidative stress, mitochondrial dysfunction, metal ion imbalance, excitotoxicity, and chronic neuroinflammation, has limited the success of single-target drugs (Brunton et al., 2023; Armstrong & Okun, 2020).

Heterocyclic compounds have emerged as one of the most important classes of molecules in medicinal chemistry because of their structural diversity, favorable pharmacokinetic properties, and ability to interact with multiple biological targets. Nitrogen-, oxygen-, and sulfur-containing heterocyclic scaffolds such as indole, quinoline, quinazoline, pyridine, pyrimidine, benzimidazole, triazole, thiazole, coumarin, and chromone are widely present in numerous approved central nervous system drugs. These scaffolds exhibit antioxidant, anti-inflammatory, anti-amyloid, anti-tau, cholinesterase inhibitory, monoamine oxidase inhibitory, and neuroprotective activities, making them

promising candidates for the development of novel therapeutics against neurodegenerative disorders (Mathew et al., 2025; Sánchez et al., 2023).

Because neurodegenerative diseases involve multiple interconnected pathological pathways, the concept of multi-target-directed ligands (MTDLs) has gained considerable attention in recent years. MTDLs are rationally designed molecules capable of simultaneously modulating two or more therapeutic targets within a single chemical entity. By combining different pharmacophores through molecular hybridization, MTDLs can inhibit cholinesterases, monoamine oxidases, β-secretase, amyloid-β aggregation, tau pathology, oxidative stress, neuroinflammation, and metal ion dysregulation simultaneously, thereby offering greater therapeutic efficacy than conventional single-target drugs. This strategy has become a promising direction for discovering disease-modifying agents for Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.

This chapter provides a comprehensive review of heterocyclic scaffolds and multi-target-directed ligands developed for neurodegenerative disorders. It discusses the medicinal importance of major heterocyclic frameworks, recent advances in MTDL design strategies, structure–activity relationships, molecular mechanisms of neuroprotection, and the therapeutic potential of these compounds against Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and other neurodegenerative conditions. The chapter also highlights current challenges, emerging computational approaches, and future perspectives for developing safer and more effective neuroprotective agents.

2. Heterocyclic Scaffolds in Neurodegenerative Drug Discovery

2.1 Importance of Heterocyclic Chemistry

Heterocyclic compounds constitute one of the most important classes of molecules in medicinal chemistry because they are present in a large proportion of marketed drugs. The incorporation of nitrogen, oxygen, or sulfur atoms into cyclic structures provides unique physicochemical and biological properties that improve receptor binding, metabolic stability, aqueous solubility, and blood–brain barrier permeability. These characteristics make heterocyclic scaffolds particularly attractive for developing therapeutics against complex neurodegenerative disorders.

From a biological perspective, heterocyclic compounds interact with numerous molecular targets involved in Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Depending on their structural features, these molecules exhibit antioxidant, anti-inflammatory, cholinesterase inhibitory, monoamine oxidase inhibitory, β-secretase inhibitory, anti-amyloid, anti-tau, and metal-chelating activities. Their ability to modulate multiple pathological pathways has encouraged their application in multitarget-directed ligand (MTDL) design.

The drug-like properties of heterocyclic scaffolds include structural diversity, favorable pharmacokinetics, synthetic flexibility, and easy functionalization. Medicinal chemists can introduce suitable substituents to optimize potency, selectivity, safety, and blood–brain barrier penetration while minimizing toxicity. Consequently, heterocyclic chemistry remains a cornerstone of modern neurotherapeutic drug discovery.

2.2 Major Heterocyclic Scaffolds

Several heterocyclic scaffolds have demonstrated considerable promise in the treatment of neurodegenerative disorders. Nitrogen-containing heterocycles such as pyridine, pyrimidine, quinoline, quinazoline, indole, benzimidazole, imidazole, and triazole possess excellent receptor-binding capabilities and frequently exhibit cholinesterase inhibition, monoamine oxidase inhibition, antioxidant activity, and neuroprotection. Oxygen-containing heterocycles including coumarin and chromone display strong antioxidant, anti-inflammatory, metal-chelating, and anti-amyloid properties, whereas sulfur-containing scaffolds such as thiazole contribute to enzyme inhibition and improved pharmacological activity. Oxazole derivatives have also emerged as promising neuroprotective molecules because of their favorable pharmacokinetic profiles and versatile biological activities.

Table 2.1. Major heterocyclic scaffolds and their pharmacological relevance

Heterocyclic scaffold	Major biological activity	Neurodegenerative application
Pyridine	Cholinesterase inhibition	Alzheimer's disease
Pyrimidine	Kinase modulation	AD, PD
Quinoline	Metal chelation, antioxidant	AD, PD
Quinazoline	Multi-target inhibition	AD
Indole	Neuroprotection, antioxidant	AD, PD
Benzimidazole	Anti-inflammatory	AD, PD
Imidazole	MAO inhibition	PD
Thiazole	Enzyme inhibition	AD
Oxazole	Neuroprotective activity	AD, PD
Triazole	Multifunctional pharmacophore	AD
Coumarin	AChE inhibition, antioxidant	AD
Chromone	Anti-inflammatory, antioxidant	AD, PD

2.3 Structure–Activity Relationship (SAR)

Structure–activity relationship (SAR) studies are fundamental for optimizing heterocyclic compounds as neuroprotective agents. Small modifications in the heterocyclic ring system can markedly influence biological activity, receptor affinity, and pharmacokinetic behavior. Ring fusion, heteroatom substitution, and variation in ring size often improve target selectivity and enhance blood–brain barrier permeability.

Electronic effects produced by electron-donating or electron-withdrawing substituents alter molecular polarity and binding interactions, whereas steric effects influence molecular orientation within enzyme active sites. Furthermore, functional group optimization, including hydroxyl, methoxy, amino, halogen, and alkyl substitutions, improves potency, metabolic stability, and multitarget activity. These SAR-guided modifications have enabled the development of highly effective heterocyclic MTDLs capable of simultaneously modulating several pathological mechanisms associated with neurodegeneration.

Table 2.2. Common SAR modifications and their effects

Structural modification	Pharmacological effect

Ring fusion	Increased receptor affinity
Nitrogen atom incorporation	Improved hydrogen bonding
Methoxy substitution	Enhanced antioxidant activity
Hydroxyl substitution	Better radical scavenging activity
Halogen substitution	Increased lipophilicity and BBB penetration
Amino group introduction	Improved enzyme inhibition
Linker optimization	Enhanced multitarget activity
Molecular hybridization	Simultaneous modulation of multiple targets

2.4 Representative Neuroprotective Drugs Containing Heterocycles

Several clinically approved and investigational neuroprotective agents contain heterocyclic scaffolds. **Donepezil** contains a piperidine-based heterocyclic pharmacophore and acts as an acetylcholinesterase inhibitor for Alzheimer's disease. **Rivastigmine** possesses a carbamate-containing heterocyclic framework that inhibits both acetylcholinesterase and butyrylcholinesterase. **Rasagiline**, an indane/propargylamine derivative with heterocyclic features, functions as a selective MAO-B inhibitor for Parkinson's disease. **Safinamide** contains an aminoamide heterocyclic architecture with dual MAO-B inhibitory and glutamate-modulating activities. New quinazoline-, quinoline-, coumarin-, and indole-based derivatives are being developed as multitarget-directed ligands capable of inhibiting cholinesterases, β-secretase, amyloid-β aggregation, oxidative stress, and neuroinflammation simultaneously, offering promising disease-modifying strategies for neurodegenerative disorders.

3. Multi-Target-Directed Ligands (MTDLs): Design and Mechanisms

3.1 Concept and Evolution of MTDLs

The concept of **Multi-Target-Directed Ligands (MTDLs)** has emerged as an innovative strategy to address the multifactorial nature of neurodegenerative disorders. Unlike the traditional "one drug–one target" approach, MTDLs are single molecular entities intentionally designed to interact with two or more disease-related targets simultaneously. This strategy aims to produce synergistic therapeutic effects while minimizing drug–drug interactions, improving patient compliance, and reducing adverse effects associated with combination therapy.

The evolution of MTDLs has been driven by the limited clinical success of single-target drugs in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Advances in medicinal chemistry, molecular biology, computational modeling, and pharmacophore-based drug design have facilitated the development of hybrid molecules capable of modulating multiple interconnected pathological pathways within a single therapeutic agent.

3.2 Why Multi-Target Therapy is Needed

Neurodegenerative diseases result from complex interactions among protein aggregation, neurotransmitter imbalance, oxidative stress, mitochondrial dysfunction, chronic neuroinflammation, excitotoxicity, and metal ion dyshomeostasis. Targeting only one pathological pathway rarely produces disease-modifying effects because several mechanisms continue to promote neuronal degeneration simultaneously.

MTDLs overcome these limitations by simultaneously regulating multiple disease mechanisms. A single multitarget molecule can inhibit cholinesterases, reduce amyloid-β aggregation, suppress oxidative stress, modulate neuroinflammation, and improve neurotransmission, thereby providing greater therapeutic efficacy than conventional monotherapy.

3.3 Major Therapeutic Targets

Multiple molecular targets have been identified for developing effective MTDLs against neurodegenerative disorders. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) regulate cholinergic neurotransmission and remain primary targets for Alzheimer's disease. Monoamine oxidase-A and monoamine oxidase-B (MAO-A/B) influence dopamine metabolism and oxidative stress, making them important in Parkinson's disease therapy. β-Secretase (BACE-1), tau protein hyperphosphorylation, and amyloid-β aggregation are directly involved in Alzheimer's disease pathology. Additional targets include NMDA receptors, reactive oxygen species, inflammatory mediators, and abnormal metal ion accumulation, all of which contribute to progressive neuronal damage. Effective MTDLs are therefore designed to modulate several of these targets simultaneously.

Table 3.1. Major therapeutic targets in MTDL development

Therapeutic target	Primary role	Disease relevance
Acetylcholinesterase (AChE)	Increases acetylcholine levels	Alzheimer's disease
Butyrylcholinesterase (BChE)	Supports cholinergic transmission	Alzheimer's disease
Monoamine oxidase (MAO-A/B)	Dopamine metabolism	Parkinson's disease
β-Secretase (BACE-1)	Amyloid-β production	Alzheimer's disease
Tau protein	Neurofibrillary tangle formation	Alzheimer's disease
Amyloid-β aggregation	Plaque formation	Alzheimer's disease
NMDA receptor	Excitotoxicity	AD, PD
Oxidative stress	ROS-mediated neuronal injury	AD, PD, HD
Neuroinflammation	Microglial activation	AD, PD, ALS
Metal ion dysregulation	Protein aggregation and ROS generation	AD

3.4 Rational Design Strategies

The rational design of MTDLs combines different pharmacological features into a single molecule. **Molecular hybridization** links two or more bioactive pharmacophores to produce compounds with complementary mechanisms of action. **Pharmacophore fusion** integrates overlapping structural elements while maintaining biological activity. **Fragment-based drug design** identifies small fragments that bind different targets and subsequently combines them into optimized multitarget molecules. In addition, **computer-aided drug design (CADD)**, including molecular docking, molecular dynamics simulations, virtual screening, and artificial intelligence, has significantly accelerated the discovery and optimization of novel MTDLs with improved selectivity and blood–brain barrier permeability.

Table 3.2. Rational strategies for MTDL development

Design strategy	Principle	Major advantage
Molecular hybridization	Linking multiple pharmacophores	Simultaneous target modulation
Pharmacophore fusion	Combining overlapping active motifs	Smaller and more efficient molecules
Fragment-based design	Assembly of active molecular fragments	Improved lead optimization
Computer-aided drug design	Docking, virtual screening, AI, molecular dynamics	Faster and cost-effective drug discovery

3.5 Molecular Mechanisms of Neuroprotection

MTDLs provide neuroprotection through multiple complementary mechanisms. These compounds inhibit acetylcholinesterase and butyrylcholinesterase to improve cholinergic neurotransmission, suppress monoamine oxidase activity to reduce oxidative metabolism, inhibit β-secretase and amyloid-β aggregation, prevent tau hyperphosphorylation, and reduce excitotoxicity by modulating NMDA receptors. Many MTDLs also possess antioxidant properties that neutralize reactive oxygen species, anti-inflammatory activity that suppresses activated microglia and pro-inflammatory cytokines, and metal-chelating ability that limits iron- and copper-induced oxidative damage. Collectively, these actions protect neurons, preserve synaptic function, and slow disease progression, making MTDLs one of the most promising therapeutic approaches for future neurodegenerative disease management.

4. Recent Advances in Heterocyclic MTDLs for Neurodegenerative Disorders

4.1 Alzheimer's Disease

Alzheimer's disease (AD) has received the greatest attention in the development of heterocyclic multi-target-directed ligands. Recent compounds based on **benzofuran, coumarin, quinoline, indole, pyridine, benzimidazole, and related heterocyclic systems** have been designed to act simultaneously on cholinesterases, BACE-1, amyloid-β aggregation, tau pathology, oxidative stress, and neuroinflammation. Modern MTDLs attempt to combine symptomatic improvement with possible disease-modifying activity rather than focusing on cholinergic transmission alone (Mayo et al., 2024).

Particular interest has been given to dual AChE/BACE-1 inhibitors, AChE/MAO inhibitors, and compounds combining cholinesterase inhibition with antioxidant and metal-chelating functions. Such molecules may interfere with several interconnected steps of AD pathology and therefore provide broader neuroprotection than conventional single-target molecules (Kumar et al., 2024).

4.2 Parkinson's Disease

For Parkinson's disease (PD), multitarget heterocyclic ligands are mainly directed toward **MAO-B inhibition, dopamine signaling, adenosine A_2A receptors, oxidative stress, mitochondrial dysfunction, and neuroinflammation**. Xanthine–dopamine hybrid molecules have demonstrated nanomolar MAO-B inhibition together with A_2A receptor antagonism and additional modulation of phosphodiesterase and dopamine D_2 receptors. Some compounds also show antioxidant and cellular neuroprotective properties (Pretorius et al., 2023

Benzimidazole derivatives are another promising class. Certain benzimidazole arylhydrazones exhibit simultaneous MAO-B inhibitory, free-radical scavenging, antioxidant, and neuroprotective effects in experimental models, suggesting their suitability for multifunctional PD therapy (Anastassova et al., 2022).

4.3 Huntington's Disease

MTDL research specifically focused on Huntington's disease (HD) remains less developed than that for AD and PD. Nevertheless, HD involves several overlapping pathological processes, including mutant huntingtin aggregation, mitochondrial dysfunction, oxidative stress, excitotoxicity, impaired proteostasis, and neuroinflammation. Therefore, heterocyclic compounds capable of influencing several of these mechanisms simultaneously are increasingly being explored.

For example, **3-aryl-5,6-dihydrobenzo[h]cinnoline derivatives** have been investigated computationally against numerous neurodegeneration-related targets, including MAO-A/B, cholinesterases, BACE enzymes, GSK-3β, NMDA receptors, inflammatory kinases, and oxidative-stress-related enzymes. Such broad target profiles illustrate how heterocyclic scaffolds may serve as starting points for developing HD-oriented MTDLs (Mousavi et al., 2024).

4.4 Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor-neuron degeneration involving oxidative stress, mitochondrial abnormalities, protein aggregation, defective RNA metabolism, excitotoxicity, and neuroinflammation. These interconnected mechanisms provide a strong rationale for multitarget therapeutic strategies.

In particular, abnormalities involving **SOD1, TDP-43, FUS, mitochondrial homeostasis, and Nrf2-dependent antioxidant signaling** represent potential intervention points. Compounds capable of simultaneously enhancing antioxidant defense, reducing inflammatory signaling, protecting mitochondria, and limiting protein-associated toxicity could offer advantages over narrowly targeted agents (Ayer et al., 2024).

4.5 Other Neurodegenerative Disorders

Multitarget strategies are also being investigated for **frontotemporal dementia, Lewy body dementia, multiple-system neurodegeneration, and other tauopathies**. Many of these disorders share common pathological features such as abnormal protein accumulation, oxidative damage, mitochondrial dysfunction, synaptic failure, and chronic neuroinflammation.

Frontotemporal dementia, for example, frequently involves pathological tau or other protein aggregates and currently lacks broadly effective disease-modifying pharmacotherapy. Consequently, molecules that simultaneously influence protein homeostasis, oxidative stress, inflammatory pathways, and neuronal survival are receiving increasing attention (El-Dessouky et al., 2025).

Table 4.1. Recent heterocyclic MTDL approaches in major neurodegenerative disorders

Disorder	Important heterocyclic/MTDL	Major targets or mechanisms	Expected benefit

	approach		
Alzheimer's disease	Coumarin, benzofuran, quinoline and benzimidazole hybrids	AChE, BChE, BACE-1, Aβ, MAO, oxidative stress	Cognitive and disease-modifying effects
Parkinson's disease	Xanthine and benzimidazole hybrids	MAO-B, A_2A receptor, D_2 receptor, ROS	Dopaminergic and neuroprotective effects
Huntington's disease	Cinnoline-based compounds	GSK-3β, NMDA, MAO, inflammatory pathways	Reduction of excitotoxicity and oxidative damage
ALS	Multifunctional neuroprotective molecules	Nrf2, ROS, mitochondria, inflammation	Motor-neuron protection
Frontotemporal dementia	Multitarget neuroprotective approaches	Tau, inflammation, oxidative stress	Reduction of neuronal degeneration

4.6 Experimental and Clinical Progress

In Vitro Studies

Most newly developed heterocyclic MTDLs initially undergo enzyme inhibition and cell-based screening. Common experiments include AChE/BChE inhibition, MAO-A/B inhibition, BACE-1 assays, amyloid aggregation tests, antioxidant studies, metal-chelation assays, and neuroprotection in neuronal cell lines. These assays help establish whether a single compound can maintain balanced activity against several therapeutic targets.

Recent cinnoline, benzimidazole, xanthine, and related hybrids have demonstrated encouraging multitarget profiles in enzymatic, computational, and cellular studies (Anastassova et al., 2022; Mousavi et al., 2024).

In Vivo Studies

Promising compounds are subsequently investigated in animal models to assess cognition, motor performance, oxidative damage, inflammatory markers, neurotransmitter concentrations, and neuronal survival. However, potent in vitro multitarget activity does not always translate into successful in vivo efficacy because of poor blood–brain barrier penetration, metabolism, toxicity, or inadequate pharmacokinetics.

Consequently, contemporary MTDL optimization increasingly integrates ADMET prediction and computational methods at early stages to improve the probability of successful translation (Maddeboina et al., 2024).

Clinical Trials

Clinical translation of rationally designed heterocyclic MTDLs remains considerably behind preclinical development. Nevertheless, multitarget and network-based therapeutic concepts are increasingly represented in neurodegenerative drug-development pipelines. The **2025 Alzheimer's disease pipeline contained 138 drugs evaluated across 182 clinical trials**, with candidates directed

toward multiple disease processes; however, only a small proportion represented explicitly designed multitarget molecules (Cummings et al., 2025).

This gap between extensive preclinical MTDL research and relatively limited clinical translation emphasizes the need for improved brain exposure, safety evaluation, pharmacokinetic balance, biomarkers, and carefully designed clinical studies.

Patent Landscape

Patent activity surrounding neurodegenerative MTDLs has expanded alongside advances in molecular hybridization, heterocyclic chemistry, and computer-aided drug design. Patentable developments commonly include new chemical entities, hybrid pharmacophores, specific linker architectures, novel combinations of therapeutic activities, and CNS-optimized analogues.

The major challenge is to demonstrate that newly patented compounds provide a meaningful improvement over existing scaffolds in terms of balanced multitarget potency, BBB penetration, pharmacokinetic properties, safety, and in vivo efficacy. Therefore, future intellectual-property development is expected to focus increasingly on structurally novel and experimentally validated MTDLs rather than simple combinations of previously known pharmacophores.

Table 4.2. Developmental progress of heterocyclic MTDLs

Development stage	Major evaluation	Current status	Major challenge
In silico	Docking, molecular dynamics, ADMET	Extensively used	Prediction accuracy
In vitro	Enzyme and cellular assays	Large number of promising leads	Balanced target activity
In vivo	Behavioral and disease models	Moderate number of candidates	BBB penetration and PK
Clinical trials	Safety and therapeutic efficacy	Relatively limited for true MTDLs	Human translation
Patent development	Novel scaffold and hybrid protection	Growing research interest	Novelty and clinical relevance

5. Drug Development Approaches and Future Perspectives

5.1 Blood–Brain Barrier (BBB) Penetration

The blood–brain barrier (BBB) represents one of the major challenges in the development of drugs for neurodegenerative disorders. The BBB consists of tightly connected endothelial cells, astrocytes, and pericytes that regulate the movement of molecules between systemic circulation and the central nervous system. Although this barrier protects the brain from harmful substances, it significantly restricts the penetration of many therapeutic molecules, particularly large, polar, and poorly lipophilic compounds.

For heterocyclic multi-target-directed ligands (MTDLs), achieving optimal BBB permeability requires careful structural optimization of molecular weight, lipophilicity, hydrogen bonding capacity,

and polar surface area. Strategies such as reducing excessive polarity, introducing lipophilic substituents, designing transporter-mediated delivery systems, and developing nanocarriers are increasingly applied to enhance brain exposure of neuroprotective agents (Dhariwal et al., 2025).

5.2 Pharmacokinetics and Pharmacodynamics

Successful neurotherapeutic development requires a balance between pharmacokinetic (PK) and pharmacodynamic (PD) properties. Pharmacokinetic parameters including absorption, distribution, metabolism, elimination, half-life, and brain availability determine the effective concentration of MTDLs at neuronal targets. Meanwhile, pharmacodynamic properties define target interaction, potency, selectivity, and biological response.

Heterocyclic MTDLs must demonstrate adequate metabolic stability, prolonged activity, selective target modulation, and reduced off-target effects. Computational ADMET prediction and early pharmacological screening are increasingly integrated into drug-development pipelines to identify molecules with improved PK/PD profiles before clinical evaluation (Guerguer et al., 2025).

5.3 Safety and Toxicity Considerations

Safety evaluation remains a critical step in the development of multitarget neuroprotective compounds because simultaneous interaction with multiple biological pathways may increase the possibility of adverse effects. Important toxicity parameters include hepatotoxicity, cardiotoxicity, neurotoxicity, metabolic instability, and unwanted receptor interactions.

Modern drug-discovery approaches incorporate cytotoxicity screening, mitochondrial toxicity assessment, reactive oxygen species evaluation, and computational toxicity prediction during early stages of development. Optimizing molecular selectivity while maintaining multitarget activity remains a major challenge in designing clinically acceptable MTDLs.

5.4 Computational Drug Design

Computational approaches have revolutionized the discovery and optimization of heterocyclic MTDLs by reducing time, cost, and experimental workload. Computer-aided drug design (CADD) methods enable researchers to predict molecular interactions, optimize chemical structures, and identify promising candidates.

Molecular Docking

Molecular docking predicts the binding interactions between heterocyclic ligands and multiple therapeutic targets such as AChE, BACE-1, MAO-B, tau-related proteins, and inflammatory enzymes. It provides information regarding binding energy, hydrogen bonding, hydrophobic interactions, and active-site compatibility.

Molecular Dynamics

Molecular dynamics simulations evaluate the stability and flexibility of ligand–target complexes under physiological conditions. Parameters such as root mean square deviation (RMSD), radius of

gyration, hydrogen bonding, and solvent accessibility help determine the long-term stability of MTDLs.

QSAR Studies

Quantitative structure–activity relationship (QSAR) approaches correlate chemical structures with biological activities. QSAR models assist in predicting potency, toxicity, and pharmacokinetic properties by identifying structural features responsible for improved therapeutic effects.

Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning approaches are increasingly used for virtual screening, molecular property prediction, target identification, and de novo drug design. AI-based platforms can analyze large chemical datasets and accelerate the identification of novel multitarget compounds for neurodegenerative diseases (Hossain & Hussain, 2025).

Table 5.1. Computational approaches used in heterocyclic MTDL development

Computational approach	Application	Major advantage
Molecular docking	Prediction of ligand–target interaction	Identifies binding potential
Molecular dynamics	Complex stability evaluation	Provides dynamic molecular information
QSAR modelling	Structure–activity prediction	Guides structural optimization
Virtual screening	Identification of lead compounds	Reduces experimental cost
Artificial intelligence	Drug prediction and design	Accelerates discovery process

5.5 Nanotechnology-Based Drug Delivery

Nanotechnology has emerged as a promising strategy to overcome limitations associated with conventional neurotherapeutics, including poor solubility, rapid degradation, limited BBB penetration, and insufficient brain accumulation. Nanocarriers such as polymeric nanoparticles, liposomes, dendrimers, solid lipid nanoparticles, and biomimetic systems can improve drug stability, enhance brain targeting, and provide controlled release.

Nanotechnology-based delivery systems can also facilitate the transport of heterocyclic MTDLs across the BBB through surface modification with targeting ligands, receptor-mediated transport mechanisms, and stimulus-responsive release systems. These approaches provide opportunities for achieving higher therapeutic concentrations at neuronal sites while reducing systemic toxicity (Biswas et al., 2025).

Table 5.2. Nanotechnology strategies for neurodegenerative drug delivery

Nanocarrier system	Advantages	Potential application
Polymeric nanoparticles	Controlled release and stability	AD, PD drug delivery
Liposomes	Biocompatibility and targeting	CNS drug transport

	ability	
Dendrimers	High drug-loading capacity	Brain-targeted therapy
Solid lipid nanoparticles	Improved solubility and BBB penetration	Neuroprotective agents
Biomimetic nanoparticles	Enhanced cellular uptake	Targeted neurotherapy

5.6 Challenges in Clinical Translation

Although numerous heterocyclic MTDLs demonstrate promising biological activity, translation from laboratory studies to clinical applications remains challenging. Major limitations include inadequate BBB penetration, poor pharmacokinetic properties, complex toxicity profiles, lack of disease-specific biomarkers, and difficulties in balancing activity against multiple targets.

Furthermore, many compounds show excellent enzyme inhibition in vitro but fail during animal studies because of insufficient brain exposure, rapid metabolism, or unexpected toxicity. Therefore, future development requires integration of medicinal chemistry, computational modeling, advanced delivery systems, and clinically relevant disease models (Katsoulaki et al., 2025).

5.7 Future Directions and Emerging Opportunities

Future neurodegenerative drug discovery is expected to focus on combining heterocyclic chemistry with advanced computational technologies, artificial intelligence, and nanomedicine. The development of next-generation MTDLs will involve rational molecular hybridization, patient-specific therapeutic approaches, biomarker-guided treatment, and precision medicine strategies.

Emerging opportunities include AI-assisted drug discovery, brain-targeted nanoparticles, multifunctional hybrid molecules, organelle-specific delivery systems, and combination of MTDLs with regenerative approaches. These innovations may overcome current limitations and accelerate the development of disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS, and related disorders.

6. Conclusion

Neurodegenerative disorders are complex and progressive diseases involving multiple pathological mechanisms, including abnormal protein aggregation, oxidative stress, neuroinflammation, mitochondrial dysfunction, excitotoxicity, and neuronal loss. The limitations of conventional single-target therapies have encouraged the development of innovative strategies based on heterocyclic scaffolds and multi-target-directed ligands (MTDLs). Recent advances demonstrate that multifunctional molecules capable of simultaneously regulating several disease-associated pathways may provide improved therapeutic outcomes compared with traditional approaches (Katsoulaki et al., 2025).

Heterocyclic scaffolds have become essential components in neurotherapeutic drug discovery because of their structural versatility, favorable biological interactions, and ability to be optimized through medicinal chemistry approaches. Nitrogen-, oxygen-, and sulfur-containing heterocycles such as quinoline, quinazoline, indole, benzimidazole, triazole, coumarin, and chromone derivatives have

shown promising neuroprotective activities by targeting cholinesterases, monoamine oxidases, amyloid-β aggregation, tau pathology, oxidative damage, and inflammatory pathways. These scaffolds provide valuable frameworks for designing novel multifunctional neuroprotective agents (Shikha et al., 2025).

The development of MTDLs represents a major paradigm shift from the traditional single-target drug discovery model toward a network-based therapeutic approach. By integrating multiple pharmacophores into one chemical entity, MTDLs can simultaneously modulate different pathological mechanisms involved in Alzheimer's disease, Parkinson's disease, Huntington's disease, and other neurodegenerative disorders. Molecular hybridization, pharmacophore fusion, computational design, and structure–activity relationship studies have significantly accelerated the discovery of these multifunctional molecules (Deb et al., 2025).

Despite significant progress, several challenges remain before heterocyclic MTDLs can achieve clinical success. Major limitations include insufficient blood–brain barrier penetration, unpredictable pharmacokinetic behavior, toxicity concerns, lack of reliable biomarkers, and difficulties in translating promising in vitro findings into effective clinical therapies. Furthermore, achieving an optimal balance between multitarget activity and molecular selectivity remains a critical challenge in future drug development.

Future research should focus on integrating artificial intelligence, computational drug design, nanotechnology-based delivery systems, advanced biological models, and precision medicine approaches to improve the discovery of safer and more effective neuroprotective agents. The combination of novel heterocyclic chemistry with multitarget strategies offers a promising pathway toward disease-modifying therapies for neurodegenerative disorders. Continued interdisciplinary efforts involving medicinal chemistry, pharmacology, computational biology, and clinical research will be essential for transforming promising MTDLs into successful therapeutic candidates (Guerguer et al., 2025).

References

- Alcaro, S., Bolognesi, M. L., & Rapposelli, S. (2025). Multitarget compounds designed for Alzheimer, Parkinson, and Huntington neurodegenerative diseases. *Pharmaceuticals, 18*(6), 831. https://doi.org/10.3390/ph18060831
- Anastassova, N., Aluani, D., Hristova-Avakumova, N., et al. (2022). Study on the neuroprotective, radical-scavenging and MAO-B inhibiting properties of new benzimidazole arylhydrazones as potential multi-target drugs for the treatment of Parkinson's disease. *Antioxidants, 11*(5), 884. https://doi.org/10.3390/antiox11050884
- Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. *JAMA, 323*(6), 548–560. https://doi.org/10.1001/jama.2019.22360
- Ayer, A., et al. (2024). Therapeutic targeting of the oxidative stress generated by pathological molecular pathways in the neurodegenerative diseases, ALS and Huntington's disease. *Free Radical Biology and Medicine*.
- Bajda, M., Jończyk, J., Malawska, B., & Filipek, B. (2021). Multi-target-directed ligands as an effective strategy for the treatment of Alzheimer's disease. *Current Neuropharmacology, 19*(8), 1205–1232.

- Bharadwaj, S., et al. (2024). A comprehensive review of multi-target-directed ligands in the treatment of Alzheimer's disease. *Bioorganic Chemistry, 144*, 107152.
- Biswas, A., Hivare, P., Solanki, R., Gupta, S., & Bhatia, D. (2025). Applications of bionanomaterials in neurodegenerative diseases. *Materials Advances, 6*, 3785–3804. https://doi.org/10.1039/D4MA01215A
- Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). *Goodman & Gilman's the pharmacological basis of therapeutics* (14th ed.). McGraw Hill Education.
- Cemali, A., et al. (2025). Recent insights in multi-target drugs in pharmacology and medicinal chemistry. *ChemMedChem*. https://doi.org/10.1002/cmdc.202500447
- Chauhan, S., Umar, T., & Aulakh, M. K. (2023). Quinolines: Privileged scaffolds for developing new anti-neurodegenerative agents. *ChemistrySelect, 8*(14), e202204960.
- Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*.
- Dash, S., & Dhar, A. K. (2025). Carboline hybrids as potential multitarget-directed anti-Alzheimer's disease agents: A comprehensive analysis of design strategies and structure–activity relationships. *Archiv der Pharmazie*. https://doi.org/10.1002/ardp.70166
- Deb, D., Dhanawat, M., Bhushan, B., Pachuau, L., & Das, N. (2025). Targeting neurodegeneration: The emerging role of hybrid drugs. *Current Neuropharmacology, 26*(6), 410–434. https://doi.org/10.2174/0113894501365588250131073304
- Dhariwal, R., Jain, M., Mir, Y. R., Singh, A., Jain, B., Kumar, P., Tariq, M., Verma, D., Deshmukh, K., Yadav, V. K., & Malik, T. (2025). Targeted drug delivery in neurodegenerative diseases: The role of nanotechnology. *Frontiers in Medicine, 12*, 1522223. https://doi.org/10.3389/fmed.2025.1522223
- Feigin, V. L., Stark, B. A., Johnson, C. O., Bisignano, C., et al. (2021). Global, regional, and national burden of neurological disorders, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology, 20*(10), 795–820.
- Gao, L., Wang, J., & Bi, Y. (2025). Nanotechnology for neurodegenerative diseases: Recent progress in brain-targeted delivery, stimuli-responsive platforms, and organelle-specific therapeutics. *International Journal of Nanomedicine, 20*, 11015–11044.
- Ghoneim, M. M., Abdelgawad, M. A., Elkanzi, N. A. A., et al. (2024). A literature review on pharmacological aspects, docking studies, and synthetic approaches of quinazoline and quinazolinone derivatives. *Archiv der Pharmazie, 357*(8), e2400057.
- Gucký, A., & Hamuľaková, S. (2024). Targeting biometals in Alzheimer's disease with metal chelating agents including coumarin derivatives. *CNS Drugs, 38*, 507–532.
- Guerguer, F. Z., Khedraoui, M., Samadi, A., & Chtita, S. (2025). Computational approaches for multitarget drug design in Alzheimer's disease: A comprehensive review. *Current Medicinal Chemistry, 32*(32), 7017–7044.
- Haghighijoo, Z., Zamani, L., Moosavi, F., & Emami, S. (2022). Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review. *European Journal of Medicinal Chemistry, 227*, 113949.
- Hossain, M. S., & Hussain, M. H. (2025). Multi-target drug design in Alzheimer's disease treatment: Emerging technologies, advantages, challenges, and limitations. *Pharmacology Research & Perspectives, 13*(4), e70131.
- Katsoulaki, E. E., Dimopoulos, D., & Hadjipavlou-Litina, D. (2025). Multitarget compounds designed for Alzheimer, Parkinson, and Huntington neurodegenerative diseases. *Pharmaceuticals, 18*(6), 831. https://doi.org/10.3390/ph18060831

- Kumar, S., Mahajan, A., Ambatwar, R., & Khatik, G. L. (2024). Recent advancements in the treatment of Alzheimer's disease: A multitarget-directed ligand approach. *Current Medicinal Chemistry, 31*(37), 6032–6062. https://doi.org/10.2174/0109298673264076230921065945
- Maddeboina, K., Yada, B., Kumari, S., McHale, C., Pal, D., & Durden, D. L. (2024). Recent advances in multitarget-directed ligands via in silico drug discovery. *Drug Discovery Today, 29*(3), 103904. https://doi.org/10.1016/j.drudis.2024.103904
- Mathew, B., et al. (2025). Therapeutic role of heterocyclic compounds in neurodegenerative diseases: Insights from Alzheimer's and Parkinson's diseases. *Neurology International, 17*(2), 26. https://doi.org/10.3390/neurolint17020026
- Mayo, P., Pascual, J., Crisman, E., Domínguez, C., López, M. G., & León, R. (2024). Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment. *Medicinal Research Reviews, 44*(6), 2367–2419. https://doi.org/10.1002/med.22045
- Mousavi, S. M., et al. (2024). Practical three-component regioselective synthesis of drug-like 3-aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as potential non-covalent multi-targeting inhibitors to combat neurodegenerative diseases. *Journal of Organic Chemistry*.
- Pretorius, J., et al. (2023). Xanthine-dopamine hybrid molecules as multitarget drugs with potential for the treatment of neurodegenerative diseases. *Journal of Medicinal Chemistry*.
- Rehman, M. U., Sehar, N., Dar, N. J., et al. (2023). Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: An update on current advances and impediments. *Neuroscience & Biobehavioral Reviews, 144*, 104961.
- Sánchez, J. D., Alcántara, A. R., González, J. F., & Sánchez-Montero, J. M. (2023). Advances in the discovery of heterocyclic-based drugs against Alzheimer's disease. *Expert Opinion on Drug Discovery, 18*(12), 1413–1428. https://doi.org/10.1080/17460441.2023.2262458
- Sharma, K., Kumar, V., & Singh, P. (2022). Effects of linkers and substitutions on multitarget-directed ligands for Alzheimer's disease: Emerging paradigms and strategies. *International Journal of Molecular Sciences, 23*(11), 6085.
- Shikha, R., Kumar, D., Lari, M. Q., Ashesh, A. M., Wal, P., Singh, B., Pandey, S., Kumar, D., & Kumar, A. (2025). Unraveling neurodegenerative disorders: The potential of indole and imidazole-based heterocycles. *Current Neuropharmacology, 26*(4), 310–328.
- Sirignano, C., et al. (2024). Indole-based compounds in the development of anti-neurodegenerative agents. *Molecules, 29*(9), 2127.
- Yadav, R., Sharma, A., & Gupta, P. (2025). Multi-target-directed ligands as potential therapeutic candidates targeting multiple pathogenic factors of Alzheimer's disease. *CNS Neuroscience & Therapeutics*.

Chapter 9: Artificial Intelligence, Computer-Aided Drug Design and Structure–Activity Relationship Studies in CNS Drug Discovery

Bhawana Sati[*1], Ujashkumar Shah[2], Hema Arya[3], Mangilal Chouhan[4], Sanmati Kumar Jain[5]

[1]*Assistant Professor, Department of Pharmacy, Banasthali Vidyapith, Rajasthan, India.*

[2]*Professor & Head, Nootan Pharmacy College, Sankalchand Patel University, SK Campus, Visnagar–384315, Gujarat, India.*

[3]*Associate Professor, Department of Pharmaceutical Chemistry, Sharda University, Plot No. 32–34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India.*

[4]*Assistant Professor, Department of Pharmaceutical Chemistry, Mohanlal Sukhadia University, University Campus, Udaipur, Rajasthan–313001, India.*

[5]*Professor, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Koni, Bilaspur, India.*

*Corresponding Author: Bhawana Sati, Assistant Professor, Department of Pharmacy, Banasthali Vidyapith, Rajasthan, India.

Abstract

Central nervous system (CNS) drug discovery remains one of the most challenging areas of pharmaceutical research due to the complexity of neurological disorders, limited understanding of disease mechanisms, poor blood–brain barrier (BBB) penetration, and high failure rates during clinical development. Recent advances in artificial intelligence (AI), computer-aided drug design (CADD), and structure–activity relationship (SAR) studies have provided innovative strategies to overcome these challenges by enabling faster, cost-effective, and rational drug discovery approaches. AI-based methods, including machine learning and deep learning, facilitate large-scale biological data analysis, target identification, molecular property prediction, drug repurposing, and generation of novel therapeutic molecules. CADD approaches such as molecular docking, molecular dynamics simulation, pharmacophore modeling, virtual screening, and ADMET prediction assist in identifying and optimizing CNS-active compounds with improved efficacy and safety profiles. SAR and QSAR approaches further support medicinal chemistry by establishing relationships between molecular structures and biological activities, enabling systematic lead optimization through functional group modification, bioisosteric replacement, scaffold hopping, and hybrid molecule design. The integration of AI with CADD and SAR has created a next-generation computational framework for CNS drug discovery, allowing improved prediction of potency, selectivity, toxicity, and pharmacokinetic properties. Emerging technologies such as generative AI, explainable AI, digital twins, quantum computing, and multi-omics integration are expected to further enhance personalized CNS therapeutics. Despite challenges related to data quality, model interpretability, regulatory acceptance, and experimental validation, interdisciplinary collaboration between computational scientists, medicinal chemists, pharmacologists, and clinicians will accelerate the translation of computational predictions into effective neurological therapies. This chapter highlights the principles, applications, advantages, limitations, and future perspectives of AI, CADD, and SAR-based approaches in the development of innovative CNS drugs.

Keywords: Artificial intelligence; Computer-aided drug design; Structure–activity relationship; CNS drug discovery; Machine learning; Deep learning; QSAR; Molecular docking; Virtual screening; Blood–brain barrier; Drug design; Precision medicine.

1. Introduction

Central nervous system (CNS) disorders comprise a broad range of neurological and psychiatric diseases, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, stroke, depression, schizophrenia, and anxiety disorders. These disorders are among the leading causes of disability and mortality worldwide, significantly affecting patients' quality of life and imposing substantial social and economic burdens on healthcare systems (Feigin et al., 2021; Vatansever et al., 2021). Recent estimates indicate that the global prevalence of neurological disorders continues to increase because of population aging, environmental factors, and improved disease diagnosis, emphasizing the urgent need for effective and safer therapeutic strategies (Feigin et al., 2021).

Despite remarkable advances in neuroscience, CNS drug discovery remains one of the most challenging areas of pharmaceutical research. The blood–brain barrier (BBB) restricts the transport of many therapeutic molecules into the brain, while the complex pathophysiology of CNS diseases often limits the identification of effective drug targets. Furthermore, CNS drug candidates experience high attrition rates during clinical development because of inadequate efficacy, poor brain penetration, and safety or toxicity concerns, resulting in lengthy development timelines and substantial financial investment (Brunton et al., 2023; Vatansever et al., 2021).

To overcome these limitations, computational technologies have become integral components of modern drug discovery. Artificial intelligence (AI) enables the analysis of large biological datasets, prediction of molecular properties, target identification, and optimization of lead compounds using machine learning and deep learning algorithms. Computer-aided drug design (CADD) facilitates virtual screening, molecular docking, molecular dynamics simulations, pharmacophore modeling, and quantitative structure–activity relationship (QSAR) analysis, thereby reducing the time, cost, and complexity of drug discovery. Structure–activity relationship (SAR) studies further support medicinal chemists in understanding how structural modifications influence biological activity, selectivity, pharmacokinetics, and toxicity, enabling rational optimization of CNS drug candidates (Kim et al., 2020; Vatansever et al., 2021).

This chapter provides a comprehensive review of the applications of AI, CADD, and SAR studies in CNS drug discovery. It discusses their fundamental principles, current methodologies, recent advances, successful applications in neurological disorders, major challenges, and future perspectives for developing safer and more effective CNS therapeutics.

2. Artificial Intelligence in CNS Drug Discovery

2.1 Fundamentals of Artificial Intelligence

Artificial intelligence (AI) refers to computational systems capable of learning from data, recognizing patterns, and making predictions that assist decision-making in drug discovery. Machine learning (ML), a major branch of AI, uses algorithms to identify relationships within biological and chemical datasets without explicit programming. Deep learning (DL), a subset of ML, employs multi-layered artificial neural networks to process complex and high-dimensional data, making it particularly useful

for image analysis, molecular property prediction, and disease classification. Neural networks imitate the interconnected architecture of the human brain and enable accurate prediction of molecular interactions, while the availability of big data from genomic, proteomic, chemical, and clinical databases has greatly improved AI model performance in pharmaceutical research (Chen et al., 2023; Askr et al., 2023).

Table 2.1. Major AI techniques used in CNS drug discovery

AI Technique	Principle	Common Applications
Machine Learning	Learns patterns from datasets	Target prediction, QSAR, ADMET
Deep Learning	Multi-layer neural networks	Molecular property prediction, image analysis
Artificial Neural Networks	Brain-inspired computational models	Drug activity prediction, toxicity estimation
Big Data Analytics	Integration of large biological datasets	Biomarker discovery and precision medicine

2.2 AI-Based Drug Target Identification

Identification of appropriate therapeutic targets is one of the most important steps in CNS drug discovery. AI integrates genomic, transcriptomic, proteomic, metabolomic, and clinical datasets to identify disease-associated biomarkers and prioritize potential drug targets. Machine learning algorithms can detect hidden biological relationships that are difficult to identify using conventional statistical methods. These approaches improve target validation, facilitate precision medicine, and reduce the likelihood of failure during later stages of drug development (Cerchia & Lavecchia, 2023; Chen et al., 2023).

2.3 AI in Drug Design

AI has transformed modern drug design by accelerating virtual screening, de novo molecular generation, and lead optimization. Generative AI models can design novel chemical structures with desired pharmacological properties, while AI-assisted virtual screening rapidly identifies promising compounds from millions of molecules. Machine learning algorithms are also widely applied in drug repurposing by identifying new therapeutic indications for approved drugs. Furthermore, AI predicts biological activity, pharmacokinetic behavior, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles, enabling researchers to eliminate unsuitable compounds before experimental evaluation (Chen et al., 2023; Srivathsa et al., 2023).

2.4 AI Applications in CNS Disorders

AI has demonstrated considerable success in several neurological disorders. In Alzheimer's disease, AI identifies disease biomarkers, predicts amyloid and tau pathology, and supports early diagnosis. For Parkinson's disease, machine learning assists in biomarker identification, disease progression analysis, and therapeutic target discovery. AI-based tools are also employed in epilepsy for seizure prediction, in depression and anxiety disorders for personalized treatment selection, and in brain tumors for image interpretation, molecular classification, and drug discovery. These applications

improve diagnostic accuracy and accelerate the development of targeted CNS therapeutics (Vatansever et al., 2021; Chen et al., 2023).

Table 2.2. Applications of AI in major CNS disorders

CNS Disorder	AI Applications	Expected Benefits
Alzheimer's disease	Biomarker discovery, target identification	Early diagnosis and novel therapeutics
Parkinson's disease	Disease prediction, lead optimization	Improved treatment strategies
Epilepsy	Seizure prediction, drug screening	Better disease management
Depression and anxiety	Personalized therapy, drug repurposing	Improved treatment response
Brain tumors	Image analysis, molecular classification	Precision oncology and targeted therapy

2.5 Advantages and Limitations of AI

Artificial intelligence significantly reduces the time and cost associated with drug discovery by automating data analysis, virtual screening, lead optimization, and toxicity prediction. AI improves decision-making, increases the probability of identifying promising drug candidates, and supports personalized medicine. However, several limitations remain, including dependence on high-quality datasets, limited interpretability of complex models, algorithm bias, insufficient experimental validation, and regulatory challenges. Future developments in explainable AI, federated learning, multimodal data integration, and generative AI are expected to further enhance CNS drug discovery and improve the translation of computational predictions into clinical applications (Hasselgren & Oprea, 2023; Cerchia & Lavecchia, 2023).

3. Computer-Aided Drug Design (CADD) for CNS Drug Discovery

3.1 Introduction to CADD

Computer-aided drug design (CADD) is an important computational approach that accelerates the identification and optimization of drug candidates by integrating chemistry, biology, pharmacology, and bioinformatics. Compared with conventional drug discovery, CADD significantly reduces the time, cost, and experimental workload required to identify promising lead molecules. A typical CADD workflow includes target identification, protein structure analysis, virtual screening, lead identification, lead optimization, and experimental validation. In CNS drug discovery, CADD is particularly valuable because it enables the rational design of compounds capable of crossing the blood–brain barrier (BBB) while maintaining desirable pharmacological properties (Dorahy et al., 2023; Bassani & Moro, 2023).

Table 3.1. Major components of CADD in CNS drug discovery

CADD Component	Purpose	Outcome
Target identification	Selection of therapeutic target	Disease-specific target
Structure-based design	Protein–ligand interaction analysis	Lead compounds
Ligand-based design	Activity prediction from known	Novel analogues

	ligands	
Virtual screening	Screening of chemical libraries	Hit identification
Lead optimization	Improve efficacy and safety	Optimized drug candidate

3.2 Structure-Based Drug Design (SBDD)

Structure-based drug design (SBDD) utilizes the three-dimensional structure of biological targets to design molecules with high binding affinity. Protein structures are obtained from X-ray crystallography, cryo-electron microscopy, or computational modeling. Molecular docking predicts ligand orientation and binding interactions within the active site, whereas molecular dynamics (MD) simulations evaluate the stability and flexibility of protein–ligand complexes over time. Binding free-energy calculations further estimate the strength of molecular interactions and assist in selecting the most promising compounds for experimental studies (Bassani & Moro, 2023; Niazi & Mariam, 2024).

3.3 Ligand-Based Drug Design (LBDD)

Ligand-based drug design (LBDD) is applied when the three-dimensional structure of the target protein is unavailable. This approach relies on the structural and biological information of known active compounds to predict new molecules with similar activity. Pharmacophore modeling identifies essential chemical features responsible for biological activity, while quantitative structure–activity relationship (QSAR) models establish mathematical relationships between molecular descriptors and biological responses. Similarity searching further identifies structurally related compounds from chemical databases, thereby facilitating lead discovery and optimization (Dorahy et al., 2023).

3.4 Virtual Screening

Virtual screening is a high-throughput computational technique used to evaluate millions of chemical compounds against therapeutic targets. The process begins with database preparation, followed by molecular docking and scoring to identify compounds with high binding affinity. Selected hits are subsequently optimized through computational refinement to improve potency, selectivity, and pharmacokinetic characteristics before laboratory validation. Virtual screening substantially reduces experimental costs and accelerates early-stage drug discovery (Niazi & Mariam, 2024; Bassani & Moro, 2023).

3.5 Prediction of CNS Drug Properties

Successful CNS therapeutics require adequate BBB penetration along with favorable pharmacokinetic and safety profiles. CADD incorporates computational models that predict BBB permeability, absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties at an early stage of drug development. Drug-likeness evaluation based on physicochemical descriptors, such as molecular weight, lipophilicity, hydrogen-bonding capacity, and polar surface area, helps eliminate compounds with poor CNS drug potential before experimental testing (Dorahy et al., 2023; Niazi & Mariam, 2024).

Table 3.2. Computational tools commonly used in CADD

Method	Primary Application	Typical Output
Molecular Docking	Binding interaction prediction	Docking score

Molecular Dynamics	Complex stability analysis	Stable binding trajectory
Pharmacophore Modeling	Identification of key molecular features	Pharmacophore model
QSAR Modeling	Activity prediction	Predicted biological activity
Virtual Screening	Hit identification	Lead molecules
ADMET Prediction	Pharmacokinetic evaluation	Drug-likeness and safety profile

3.6 Success Stories of CADD

CADD has significantly contributed to the discovery of therapeutic candidates for several CNS disorders. In Alzheimer's disease, computational approaches have identified inhibitors targeting acetylcholinesterase, β-secretase, and tau-related proteins. For Parkinson's disease, molecular docking and virtual screening have facilitated the development of compounds targeting α-synuclein aggregation and dopamine receptors. Similar computational strategies have accelerated the identification of novel therapeutics for glioblastoma by targeting growth factor receptors and signaling pathways, while in epilepsy, CADD has supported the discovery of anticonvulsant compounds acting on ion channels and neurotransmitter receptors. These examples demonstrate the growing impact of CADD in improving the efficiency and success rate of CNS drug discovery (Dorahy et al., 2023; Bassani & Moro, 2023).

4. Structure–Activity Relationship (SAR) Studies in CNS Drug Discovery

4.1 Fundamentals of SAR

Structure–activity relationship (SAR) is a fundamental concept in medicinal chemistry that explains how changes in the chemical structure of a molecule influence its biological activity. SAR analysis enables researchers to identify the structural features responsible for potency, selectivity, pharmacokinetic behavior, and toxicity. By systematically modifying functional groups or molecular scaffolds and evaluating their biological effects, medicinal chemists can optimize lead compounds into safer and more effective drug candidates. In CNS drug discovery, SAR is particularly important because compounds must possess high target affinity while maintaining adequate blood–brain barrier (BBB) permeability and minimal adverse effects (Callis et al., 2022; Chatterjee & Roy, 2023).

Table 4.1. Major SAR approaches used in CNS drug discovery

SAR Strategy	Purpose	Expected Outcome
Functional group modification	Improve biological activity	Increased potency
Bioisosteric replacement	Replace unfavorable groups	Better safety and stability
Scaffold hopping	Generate novel chemical cores	Improved selectivity and patentability
Hybrid molecule design	Combine active pharmacophores	Enhanced multitarget activity

4.2 Lead Optimization

Lead optimization is the process of improving the biological and pharmaceutical properties of a lead compound through rational structural modifications. Functional group modification can increase

receptor binding and metabolic stability, whereas bioisosteric replacement improves pharmacokinetic properties without compromising biological activity. Scaffold hopping replaces the central molecular framework with alternative cores to generate structurally novel compounds possessing improved efficacy, selectivity, and intellectual property potential. Hybrid molecule design combines two or more pharmacologically active scaffolds into a single molecule to achieve multitarget therapeutic effects, an approach increasingly explored for complex CNS disorders such as Alzheimer's and Parkinson's diseases (Acharya et al., 2024; Callis et al., 2022).

4.3 SAR Strategies for CNS Drugs

Successful CNS drug candidates require an optimal balance between potency, selectivity, brain penetration, and safety. SAR studies help identify structural modifications that strengthen interactions with CNS targets while reducing off-target effects. Lipophilicity, molecular size, hydrogen-bonding capacity, and polar surface area are carefully optimized to improve BBB permeability. Simultaneously, structural modifications are introduced to reduce toxicity, enhance metabolic stability, and improve oral bioavailability, thereby increasing the probability of clinical success (Callis et al., 2022; Zha et al., 2023).

4.4 QSAR Approaches

Quantitative structure–activity relationship (QSAR) modeling quantitatively correlates molecular descriptors with biological activity and has become an indispensable component of modern medicinal chemistry. Traditional 2D-QSAR utilizes physicochemical descriptors, whereas 3D-QSAR incorporates the three-dimensional arrangement of molecular features to improve predictive accuracy. Recent advances integrate machine learning and deep learning algorithms with QSAR, enabling the analysis of large chemical datasets and improving prediction of biological activity, toxicity, and pharmacokinetic properties. These computational approaches significantly accelerate lead optimization while reducing experimental costs (Tropsha et al., 2024; Novič, 2023).

Table 4.2. QSAR approaches in medicinal chemistry

QSAR Method	Principle	Major Applications
2D-QSAR	Uses molecular descriptors	Activity prediction
3D-QSAR	Uses three-dimensional molecular fields	Lead optimization
Machine learning-assisted QSAR	AI-based predictive modeling	Potency and toxicity prediction
Deep QSAR	Deep neural network models	Large-scale virtual screening and molecular design

4.5 Case Studies

SAR-guided medicinal chemistry has contributed significantly to the development of therapeutics for major CNS disorders. In Alzheimer's disease, SAR optimization has improved inhibitors targeting acetylcholinesterase and β-secretase enzymes. For Parkinson's disease, scaffold modification has enhanced dopamine receptor affinity and reduced adverse effects. Similar SAR strategies have been applied to antidepressants by improving serotonin and norepinephrine transporter selectivity, while optimization of ion channel modulators has produced safer and more effective antiepileptic agents.

These examples demonstrate that SAR remains a cornerstone of rational CNS drug discovery and continues to facilitate the development of next-generation therapeutics (Callis et al., 2022; Acharya et al., 2024).

5. Integration of AI, CADD and SAR for Next-Generation CNS Drug Discovery

5.1 AI-Driven Drug Discovery Workflow

The integration of artificial intelligence (AI) with computer-aided drug design (CADD) and structure–activity relationship (SAR) approaches has created a powerful framework for accelerating CNS drug discovery. AI-driven workflows begin with the collection and preprocessing of large-scale biological, chemical, and clinical datasets obtained from genomic, proteomic, molecular, and pharmacological studies. These datasets are analyzed using machine learning algorithms to identify disease-related targets and predict potential therapeutic interactions. Molecular modeling approaches are then applied to understand ligand–target interactions, followed by AI-assisted virtual screening to identify promising lead compounds. Subsequent lead optimization uses predictive models to improve potency, selectivity, pharmacokinetics, and safety before experimental validation. This integrated workflow reduces the time and cost associated with conventional CNS drug development (Walters & Murcko, 2023; Schneider et al., 2023).

Table 5.1. AI-integrated workflow in CNS drug discovery

Discovery Stage	AI/CADD Application	Major Outcome
Data collection	Biological and chemical database analysis	High-quality training datasets
Target identification	AI-based biomarker and target prediction	Novel therapeutic targets
Molecular modeling	Docking and molecular simulation	Prediction of ligand interactions
Virtual screening	AI-based compound prioritization	Identification of lead molecules
Lead optimization	QSAR and ADMET prediction	Improved drug candidates
Experimental validation	Biological testing and clinical evaluation	Confirmed therapeutic potential

5.2 AI-Assisted CADD

Artificial intelligence has significantly improved traditional CADD methods by enhancing prediction accuracy and computational efficiency. AI-enhanced molecular docking uses deep learning algorithms to improve ligand-binding prediction and overcome limitations associated with conventional scoring functions. AI-guided molecular dynamics simulations assist in analyzing complex protein–ligand interactions by predicting molecular stability, conformational changes, and binding behavior. Additionally, AI-based de novo molecular design enables the generation of novel chemical structures with optimized biological activity and drug-like properties. These approaches are particularly valuable in CNS drug discovery because they support the design of molecules with improved brain penetration, selectivity, and reduced toxicity (Yang et al., 2022; Liu et al., 2024).

5.3 AI-Assisted SAR Analysis

AI-based SAR analysis has transformed traditional medicinal chemistry by enabling rapid prediction of relationships between molecular structures and biological activities. Machine learning-assisted QSAR models analyze molecular descriptors and chemical features to predict potency, selectivity, and pharmacological responses. Automated SAR prediction allows researchers to identify important structural modifications responsible for improved activity and optimize lead compounds efficiently. Furthermore, AI models can predict toxicity, metabolic stability, and adverse effects at early stages, reducing the failure rate of CNS drug candidates during clinical development (Huang et al., 2023).

Table 5.2. Applications of AI-assisted SAR approaches

AI-SAR Approach	Function	Application in CNS Drug Discovery
Automated SAR prediction	Identifies structure–activity relationships	Lead optimization
Machine learning QSAR	Predicts biological activity	Drug potency prediction
Deep learning models	Extracts complex molecular patterns	Novel CNS molecule design
Toxicity prediction models	Estimates safety profiles	Reducing drug failure

5.4 Emerging Technologies

Recent technological advancements are further expanding the potential of AI-driven CNS drug discovery. Digital twins represent computational models of biological systems that simulate disease progression and predict individual responses to therapies. Explainable artificial intelligence (XAI) improves transparency by identifying the reasons behind AI-generated predictions, increasing confidence among researchers and regulatory authorities. Generative AI models, including transformer-based and deep generative networks, can design novel molecules with desired pharmacological properties. Quantum computing is also emerging as a promising technology for improving molecular simulation and complex chemical calculations. Integration of multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics, provides a comprehensive understanding of CNS disease mechanisms and supports personalized therapeutic development (Paul et al., 2023; Boehme et al., 2024).

5.5 Current Challenges and Future Perspectives

Although AI, CADD, and SAR integration offer significant advantages, several challenges must be addressed before widespread clinical implementation. The accuracy of AI models depends strongly on the quality, diversity, and reliability of training datasets. Limited model interpretability remains a major concern, as many advanced deep learning systems function as “black boxes.” Regulatory acceptance of AI-generated drug candidates requires standardized validation protocols and transparent decision-making processes. Future developments in explainable AI, high-quality biological databases, personalized medicine approaches, and integration of human expertise with computational technologies are expected to improve the success rate of CNS drug discovery. The combination of AI, CADD, and SAR is likely to enable the development of safer, more effective, and patient-specific CNS therapeutics (Schneider et al., 2023; Boehme et al., 2024).

6. Conclusion

The integration of artificial intelligence (AI), computer-aided drug design (CADD), and structure–activity relationship (SAR) approaches has significantly transformed modern CNS drug discovery. AI-driven methods enable rapid analysis of complex biological datasets, identification of novel therapeutic targets, prediction of drug properties, and optimization of lead molecules. CADD provides powerful computational strategies, including molecular modeling, virtual screening, and molecular simulation, which improve the efficiency of drug candidate identification. SAR studies further support rational molecular optimization by understanding the relationship between chemical structure and biological activity. Together, these computational approaches reduce development time, minimize experimental costs, and improve the probability of discovering effective CNS therapeutics (Hasselgren & Oprea, 2024).

Future CNS drug discovery is expected to be increasingly influenced by AI-enabled precision medicine, where computational models integrate patient-specific genomic, molecular, and clinical information to develop personalized therapeutic strategies. Emerging technologies such as generative AI, explainable AI, multi-omics analysis, and advanced computational simulations will provide new opportunities for designing next-generation CNS drugs with improved efficacy, safety, and brain-targeting ability. However, successful implementation will require multidisciplinary collaboration among computational scientists, medicinal chemists, neuroscientists, pharmacologists, and clinicians to ensure reliable model validation and clinical translation (Carini & Seyhan, 2024; Wenteler et al., 2024).

The future of computational CNS drug discovery lies in the development of integrated platforms combining AI, CADD, SAR, and experimental approaches. These innovations are expected to overcome current limitations associated with CNS complexity, drug delivery barriers, and high clinical failure rates, ultimately supporting the discovery of safer and more effective therapies for neurological and psychiatric disorders.

References

- Acharya, A., Yadav, M., Nagpure, M., Kumaresan, S., & Guchhait, S. K. (2024). Molecular medicinal insights into scaffold hopping-based drug discovery success. *Drug Discovery Today*, *29*(1), 103845.
- Askr, H., Elgeldawi, E., Aboul Ella, H., Elshaier, Y. A. M. M., Gomaa, M. M., & Hassanien, A. E. (2023). Deep learning in drug discovery: An integrative review and future challenges. *Artificial Intelligence Review*, *56*, 5975–6037.
- Bassani, D., & Moro, S. (2023). Past, present, and future perspectives on computer-aided drug design methodologies. *Molecules*, *28*(9), 3906.
- Boehme, P., Woolley, J. P., & Kallianos, A. (2024). Artificial intelligence, digital twins, and personalized medicine: Emerging technologies for future healthcare. *Nature Medicine, 30*, 120–132.
- Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (14th ed.). McGraw Hill.
- Callis, T. B., Garrett, T. R., Montgomery, A. P., Danon, J. J., & Kassiou, M. (2022). Recent scaffold hopping applications in central nervous system drug discovery. *Journal of Medicinal Chemistry, 65*(20), 13483–13504.

- Carini, C., & Seyhan, A. A. (2024). Tribulations and future opportunities for artificial intelligence in precision medicine. *Journal of Translational Medicine, 22*, 411. https://doi.org/10.1186/s12967-024-05067-0
- Cerchia, C., & Lavecchia, A. (2023). New avenues in artificial-intelligence-assisted drug discovery. *Drug Discovery Today, 28*(4), 103516.
- Chatterjee, M., & Roy, K. (2023). Quantitative structure–activity relationships (QSARs) in medicinal chemistry. In *Cheminformatics, QSAR and Machine Learning Applications for Novel Drug Development* (pp. 3–38). Elsevier.
- Chen, W., Liu, X., Zhang, S., et al. (2023). Artificial intelligence for drug discovery: Resources, methods, and applications. *Molecular Therapy – Nucleic Acids, 31*, 691–702.
- Dorahy, G., Chen, J. Z., & Balle, T. (2023). Computer-aided drug design towards new psychotropic and neurological drugs. *Molecules, 28*(3), 1324.
- Feigin, V. L., Stark, B. A., Johnson, C. O., Bisignano, C., Abady, G. G., Abbasifard, M., et al. (2021). Global, regional, and national burden of neurological disorders, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology, 20*(10), 795–820.
- Hasselgren, C., & Oprea, T. I. (2023). Artificial intelligence for drug discovery: Are we there yet? *arXiv*. https://arxiv.org/abs/2307.06521
- Hasselgren, C., & Oprea, T. I. (2024). Artificial intelligence for drug discovery: Are we there yet? *Annual Review of Pharmacology and Toxicology, 64*, 527–550. https://doi.org/10.1146/annurev-pharmtox-040323-040828
- Huang, K., Fu, T., Gao, W., Zhao, Y., Roohani, Y., Leskovec, J., & Coley, C. W. (2023). Therapeutics data commons: Machine learning datasets and tasks for drug discovery. *Nature Chemical Biology, 19*, 1215–1224.
- Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., et al. (2020). PubChem in 2021: New data content and improved web interfaces. *Nucleic Acids Research, 49*(D1), D1388–D1395.
- Liu, X., Wang, Y., & Zhang, H. (2024). Artificial intelligence-assisted molecular design and optimization in drug discovery. *Briefings in Bioinformatics, 25*(1), bbad450.
- Niazi, S. K., & Mariam, Z. (2024). Computer-aided drug design and drug discovery: A prospective analysis. *Pharmaceuticals, 17*(1), 22.
- Novič, M. (2023). Quantitative structure activity/toxicity relationship through neural networks for drug discovery or regulatory use. *Current Drug Discovery Technologies, 23*(29), 2792–2804.
- Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2023). Artificial intelligence in drug discovery and development. *Drug Discovery Today, 28*(1), 103406.
- Schneider, G., Walters, W. P., & Murcko, M. A. (2023). AI in drug discovery: Current status and future perspectives. *Nature Reviews Drug Discovery, 22*, 551–572.
- Sharma, P., Nandave, M., et al. (2023). Computer-aided drug design: An overview. In *Cheminformatics, QSAR and Machine Learning Applications for Novel Drug Development* (pp. 39–68). Elsevier.
- Srivathsa, A. V., Sadashivappa, N. M., Hegde, A. K., et al. (2023). A review on artificial intelligence approaches and rational approaches in drug discovery. *Current Pharmaceutical Design, 29*(15), 1180–1192.
- Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. (2024). Integrating QSAR modelling and deep learning in drug discovery: The emergence of deep QSAR. *Nature Reviews Drug Discovery, 23*(2), 141–155.

- Vatansever, S., Schlessinger, A., Wacker, D., & Kaniskan, H. Ü. (2021). Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-art and future directions. *Medicinal Research Reviews, 41*(3), 1427–1473.
- Walters, W. P., & Murcko, M. A. (2023). Assessing the impact of AI on medicinal chemistry. *Nature Biotechnology, 41*, 147–150.
- Wenteler, A., Cabrera, C. P., Wei, W., Neduva, V., & Barnes, M. R. (2024). AI approaches for the discovery and validation of drug targets. *Cambridge Prisms: Precision Medicine, 2*, e7. https://doi.org/10.1017/pcm.2024.4
- Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2022). Concepts of artificial intelligence for computer-assisted drug discovery. *Chemical Reviews, 122*(5), 6043–6080.
- Zha, J., He, J., Wu, C., Zhang, M., Liu, X., & Zhang, J. (2023). Designing drugs and chemical probes with the dualsteric approach. *Chemical Society Reviews, 52*, 8651–8677.
- Zhang, Y., Chen, Y., & Li, X. (2024). Artificial intelligence revolutionizing CNS drug discovery and development: Emerging strategies and future perspectives. *Drug Discovery Today, 29*(9), 104012. https://doi.org/10.1016/j.drudis.2024.104012

Chapter 10: Natural Products and Phytopharmaceuticals for Neurodegenerative and Neuropsychiatric Disorders: A Comprehensive Review

Neha Gupta[*1], Smita Vasant Nhawkar[2], Pooja Khanpara[3], Tanaya Shirish Pandhare[4], Jiju V[5]

[1]Assistant Professor, Department of Pharmaceutics, Sahu Onkar Saran School of Pharmacy, Faculty of Pharmacy, IFTM University, Lodhipur Rajput, Delhi Road, NH-24, Moradabad, Uttar Pradesh, India.

[2]Assistant Professor, Department of Pharmacognosy, Ashokrao Mane College of Pharmacy, Pethvadgaon Kolhapur, Vathar Tarf Vadgaon, Maharashtra, India.

[3]Professor, Department of Pharmacognosy, Smt. R. D. Gardi B.Pharmacy College, Opposite Garden Dinner Club, Rajkot–Jamnagar Highway, Rajkot–360110, Gujarat, India.

[4]Assistant Professor, M. Pharmacy Pharmacognosy, Late Shree Fakirbhai Pansare Education Foundation's College of Pharmacy, Pimpalkunthe, Pune, Gat No.95, At. Post, Tal, Maval, Pimpal Khunte, Maharashtra 410506, India.

[5]Professor, Department of Pharmacognosy, Nazareth College of Pharmacy, Othera P.O., Thiruvalla, Kerala, India.

*Corresponding Author: Neha Gupta, Assistant Professor, Department of Pharmaceutics, Sahu Onkar Saran School of Pharmacy, Faculty of Pharmacy, IFTM University, Lodhipur Rajput, Delhi Road, NH-24, Moradabad, Uttar Pradesh, India.

Abstract

Neurodegenerative and neuropsychiatric disorders represent major global health challenges due to their progressive nature, complex pathophysiology, and limited availability of disease-modifying therapies. Conventional pharmacological treatments often provide symptomatic relief but are associated with adverse effects, limited efficacy, and challenges in long-term management. Natural products and phytopharmaceuticals have gained considerable attention as promising therapeutic alternatives because of their diverse biological activities, including antioxidant, anti-inflammatory, neuroprotective, and neuromodulatory effects. Bioactive compounds such as flavonoids, polyphenols, alkaloids, terpenoids, and glycosides have demonstrated potential against Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, depression, anxiety, and other neuropsychiatric disorders. These compounds exert their effects through multiple mechanisms, including reduction of oxidative stress, inhibition of neuroinflammation, regulation of neurotransmitter systems, enhancement of neurotrophic signaling, and protection against neuronal apoptosis. However, poor aqueous solubility, low bioavailability, rapid metabolism, and limited blood–brain barrier permeability remain major challenges restricting their clinical translation. Recent advances in nanotechnology-based delivery systems, targeted brain delivery strategies, computational drug discovery, and omics-based approaches have provided new opportunities to improve the therapeutic potential of phytochemicals. Furthermore, personalized phytomedicine and precision medicine approaches may facilitate the development of more effective and individualized neurotherapeutic interventions. This review highlights the classification, pharmacological potential, molecular mechanisms, advanced delivery approaches, and future perspectives of natural products and phytopharmaceuticals in the management of neurodegenerative and neuropsychiatric disorders.

Keywords: Natural products; Phytochemicals; Neuroprotection; Neurodegenerative disorders; Neuropsychiatric disorders; Polyphenols; Flavonoids; Nanotechnology; Blood–brain barrier; Phytopharmaceuticals.

1. Introduction

Neurodegenerative and neuropsychiatric disorders represent a major global health challenge due to their progressive nature, complex pathology, and limited disease-modifying therapies. Disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), depression, and anxiety are associated with neuronal dysfunction, oxidative stress, neuroinflammation, mitochondrial impairment, and neurotransmitter imbalance. Current therapeutic approaches mainly provide symptomatic relief and are often limited by adverse effects and poor long-term efficacy. Therefore, natural products and phytopharmaceuticals have gained significant attention as potential neuroprotective agents because of their antioxidant, anti-inflammatory, anti-apoptotic, and neuroregenerative properties (Goyal et al., 2024; Gao et al., 2024).

Natural products derived from medicinal plants, dietary sources, marine organisms, and microorganisms have historically contributed to drug discovery. Phytochemicals such as polyphenols, flavonoids, alkaloids, terpenoids, and carotenoids exhibit promising neuroprotective activities by regulating multiple molecular pathways involved in neuronal survival. Compounds including curcumin, quercetin, resveratrol, epigallocatechin gallate (EGCG), ginkgo flavonoids, and cannabinoids have demonstrated potential in reducing oxidative damage, inhibiting neuroinflammatory pathways, and improving cognitive functions (Madhubala et al., 2024).

Oxidative stress is considered one of the major contributors to neuronal degeneration because the brain consumes high amounts of oxygen and contains high levels of polyunsaturated fatty acids, making neurons highly vulnerable to reactive oxygen species (ROS). Natural antioxidants can neutralize free radicals and enhance endogenous antioxidant defense systems. Polyphenolic compounds such as curcumin and quercetin have shown the ability to modulate antioxidant enzymes, reduce lipid peroxidation, and protect neuronal cells from oxidative injury (Anand David et al., 2016; Lim et al., 2024).

Neuroinflammation plays an important role in the progression of neurodegenerative diseases through activation of microglia and release of inflammatory mediators. Several phytochemicals suppress inflammatory pathways such as nuclear factor-kappa B (NF-κB), cyclooxygenase-2 (COX-2), and pro-inflammatory cytokines. Curcumin, obtained from *Curcuma longa*, has been extensively studied for its anti-inflammatory and neuroprotective effects, while resveratrol and flavonoids have shown potential in regulating inflammatory responses and neuronal communication (Madhubala et al., 2024).

In Alzheimer's disease, natural products have demonstrated potential through multiple mechanisms, including inhibition of amyloid-beta aggregation, reduction of tau phosphorylation, improvement of cholinergic neurotransmission, and enhancement of synaptic plasticity. Flavonoids, polyphenols, and herbal extracts have shown promising effects in experimental models by protecting neurons and improving memory-related functions (Lim et al., 2024). However, clinical translation remains challenging because of issues related to bioavailability, stability, dosage optimization, and blood–brain barrier permeability.

Parkinson's disease is characterized by progressive loss of dopaminergic neurons and accumulation of oxidative stress and mitochondrial dysfunction. Natural compounds such as quercetin, curcumin, EGCG, and ginsenosides have demonstrated neuroprotective effects by reducing oxidative injury, regulating mitochondrial function, and preventing neuronal apoptosis. These compounds may provide supportive therapeutic strategies for slowing disease progression and improving neuronal health (Madhubala et al., 2024).

Phytopharmaceutical approaches are also being explored for neuropsychiatric disorders including depression, anxiety, and cognitive impairment. Plant-derived compounds may influence neurotransmitter systems such as serotonin, dopamine, gamma-aminobutyric acid (GABA), and glutamate. Herbal medicines including *Withania somnifera*, *Bacopa monnieri*, *Ginkgo biloba*, and saffron-derived compounds have shown potential antidepressant, anxiolytic, and cognitive-enhancing activities through modulation of stress pathways and neuroplasticity mechanisms (Islam et al., 2023).

Despite promising biological activities, many natural compounds suffer from poor aqueous solubility, rapid metabolism, and limited absorption, restricting their therapeutic applications. Advanced pharmaceutical technologies such as nanoparticles, liposomes, nanogels, and other targeted delivery systems are being developed to enhance stability, bioavailability, and brain-specific delivery of phytoconstituents. Nanoformulated natural products represent an emerging strategy for improving the effectiveness of phytopharmaceutical therapies in neurological disorders (Goyal et al., 2024).

Future research should focus on well-designed clinical trials, pharmacokinetic evaluation, molecular mechanism studies, and development of standardized phytopharmaceutical formulations. Integration of natural product chemistry with nanotechnology, computational drug discovery, and modern pharmacological approaches may provide innovative therapeutic solutions for neurodegenerative and neuropsychiatric disorders. Although natural products cannot completely replace conventional therapies, they represent valuable candidates for developing safer and multifunctional neuroprotective medicines (Gao et al., 2024).

2. Bioactive Natural Products and Phytochemicals in Neuroprotection

2.1 Classification of Natural Products

Natural products derived from medicinal plants, microorganisms, and marine sources represent a diverse group of bioactive molecules with significant neuroprotective potential. These compounds exert beneficial effects through antioxidant, anti-inflammatory, anti-apoptotic, and neuroregenerative mechanisms. Plant-derived phytochemicals are broadly classified into polyphenols, flavonoids, alkaloids, terpenoids, phenolic acids, glycosides, and saponins based on their chemical structures and biological activities (Atanasov et al., 2021).

Polyphenols and flavonoids are among the most extensively studied groups due to their ability to neutralize reactive oxygen species (ROS), regulate inflammatory pathways, and protect neuronal cells against oxidative damage. Alkaloids such as galantamine and huperzine A demonstrate cognitive-enhancing effects through modulation of cholinergic neurotransmission. Terpenoids, glycosides, and saponins also contribute to neuroprotection by regulating mitochondrial function, reducing neuroinflammation, and promoting neuronal survival.

Table 2.1. Major Classes of Natural Products with Neuroprotective Potential

Class of Natural Product	Representative Compounds	Major Neuroprotective Actions
Polyphenols	Curcumin, Resveratrol, Catechins	Antioxidant activity, anti-inflammatory effects, mitochondrial protection
Flavonoids	Quercetin, Kaempferol, Luteolin, Apigenin	ROS scavenging, neuroinflammation inhibition, neuronal signaling regulation
Alkaloids	Berberine, Galantamine, Huperzine A, Caffeine	Cholinesterase inhibition, cognitive improvement, neurotransmitter regulation
Terpenoids	Ginsenosides, Withanolides, Bacopaside	Neuroregeneration, stress regulation, neuronal survival
Phenolic acids	Caffeic acid, Ferulic acid	Antioxidant and anti-apoptotic effects
Glycosides/Saponins	Ginsenosides, Bacopasides	Neuroprotective signaling and synaptic function improvement

2.2 Flavonoids as Neuroprotective Agents

Flavonoids are polyphenolic compounds widely distributed in fruits, vegetables, and medicinal plants. They have gained considerable attention in neuroscience due to their ability to cross biological barriers and interact with multiple molecular pathways involved in neuronal dysfunction. Flavonoids protect neurons by reducing oxidative stress, regulating inflammatory responses, and improving synaptic plasticity (Spencer, 2010).

Quercetin

Quercetin is a naturally occurring flavonol known for strong antioxidant and anti-inflammatory activities. It protects neuronal cells by activating endogenous antioxidant defense systems, reducing lipid peroxidation, and inhibiting inflammatory mediators. Quercetin has also demonstrated potential against amyloid-β-induced neurotoxicity and cognitive impairment.

Kaempferol

Kaempferol exhibits neuroprotective effects through oxidative stress reduction and inhibition of inflammatory signaling pathways. It enhances neuronal survival by regulating mitochondrial function and suppressing apoptosis-related mechanisms.

Rutin

Rutin, a glycosylated flavonoid, improves neuronal resistance against oxidative injury. It enhances antioxidant enzyme activity and reduces inflammatory responses associated with neurodegenerative disorders.

Luteolin and Apigenin

Luteolin and apigenin demonstrate neuroprotective effects by regulating microglial activation, decreasing inflammatory cytokine production, and improving neuronal communication. These compounds have shown potential in memory enhancement and protection against neurodegenerative damage.

Mechanisms of Flavonoid-Mediated Neuroprotection

- Direct scavenging of reactive oxygen species
- Activation of antioxidant pathways such as Nrf2/ARE signaling
- Suppression of inflammatory mediators including NF-κB
- Regulation of neuronal survival pathways
- Prevention of oxidative neuronal damage

2.3 Polyphenolic Compounds

Polyphenols represent one of the largest groups of plant-derived bioactive compounds with promising applications in neurological disorders. Their neuroprotective properties are associated with antioxidant activity, regulation of protein aggregation, mitochondrial stabilization, and modulation of inflammatory pathways.

Curcumin

Curcumin, obtained from *Curcuma longa*, exhibits antioxidant, anti-inflammatory, and neuroprotective effects. It reduces amyloid-β aggregation, inhibits neuroinflammatory signaling, and improves mitochondrial function. However, its therapeutic application is limited by poor bioavailability, leading to interest in advanced delivery systems.

Resveratrol

Resveratrol, a stilbene polyphenol found in grapes and berries, activates sirtuin-mediated pathways and improves mitochondrial activity. It protects neurons by reducing oxidative stress, regulating apoptosis, and promoting cellular longevity.

Catechins and Epigallocatechin Gallate (EGCG)

Catechins, particularly EGCG from green tea, demonstrate neuroprotective activity by reducing oxidative injury, preventing abnormal protein aggregation, and regulating inflammatory responses. EGCG has been investigated for its potential role in Alzheimer's and Parkinson's disease models.

Table 2.2. Important Polyphenolic and Alkaloid Neuroprotective Compounds

Compound	Natural Source	Neuroprotective Mechanism
Curcumin	*Curcuma longa*	Amyloid-β inhibition, antioxidant activity, NF-κB suppression

Resveratrol	Grapes, berries	SIRT1 activation, mitochondrial protection
EGCG	Green tea	Protein aggregation inhibition, anti-inflammatory activity
Berberine	*Berberis* species	Neuroinflammation reduction, metabolic regulation
Galantamine	*Galanthus* species	Acetylcholinesterase inhibition, cognitive improvement
Huperzine A	*Huperzia serrata*	Cholinergic enhancement and neuroprotection

2.4 Alkaloids and Nitrogen-Containing Compounds

Alkaloids are nitrogen-containing secondary metabolites with important pharmacological properties. Several alkaloids have demonstrated significant effects in cognitive enhancement, neurotransmitter regulation, and neuronal protection.

Berberine

Berberine exhibits antioxidant and anti-inflammatory properties and regulates mitochondrial pathways associated with neuronal survival. It has shown potential against cognitive decline and neurodegenerative processes.

Caffeine

Caffeine, a methylxanthine alkaloid, improves alertness and cognitive performance through adenosine receptor antagonism. It also provides neuroprotective effects by regulating dopamine signaling and reducing neuroinflammation.

Galantamine and Huperzine A

Galantamine and huperzine A are clinically investigated acetylcholinesterase inhibitors that enhance cholinergic transmission. They improve cognitive function by increasing acetylcholine availability and slowing cognitive decline in neurodegenerative conditions.

2.5 Terpenoids and Other Phytoconstituents

Terpenoids and related phytoconstituents represent another important category of neuroactive natural compounds. These molecules influence neuronal survival, stress responses, and cognitive functions.

Ginsenosides

Ginsenosides obtained from *Panax ginseng* demonstrate antioxidant and anti-inflammatory properties. They regulate neuronal signaling pathways and improve memory function.

Withanolides

Withanolides from *Withania somnifera* exhibit neuroprotective and adaptogenic activities by reducing oxidative stress and enhancing neurogenesis.

Bacopaside

Bacopaside, derived from *Bacopa monnieri*, improves memory and learning ability through antioxidant effects and modulation of neurotransmitter systems.

Cannabinoids

Plant-derived cannabinoids regulate neuronal signaling through cannabinoid receptors and exhibit neuroprotective, anti-inflammatory, and antioxidant properties.

2.6 Mechanistic Basis of Natural Product-Mediated Neuroprotection

Natural products exert neuroprotective effects through multiple molecular mechanisms rather than acting on a single target. Their multi-target activity makes them promising candidates for complex neurological disorders.

Antioxidant Pathways

Many phytochemicals activate the Nrf2/ARE pathway, increasing antioxidant enzymes such as superoxide dismutase and glutathione peroxidase. This reduces oxidative stress-induced neuronal injury.

Anti-inflammatory Pathways

Natural compounds suppress NF-κB activation and decrease production of inflammatory cytokines such as TNF-α, IL-1β, and IL-6. This reduces microglial activation and neuroinflammation.

Regulation of Apoptosis

Phytochemicals regulate apoptotic proteins by increasing anti-apoptotic factors and reducing mitochondrial-mediated neuronal cell death.

Neurotransmitter Modulation

Several natural compounds regulate cholinergic, dopaminergic, serotonergic, and GABAergic pathways, contributing to improved cognition and emotional regulation.

Activation of Neurotrophic Factors

Natural products enhance expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), promoting neuronal growth, synaptic plasticity, and repair.

3. Natural Products in Neurodegenerative Disorders

Neurodegenerative disorders are characterized by progressive loss of neuronal structure and function, leading to cognitive decline, movement impairment, and reduced quality of life. Although current therapies provide symptomatic relief, they do not completely prevent neuronal degeneration. Natural

products have attracted significant attention due to their antioxidant, anti-inflammatory, anti-apoptotic, and neuroregenerative properties. Several phytochemicals have demonstrated promising effects in experimental models of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).

3.1 Natural Products Against Alzheimer's Disease

Alzheimer's disease (AD) is the most common neurodegenerative disorder associated with progressive memory loss and cognitive impairment. The major pathological features of AD include extracellular amyloid-β (Aβ) plaque accumulation, intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein, oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation (Scheltens et al., 2021).

Pathological Mechanisms of Alzheimer's Disease

Amyloid-β Plaque Formation

Abnormal processing of amyloid precursor protein leads to excessive production and aggregation of Aβ peptides. These aggregates induce neuronal toxicity, oxidative damage, and synaptic dysfunction.

Tau Hyperphosphorylation

Hyperphosphorylation of tau proteins results in neurofibrillary tangle formation, disrupting axonal transport and neuronal communication.

Neuroinflammation and Oxidative Stress

Activation of microglia and increased production of inflammatory cytokines contribute to neuronal damage. Excessive reactive oxygen species (ROS) generation further accelerates neurodegeneration.

Potential Phytotherapeutics for Alzheimer's Disease

- **Curcumin:** Reduces Aβ aggregation, suppresses inflammatory pathways, and improves antioxidant defense.
- **Resveratrol:** Activates SIRT1 signaling and protects neurons against oxidative injury.
- **Ginkgo biloba extracts:** Improve cerebral blood flow and provide antioxidant effects.
- **Bacopa monnieri:** Enhances memory and cognitive function through neuroprotective mechanisms.
- **Huperzine A:** Acts as an acetylcholinesterase inhibitor and improves cholinergic neurotransmission.

3.2 Natural Products for Parkinson's Disease

Parkinson's disease (PD) is characterized by selective degeneration of dopaminergic neurons in the substantia nigra, resulting in dopamine deficiency and motor dysfunction. Oxidative stress, mitochondrial impairment, neuroinflammation, and abnormal protein aggregation contribute significantly to disease progression (Armstrong & Okun, 2020).

Dopaminergic Neuron Degeneration

Loss of dopamine-producing neurons reduces neurotransmission in basal ganglia pathways, causing symptoms such as tremor, rigidity, and impaired movement.

Oxidative Stress and Mitochondrial Dysfunction

Mitochondrial damage increases ROS production, leading to neuronal apoptosis. Natural antioxidants can restore mitochondrial function and protect dopaminergic neurons.

Natural Compounds Investigated in Parkinson's Disease

- **Mucuna pruriens:** A natural source of L-DOPA that improves dopamine availability.
- **Quercetin:** Protects dopaminergic neurons through antioxidant and anti-inflammatory mechanisms.
- **Green tea catechins:** Reduce oxidative damage and regulate mitochondrial pathways.
- **Withania somnifera:** Provides neuroprotection through antioxidant and anti-stress activities.

3.3 Natural Products in Huntington's Disease and ALS

Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) are progressive neurodegenerative disorders associated with neuronal loss, abnormal protein accumulation, oxidative stress, and inflammatory responses.

Protein Aggregation Mechanisms

In Huntington's disease, mutant huntingtin protein aggregation disrupts neuronal function. Similarly, ALS involves abnormal accumulation of proteins such as TDP-43 and impaired motor neuron survival.

Oxidative Damage and Neuroinflammation

Oxidative imbalance and chronic activation of inflammatory pathways accelerate neuronal injury. Natural antioxidants have shown potential in reducing oxidative damage and improving neuronal survival.

Potential Natural Therapeutic Agents

- Polyphenols such as resveratrol and curcumin
- Flavonoids including quercetin and luteolin
- Antioxidant phytochemicals that enhance endogenous defense systems

These compounds regulate mitochondrial function, reduce inflammatory signaling, and prevent neuronal apoptosis.

3.4 Natural Products in Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune-mediated neurological disorder characterized by inflammation, demyelination, and damage to central nervous system neurons. Immune dysregulation results in destruction of myelin sheath, affecting nerve conduction.

Immune-Mediated Neuronal Damage

Activation of immune cells leads to increased inflammatory cytokines and oxidative stress, causing neuronal injury.

Demyelination Mechanisms

Loss of myelin disrupts communication between neurons and contributes to motor and sensory abnormalities.

Potential Phytochemicals in Multiple Sclerosis

- **Curcumin:** Modulates immune responses and reduces inflammatory cytokine production.
- **Resveratrol:** Regulates immune signaling and protects neurons against oxidative injury.
- **Epigallocatechin gallate (EGCG):** Suppresses inflammatory pathways and provides antioxidant protection.

Table 3.1. Natural Products and Their Neuroprotective Roles in Neurodegenerative Disorders

Neurodegenerative Disorder	Natural Product	Major Therapeutic Actions
Alzheimer's disease	Curcumin	Reduces amyloid-β aggregation, antioxidant activity
Alzheimer's disease	Huperzine A	Acetylcholinesterase inhibition, cognitive improvement
Parkinson's disease	Mucuna pruriens	Natural L-DOPA source, dopamine restoration
Parkinson's disease	Green tea catechins	Mitochondrial protection and ROS reduction
Huntington's disease	Resveratrol	Reduces oxidative stress and inflammation
ALS	Polyphenols	Protection against neuronal apoptosis
Multiple sclerosis	EGCG	Immunomodulation and antioxidant effects

3.5 Neuroprotective Mechanisms of Phytochemicals

Natural products exert neuroprotective effects through multiple molecular pathways, making them attractive candidates for complex neurological diseases.

Reduction of Oxidative Stress

Phytochemicals neutralize ROS and enhance antioxidant enzymes such as superoxide dismutase and glutathione peroxidase. Activation of antioxidant pathways reduces oxidative neuronal injury.

Modulation of Inflammatory Mediators

Natural compounds inhibit inflammatory pathways including NF-κB signaling and reduce production of cytokines such as TNF-α, IL-1β, and IL-6.

Protection of Neuronal Cells

Phytochemicals regulate apoptosis-related proteins, maintain mitochondrial integrity, and enhance neuronal survival.

Improvement of Cognitive Functions

Several natural compounds enhance synaptic plasticity, neurotransmitter regulation, and neurotrophic factor expression, contributing to improved memory and learning.

3.6 Clinical Evidence and Current Challenges

Although numerous natural products demonstrate neuroprotective activity in laboratory and animal studies, their clinical translation remains challenging.

Preclinical and Clinical Studies

Experimental studies have demonstrated promising effects of curcumin, resveratrol, flavonoids, and herbal extracts. However, large-scale clinical trials are required to establish therapeutic efficacy and safety.

Bioavailability Limitations

Many phytochemicals show poor water solubility, rapid metabolism, and limited blood–brain barrier penetration, reducing their therapeutic effectiveness.

Standardization Issues

Variability in plant sources, extraction methods, and active compound concentration creates challenges in quality control of phytopharmaceutical products.

Need for Advanced Delivery Systems

Nanotechnology-based approaches such as nanoparticles, liposomes, nanoemulsions, and lipid-based carriers may improve bioavailability, stability, and brain-targeted delivery of natural compounds.

Table 3.2. Major Challenges and Future Strategies for Natural Neurotherapeutics

Challenges	Possible Solutions	Challenges
Poor bioavailability	Nanoformulations, liposomes, polymeric nanoparticles	Poor bioavailability
Limited BBB penetration	Targeted drug delivery systems	Limited BBB penetration
Lack of standardization	Advanced analytical characterization	Lack of standardization
Insufficient clinical evidence	Long-term randomized clinical trials	Insufficient clinical evidence
Rapid metabolism	Structural modification and formulation optimization	Rapid metabolism

4. Natural Products in Neuropsychiatric Disorders

Neuropsychiatric disorders are complex conditions involving disturbances in mood, cognition, behaviour, and emotional regulation. Conventional pharmacological treatments are effective in many patients; however, limitations such as delayed therapeutic response, adverse effects, and incomplete symptom control have encouraged the exploration of natural products as complementary therapeutic approaches. Phytochemicals derived from medicinal plants exhibit antidepressant, anxiolytic, antipsychotic, and neuroprotective properties through modulation of neurotransmitters, oxidative stress, inflammation, and neuroplasticity pathways.

4.1 Natural Products for Depression

Depression is a major neuropsychiatric disorder characterized by persistent sadness, loss of interest, cognitive impairment, and emotional disturbances. The neurobiology of depression involves complex interactions between neurotransmitter imbalance, hypothalamic–pituitary–adrenal (HPA) axis dysregulation, inflammation, oxidative stress, and impaired neuroplasticity.

Neurobiology of Depression

Classical theories suggest that depression is associated with reduced activity of monoamine neurotransmitters, including serotonin (5-HT), dopamine (DA), and norepinephrine (NE). Altered neurotransmission affects mood regulation, motivation, reward pathways, and cognitive functions. Additionally, reduced brain-derived neurotrophic factor (BDNF) levels contribute to impaired neuronal adaptation.

Phytotherapeutic Agents

Hypericum perforatum (St. John's Wort)

St. John's wort is one of the most extensively studied herbal antidepressants. Its active constituents, including hypericin and hyperforin, regulate serotonin, dopamine, and norepinephrine reuptake pathways, contributing to mood improvement.

Curcumin

Curcumin exhibits antidepressant-like effects by reducing neuroinflammation, regulating monoamine neurotransmission, and enhancing BDNF signaling.

Saffron

Saffron (*Crocus sativus*) contains crocin and safranal, which influence serotonergic pathways and demonstrate antidepressant activity in clinical studies.

Omega-3 Fatty Acids

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA), regulate inflammatory pathways and neuronal membrane function, supporting emotional regulation.

4.2 Natural Products for Anxiety Disorders

Anxiety disorders involve excessive fear, stress responses, and emotional dysregulation. Alterations in GABAergic, serotonergic, and glutamatergic neurotransmission contribute to anxiety symptoms.

Neurochemical Basis of Anxiety

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter responsible for controlling neuronal excitability. Reduced GABA activity is associated with increased anxiety and stress responses. Natural compounds that enhance GABAergic signaling may provide anxiolytic effects.

Potential Natural Compounds

Ashwagandha

(*Withania somnifera*) is an adaptogenic herb that reduces stress-related responses by regulating cortisol levels and improving emotional resilience.

Lavender

Lavender contains linalool and linalyl acetate, which influence GABAergic neurotransmission and produce calming effects.

Chamomile

Chamomile contains apigenin, a flavonoid that interacts with GABA-A receptors and contributes to anxiolytic activity.

Valerian

Valerian extracts enhance GABA signaling and have traditionally been used for anxiety and sleep-related disorders.

4.3 Natural Products in Schizophrenia and Psychotic Disorders

Schizophrenia is a severe psychiatric disorder characterized by hallucinations, delusions, cognitive impairment, and social dysfunction. Although dopamine dysregulation remains a major hypothesis, oxidative stress, neuroinflammation, and immune dysfunction also contribute to disease progression.

Neuroinflammation and Oxidative Imbalance

Increased oxidative damage, mitochondrial dysfunction, and inflammatory cytokine activation have been observed in schizophrenia. Antioxidant compounds may help restore neuronal balance and reduce oxidative injury.

Dopamine Hypothesis

Excessive dopamine activity in mesolimbic pathways contributes to positive symptoms, whereas reduced dopamine signaling in cortical regions affects cognition and motivation.

Investigated Natural Agents

N-Acetyl Cysteine (NAC)

NAC improves antioxidant capacity by increasing glutathione levels and may regulate glutamatergic neurotransmission.

Omega-3 Fatty Acids

Omega-3 fatty acids influence neuronal membrane stability, inflammation, and neurotransmitter function.

Polyphenols

Polyphenolic compounds such as resveratrol, curcumin, and flavonoids demonstrate antioxidant and anti-inflammatory activities that may support psychiatric health.

4.4 Natural Products for Bipolar Disorder and Stress-Related Disorders

Bipolar disorder is characterized by alternating episodes of mania and depression. Dysregulation of neurotransmitters, circadian rhythms, oxidative balance, and stress pathways contributes to disease development.

Mood Regulation Mechanisms

Altered serotonin, dopamine, glutamate, and GABA signaling affects mood stability. Neuroinflammation and mitochondrial dysfunction are also implicated in bipolar disorder.

Neuroendocrine Imbalance

Chronic stress activates the HPA axis, resulting in increased cortisol secretion and impaired emotional regulation.

Potential Phytochemicals

Resveratrol

Resveratrol regulates oxidative stress, inflammatory pathways, and mitochondrial function, showing potential mood-stabilizing effects.

Curcumin

Curcumin influences inflammatory mediators and neurotransmitter pathways associated with mood regulation.

Adaptogenic Herbs

Adaptogens such as *Withania somnifera* and other medicinal plants help regulate stress responses and improve resilience against psychological stress.

Table 4.1. Natural Products Investigated in Neuropsychiatric Disorders

Disorder	Natural Product	Major Therapeutic Mechanisms
Depression	St. John's wort	Monoamine regulation and antidepressant activity
Depression	Curcumin	Anti-inflammatory action, BDNF enhancement
Depression	Saffron	Serotonergic modulation
Anxiety	Ashwagandha	Stress reduction and cortisol regulation
Anxiety	Lavender	GABAergic modulation
Anxiety	Chamomile	GABA-A receptor interaction
Schizophrenia	N-acetyl cysteine	Glutathione restoration and antioxidant effects
Bipolar disorder	Resveratrol	Mitochondrial protection and inflammation control

4.5 Mechanisms of Psychopharmacological Actions

Natural products exert psychiatric benefits through multiple mechanisms involving neurotransmitter regulation, stress-response pathways, and neuronal adaptation.

Modulation of Neurotransmitters

Phytochemicals influence serotonin, dopamine, norepinephrine, GABA, and glutamate pathways involved in mood, cognition, and emotional regulation.

Regulation of HPA Axis

Adaptogenic compounds regulate stress hormone production by controlling excessive cortisol release and improving stress adaptation.

Reduction of Inflammation

Natural compounds suppress inflammatory mediators such as NF-κB, IL-6, and TNF-α, which are associated with psychiatric disorders.

Enhancement of Neuroplasticity

Several phytochemicals increase BDNF expression, promote synaptic remodeling, and support neuronal communication.

4.6 Clinical Applications and Safety Considerations

Although natural products demonstrate promising psychopharmacological effects, their clinical application requires careful evaluation.

Evidence from Clinical Trials

Clinical studies have demonstrated beneficial effects of certain natural products, particularly St. John's wort for mild-to-moderate depression, saffron for mood improvement, and omega-3 fatty acids as supportive therapy. However, further large-scale trials are needed.

Drug–Herb Interactions

Herbal products may interact with conventional psychiatric medications by affecting drug metabolism enzymes, neurotransmitter systems, or therapeutic efficacy.

Toxicity Concerns

Although many natural compounds are considered safe, excessive doses, contamination, and long-term use may produce adverse effects.

Regulatory Challenges

Variability in plant sources, extraction methods, and active constituent concentrations creates challenges in standardization and regulatory approval.

Table 4.2. Challenges and Future Directions of Natural Psychotherapeutics

Challenges	Future Approaches	Challenges
Variable phytochemical composition	Standardized extracts and quality control	Variable phytochemical composition

Limited clinical validation	Large-scale randomized clinical trials	Limited clinical validation
Poor bioavailability	Nanoformulations and advanced delivery systems	Poor bioavailability
Drug interactions	Pharmacokinetic and safety studies	Drug interactions
Regulatory limitations	Improved pharmaceutical guidelines	Regulatory limitations

5. Advanced Approaches for Improving Neurotherapeutic Potential of Natural Products

Natural products possess significant neuroprotective and neurotherapeutic potential; however, their clinical translation is often restricted by poor pharmacokinetic properties, limited brain availability, and inconsistent therapeutic outcomes. Recent advances in nanotechnology, pharmaceutical development, computational approaches, and combination therapies have provided innovative strategies to enhance the efficacy of phytochemicals in neurological and psychiatric disorders.

5.1 Challenges Associated with Natural Products

Although phytochemicals demonstrate promising biological activities, several limitations affect their therapeutic application.

Poor Aqueous Solubility

Many bioactive natural compounds such as curcumin, resveratrol, and flavonoids exhibit poor water solubility due to their hydrophobic chemical nature. Low solubility reduces dissolution rate and limits absorption after administration.

Low Bioavailability

Rapid metabolism, poor intestinal absorption, and extensive first-pass metabolism significantly decrease systemic availability of phytochemicals. As a result, therapeutic concentrations may not be achieved at target sites.

Rapid Metabolism

Natural compounds are frequently metabolized quickly through enzymatic pathways, resulting in short half-life and reduced pharmacological effects.

Limited Blood–Brain Barrier (BBB) Permeability

The BBB restricts entry of many therapeutic molecules into the central nervous system. Limited penetration reduces the effectiveness of natural products against brain disorders.

5.2 Nanotechnology-Based Delivery Systems

Nanotechnology-based drug delivery systems have emerged as promising approaches to overcome the limitations of phytochemicals. These systems improve solubility, stability, controlled release, and targeted delivery to the brain.

Polymeric Nanoparticles

Polymeric nanoparticles provide controlled and sustained release of natural compounds. Biocompatible polymers such as PLGA and chitosan enhance drug stability and improve BBB penetration.

Liposomes

Liposomes are lipid-based vesicular systems capable of encapsulating hydrophilic and hydrophobic compounds. They improve bioavailability and facilitate targeted delivery of neuroprotective agents.

Solid Lipid Nanoparticles (SLNs)

SLNs enhance the stability of poorly soluble phytochemicals and provide controlled drug release. They are widely investigated for brain-targeted delivery.

Nanoemulsions

Nanoemulsions improve dissolution and absorption of lipophilic natural products by reducing particle size and increasing surface area.

Nanostructured Lipid Carriers (NLCs)

NLCs combine solid and liquid lipids to improve drug loading capacity, stability, and controlled release compared with conventional lipid nanoparticles.

Table 5.1. Nanotechnology-Based Delivery Systems for Neurotherapeutic Natural Products

Delivery System	Advantages	Examples of Natural Compounds Delivered
Polymeric nanoparticles	Controlled release, improved stability	Curcumin, resveratrol
Liposomes	Enhanced bioavailability and targeting	Quercetin, EGCG
Solid lipid nanoparticles	Improved solubility and BBB transport	Curcumin, flavonoids
Nanoemulsions	Increased absorption and dissolution	Essential oils, polyphenols
Nanostructured lipid carriers	High drug loading and stability	Resveratrol, phytosterols

5.3 Targeted Brain Delivery Strategies

Efficient delivery of natural products to the brain remains a major challenge due to BBB restrictions. Targeted delivery approaches aim to improve accumulation of therapeutic molecules in neuronal tissues.

Blood–Brain Barrier Transport Mechanisms

The BBB consists of endothelial cells, tight junction proteins, astrocytes, and pericytes that regulate molecular transport into the brain. Nanocarriers can improve BBB penetration through receptor-mediated transport and enhanced permeability mechanisms.

Surface Modification Approaches

Modification of nanoparticle surfaces with polymers, peptides, or functional groups improves stability and enhances interaction with BBB transport systems.

Common approaches include:

- PEGylation for improved circulation time
- Peptide functionalization for brain targeting
- Surface charge modification for enhanced uptake

Ligand-Mediated Targeting

Ligands such as transferrin, lactoferrin, and apolipoprotein-derived peptides facilitate receptor-mediated transport across the BBB, improving delivery of neuroactive compounds.

5.4 Phytopharmaceutical Development

The development of phytopharmaceuticals requires systematic extraction, characterization, standardization, and quality evaluation to ensure safety and therapeutic effectiveness.

Extraction and Purification Methods

Advanced extraction techniques such as supercritical fluid extraction, microwave-assisted extraction, and ultrasound-assisted extraction improve recovery of bioactive compounds.

Standardization of Herbal Products

Standardization ensures consistent concentration of active constituents. Analytical techniques including HPLC, LC-MS, GC-MS, and NMR are used for chemical profiling.

Quality Control and Regulatory Requirements

Quality control involves evaluation of purity, stability, toxicity, microbial contamination, and batch-to-batch consistency. Regulatory guidelines are essential for converting traditional herbal medicines into evidence-based pharmaceutical products.

5.5 Computational and Modern Drug Discovery Approaches

Computational technologies accelerate identification and optimization of natural compounds with neurotherapeutic potential.

Molecular Docking Studies

Molecular docking predicts interactions between phytochemicals and biological targets such as enzymes, receptors, and signaling proteins involved in neurological disorders.

ADMET Prediction

Absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis helps predict pharmacokinetic properties and safety profiles of natural compounds.

Network Pharmacology

Network pharmacology evaluates multi-target interactions of phytochemicals, providing insights into complex mechanisms underlying neurological diseases.

Artificial Intelligence-Assisted Phytochemical Screening

Artificial intelligence and machine learning approaches assist in:

- Identification of promising phytochemicals
- Prediction of biological activity
- Optimization of molecular structures
- Drug–target interaction analysis

5.6 Combination Therapy Approaches

Combination strategies using natural products with conventional drugs may provide enhanced therapeutic effects through synergistic mechanisms.

Natural Product–Drug Combinations

Combining phytochemicals with existing medicines may improve efficacy, reduce toxicity, and overcome therapeutic limitations.

Examples include:

- Curcumin with anticancer or neuroprotective drugs
- Resveratrol with anti-inflammatory therapies
- Omega-3 fatty acids with psychiatric medications

Synergistic Neuroprotective Effects

Combination approaches may simultaneously regulate oxidative stress, inflammation, mitochondrial dysfunction, and neurotransmitter imbalance.

Multi-Target Therapeutic Strategies

Neurological disorders involve multiple pathological pathways; therefore, multi-target compounds or combinations may provide superior outcomes compared with single-target therapies.

Table 5.2. Modern Strategies to Enhance Neurotherapeutic Applications of Natural Products

Approach	Purpose	Therapeutic Benefit
Nanotechnology-based delivery	Improve solubility and stability	Enhanced brain availability
Targeted delivery systems	Increase CNS accumulation	Reduced systemic toxicity
Phytopharmaceutical standardization	Ensure quality and consistency	Reliable therapeutic effects
Computational drug discovery	Identify effective molecules	Faster lead optimization
Combination therapy	Multiple pathway regulation	Improved efficacy and reduced adverse effects

6. Future Perspectives and Conclusion

Natural products and phytopharmaceuticals represent a promising direction for the development of safer and multifunctional therapies for neurodegenerative and neuropsychiatric disorders. Advances in molecular biology, biotechnology, and pharmaceutical sciences are transforming traditional herbal medicines into evidence-based therapeutic approaches. Future neurotherapeutics will likely focus on personalized, targeted, and mechanism-driven strategies to improve treatment outcomes.

Personalized phytomedicine is emerging as an important concept in which therapeutic selection is guided by individual genetic background, metabolic profile, disease stage, and response patterns. Precision medicine approaches combined with multi-target natural compounds may provide improved management of complex neurological disorders because diseases such as Alzheimer's disease, Parkinson's disease, and depression involve multiple pathological pathways rather than a single molecular target. Natural compounds with antioxidant, anti-inflammatory, and neuroregenerative properties offer advantages by simultaneously regulating several disease-associated mechanisms (Kumar et al., 2023).

Integration of omics technologies, including genomics, proteomics, metabolomics, and systems biology, has expanded understanding of the molecular effects of phytochemicals. These approaches allow identification of therapeutic targets, biomarker discovery, and evaluation of complex interactions between natural compounds and biological networks. Network-based analysis can further explain the multi-component and multi-target nature of phytopharmaceuticals, supporting rational drug development (Wishart, 2019).

Future research should focus on large-scale randomized clinical trials to validate the therapeutic efficacy and safety of natural products. Although many phytochemicals show promising results in experimental studies, clinical translation remains limited due to variations in dosage, bioavailability, and formulation quality. Development of advanced delivery systems, including nanoparticles, liposomes, and brain-targeted carriers, may improve stability, bioavailability, and central nervous system delivery. Additionally, detailed mechanistic investigations and long-term safety evaluations are essential for establishing natural products as clinically approved neurotherapeutics.

Despite significant progress, regulatory and translational challenges remain major barriers. Standardization of phytopharmaceutical products, quality assurance of herbal extracts, reproducibility of biological effects, and commercial-scale production require strict scientific and regulatory frameworks. Harmonization of guidelines for extraction methods, chemical characterization, and clinical evaluation will support the transition of natural products from traditional medicine to modern pharmaceutical applications.

In conclusion, natural products provide a valuable source of neuroprotective and neuropsychiatric therapeutic candidates due to their diverse biological activities and multi-target mechanisms. Phytochemicals such as polyphenols, flavonoids, alkaloids, and terpenoids have demonstrated potential to reduce oxidative stress, control inflammation, regulate neurotransmission, and promote neuronal survival. Future integration of omics-based technologies, artificial intelligence, nanotechnology, and precision medicine approaches may accelerate the development of advanced phytopharmaceuticals for neurological medicine.

References

- Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U., & Jain, N. K. (2018). Stimuli-responsive in situ gel systems for nose-to-brain drug delivery. *Journal of Controlled Release, 279*, 225–241.
- Akhlaquer Rahman, M., Hussain, A., Iqbal, Z., Harwansh, R. K., Singh, L. R., & Ahmad, S. (2013). Nanosuspension: A potential nanoformulation for improved delivery of poorly bioavailable drugs. *Micro and Nanosystems, 5*(4), 273–287.
- Anand David, A. V., Arulmoli, R., & Parasuraman, S. (2016). Overviews of biological importance of quercetin: A bioactive flavonoid. *Pharmacognosy Reviews, 10*(20), 84–89. https://doi.org/10.4103/0973-7847.194044
- Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. *JAMA, 323*(6), 548–560. https://doi.org/10.1001/jama.2019.22360
- Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. *Nature Reviews Drug Discovery, 20*, 200–216. https://doi.org/10.1038/s41573-020-00114-z
- Bastianetto, S., Ménard, C., & Quirion, R. (2015). Neuroprotective action of resveratrol. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1852*(6), 1195–1201.
- Berrino, E., & Supuran, C. T. (2019). Natural products as lead compounds for neurodegenerative diseases. *Journal of Enzyme Inhibition and Medicinal Chemistry, 34*(1), 125–136.
- Braidy, N., Jugder, B. E., Poljak, A., Jayasena, T., Mansour, H., Heath, P. R., Grant, R., & Sachdev, P. (2019). Neuroprotective effects of resveratrol in neurological disorders: Mechanisms and therapeutic potential. *Molecular Neurobiology, 56*, 4921–4936.

- Colin, F., & Chédotal, A. (2020). Neuroprotective effects of natural compounds in neurodegenerative diseases. *Frontiers in Neuroscience, 14*, 587.
- Fusar-Poli, P., Radua, J., McGuire, P., & Borgwardt, S. (2012). Neuroanatomical maps of psychosis onset: A meta-analysis of structural and functional imaging studies. *JAMA Psychiatry, 69*(11), 1127–1137.
- Gao, L., Yang, X. N., Dong, Y. X., Han, Y. J., Zhang, X. Y., Zhou, X. L., Liu, Y., Liu, F., Fang, J. S., Ji, J. L., Gao, Z. R., & Qin, X. M. (2024). The potential therapeutic strategy in combating neurodegenerative diseases: Focusing on natural products. *Pharmacology & Therapeutics, 264*, 108751. https://doi.org/10.1016/j.pharmthera.2024.108751
- Goyal, R., Mittal, P., Gautam, R. K., & Kamal, M. A. (2024). Natural products in the management of neurodegenerative diseases. *Nutrition & Metabolism, 21*, 26. https://doi.org/10.1186/s12986-024-00800-4
- Islam, A., Mishra, A., Ahsan, R., & Fareha, S. (2023). Phytopharmaceuticals and herbal approaches to target neurodegenerative disorders. *Drug Research, 73*(7), 388–407. https://doi.org/10.1055/a-2076-7939
- Kumar, A., & Ahuja, A. (2021). Nanotechnology-based approaches for brain delivery of natural compounds in neurodegenerative disorders. *International Journal of Pharmaceutics, 606*, 120912.
- Kumar, A., & Singh, A. (2020). A review on molecular mechanisms of neurodegenerative diseases and therapeutic approaches using natural compounds. *Current Neuropharmacology, 18*(8), 700–718.
- Kumar, S., Sharma, A., & Singh, R. (2023). Emerging approaches in precision medicine for neurological disorders: Role of molecular biomarkers and therapeutic innovations. *Frontiers in Pharmacology, 14*, 1187654.
- Lim, D. W., Lee, J. E., & Lee, C. (2024). Natural products and their neuroprotective effects in degenerative brain diseases: A comprehensive review. *International Journal of Molecular Sciences, 25*(20), 11223. https://doi.org/10.3390/ijms252011223
- Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2012). A review of the use of curcumin for the treatment of depression. *Journal of Affective Disorders, 151*(1), 1–8.
- Lopresti, A. L., Smith, S. J., Malvi, H., & Kodgule, R. (2019). An investigation into the stress-relieving and pharmacological actions of Ashwagandha. *Medicine, 98*(37), e17186.
- Madhubala, D., Patra, A., Khan, M. R., & Mukherjee, A. K. (2024). Phytomedicine for neurodegenerative diseases: The road ahead. *Phytotherapy Research, 38*(6), 2993–3019. https://doi.org/10.1002/ptr.8192
- Miller, D. B., & O'Callaghan, J. P. (2017). Biomarkers of neuroinflammation and neurodegeneration: Challenges and opportunities. *Progress in Neurobiology, 159*, 1–16.
- Moussa, C., Hebron, M., Huang, X., Ahn, J., Rissman, R. A., & Bazzano, L. (2017). Resveratrol regulates neuroinflammation and improves neuronal function. *Journal of Neuroinflammation, 14*, 1–12.
- Ng, Q. X., Venkatanarayanan, N., & Ho, C. Y. X. (2017). Clinical use of *Hypericum perforatum* (St. John's wort) in depression: A meta-analysis. *Journal of Affective Disorders, 210*, 211–221.
- Pardridge, W. M. (2019). Blood–brain barrier and delivery of protein and gene therapeutics to brain. *Frontiers in Aging Neuroscience, 11*, 373.
- Raza, A., Hayat, U., Rasheed, M. A., Bilal, M., & Iqbal, H. M. N. (2018). Redox-responsive nanocarriers as an emerging platform for targeted delivery of bioactive compounds. *Journal of Controlled Release, 282*, 102–115.

- Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chetelat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021). Alzheimer's disease. *The Lancet, 397*(10284), 1577–1590.
- Spencer, J. P. E. (2010). The impact of flavonoids on memory: Physiological and molecular considerations. *Chemical Society Reviews, 39*(8), 2902–2909.
- Sarris, J., Logan, A. C., Akbaraly, T. N., Amminger, G. P., Balanza-Martinez, V., Freeman, M. P., Hibbeln, J., Matsuoka, Y., Mischoulon, D., Mizoue, T., & others. (2015). Nutritional medicine as mainstream in psychiatry. *The Lancet Psychiatry, 2*(3), 271–274.
- Vauzour, D. (2012). Dietary polyphenols as modulators of brain functions: Biological actions and mechanisms of effects. *Nutritional Neuroscience, 15*(1), 1–10.
- Wishart, D. S. (2019). Metabolomics for investigating physiological and pathological processes. *Physiological Reviews, 99*(4), 1819–1875.
- Zhang, Y., Li, P., & Li, X. (2022). Natural products and their bioactive compounds in the prevention and treatment of neurodegenerative diseases. *Pharmacological Research, 177*, 106122. https://doi.org/10.1016/j.phrs.2022.106122
- Zhang, Y., Li, P., & Li, X. (2022). Natural products and their bioactive compounds in psychiatric and neurological disorders. *Pharmacological Research, 177*, 106122. https://doi.org/10.1016/j.phrs.2022.106122
- Zhou, Y., Chen, Y., & Zhang, X. (2021). Nanotechnology-based strategies for improving brain delivery of therapeutic agents. *Journal of Controlled Release, 338*, 35–49.

About Editors

Mr. Abhishek is a pharmacy professional and academic whose career spans pharmaceutical research, higher education, and drug safety. He was awarded a Bachelor of Pharmacy from Pandit Bhagwat Dyal Sharma University of Health Science, followed by a Master of Pharmacy in Pharmacology and Toxicology from Kurukshetra University, India, where his dissertation examined the phytochemical composition and pharmacological properties of plant-derived extracts. He began his professional career as a Drug Safety Associate at Wipro Ltd, where he developed expertise in pharmacovigilance, case processing, and the evaluation of adverse drug reactions. He subsequently spent seven years as an Assistant Professor at Guru Gobind Singh College of Pharmacy, Yamunanagar, teaching human anatomy, physiology, and pharmacology, while concurrently working as a part-time pharmacist at GABA Hospital. Following his relocation to the United Kingdom, Abhishek has remained closely engaged with the pharmacy profession, continuing to contribute to the field through patents, journal publications, and book chapters. He is named as co-inventor on several design patents registered in both India and the United Kingdom, covering laboratory diagnostic equipment, drug-delivery devices, and neonatal care instruments. He has also co-authored a number of peer-reviewed articles addressing subjects such as antiviral therapeutics and the management of Alzheimer's disease, reflecting his sustained contribution to pharmaceutical science and innovation.

Dr. Ashish Patel is an Associate Professor of Pharmaceutical Chemistry at Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India. He is an accomplished academician and researcher with extensive contributions to pharmaceutical and medicinal chemistry. He has published numerous research and review articles in reputed high-impact journals and has contributed to several books and book chapters. Dr. Patel is also actively involved in intellectual property and innovation, with multiple patents filed/granted in India and international jurisdictions, including the UK. He serves as a reviewer for several national and international journals and has delivered numerous expert lectures and invited talks at academic and scientific forums. His diverse scholarly contributions reflect his commitment to pharmaceutical research, education, innovation, and scientific advancement.

Dr. Ajab Singh Choudhary is an Assistant Professor in Medical Laboratory Technology at the School of Allied Health Sciences, Noida International University, Greater Noida, Uttar Pradesh, India. He is an academician and researcher with interests in medical laboratory technology, clinical research, biomedical sciences, and healthcare. He has contributed to scientific research through research and review publications, book chapters, and academic activities. Dr. Choudhary is also actively involved in scholarly reviewing, scientific writing, and academic events, and has delivered expert lectures and presentations at various academic and research forums.

Dr. Hemlata Bhatt is an Assistant Professor in the Department of Pharmaceutical Sciences at H. N. B. Garhwal University, Uttarakhand, India, with more than 20 years of academic and research experience. She completed her M.Pharm from Rajiv Gandhi University of Health Sciences, Bangalore, and Ph.D. from Uttarakhand Technical University. Her professional interests include pharmaceutical education, research, academic mentoring, and scientific writing. She has published 30+ research papers in reputed scientific journals and contributed to numerous book chapters in pharmaceutical and healthcare sciences. Dr. Bhatt remains actively engaged in teaching, research, and scholarly activities, contributing to the advancement of pharmaceutical education and scientific knowledge.

Dr. Bhawana Sati is an Assistant Professor in the Department of Pharmacy at Banasthali Vidyapith. She holds an M.Pharm from Rajiv Gandhi University of Health Sciences, Bangalore, and earned her Ph.D. from Banasthali Vidyapith. With nineteen years of teaching and research experience, Dr. Sati has published over thirty papers in reputed national and international scientific journals. A dedicated academic mentor, she has supervised more than twenty postgraduate proposals and currently guides eleven Ph.D. scholars.

ISBN: 978-81-68473-03-4
9 788168 473034
e-ISBN

Mantra Publication

ISBN: 978-81-68473-02-7
9 788168 473027
P-ISBN